<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005468.pub2" GROUP_ID="MUSKEL" ID="661504062015062305" MERGED_FROM="" MODIFIED="2015-03-26 14:14:21 +0000" MODIFIED_BY="Jordi Pardo Pardo" REVIEW_NO="" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="3.0">
<COVER_SHEET MODIFIED="2015-03-26 14:14:21 +0000" MODIFIED_BY="Jordi Pardo Pardo">
<TITLE>TNF-alpha inhibitors for ankylosing spondylitis</TITLE>
<CONTACT MODIFIED="2015-03-26 14:14:21 +0000" MODIFIED_BY="Jordi Pardo Pardo"><PERSON ID="17387" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Lara</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Maxwell</LAST_NAME><POSITION>Managing Editor, Cochrane Musculoskeletal Group</POSITION><EMAIL_1>lmaxwell@uottawa.ca</EMAIL_1><ADDRESS><DEPARTMENT>Centre for Practice-Changing Research (CPCR)</DEPARTMENT><ORGANISATION>Ottawa Hospital Research Institute (OHRI), The Ottawa Hospital - General Campus</ORGANISATION><ADDRESS_1>501 Smyth Road, Box 711</ADDRESS_1><CITY>Ottawa</CITY><ZIP>K1H 8L6</ZIP><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>1 613-737-8899 ext 75081</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2015-03-26 14:14:21 +0000" MODIFIED_BY="Jordi Pardo Pardo"><PERSON ID="17387" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Lara</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Maxwell</LAST_NAME><POSITION>Managing Editor, Cochrane Musculoskeletal Group</POSITION><EMAIL_1>lmaxwell@uottawa.ca</EMAIL_1><ADDRESS><DEPARTMENT>Centre for Practice-Changing Research (CPCR)</DEPARTMENT><ORGANISATION>Ottawa Hospital Research Institute (OHRI), The Ottawa Hospital - General Campus</ORGANISATION><ADDRESS_1>501 Smyth Road, Box 711</ADDRESS_1><CITY>Ottawa</CITY><ZIP>K1H 8L6</ZIP><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>1 613-737-8899 ext 75081</PHONE_1></ADDRESS></PERSON><PERSON ID="159C488482E26AA2010AB3F2EF5D58F1" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Jane</FIRST_NAME><LAST_NAME>Zochling</LAST_NAME><EMAIL_1>jane.zochling@utas.edu.au</EMAIL_1><EMAIL_2>jzochling@bigpond.com</EMAIL_2><MOBILE_PHONE>+61 411 223 974</MOBILE_PHONE><ADDRESS><ORGANISATION>Menzies Research Institute</ORGANISATION><ADDRESS_1>Private Bag 23</ADDRESS_1><CITY>Hobart</CITY><ZIP>7001</ZIP><REGION>Tasmania</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 3 6226 7737 (Mon-Thurs)</PHONE_1><PHONE_2>+61 3 6225 4462 (Home)</PHONE_2></ADDRESS></PERSON><PERSON ID="0EB88F0282E26AA2001AF2BC98C40172" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Annelies</FIRST_NAME><LAST_NAME>Boonen</LAST_NAME><POSITION>Rheumatologist</POSITION><EMAIL_1>a.boonen@mumc.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Rheumatology</DEPARTMENT><ORGANISATION>Caphri Research Institute</ORGANISATION><ADDRESS_1>P Debeyelaan 25</ADDRESS_1><ADDRESS_2>PO Box 5800</ADDRESS_2><CITY>6202 AZ Maastricht</CITY><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+ 31 43 387 7382</PHONE_1><FAX_1>+ 31 43 387 5006</FAX_1></ADDRESS></PERSON><PERSON ID="15590F7882E26AA2010AB3F26EA8D870" ROLE="AUTHOR"><FIRST_NAME>Jasvinder</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Singh</LAST_NAME><SUFFIX>MD, MPH</SUFFIX><POSITION>Associate Professor of Medicine, Staff Physician</POSITION><EMAIL_1>jasvinder.md@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Medicine</DEPARTMENT><ORGANISATION>Birmingham VA Medical Center</ORGANISATION><ADDRESS_1>Faculty Office Tower 805B</ADDRESS_1><ADDRESS_2>510 20th Street South</ADDRESS_2><CITY>Birmingham</CITY><ZIP>35294</ZIP><REGION>AL</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>205-996-5855</PHONE_1><FAX_1>205-996-9685</FAX_1></ADDRESS></PERSON><PERSON ID="93906542823429167874100201221444" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Mirella</FIRST_NAME><MIDDLE_INITIALS>MS</MIDDLE_INITIALS><LAST_NAME>Veras</LAST_NAME><EMAIL_1>Mvera025@uottawa.ca</EMAIL_1><ADDRESS><DEPARTMENT>École de Readaptación</DEPARTMENT><ORGANISATION>Université de Montreal</ORGANISATION><CITY>Montreal</CITY><REGION>QC</REGION><COUNTRY CODE="CA">Canada</COUNTRY></ADDRESS></PERSON><PERSON ID="45BA46DE82E26AA200C069ECEBB1DB93" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Elizabeth</FIRST_NAME><LAST_NAME>Tanjong Ghogomu</LAST_NAME><EMAIL_1>cmsg@uottawa.ca</EMAIL_1><EMAIL_2>eghogomu@ohri.ca</EMAIL_2><ADDRESS><DEPARTMENT>Bruyère Research Institute</DEPARTMENT><ORGANISATION>University of Ottawa</ORGANISATION><ADDRESS_1>43 Bruyère St</ADDRESS_1><ADDRESS_2>Annex E, room 302</ADDRESS_2><CITY>Ottawa</CITY><ZIP>K1N 5C8</ZIP><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>1 613-562-6262 ext 2962</PHONE_1></ADDRESS></PERSON><PERSON ID="D045AEDF82E26AA20114B3AF650751B5" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Maria</FIRST_NAME><LAST_NAME>Benkhalti Jandu</LAST_NAME><POSITION>Project assistant</POSITION><EMAIL_1>maria.benkhalti@uottawa.ca</EMAIL_1><ADDRESS><DEPARTMENT>Centre for Global Health, Institute of Population Health</DEPARTMENT><ORGANISATION>University of Ottawa</ORGANISATION><ADDRESS_1>1 Stewart Street</ADDRESS_1><CITY>Ottawa</CITY><ZIP>K1N 6N5</ZIP><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>1 613 562 5800 ext 2357</PHONE_1></ADDRESS></PERSON><PERSON ID="5474" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Peter</FIRST_NAME><LAST_NAME>Tugwell</LAST_NAME><POSITION>Professor of Medicine, &amp; Epidemiology and Community Medicine, Canada</POSITION><EMAIL_1>tugwell.bb@uottawa.ca</EMAIL_1><EMAIL_2>kerry.obrien@uottawa.ca</EMAIL_2><ADDRESS><DEPARTMENT>Department of Medicine</DEPARTMENT><ORGANISATION>Faculty of Medicine, University of Ottawa</ORGANISATION><CITY>Ottawa</CITY><ZIP>K1H 8M5</ZIP><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>613-562-5800 ext: 1945</PHONE_1><FAX_1>613-562-5659</FAX_1></ADDRESS></PERSON><PERSON ID="12662" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>George</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Wells</LAST_NAME><SUFFIX>MSc, PhD</SUFFIX><POSITION>Professor</POSITION><EMAIL_1>gawells@ottawaheart.ca</EMAIL_1><ADDRESS><DEPARTMENT>Department of Epidemiology and Community Medicine</DEPARTMENT><ORGANISATION>University of Ottawa</ORGANISATION><ADDRESS_1>Room H1281</ADDRESS_1><ADDRESS_2>40 Ruskin Street</ADDRESS_2><CITY>Ottawa</CITY><ZIP>K1Y 4W7</ZIP><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 613 798 5555 x18640</PHONE_1><PHONE_2>+1 613 798 5555 x18642</PHONE_2></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2014-11-30 08:03:42 -0500" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="3" MONTH="6" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="3" MONTH="6" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="6" YEAR="2016"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2005"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2015"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2015"/>
</DATES>
<WHATS_NEW MODIFIED="2010-08-25 09:34:36 -0400" MODIFIED_BY="[Empty name]"/>
<HISTORY MODIFIED="2015-02-17 23:46:31 -0500" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-02-17 23:46:31 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="11" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="20" MONTH="5" YEAR="2005"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2015-01-29 10:46:13 -0500" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Institute of Population Health, University of Ottawa</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Rheumazentrum Ruhrgebiet</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2015-01-29 10:46:13 -0500" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2015-01-29 10:46:13 -0500" MODIFIED_BY="[Empty name]">
<NAME>NIHR Cochrane Incentive Award 2013</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>Award to assist with completion of the review.</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-03-26 05:02:07 -0400" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2015-03-25 08:07:29 -0400" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2015-03-20 09:53:14 -0400" MODIFIED_BY="[Empty name]">Anti-TNF-alpha drugs for treating ankylosing spondylitis</TITLE>
<SUMMARY_BODY MODIFIED="2015-03-25 08:07:29 -0400" MODIFIED_BY="[Empty name]">
<P>Researchers looked at trials done up to June 2014 on the effect of anti-TNF drugs (adalimumab (Humira®), etanercept (Enbrel®), golimumab (Simponi®), and infliximab (Remicade®)) on ankylosing spondylitis. They found 21 trials with 3308 participants. Most studies were funded by pharmaceutical companies.</P>
<P>
<B>What is ankylosing spondylitis and what are anti-TNF drugs? </B>
</P>
<P>Ankylosing spondylitis is a type of arthritis, usually in the joints and ligaments of the spine, but it may also affect other joints. Pain and stiffness occurs and limits movement in the back and affected joints. It can come and go, last for long periods, and be quite severe.</P>
<P>Anti-TNF drugs target a protein called 'tumor necrosis factor' that causes inflammation. These drugs suppress the immune system and reduce the inflammation in the joints, with the aim of preventing damage. Even though suppressing the immune system can make it slightly harder to fight off infections, it also helps to stabilize an overactive immune system.</P>
<P>
<B>The review shows that in people with ankylosing spondylitis, using anti-TNF drugs for up to 24 weeks: </B>
</P>
<P>- improves pain, function and other symptoms of ankylosing spondylitis;<BR/>- may increase the chance of achieving partial remission of symptoms of ankylosing spondylitis;<BR/>- probably slightly improves spinal inflammation, as measured by magnetic resonance imaging (MRI); and<BR/>- probably causes slightly more people to drop out of studies because of side effects.</P>
<P>We do not have precise information about side effects and complications, but in these short-term studies there was no evidence of an increase in serious adverse events. Possible side effects may include a serious infection (like tuberculosis) or upper respiratory infection.  Rare complications may include certain types of cancer. </P>
<P>
<BR/>
<B>Best estimate of what happens to people with ankylosing spondylitis who take anti-TNF drugs for up to 24 weeks: </B>
</P>
<P>
<B>ASAS40 (40% improvement in pain, function, and inflammation as measured by morning stiffness, and patient overall well-being)</B>
<BR/>
<BR/>Compared to 13 people out of 100 who experienced an improvement with a placebo, among people who took:</P>
<P>- adalimumab: 46 people out of 100 experienced improvement (33% improvement);<BR/>- etanercept: 43 people out of 100 experienced improvement (30% improvement);<BR/>- golimumab: 38 people out of 100 experienced improvement (25% improvement); and<BR/>- infliximab: 53 people out of 100 experienced improvement (40% improvement).<BR/>
</P>
<P>
<B>Partial remission (defined as a value of less than 2 on a 0 to 10 scale in each of</B> <B>pain, function, and inflammation as measured by morning stiffness, and patient overall well-being)</B>
<BR/>
<BR/>Compared to 3 people out of 100 who experienced an improvement with a placebo, among people who took:</P>
<P>- adalimumab: 19 people out of 100 experienced partial remission (16% improvement);<BR/>- etanercept: 13 people out of 100 experienced partial remission (10% improvement);<BR/>- golimumab: 16 people out of 100 experienced partial remission (13% improvement); and<BR/>- infliximab: 47 people out of 100 experienced partial remission (44% improvement).<BR/>
<BR/>
</P>
<P>
<B>Physical function (lower score means better function; 0 to 10 scale)</B>
</P>
<P>Compared to a score of 5 in people who took placebo, among people who took:</P>
<P>- adalimumab, they rated their function to be 3.4 (16% improvement);<BR/>- etanercept, they rated their function to be 3.9 (11% improvement);<BR/>- golimumab, they rated their function to be 3.5 (15% improvement); and<BR/>- infliximab, they rated their function to be 2.9 (21% improvement).<BR/>
<BR/>
</P>
<P>
<B>Spinal inflammation as measured by magnetic resonance imaging (MRI) </B>
<BR/>
<BR/>Compared to people who took placebo, a small improvement in spinal inflammation was seen in:</P>
<P>- adalimumab (6% improvement);<BR/>- golimumab (2.5% improvement); and<BR/>- infliximab (3% improvement).</P>
<P>
<B>X-rays of the joints</B>
</P>
<P>Only one study looked at x-rays and found that joint changes were similar in both groups (detailed data not provided).</P>
<P>
<B>Side effects</B>
</P>
<P>When all the anti-TNF drugs were combined, 16 people out of 1000 dropped out of the study because of side effects compared to 7 people out of 1000 who took placebo (absolute increase 1%).</P>
<P>There may be little or no difference in the number of people who have a serious side effect with an anti-TNF drug compared to people who take a fake pill.<BR/>
</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2015-03-25 08:05:49 -0400" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2015-02-18 00:21:42 -0500" MODIFIED_BY="[Empty name]">
<P>TNF (tumor necrosis factor)-alpha inhibitors block a key protein in the inflammatory chain reaction responsible for joint inflammation, pain, and damage in ankylosing spondylitis.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2015-03-20 09:51:59 -0400" MODIFIED_BY="[Empty name]">
<P>To assess the benefit and harms of adalimumab, etanercept, golimumab, and infliximab (TNF-alpha inhibitors) in people with ankylosing spondylitis.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2015-03-20 07:16:44 -0400" MODIFIED_BY="[Empty name]">
<P>We searched the following databases to January 26, 2009: MEDLINE (from 1966); EMBASE (from 1980); the Cochrane Central Register of Controlled Trials (CENTRAL; 2008, Issue 4); ACP Journal Club; CINAHL (from 1982); and ISI Web of Knowledge (from 1900). We ran updated searches in May 2012, October 2013, and in June 2014 for McMaster PLUS. We searched major regulatory agencies for safety warnings and clinicaltrials.gov for registered trials.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2015-01-29 08:25:25 -0500" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trials (RCTs) comparing adalimumab, etanercept, golimumab and infliximab to placebo, other drugs or usual care in patients with ankylosing spondylitis, reported in abstract or full-text.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2015-03-25 07:10:08 -0400" MODIFIED_BY="[Empty name]">
<P>Two authors independently assessed search results, risk of bias, and extracted data. We conducted Bayesian mixed treatment comparison (MTC) meta-analyses using WinBUGS software. To investigate a class-effect of harms across biologics, we pooled harms data using Review Manager 5.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2015-03-25 08:05:49 -0400" MODIFIED_BY="[Empty name]">
<P>We included twenty-one, short-term (24 weeks or less) RCTs with a total of 3308 participants; 18 contributed data to the MTC analysis: adalimumab (4 studies), etanercept (8 studies), golimumab (2 studies), infliximab (3 studies), and one head-to-head study (etanercept versus infliximab) which was unblinded and considered at a higher risk of bias. The risk of selection and detection bias was low or unclear for most of the studies. The risk of selective outcome reporting was low for most studies as they reported on outcomes recommended by the Assessment of SpondyloArthritis international Society. We found little heterogeneity and no significant inconsistency in the MTC analyses. The majority of the studies were funded by pharmaceutical companies. Most studies permitted concomitant therapy of stable doses of disease-modifying anti-rheumatic drugs, non-steroidal anti-inflammatory drugs, or corticosteroids, but allowances varied across studies.</P>
<P>Compared with placebo, there was high quality evidence that patients on an anti-TNF agent were three to four times more likely to achieve an ASAS40 response (assessing spinal pain, function, and inflammation, as measured by the mean of intensity and duration of morning stiffness, and patient global assessment) by six months (adalimumab: risk ratio (RR) 3.53, 95% credible interval (Crl) 2.49 to 4.91; etanercept: RR 3.31, 95% Crl 2.38 to 4.53; golimumab: RR 2.90, 95% Crl 1.90 to 4.23; infliximab: RR 4.07, 95% Crl 2.80 to 5.74, with a 25% to 40% absolute difference between treatment and placebo groups. The number needed to treat (NNT) to achieve an ASAS 40 response ranged from 3 to 5.</P>
<P>There was high quality evidence of improvement in physical function on a 0 to 10 scale (adalimumab: mean difference (MD) -1.6, 95% Crl -2.2 to -0.9; etanercept: MD -1.1, 95% CrI -1.6 to -0.6; golimumab: MD -1.5, 95% Crl -2.3 to -0.7; infliximab: MD -2.1, 95% Crl -2.7 to -1.4, with an 11% to 21% absolute difference between treatment and placebo groups. The NNT to achieve the minimally clinically important difference of 0.7 points ranged from 2 to 4.</P>
<P>Compared with placebo, there was moderate quality evidence (downgraded for imprecision) that patients on an anti-TNF agent were more likely to achieve an ASAS partial remission by six months (adalimumab: RR 6.28, 95% Crl 3.13 to 12.78; etanercept: RR 4.24, 95% Crl 2.31 to 8.09; golimumab: RR 5.18, 95% Crl 1.90 to 14.79; infliximab: RR 15.41, 95% Crl 5.09 to 47.98 with a 10% to 44% absolute difference between treatment and placebo groups. The NNT to achieve an ASAS partial remission response ranged from 3 to 11.</P>
<P>There was low to moderate level evidence of a greater reduction in spinal inflammation as measured by magnetic resonance imaging though the absolute differences were small and the clinical relevance of the difference was unclear: adalimumab (1 trial; -6% (95% confidence interval (CI) -12% to 0.05%); 1 trial: 53.6% mean decrease from baseline versus 9.4% mean increase in the placebo group), golimumab (1 trial; -2.5%, (95% CI -5.6% to -0.7%)), and infliximab (1 trial; -3% (95% CI -4% to -2.4%)).</P>
<P>Radiographic progression was measured in one trial (N = 60) of etanercept versus placebo and it found that radiologic changes were similar in both groups (detailed data not provided).</P>
<P>There were few events of withdrawals due to adverse events leading to imprecision around the estimates. When all the anti-TNF agents were combined against placebo, there was moderate quality evidence from 16 studies of an increased risk of withdrawals due to adverse events in the anti-TNF group (Peto odds ratio (OR) 2.44, 95% CI 1.26 to 4.72; total events: 38/1637 in biologic group; 7/986 in placebo) though the absolute increase in harm was small (1%; 95% CI 0% to 2%).</P>
<P>Due to low event rates, evidence of the effect of individual TNF-inhibitors against placebo or for all four biologics pooled together versus placebo on serious adverse events is inconclusive (moderate quality; downgraded for imprecision). For all anti-TNF pooled versus placebo based on 16 studies: Peto OR 1.45, 95% CI 0.85 to 2.48; 51/1530 in biologic group; 18/878 in placebo; absolute difference: 1% (95% CI 0% to 2%). </P>
<P>Using indirect comparison methodology, and one head-to-head study of etanercept versus infliximab, wide confidence intervals meant that results were inconclusive for evidence of differences in the major outcomes between different anti-TNF agents. Regulatory agencies have published warnings about rare adverse events of serious infections, including tuberculosis, malignancies and lymphoma.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2015-03-25 06:28:26 -0400" MODIFIED_BY="[Empty name]">
<P>There is moderate to high quality evidence that anti-TNF agents improve clinical symptoms in the treatment of ankylosing spondylitis. More participants withdrew due to adverse events when on an anti-TNF agent but we did not find evidence of an increase in serious adverse events, though event rates were low and trials had a short duration. The short-term toxicity profile appears acceptable. Based on indirect comparison methodology, we are uncertain whether there are differences between anti-TNF agents in terms of the key benefit or harm outcomes.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2015-03-26 05:01:48 -0400" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2015-03-20 09:57:48 -0400" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2015-03-20 09:57:48 -0400" MODIFIED_BY="[Empty name]">
<P>Ankylosing spondylitis is a chronic, inflammatory rheumatic disease characterized by inflammatory back pain due to sacroiliitis and spondylitis, enthesitis, and the formation of syndesmophytes (bony growths) leading to ankylosis. Extraspinal manifestations are common, including peripheral arthritis (25% to 50%), uveitis (eye inflammation) (25% to 40%), and inflammatory bowel disease (26%), and contribute to disease morbidity (<LINK REF="REF-Edmunds-1991" TYPE="REFERENCE">Edmunds 1991</LINK>; <LINK REF="REF-Inman-2011" TYPE="REFERENCE">Inman 2011</LINK>).</P>
<P>The etiology of the disease is not yet fully understood but there is a strong association with the HLA-B27 gene (<LINK REF="REF-Inman-2011" TYPE="REFERENCE">Inman 2011</LINK>). Studies have shown the prevalence of ankylosing spondylitis in the adult general population to vary from 0.4% (Alaskan Inuit) to 1.4% (Northern Norway) (<LINK REF="REF-Khan-2002" TYPE="REFERENCE">Khan 2002</LINK>). A general rule is that the prevalence of ankylosing spondylitis is highest in HLA-B27-positive patients with a family member who also has the disease (20%), is least in the general population (0.2%), and is about 2% in those positive for HLA-B27 (<LINK REF="REF-Inman-2011" TYPE="REFERENCE">Inman 2011</LINK>). The peak age of onset is in young adults between 20 and 30 years, although there is often a five to six year delay in diagnosis (<LINK REF="REF-Khan-2002" TYPE="REFERENCE">Khan 2002</LINK>).</P>
<P>Clinical symptoms usually begin with back pain and stiffness in adolescence and early adulthood which shows improvement with exercise and can lead to impaired spinal mobility, or chest expansion, or both. The disease course of ankylosing spondylitis is highly variable, with back pain and stiffness often the primary features early in the process, and chronic pain and joint changes later on (<LINK REF="REF-Inman-2011" TYPE="REFERENCE">Inman 2011</LINK>). The burden of disease in ankylosing spondylitis has been found to be similar to that of rheumatoid arthritis in terms of pain, disability and decreased well-being (<LINK REF="REF-Zink-2000" TYPE="REFERENCE">Zink 2000</LINK>). Additionally, compared to the general population, those with ankylosing spondylitis experience higher work disability and absence from work, which can lead to substantial direct and indirect socioeconomic costs (<LINK REF="REF-Boonen-2001a" TYPE="REFERENCE">Boonen 2001a</LINK>; <LINK REF="REF-Boonen-2001b" TYPE="REFERENCE">Boonen 2001b</LINK>; <LINK REF="REF-Montacer-2009" TYPE="REFERENCE">Montacer 2009</LINK>).</P>
<P>The goals of treatment of ankylosing spondylitis are to relieve symptoms (pain, stiffness, joint swelling), improve physical function, and delay or avoid structural damage which leads to physical impairments and deformities. Ankylosing spondylitis requires a multidisciplinary treatment approach and is usually managed with a combination of exercises, physiotherapy and drug therapy. Regular exercise is crucial for maintaining or improving spinal mobility and physical function (<LINK REF="REF-Dagfinrud-2008" TYPE="REFERENCE">Dagfinrud 2008</LINK>). Non-steroidal anti-inflammatory drugs (NSAIDs) are the mainstay of symptomatic drug therapy, reducing the pain and stiffness of inflammation. Although these interventions can alleviate the symptoms of the disease, it is not clear whether they are able to prevent or delay the structural damage leading to physical disability. Some evidence suggests continuous NSAID therapy may have an effect on the spinal radiographic changes seen in ankylosing spondylitis (<LINK REF="REF-Wanders-2005" TYPE="REFERENCE">Wanders 2005</LINK>). At least one-third of patients respond insufficiently to NSAID therapy or experience serious side effects from NSAIDs and thus require disease controlling drugs in addition to symptom-modifying treatment. In contrast to rheumatoid arthritis, there are no established disease-modifying anti-rheumatic treatments in ankylosing spondylitis, although sulphasalazine may be effective for peripheral joint symptoms but not for axial disease (<LINK REF="REF-Dougados-2002" TYPE="REFERENCE">Dougados 2002</LINK>; <LINK REF="REF-Chen-2014" TYPE="REFERENCE">Chen 2014</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2015-02-22 22:43:09 -0500" MODIFIED_BY="[Empty name]">
<P>A major advance in treatment options for ankylosing spondylitis is the development of biologic therapies which target specific elements of the immune system. Tumor necrosis factor (TNF)-alpha is a protein that the body produces during the inflammatory response. TNF-alpha promotes inflammation and subsequent pain, tenderness, swelling and fever in several inflammatory conditions, including ankylosing spondylitis. Four anti-TNF agents, also known as TNF-inhibitors, have been developed to target the binding of this protein, thus reducing the pain, swelling, and inflammation associated with ankylosing spondylitis. The generic and trademark drug names are: adalimumab (Humira®), etanercept (Enbrel®), golimumab (Simponi®), and infliximab (Remicade®). Infliximab is given as an intravenous infusion over one to two hours while etanercept, adalimumab, and golimumab are given as subcutaneous injections. Etanercept and adalimumab are given as weekly or bi-weekly injections, while golimumab is injected once a month. Recognized contraindications for treatment include tuberculosis, multiple sclerosis, lupus, malignancy, pregnant or lactating women, heart failure, hepatitis, and pneumonia.</P>
</INTERVENTION>
<THEORY MODIFIED="2015-02-22 22:43:13 -0500" MODIFIED_BY="[Empty name]">
<P>As the result of research demonstrating that tumor necrosis factor-alpha (TNF-alpha) is present in inflamed sacroiliac joints (<LINK REF="REF-Braun-1995" TYPE="REFERENCE">Braun 1995</LINK>), treatments were developed to block TNF-alpha. Etanercept is a receptor fusion protein that binds to TNF-alpha, thus competitively inhibiting the binding of TNF-alpha to the cell surface. Infliximab is a chimeric (mouse/human) monoclonal antibody of the IgG1&#954; isotype that binds with a high affinity to TNF-alpha. Adalimumab is a recombinant human IgG1 monoclonal antibody specific for human TNF-alpha, and golimumab is a human monoclonal antibody that binds to both soluble and transmembrane TNF-alpha. These four agents prevent TNF-alpha from promoting inflammation and therefore are thought to interrupt the processes responsible for the pain, tenderness, and swelling of joints in patients with ankylosing spondylitis.</P>
</THEORY>
<IMPORTANCE MODIFIED="2015-02-19 21:17:34 -0500" MODIFIED_BY="[Empty name]">
<P>Early open label studies demonstrated that biologics are efficacious in ankylosing spondylitis (<LINK REF="REF-Brandt-2000" TYPE="REFERENCE">Brandt 2000</LINK>; <LINK REF="REF-Haibel-2004" TYPE="REFERENCE">Haibel 2004</LINK>; <LINK REF="REF-Maksymowych-2002" TYPE="REFERENCE">Maksymowych 2002</LINK>; <LINK REF="REF-Marzo_x002d_Ortega-2001" TYPE="REFERENCE">Marzo-Ortega 2001</LINK>; <LINK REF="REF-Stone-2001" TYPE="REFERENCE">Stone 2001</LINK>) and RCTs showed them to be effective in improving disease activity, spinal mobility, function, and pain (<LINK REF="STD-Braun-2002" TYPE="STUDY">Braun 2002</LINK>; <LINK REF="STD-Gorman-2002" TYPE="STUDY">Gorman 2002</LINK>; <LINK REF="REF-Van-Den-Bosch-2002" TYPE="REFERENCE">Van Den Bosch 2002</LINK>). Recognized adverse effects of anti-TNF-alpha therapy include serious infections such as tuberculosis, allergic reactions and autoimmune reactions.</P>
<P>The relatively high cost of treatment and possible serious side effects of anti-TNF-alpha therapy led the Assessment of SpondyloArthritis international Society (ASAS) (<LINK REF="REF-Braun-2003" TYPE="REFERENCE">Braun 2003</LINK>; <LINK REF="REF-van-der-Heijde-2011" TYPE="REFERENCE">van der Heijde 2011</LINK>) and the Spondyloarthritis Research Consortium of Canada (<LINK REF="REF-Maksymowych-2003" TYPE="REFERENCE">Maksymowych 2003</LINK>) to develop recommendations for the use of TNF-alpha inhibitors in ankylosing spondylitis.</P>
<P>While these biologics offer an important therapeutic advance by appearing to reduce disease activity and improve function and well-being of patients, it is important to understand and try to quantify not only the potential benefits of this treatment, but also the potential harms. Clinicians and patients need this information in order to make an informed decision about the trade-offs of using this treatment option. The evidence base for the individual biologics compared to each other is of interest to patients and other healthcare decision makers. We will include certolizumab in an update of this review. Head-to-head studies (i.e. one biologic versus another) are usually rare so we will undertake indirect comparisons using network meta-analysis methodology to address this question.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2015-03-20 09:52:13 -0400" MODIFIED_BY="[Empty name]">
<P>To assess the benefits and harms of adalimumab, etanercept, golimumab, and infliximab (TNF-alpha inhibitors) in people with ankylosing spondylitis.</P>
</OBJECTIVES>
<METHODS MODIFIED="2015-03-26 04:59:37 -0400" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2015-03-26 04:51:09 -0400" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2015-03-12 07:02:39 -0400" MODIFIED_BY="[Empty name]">
<P>We included randomized controlled trials (RCTs) and controlled clinical trials (CCTs). We defined 'short-term' benefit and harms as those with equal to or less than six months duration and 'long-term' benefit and harms as longer than six months.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2015-03-26 04:39:49 -0400" MODIFIED_BY="[Empty name]">
<P>We included studies of patients meeting the following ankylosing spondylitis classification criteria: 1961 Rome, 1966 New York, or modified 1984 New York. We did not apply any additional restrictions in studies with regard to age of patients, past or present (co-)medication or ankylosing spondylitis-related comorbidity. We included studies on spondyloarthropathies that mentioned ankylosing spondylitis patients as a subgroup, as far as the subgroup was properly randomized and outcome measures were available, specifically for the ankylosing spondylitis subgroup. We included patients on other medications, and with or without ankylosing spondylitis-related comorbidity (e.g. peripheral joint impairment, inflammatory bowel disease, psoriasis). We did not impose restrictions on age or disease duration. We did not include diagnoses of axial spondyloarthritis, though we may consider this for an update of this review based on the classification criteria developed by ASAS (<LINK REF="REF-Rudwaleit-2009a" TYPE="REFERENCE">Rudwaleit 2009a</LINK>; <LINK REF="REF-Rudwaleit-2009b" TYPE="REFERENCE">Rudwaleit 2009b</LINK>).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2015-03-25 07:29:45 -0400" MODIFIED_BY="[Empty name]">
<UL>
<LI>Adalimumab versus placebo, other medications, or usual care.</LI>
<LI>Etanercept versus placebo, other medications, or usual care.</LI>
<LI>Golimumab versus placebo, other medications, or usual care.</LI>
<LI>Infliximab versus placebo, other medications, or usual care.</LI>
</UL>
<P>Note that we added golimumab after the protocol for this review (<LINK REF="REF-Zochling-2005" TYPE="REFERENCE">Zochling 2005</LINK>).</P>
<P>We did not impose any restrictions with regard to dose or concomitant treatments in the placebo group (for example, physical exercises, or NSAIDs, or both).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2015-03-26 04:51:09 -0400" MODIFIED_BY="[Empty name]">
<P>The primary and secondary outcomes defined in the protocol and listed in the <LINK TAG="PRO_REV_DIFF" TYPE="SECTION">Differences between protocol and review</LINK> section were chosen in 2005 when the protocol for this review was published (<LINK REF="REF-Zochling-2005" TYPE="REFERENCE">Zochling 2005</LINK>). Since then, the Cochrane Collaboration has developed Summary of Findings tables which require choosing a maximum of seven major outcomes for presentation in the table. The Assessment of SpondyloArthritis international Society (formerly ASsessment in Ankylosing Spondylitis) (ASAS) Working Group) (<A HREF="http://www.asas-group.org">http://www.asas-group.org</A>) has developed core sets of standardized outcome measures for use in clinical practice and trial settings. This work has been undertaken in conjunction with the OMERACT (Outcome Measures in Rheumatology, <A HREF="http://www.omeract.org">www.omeract.org</A>) initiative which aims to establish standardized, validated outcome measures for use in clinical trials in the field of rheumatology. Following discussion with experts from ASAS, the following outcomes were chosen to be the major outcomes for this review:</P>
<OL>
<LI>ASAS40 (<LINK REF="REF-Brandt-2004" TYPE="REFERENCE">Brandt 2004</LINK>)</LI>
<LI>BASFI (Bath Ankylosing Spondylitis Functional Index) (<LINK REF="REF-Calin-1994" TYPE="REFERENCE">Calin 1994</LINK>)</LI>
<LI>ASAS partial remission (<LINK REF="REF-Anderson-2001" TYPE="REFERENCE">Anderson 2001</LINK>)</LI>
<LI>Magnetic resonance imaging (MRI) for evidence of inflammation</LI>
<LI>Radiographic progression</LI>
<LI>Withdrawals due to adverse events</LI>
<LI>Serious adverse events</LI>
</OL>
<P>The criteria for an ASAS40 response is: at least a 40% improvement with a minimum of 20 units (0 to 100 scale) improvement compared with baseline in at least three of four domains (spinal pain, function (BASFI), inflammation as measured by the mean of intensity and duration of morning stiffness in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), and patient global assessment), and with no worsening in the fourth domain. Partial remission is defined as a value of less than 2 on a 0 to 10 scale in each of the four domains as described above for the ASAS40.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2015-03-22 04:06:24 -0400" MODIFIED_BY="[Empty name]">
<P>The Cochrane Musculoskeletal Group's Trial Search Co-ordinators developed the search strategies. In the original search in January 2009, we searched the following electronic databases: Cochrane Library (2008, Issue 4) including the following databases: Cochrane Central Register of Controlled Trials (CENTRAL), Cochrane Database of Systematic Reviews (CDSR), Database of Abstracts of Reviews of Effects (DARE), Cochrane Library Health Technology Assessment Database (CLHTA), and NHS Economic Evaluation Database (NHS EED); MEDLINE (1966 to January 26, 2009); EMBASE (1980 to January 26, 2009); CINAHL (1982 to January 26, 2009); ISI Web of Knowledge (1900 to January 2009).</P>
<P>We reviewed the reference section of retrieved articles. We contacted authors of relevant papers and experts in the field regarding any further published or unpublished work. One review author (LM) handsearched conference proceedings from the American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR, <A HREF="http://www.abstracts2view.com/eular/">http://www.abstracts2view.com/eular/</A> textword search: ankylosing AND etanercept OR infliximab OR adalimumab) from 2005 to 2009, for both benefit and harms.</P>
<P>We conducted an updated search in May 2012. In October 2013, we conducted another updated search of all databases and also included a search for 'golimumab' from database inception. From September 2013 to June 2014 we received alerts of potential new studies identified by the McMaster PLUS database (<A HREF="http://hiru.mcmaster.ca/hiru/HIRU_McMaster_PLUS_Projects.aspx">McMaster PLUS evidence updates</A>) through a service provided for Cochrane Musculoskeletal Group authors.</P>
<P>In October 2014 a search of clinicaltrials.gov was conducted for any completed trials meeting the review's inclusion criteria using 'ankylosing spondylitis' in condition and Phase 3 and 4 trials.</P>
<P>For safety assessments, we searched the websites of the regulatory agencies (US Food and Drug Administration-MedWatch (<A HREF="http://www.fda.gov/Safety/MedWatch/default.htm">http://www.fda.gov/Safety/MedWatch/default.htm</A>), European Medicines Evaluation Agency (<A HREF="http://www.emea.europa.eu">http://www.emea.europa.eu</A>), Australian Adverse Drug Reactions Bulletin (<A HREF="http://www.tga.gov.au/adr/aadrb.htm">http://www.tga.gov.au/adr/aadrb.htm</A>), and UK Medicines and Healthcare products Regulatory Agency (MHRA) pharmacovigilance and drug safety updates (<A HREF="http://www.mhra.gov.uk">http://www.mhra.gov.uk</A>); note 'Current Problems in Pharmacovigilance' was superseded by 'Drug Safety Update' in July 2007) using the terms &#8220;ankylosing spondylitis,&#8221; &#8220;adalimumab,&#8221; "humira", "etanercept", "enbrel", "infliximab", and "remicade&#8221; on April 1, 2010. We updated this search and included "golimumab"/"simponi" in November 2014.</P>
<P>We did not impose any language restrictions.</P>
<P>There were some abstracts from conference proceedings that were later published as full-text articles; in this case, we only included the full-text article, however, if the abstract provided additional important information that was not provided in the full-text article, then we also included the data from the abstract. Some trials had more than one publication with the secondary publications reporting on other outcomes such as health-related quality of life, patient-reported outcomes, or magnetic resonance imaging (MRI) data.</P>
<P>The original MEDLINE search strategy is in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>. The other search strategies are available in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> and <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2015-03-26 04:59:37 -0400" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2015-03-22 04:10:32 -0400" MODIFIED_BY="[Empty name]">
<P>Two people independently reviewed the results of the search strategy. The authors involved in screening the different search results were: JZ, JS, LM, MBJ, MV. We reviewed abstracts and if more information was required to determine whether the trial met the inclusion criteria, we obtained the full text. Disagreement was resolved by a third author (AB, GW).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2015-03-25 05:07:19 -0400" MODIFIED_BY="[Empty name]">
<P>Four review authors (JZ, LM, JS, MVS) independently extracted data from the included trials and entered the data into Review Manager 5 (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>). We pilot-tested data extraction forms on a selection of trials.</P>
<P>We extracted the following data.<BR/>
</P>
<UL>
<LI>General study information such as title, authors, contact address, publication source, publication year, country, study sponsor.</LI>
<LI>Characteristics of the study: design, study setting, inclusion/exclusion criteria, risk of bias criteria (e.g. randomisation method, allocation procedure, blinding of patients, caregivers and outcome assessors).</LI>
<LI>Characteris`tics of the study population and baseline characteristics of the intervention and control groups (age, sex, type of classification criteria, duration of disease, presence of comorbidity and peripheral disease, concomitant treatments, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), patient global assessment) and numbers in each group.</LI>
<LI>Characteristics of the intervention, such as treatment comparators, dose, method of administration, frequency of administration and duration of treatment.</LI>
<LI>Outcomes measures as noted above.</LI>
<LI>Results for the intention-to-treat population (where possible), summary measures with standard deviations, confidence intervals and P values where given, dropout rate and reasons for withdrawal.</LI>
<LI>When data for more than one time point was provided, we used the longest time point for the blinded phase and prior to any early-escape option for the meta-analysis. However, for some of the harms data, only results for the double-blind period was reported, without providing data prior to the early-escape option. In this case, we used the double-blind period data with data for those that did not crossover.</LI>
<LI>We extracted both change and final values, as reported in the publication. The network meta-analysis required only end of study values so we calculated those when only a change value had been provided and used the standard deviation at baseline for the end of study standard deviation.</LI>
</UL>
<P>We used Plot Digitizer software to estimate results from five graphs (<LINK REF="REF-Plot-Digitizer-2014" TYPE="REFERENCE">Plot Digitizer 2014</LINK>) .</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2015-03-22 04:43:45 -0400" MODIFIED_BY="[Empty name]">
<P>Two independent reviewers (LM, JZ, MV, CM, MB) assessed risk of bias in the included RCTs. As recommended by the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>), we assessed the following methodological domains.</P>
<OL>
<LI>Random sequence generation - was the method used to generate the allocation sequence appropriate to produce comparable groups?</LI>
<LI>Allocation sequence concealment - was the method used to conceal the allocation sequence appropriate to prevent the allocation being known in advance of, or during, enrolment?</LI>
<LI>Blinding of participants, personnel - were measures used to blind study participants and personnel from knowledge of which intervention a participant received? We assessed patient- and physician-assessed outcomes separately.</LI>
<LI>Blinding of outcome assessors - were measures used to blind outcome assessors from knowledge of which intervention a participant received? We assessed patient- and physician-assessed outcomes separately.</LI>
<LI>Incomplete outcome data - how complete was the outcome data for the primary outcomes? Were dropout rates and reasons for withdrawal reported? Was missing data imputed appropriately? We considered an overall completion rate of 80% or higher as a low risk of bias. If completion rates were only provided by group, a less than 80% completion rate in the treatment group was considered a high risk of bias.</LI>
<LI>Selective outcome reporting - were appropriate outcomes reported and were any key outcomes missing?</LI>
<LI>Ascertainment of outcome - did the researchers actively monitor for adverse events (low risk of bias) or did they simply provide spontaneous reporting of adverse events that arise (high risk of bias)?</LI>
<LI>Definition of adverse outcomes- were definitions provided for general 'adverse event' or 'serious adverse event'?</LI>
</OL>
<P>We explicitly judged each of these criteria using: low risk of bias; high risk of bias; or unclear, meaning either lack of information or uncertainty over the potential for bias. We provided a reason for each judgement in the 'Risk of bias' table.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2015-03-25 09:11:15 -0400" MODIFIED_BY="[Empty name]">
<P>
<U>Methods for indirect and mixed treatment comparisons</U>
</P>
<P>For dichotomous outcome, we derived point estimates and 95% credible intervals for odds ratios (ORs), risk ratios (RR) and risk differences (RD). For continuous outcomes, we derived mean differences (MD) and 95% credible intervals.</P>
<P>
<U>Methods for direct treatment comparisons</U>
</P>
<P>In addition to the mixed treatment comparisons, we pooled data for serious adverse events and withdrawals due to adverse events to investigate a class-effect of harms of biologics. We analysed this using Peto odds ratio (Peto OR) with 95% CIs given that the Peto OR is recommended when the outcome is a rare event (approximately less than 10%).</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2015-03-25 08:15:22 -0400" MODIFIED_BY="[Empty name]">
<P>For studies with more than two arms, we halved the number of events and patients in the placebo arm to avoid double-counting the placebo participants in the meta-analysis. We only assessed the standard doses for each of the biologics for inclusion in the network meta-analysis when multiple trial arms with different dosages were reported.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2015-02-22 22:43:42 -0500" MODIFIED_BY="[Empty name]">
<P>We performed the following calculations for the purpose of entering data into Review Manager 5 when the mean and standard deviation was not provided in the published article. When the median change from baseline and interquartile range (IQR) change from baseline were reported (as in <LINK REF="STD-Inman-2008" TYPE="STUDY">Inman 2008</LINK> and <LINK REF="STD-van-der-Heijde-2005" TYPE="STUDY">van der Heijde 2005</LINK>), we assumed the median change to be the mean change and calculated the standard deviation as the IQR at baseline divided by 1.35 and this standard deviation (SD) assumed for the end of study score, as per the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<P>Where no SD at end of study was reported or the variance for the change from baseline was provided in the study report as the standard error of the change, the baseline SD was assumed for the end of study SD (<LINK REF="STD-Braun-2011" TYPE="STUDY">Braun 2011</LINK>; <LINK REF="STD-van-der-Heijde-2006a" TYPE="STUDY">van der Heijde 2006a</LINK>).</P>
<P>In <LINK REF="STD-Davis-2003" TYPE="STUDY">Davis 2003</LINK>, the standard error of the mean (SEM) was transformed to SD by the calculation SD = SEM *sqrt(N). In <LINK REF="STD-Barkham-2010" TYPE="STUDY">Barkham 2010</LINK> the 95% CI about the mean change was converted to SD using the formula in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). In <LINK REF="STD-Inman-2010" TYPE="STUDY">Inman 2010</LINK>, the SD was calculated from the P value for continuous outcomes. In <LINK REF="STD-Gorman-2002" TYPE="STUDY">Gorman 2002</LINK>, the median was assumed for the mean for continuous beneficial outcomes.</P>
<P>We conducted sensitivity analyses to check the robustness of the estimates to these imputations.</P>
<P>For continuous outcomes, we calculated the mean difference (MD) based on the number of patients analysed at that time point. When the number of patients analysed was not presented for each time point, we used the number of randomized patients in each group at baseline.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2015-03-25 08:17:16 -0400" MODIFIED_BY="[Empty name]">
<P>Both network meta-analysis and traditional meta-analysis require studies to be sufficiently similar in order to pool their results. As a result, we carefully assessed heterogeneity across trials in terms of patient characteristics, trial methodologies, and treatment protocols across trials.</P>
<P>As outlined in the papers by <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1501141409334549802846534978195&amp;format=REVMAN#REF-Bucher-1997">Bucher 1997</A> and <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1501141409334549802846534978195&amp;format=REVMAN#REF-Song-2009">Song 2009</A>, there are several key assumptions that must be met when undertaking indirect comparisons. Song breaks these assumptions into three components: i.homogeneity; ii. similarity of trial; iii. consistency of evidence. Homogeneity refers to the standard assumptions used for pooling studies in a meta-analysis; ie. trials comparing two treatments must be both clinically and methodologically similar to be combined. Trial similarity is comprised of clinical similarity and methodological similarity and the similarity of the bridging treatment. By 'bridging treatment' we mean the common comparator (ie. in a trial of A versus C and B versus C, the bridging treatment is 'C'). The assumption of consistency means that the results of direct and indirect evidence should not be heterogeneous and that there is a consistent effect across the direct comparisons.</P>
<P>To ensure that the consistency assumption is valid, we formally assessed inconsistency by comparing the deviance and deviance information criterion statistics of the consistency and inconsistency models (<LINK REF="REF-Dias-2010" TYPE="REFERENCE">Dias 2010</LINK>; <LINK REF="REF-Dias-2011c" TYPE="REFERENCE">Dias 2011c</LINK>). To help identify the loops in which inconsistency was present, we plotted the posterior mean deviance of the individual data points in the inconsistency model against their posterior mean deviance in the consistency model (<LINK REF="REF-Dias-2010" TYPE="REFERENCE">Dias 2010</LINK>). Using the plots, loops in which inconsistency is present could be identified.</P>
<P>In the standard Review Manager 5 meta-analyses, we tested heterogeneity of the data by visual inspection of the forest plots and by using the I<SUP>2</SUP> statistic (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). A value greater than 50% may be considered substantial heterogeneity.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2015-03-22 04:51:08 -0400" MODIFIED_BY="[Empty name]">
<P>We visually inspected funnel plots to assess publication bias when there were more than 10 included studies for an outcome; however, this applied to only two outcomes: the pooled results for all anti-TNF agents versus placebo for withdrawals due to adverse events and serious adverse events.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2015-03-26 04:59:37 -0400" MODIFIED_BY="[Empty name]">
<P>We combined data in a meta-analyses only when we decided it was meaningful to do so, i.e. when the treatments, participants and the underlying clinical question were similar enough for pooling to make sense. We planned to analyze and present separately 'short-term' outcomes ( less than or equal to 6 months duration) and 'long-term' outcomes ( greater than 6 months). However, all included studies were short-term.</P>
<P>We made a post-hoc decision to present the results combined for etanercept trials which used either 25 mg administered twice a week or 50 mg administered once a week. The results from the <LINK REF="STD-van-der-Heijde-2006b" TYPE="STUDY">van der Heijde 2006b</LINK> study showed these dosing regimens to be equivalent in both benefit and safety. We also pooled infliximab doses of 3 mg/kg and 5 mg/kg together as there was very little heterogeneity when the major outcomes for these two doses were pooled together in a standard meta-analyses.</P>
<P>
<U>Methods for direct treatment comparisons</U>
</P>
<P>We conducted a pooled analyses in RevMan5 for all the included anti-TNF inhibitors to assess for a class-effect of harms of anti-TNF agents. We used the Peto OR statistic which uses a fixed-effect model because the data consisted of rare events (&lt; 10%). Although not specified a priori, we decided to perform a sensitivity analysis using the Mantel-Haenszel OR method with a standard continuity correction of 0.5 on those meta-analyses in which we had used the Peto OR to check the robustness of our results (as recommended by <LINK REF="REF-Sweeting-2004" TYPE="REFERENCE">Sweeting 2004</LINK>).</P>
<P>
<U>Methods for indirect and mixed comparisons</U>
</P>
<P>Our primary analysis presents refined placebo estimates for the major outcomes ASAS40, partial remission, withdrawals due to AE, SAE and BASFI for each of the biologics using the network meta-analysis methods described below. Using a Bayesian framework, the mixed treatment comparison (MTC) method provides a refined estimate of the treatment effect by combining the information from the direct and indirect data to strengthen the precision of the estimate of effect. This methodology utilizes techniques to preserve the randomisation inherent in the RCTs. It avoids the &#8220;naive&#8221; method of pooling the results across trials from the different treatment arms of interest and then comparing the results of treatment A versus treatment B versus treatment C. This naive method ignores the randomisation that was present in the original RCTs and introduces biases expected in an observational cohort (i.e. potential confounders are no longer likely to be randomly distributed between the treatment groups) (<LINK REF="REF-Bucher-1997" TYPE="REFERENCE">Bucher 1997</LINK>; <LINK REF="REF-Wells-2009" TYPE="REFERENCE">Wells 2009</LINK>).</P>
<P>We used WinBUGS software (MRC Biostatistics Unit, Cambridge, UK) to conduct the Bayesian mixed treatment comparison meta-analysis using a binomial likelihood model for dichotomous outcomes or a normal likelihood model for continuous outcomes which allows for the use of multi-arm trials (<LINK REF="REF-Dias-2011a" TYPE="REFERENCE">Dias 2011a</LINK>; <LINK REF="REF-Dias-2011b" TYPE="REFERENCE">Dias 2011b</LINK>; <LINK REF="REF-Spiegelhalter-2003" TYPE="REFERENCE">Spiegelhalter 2003</LINK>) and used the placebo as the reference group. We assigned vague priors, such as N(0, 100<SUP>2</SUP>), for basic parameters of the treatment effects in the model (<LINK REF="REF-Dias-2011b" TYPE="REFERENCE">Dias 2011b</LINK>) and considered informative priors for the variance parameter in the random-effects model (<LINK REF="REF-Turner-2005" TYPE="REFERENCE">Turner 2005</LINK>). To ensure convergence was reached, we assessed trace plots and the Brooks-Gelman-Rubin statistic (<LINK REF="REF-Spiegelhalter-2003" TYPE="REFERENCE">Spiegelhalter 2003</LINK>). Three chains were fit in WinBUGS for each analysis, with at least 10,000 iterations, and a burn-in of at least 10,000 iterations (<LINK REF="REF-Ades-2008" TYPE="REFERENCE">Ades 2008</LINK>; <LINK REF="REF-Spiegelhalter-2003" TYPE="REFERENCE">Spiegelhalter 2003</LINK>).</P>
<P>We conducted both fixed-effect and random-effects network meta-analyses; we assessed the deviance information criterion and compared the residual deviance to the number of unconstrained data points to assess model fit and determine the choice of model (<LINK REF="REF-Dias-2011a" TYPE="REFERENCE">Dias 2011a</LINK>; <LINK REF="REF-Dias-2011b" TYPE="REFERENCE">Dias 2011b</LINK>; <LINK REF="REF-Spiegelhalter-2003" TYPE="REFERENCE">Spiegelhalter 2003</LINK>). For all analyses, the deviance information criterion and residual deviance for both models were close to each other. We used the random-effects model as the primary results, as this model takes into consideration between-study variation, whereas fixed-effect models assume all the trials are estimating the same treatment effect (<LINK REF="REF-Cooper-2009" TYPE="REFERENCE">Cooper 2009</LINK>; <LINK REF="REF-Dias-2011b" TYPE="REFERENCE">Dias 2011b</LINK>).</P>
<P>For the continuous outcome, we derived mean and standard deviation for mean difference (MD) using Markov Chain Monte Carlo methods. We assigned vague priors for both basic parameters and the variance parameter in the models.</P>
<SUBSECTION>
<HEADING LEVEL="4">Summary of Findings table</HEADING>
<P>We compiled 'Summary of findings' tables using GRADEpro (<LINK REF="REF-GRADEpro-2014" TYPE="REFERENCE">GRADEpro 2014</LINK>) to improve the readability of the review. The outcomes included in the 'Summary of findings' table are: ASAS40, ASAS partial remission, BASFI, MRI, radiographic progression, withdrawals due to adverse events, and serious adverse events.</P>
<P>For dichotomous outcomes, we calculated the number needed to treat (NNT) from the control group event rate and the risk ratio using the Visual Rx NNT calculator (<LINK REF="REF-Cates-2008" TYPE="REFERENCE">Cates 2008</LINK>). We calculated the corresponding risk as per the GRADEPro Help file (<LINK REF="REF-Sch_x00fc_nemann-2009" TYPE="REFERENCE">Schünemann 2009</LINK>): Risk (per 1000 people) = 1000 × assumed control risk × risk ratio (RR). We obtained the assumed control risk from the placebo estimate in the network meta-analysis. The absolute increased benefit or harm and 95% CI was calculated as the corresponding risk minus the assumed control risk. The relative percentage change was calculated as the RR-1.<BR/>
</P>
<P>For continuous outcomes, we calculated the NNT for the continuous measures of BASFI using the Wells calculator (available at the Cochrane Musculoskeletal Group editorial office). We used a minimally clinically important improvement of 0.7 points on a 0 to 10 scale as per the findings of <LINK REF="REF-Pavy-2005" TYPE="REFERENCE">Pavy 2005</LINK>. We calculated the absolute benefit as the improvement in the intervention group minus the improvement in the control group, in the original units. We calculated relative percentage change as the absolute benefit divided by the control event rate.</P>
<P>We used the GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the quality of a body of evidence as it relates to the studies which contribute data to the meta-analyses for the prespecified outcomes. We used the methods and recommendations described in Section 8.5, 8.7, Chapter 11, and Section 13.5 of the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>; <LINK REF="REF-Sch_x00fc_nemann-2011" TYPE="REFERENCE">Schünemann 2011</LINK>) using GRADEpro software. We provided footnotes to justify all decisions to down- or up-grade the quality of studies.</P>
</SUBSECTION>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2015-02-22 22:40:52 -0500" MODIFIED_BY="[Empty name]">
<P>We planned the following subgroup analyses a priori in order to explore possible effect size differences.</P>
<OL>
<LI>Intervention - different dose; trial duration.</LI>
<LI>Characteristics of participants - different ankylosing spondylitis classification criteria; severity of baseline disease (based on BASDAI, BASFI); age; disease duration; sex; with or without peripheral joint involvement.</LI>
</OL>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2015-02-22 23:04:53 -0500" MODIFIED_BY="[Empty name]">
<P>We prespecified sensitivity analysis to assess the effect of study quality (proper generation of randomisation sequence, and adequate allocation concealment and blinding) on the overall estimates of effect.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2015-03-26 05:00:56 -0400" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2015-03-26 04:59:48 -0400" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2015-03-12 10:22:27 -0400" MODIFIED_BY="[Empty name]">
<P>January 2009: The search of the electronic databases listed in the methods section for RCTs resulted in 2445 records. After de-duplication, there were 1644 records left to screen. We assessed a total of 60 records in depth to see if they met the inclusion criteria. We included two additional articles from handsearching European League Against Rheumatism (EULAR) abstracts on their website.</P>
<P>After assessing all the records, we included 14 trials, with 24 published articles (either abstracts or full-text articles) related to those trials. The additional articles related to a trial are listed as secondary references in the reference section.</P>
<P>Updated search May 2012: The search of the electronic databases listed in the methods section for RCTs resulted in 1686 records. After de-duplication, there were 1483 records left to screen. We assessed seven records to see if they met the inclusion criteria. We did not conduct any handsearching since American College of Rheumatology (ACR) and EULAR conference abstracts were indexed electronically. We added three new studies.</P>
<P>Updated search October 2013: This search also included a search for golimumab from database inception as well as an update of the original search. After de-duplication, we screened 499 records. We assessed four articles in depth and identified three new studies.</P>
<P>An update from the McMaster PLUS database in June 2014 alerted us to one new study and the full-text publication of a previously included abstract.</P>
<P>A search of clinicaltrials.gov (https://clinicaltrials.gov/) in October 2014 found 89 records, but we did not identify any new completed trials.</P>
<P>A flow chart of the search results is provided in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.<BR/>
</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2015-03-26 04:59:48 -0400" MODIFIED_BY="[Empty name]">
<P>Further details on each included study are available in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.</P>
<P>Twenty-one RCTs met the inclusion criteria with a total of 3308 participants. One thousand and twelve people received etanercept in 10 studies (<LINK REF="STD-Barkham-2010" TYPE="STUDY">Barkham 2010</LINK>; <LINK REF="STD-Brandt-2003" TYPE="STUDY">Brandt 2003</LINK>; <LINK REF="STD-Braun-2011" TYPE="STUDY">Braun 2011</LINK>; <LINK REF="STD-Calin-2004" TYPE="STUDY">Calin 2004</LINK>; <LINK REF="STD-Davis-2003" TYPE="STUDY">Davis 2003</LINK>; <LINK REF="STD-Dougados-2011" TYPE="STUDY">Dougados 2011</LINK>; <LINK REF="STD-Gorman-2002" TYPE="STUDY">Gorman 2002</LINK>; <LINK REF="STD-Giardina-2009" TYPE="STUDY">Giardina 2009</LINK>, <LINK REF="STD-Huang-2008" TYPE="STUDY">Huang 2008</LINK>; <LINK REF="STD-Navarro_x002d_Sarabia-2011" TYPE="STUDY">Navarro-Sarabia 2011</LINK>; <LINK REF="STD-van-der-Heijde-2006b" TYPE="STUDY">van der Heijde 2006b</LINK>); 327 people received infliximab in 5 studies (<LINK REF="STD-Braun-2002" TYPE="STUDY">Braun 2002</LINK>;<LINK REF="STD-Giardina-2009" TYPE="STUDY">Giardina 2009</LINK>; <LINK REF="STD-Inman-2010" TYPE="STUDY">Inman 2010</LINK>; <LINK REF="STD-van-der-Heijde-2005" TYPE="STUDY">van der Heijde 2005</LINK>) (28 in combination with methotrexate (<LINK REF="STD-Marzo_x002d_Ortega-2005" TYPE="STUDY">Marzo-Ortega 2005</LINK>); 501 received adalimumab in 4 studies (<LINK REF="STD-Hu-2012" TYPE="STUDY">Hu 2012</LINK>; <LINK REF="STD-Huang-2014" TYPE="STUDY">Huang 2014</LINK>; <LINK REF="STD-Lambert-2007" TYPE="STUDY">Lambert 2007</LINK>; <LINK REF="STD-van-der-Heijde-2006a" TYPE="STUDY">van der Heijde 2006a</LINK>); 246 received golimumab in 2 studies (<LINK REF="STD-Bao-2014" TYPE="STUDY">Bao 2014</LINK>; <LINK REF="STD-Inman-2008" TYPE="STUDY">Inman 2008</LINK>). One study was an open-label head-to-head study of etanercept (N = 25) and infliximab (N = 25) (<LINK REF="STD-Giardina-2009" TYPE="STUDY">Giardina 2009</LINK>).</P>
<P>Eighteen RCTs contributed data to the mixed treatment comparison analysis: adalimumab (4 studies; <LINK REF="STD-Hu-2012" TYPE="STUDY">Hu 2012</LINK>; <LINK REF="STD-Huang-2014" TYPE="STUDY">Huang 2014</LINK>; <LINK REF="STD-Lambert-2007" TYPE="STUDY">Lambert 2007</LINK>; <LINK REF="STD-van-der-Heijde-2006a" TYPE="STUDY">van der Heijde 2006a</LINK>), etanercept (8 studies; <LINK REF="STD-Barkham-2010" TYPE="STUDY">Barkham 2010</LINK>; <LINK REF="STD-Brandt-2003" TYPE="STUDY">Brandt 2003</LINK>; <LINK REF="STD-Calin-2004" TYPE="STUDY">Calin 2004</LINK>; <LINK REF="STD-Davis-2003" TYPE="STUDY">Davis 2003</LINK>; <LINK REF="STD-Dougados-2011" TYPE="STUDY">Dougados 2011</LINK>; <LINK REF="STD-Gorman-2002" TYPE="STUDY">Gorman 2002</LINK>; <LINK REF="STD-Huang-2008" TYPE="STUDY">Huang 2008</LINK>; <LINK REF="STD-van-der-Heijde-2006b" TYPE="STUDY">van der Heijde 2006b</LINK>), golimumab; 2 studies (<LINK REF="STD-Bao-2014" TYPE="STUDY">Bao 2014</LINK>; <LINK REF="STD-Inman-2008" TYPE="STUDY">Inman 2008</LINK>), infliximab (3 studies; <LINK REF="STD-Braun-2002" TYPE="STUDY">Braun 2002</LINK>; <LINK REF="STD-Inman-2010" TYPE="STUDY">Inman 2010</LINK>; <LINK REF="STD-van-der-Heijde-2005" TYPE="STUDY">van der Heijde 2005</LINK>)) and one head-to-head study of etanercept to infliximab (<LINK REF="STD-Giardina-2009" TYPE="STUDY">Giardina 2009</LINK>).<BR/>
</P>
<SUBSECTION>
<HEADING LEVEL="4">Additional data</HEADING>
<P>We received additional data from the trial authors for the following studies: <LINK REF="STD-Brandt-2003" TYPE="STUDY">Brandt 2003</LINK>, <LINK REF="STD-Braun-2002" TYPE="STUDY">Braun 2002</LINK>, <LINK REF="STD-Calin-2004" TYPE="STUDY">Calin 2004</LINK>, and <LINK REF="STD-Davis-2003" TYPE="STUDY">Davis 2003</LINK> (though we were unable to use data from <LINK REF="STD-Davis-2003" TYPE="STUDY">Davis 2003</LINK> since variance was not provided in the additional information received). This was mainly to obtain data on clinical endpoints where the published results for continuous outcomes had been reported as a statistic different from the mean and SD which is required for entry into Review Manager 5. We also sought additional details to clarify risk of bias items for some studies (<LINK REF="STD-Davis-2003" TYPE="STUDY">Davis 2003</LINK>; <LINK REF="STD-van-der-Heijde-2006a" TYPE="STUDY">van der Heijde 2006a</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Participants</HEADING>
<P>The majority of participants were Caucasian males in their early forties. The percentage of male participants in the treatment groups ranged between 65% to 80%, and 74% to 100% in the control groups. The mean age ranged from 38 to 45 years in the treatment groups and 39 to 47 years in the control groups. Between 75% and 98% of the participants in the treatment groups were Causasian with a similar distribution in the control groups (70% to 97%).</P>
<P>The mean disease duration in the treatment groups ranged from 8 to 16 years, and 10 to 17 years in the control groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interventions</HEADING>
<P>
<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> summarizes the concomitant therapy permitted in each study.</P>
<SUBSECTION>
<HEADING LEVEL="5">Adalimumab</HEADING>
<P>Four studies assessed adalimumab at a dose of 40 mg every other week subcutaneously. <LINK REF="STD-Lambert-2007" TYPE="STUDY">Lambert 2007</LINK> and <LINK REF="STD-van-der-Heijde-2006a" TYPE="STUDY">van der Heijde 2006a</LINK> at 40 mg every other week for a 24-week double-blind period, though an early escape option was available after week 12. Both <LINK REF="STD-Hu-2012" TYPE="STUDY">Hu 2012</LINK> and <LINK REF="STD-Huang-2014" TYPE="STUDY">Huang 2014</LINK> had a 12-week double-blind phase.</P>
<SUBSECTION>
<HEADING LEVEL="6">Concomitant therapy</HEADING>
<P>
<LINK REF="STD-Lambert-2007" TYPE="STUDY">Lambert 2007</LINK> did not mention concomitant therapy. In <LINK REF="STD-van-der-Heijde-2006a" TYPE="STUDY">van der Heijde 2006a</LINK>, patients were allowed to continue sulphasalazine (3 g/day), methotrexate (25 mg/week), hydroxychloroquine (400 mg/day), prednisone or prednisone equivalent (10 mg/day), and NSAIDs, if the dose had remained stable for at least 4 weeks before the baseline visit. In <LINK REF="STD-Hu-2012" TYPE="STUDY">Hu 2012</LINK> and <LINK REF="STD-Huang-2014" TYPE="STUDY">Huang 2014</LINK>, concomitant use of methotrexate (&#8806; 25 mg/week), sulphasalazine (&#8806; 3 g/day), prednisone (&#8806; 10 mg/day), NSAIDs and/or analgesics was allowed but dose adjustments, induction and/or discontinuation of these therapies was not permitted.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Etanercept</HEADING>
<P>Four RCTs assessed etanercept at a dose of 25 mg twice weekly, delivered subcutaneously against placebo (<LINK REF="STD-Barkham-2010" TYPE="STUDY">Barkham 2010</LINK>; <LINK REF="STD-Brandt-2003" TYPE="STUDY">Brandt 2003</LINK>; <LINK REF="STD-Calin-2004" TYPE="STUDY">Calin 2004</LINK>; <LINK REF="STD-Davis-2003" TYPE="STUDY">Davis 2003</LINK>; <LINK REF="STD-Gorman-2002" TYPE="STUDY">Gorman 2002</LINK>). <LINK REF="STD-van-der-Heijde-2006b" TYPE="STUDY">van der Heijde 2006b</LINK> assessed 50 mg once weekly versus 25 mg twice weekly versus placebo. <LINK REF="STD-Huang-2008" TYPE="STUDY">Huang 2008</LINK> used 50 mg once weekly versus placebo. <LINK REF="STD-Navarro_x002d_Sarabia-2011" TYPE="STUDY">Navarro-Sarabia 2011</LINK> assessed a high dose, 50 mg twice weekly, against the standard dose of 50 mg once weekly. <LINK REF="STD-Dougados-2011" TYPE="STUDY">Dougados 2011</LINK> assessed the effect of etanercept 50 mg once weekly against placebo in participants with advanced ankylosing spondylitis. <LINK REF="STD-Braun-2011" TYPE="STUDY">Braun 2011</LINK> compared 50 mg once weekly to 3 g daily of sulphasalazine. The length of treatment ranged from 6 weeks (<LINK REF="STD-Brandt-2003" TYPE="STUDY">Brandt 2003</LINK> and <LINK REF="STD-Huang-2008" TYPE="STUDY">Huang 2008</LINK>) to 24 weeks (<LINK REF="STD-Davis-2003" TYPE="STUDY">Davis 2003</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="6">Concomitant therapy</HEADING>
<P>
<LINK REF="STD-Brandt-2003" TYPE="STUDY">Brandt 2003</LINK> allowed NSAIDs at the same or less dose at baseline; <LINK REF="STD-Calin-2004" TYPE="STUDY">Calin 2004</LINK> allowed pre-study physiotherapy; <LINK REF="STD-Davis-2003" TYPE="STUDY">Davis 2003</LINK>; <LINK REF="STD-Gorman-2002" TYPE="STUDY">Gorman 2002</LINK> and <LINK REF="STD-van-der-Heijde-2006b" TYPE="STUDY">van der Heijde 2006b</LINK> allowed stable doses of disease-modifying anti-rheumatic drugs, NSAIDs, and oral corticosteroids; <LINK REF="STD-Huang-2008" TYPE="STUDY">Huang 2008</LINK> allowed stable disease-modifying anti-rheumatic drug doses; <LINK REF="STD-Barkham-2010" TYPE="STUDY">Barkham 2010</LINK> allowed stable doses of disease-modifying anti-rheumatic drugs sulphasalazine or methotrexate and/or a NSAID for the duration, but not corticosteroids.<BR/>
</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Golimumab</HEADING>
<P>Two studies assessed subcutaneous golimumab at a dose of 50 mg every 4 weeks (<LINK REF="STD-Bao-2014" TYPE="STUDY">Bao 2014</LINK>; <LINK REF="STD-Inman-2008" TYPE="STUDY">Inman 2008</LINK>). Both had a 24-week double-blind phase and an early escape option after week 16.</P>
<SUBSECTION>
<HEADING LEVEL="6">Concomitant therapy</HEADING>
<P>In <LINK REF="STD-Bao-2014" TYPE="STUDY">Bao 2014</LINK> and <LINK REF="STD-Inman-2008" TYPE="STUDY">Inman 2008</LINK>, patients were allowed to continue concurrent treatment with stable doses of methotrexate, sulphasalazine, and hydroxychloroquine. In <LINK REF="STD-Inman-2008" TYPE="STUDY">Inman 2008</LINK>, stable doses of corticosteroids, and NSAIDs were also allowed.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Infliximab</HEADING>
<P>Four RCTs assessed infliximab; <LINK REF="STD-Braun-2002" TYPE="STUDY">Braun 2002</LINK> assessed infliximab at 5 mg/kg intravenously at weeks 0, 2, and 6. <LINK REF="STD-van-der-Heijde-2005" TYPE="STUDY">van der Heijde 2005</LINK> delivered this same dose of infliximab at weeks 0, 2, 6, 12 and 18 weeks. <LINK REF="STD-Inman-2010" TYPE="STUDY">Inman 2010</LINK> evaluated infliximab at 3 mg/kg delivered at weeks 0, 2, and 6. <LINK REF="STD-Marzo_x002d_Ortega-2005" TYPE="STUDY">Marzo-Ortega 2005</LINK> assessed infliximab (5 mg/kg) in combination with methotrexate against placebo plus methotrexate.</P>
<SUBSECTION>
<HEADING LEVEL="6">Concomitant therapy</HEADING>
<P>In both <LINK REF="STD-Braun-2002" TYPE="STUDY">Braun 2002</LINK> and <LINK REF="STD-van-der-Heijde-2005" TYPE="STUDY">van der Heijde 2005</LINK>, patients were allowed to continue on stable doses of NSAIDs. It appears concomitant therapy of NSAIDs, corticosteroids, analgesics, and disease-modifying anti-rheumatic drugs were allowed as long as doses remained stable in the <LINK REF="STD-Inman-2010" TYPE="STUDY">Inman 2010</LINK> study. <LINK REF="STD-Marzo_x002d_Ortega-2005" TYPE="STUDY">Marzo-Ortega 2005</LINK> allowed concomitant use of NSAIDs or oral corticosteroids.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes</HEADING>
<P>All studies used the outcomes recommended by the Assessment of SpondyloArthritis international Society. The primary outcome in two studies was the BASDAI &#8805; 50% (<LINK REF="STD-Brandt-2003" TYPE="STUDY">Brandt 2003</LINK>; <LINK REF="STD-Braun-2002" TYPE="STUDY">Braun 2002</LINK>) and the ASAS20 in 14 studies (<LINK REF="STD-Bao-2014" TYPE="STUDY">Bao 2014</LINK>; <LINK REF="STD-Braun-2011" TYPE="STUDY">Braun 2011</LINK>; <LINK REF="STD-Calin-2004" TYPE="STUDY">Calin 2004</LINK>; <LINK REF="STD-Davis-2003" TYPE="STUDY">Davis 2003</LINK>; <LINK REF="STD-Gorman-2002" TYPE="STUDY">Gorman 2002</LINK>; <LINK REF="STD-Huang-2008" TYPE="STUDY">Huang 2008</LINK>; <LINK REF="STD-Huang-2014" TYPE="STUDY">Huang 2014</LINK>; <LINK REF="STD-Inman-2008" TYPE="STUDY">Inman 2008</LINK>; <LINK REF="STD-Inman-2010" TYPE="STUDY">Inman 2010</LINK>; <LINK REF="STD-Lambert-2007" TYPE="STUDY">Lambert 2007</LINK>; <LINK REF="STD-Navarro_x002d_Sarabia-2011" TYPE="STUDY">Navarro-Sarabia 2011</LINK>; <LINK REF="STD-van-der-Heijde-2005" TYPE="STUDY">van der Heijde 2005</LINK>; <LINK REF="STD-van-der-Heijde-2006a" TYPE="STUDY">van der Heijde 2006a</LINK>; <LINK REF="STD-van-der-Heijde-2006b" TYPE="STUDY">van der Heijde 2006b</LINK>). The change in BASDAI score was the primary outcome in <LINK REF="STD-Marzo_x002d_Ortega-2005" TYPE="STUDY">Marzo-Ortega 2005</LINK>.</P>
<P>In <LINK REF="STD-Dougados-2011" TYPE="STUDY">Dougados 2011</LINK>, the primary outcome was the area under the curve in the BASDAI between baseline and week 12.</P>
<P>In <LINK REF="STD-Barkham-2010" TYPE="STUDY">Barkham 2010</LINK>, the primary outcome was a change in the work instability of patients after three months, as measured by the Ankylosing Spondylitis Work Instability Scale.</P>
<P>In the abstract of <LINK REF="STD-Giardina-2009" TYPE="STUDY">Giardina 2009</LINK>, the primary outcome was stated to be the proportion of patients achieving a 50% BASDAI response at week 102; Secondary: ASAS50; BASFI, back pain, morning stiffness, C-reactive protein, and spinal mobility. However, in the full-text article, the outcome defined as primary is not stated, and the 50% BASDAI response is not reported. ASAS20, ASAS40, BASDAI, BASFI, and adverse events were reported.</P>
<P>
<LINK REF="STD-Hu-2012" TYPE="STUDY">Hu 2012</LINK> did not state a primary outcome. Clinical outcomes like BASDAI and BASFI were reported along with lab measures (C-reactive protein and serum DKK-1) and imaging (MRI of both the lumbar spine and sacroiliac joints).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Source of funding</HEADING>
<P>A total of 17 studies reported some type of industry sponsorship.</P>
<P>
<LINK REF="STD-van-der-Heijde-2005" TYPE="STUDY">van der Heijde 2005</LINK> was supported by Centocor. <LINK REF="STD-Braun-2002" TYPE="STUDY">Braun 2002</LINK> was funded by a grant from the German Minstry of Research and by Essex Pharma who provided the study drug. <LINK REF="STD-Inman-2010" TYPE="STUDY">Inman 2010</LINK> did not report the funding source in the abstracts but the trial protocol states the study was sponsored by Schering-Plough. <LINK REF="STD-Marzo_x002d_Ortega-2005" TYPE="STUDY">Marzo-Ortega 2005</LINK> reported that the study was supported by a grant in aid from Schering-Plough, UK.</P>
<P>
<LINK REF="STD-Brandt-2003" TYPE="STUDY">Brandt 2003</LINK> was supported by a grant from the German Minstry of Research and by Wyeth Pharma who provided the study drug. <LINK REF="STD-Calin-2004" TYPE="STUDY">Calin 2004</LINK> was funded by Wyeth Research. <LINK REF="STD-Gorman-2002" TYPE="STUDY">Gorman 2002</LINK> was funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases and Immunex. The trial report states that Immunex was "not involved in the study design, data collection, statistical analysis, or manuscript preparation". <LINK REF="STD-Davis-2003" TYPE="STUDY">Davis 2003</LINK> was supported by Immunex Corporation. <LINK REF="STD-van-der-Heijde-2006b" TYPE="STUDY">van der Heijde 2006b</LINK> was supported by Wyeth Pharmaceuticals (study drug and grants to investigational sites) <LINK REF="STD-Braun-2011" TYPE="STUDY">Braun 2011</LINK> and <LINK REF="STD-Dougados-2011" TYPE="STUDY">Dougados 2011</LINK> were also supported by Wyeth, which was acquired by Pfzier in 2009. <LINK REF="STD-Navarro_x002d_Sarabia-2011" TYPE="STUDY">Navarro-Sarabia 2011</LINK> was supported by Pfizer.</P>
<P>
<LINK REF="STD-van-der-Heijde-2006a" TYPE="STUDY">van der Heijde 2006a</LINK> and <LINK REF="STD-Lambert-2007" TYPE="STUDY">Lambert 2007</LINK> were sponsored by Abbott Laboratories. <LINK REF="STD-Huang-2014" TYPE="STUDY">Huang 2014</LINK> was sponsored by AbbVie.</P>
<P>
<LINK REF="STD-Bao-2014" TYPE="STUDY">Bao 2014</LINK> was funded by Janssen Research and Development. <LINK REF="STD-Inman-2008" TYPE="STUDY">Inman 2008</LINK> was supported by Centocor Research and Development, Inc. and the Schering-Plough Research Institute, Inc.</P>
<P>
<LINK REF="STD-Barkham-2010" TYPE="STUDY">Barkham 2010</LINK>, <LINK REF="STD-Giardina-2009" TYPE="STUDY">Giardina 2009</LINK>, <LINK REF="STD-Hu-2012" TYPE="STUDY">Hu 2012</LINK>, and <LINK REF="STD-Huang-2008" TYPE="STUDY">Huang 2008</LINK> did not list any source of funding.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2015-03-23 07:40:24 -0400" MODIFIED_BY="[Empty name]">
<P>We excluded 6 studies after assessing the full-text articles. The <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table provides more details for the exclusions. Briefly, the participants in three studies (<LINK REF="STD-Barkham-2008b" TYPE="STUDY">Barkham 2008b;</LINK> <LINK REF="STD-Breban-2008" TYPE="STUDY">Breban 2008</LINK>; <LINK REF="STD-Haibel-2008" TYPE="STUDY">Haibel 2008</LINK>) did not meet the review's inclusion criteria; the intervention in <LINK REF="STD-Li-2008" TYPE="STUDY">Li 2008</LINK> assesses the effect of methotrexate, not infliximab; and there is no separate information provided for ankylosing spondylitis patients in <LINK REF="STD-Van-den-Bosch-2002" TYPE="STUDY">Van den Bosch 2002</LINK> (and we were unable to obtain this from the author). <LINK REF="STD-Morency-2011" TYPE="STUDY">Morency 2011</LINK> provided data on the open-label extension results of an included study.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2015-03-25 09:15:58 -0400" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> provides a graphical summary of the risk of bias of the included studies.</P>
<P>We received additional information from study authors on methodology and data for <LINK REF="STD-Davis-2003" TYPE="STUDY">Davis 2003</LINK>, <LINK REF="STD-Gorman-2002" TYPE="STUDY">Gorman 2002</LINK>, and <LINK REF="STD-van-der-Heijde-2006a" TYPE="STUDY">van der Heijde 2006a</LINK>.</P>
<P>
<LINK REF="STD-Huang-2008" TYPE="STUDY">Huang 2008</LINK> was reported as an abstract, and did not provide enough information to make a judgement about risk of bias, and so was judged as 'unclear'.</P>
<SUBSECTION>
<HEADING LEVEL="3">Sequence generation</HEADING>
<P>
<LINK REF="STD-Bao-2014" TYPE="STUDY">Bao 2014</LINK>, <LINK REF="STD-Barkham-2010" TYPE="STUDY">Barkham 2010</LINK>, <LINK REF="STD-Calin-2004" TYPE="STUDY">Calin 2004</LINK>, <LINK REF="STD-Dougados-2011" TYPE="STUDY">Dougados 2011</LINK>, <LINK REF="STD-Giardina-2009" TYPE="STUDY">Giardina 2009</LINK>, <LINK REF="STD-Hu-2012" TYPE="STUDY">Hu 2012</LINK>, <LINK REF="STD-Inman-2010" TYPE="STUDY">Inman 2010</LINK>, <LINK REF="STD-Lambert-2007" TYPE="STUDY">Lambert 2007</LINK>, <LINK REF="STD-van-der-Heijde-2005" TYPE="STUDY">van der Heijde 2005</LINK>, and <LINK REF="STD-van-der-Heijde-2006b" TYPE="STUDY">van der Heijde 2006b</LINK> did not provide any information regarding sequence generation, and so the judgement was 'unclear'. The 10 other studies provided evidence of appropriate generation of the randomisation sequence.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Allocation</HEADING>
<P>
<LINK REF="STD-Bao-2014" TYPE="STUDY">Bao 2014</LINK>, <LINK REF="STD-Barkham-2010" TYPE="STUDY">Barkham 2010</LINK>, <LINK REF="STD-Calin-2004" TYPE="STUDY">Calin 2004</LINK>, <LINK REF="STD-Dougados-2011" TYPE="STUDY">Dougados 2011</LINK>, <LINK REF="STD-Giardina-2009" TYPE="STUDY">Giardina 2009</LINK>, <LINK REF="STD-Inman-2010" TYPE="STUDY">Inman 2010</LINK>, <LINK REF="STD-Hu-2012" TYPE="STUDY">Hu 2012</LINK>, <LINK REF="STD-Lambert-2007" TYPE="STUDY">Lambert 2007</LINK>, <LINK REF="STD-Navarro_x002d_Sarabia-2011" TYPE="STUDY">Navarro-Sarabia 2011</LINK>, <LINK REF="STD-van-der-Heijde-2005" TYPE="STUDY">van der Heijde 2005</LINK>, and <LINK REF="STD-van-der-Heijde-2006b" TYPE="STUDY">van der Heijde 2006b</LINK> did not provide information regarding the method of allocation concealment. The nine other studies provided evidence of appropriate concealment of allocation of the randomisation sequence. 
<BR/>

</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Blinding of patient assessed outcomes</HEADING>
<P>
<LINK REF="STD-Barkham-2010" TYPE="STUDY">Barkham 2010</LINK>, <LINK REF="STD-Braun-2002" TYPE="STUDY">Braun 2002</LINK>, <LINK REF="STD-Braun-2011" TYPE="STUDY">Braun 2011</LINK>, <LINK REF="STD-Brandt-2003" TYPE="STUDY">Brandt 2003</LINK>, <LINK REF="STD-Calin-2004" TYPE="STUDY">Calin 2004</LINK>, <LINK REF="STD-Davis-2003" TYPE="STUDY">Davis 2003</LINK>, <LINK REF="STD-Dougados-2011" TYPE="STUDY">Dougados 2011</LINK>, <LINK REF="STD-Gorman-2002" TYPE="STUDY">Gorman 2002</LINK>, <LINK REF="STD-Huang-2014" TYPE="STUDY">Huang 2014</LINK>, <LINK REF="STD-Inman-2008" TYPE="STUDY">Inman 2008</LINK>, and <LINK REF="STD-van-der-Heijde-2005" TYPE="STUDY">van der Heijde 2005</LINK> reported the patient was blinded. We were unclear about the methods of blinding in <LINK REF="STD-Bao-2014" TYPE="STUDY">Bao 2014</LINK>, <LINK REF="STD-Hu-2012" TYPE="STUDY">Hu 2012</LINK>, <LINK REF="STD-Inman-2010" TYPE="STUDY">Inman 2010</LINK>, <LINK REF="STD-Lambert-2007" TYPE="STUDY">Lambert 2007</LINK>, <LINK REF="STD-Marzo_x002d_Ortega-2005" TYPE="STUDY">Marzo-Ortega 2005</LINK>, <LINK REF="STD-van-der-Heijde-2006a" TYPE="STUDY">van der Heijde 2006a</LINK>, and <LINK REF="STD-van-der-Heijde-2006b" TYPE="STUDY">van der Heijde 2006b</LINK> which were reported only as "double blind". There was no blinding in <LINK REF="STD-Giardina-2009" TYPE="STUDY">Giardina 2009</LINK>, which places it at a high risk of bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Blinding of physician reported outcomes</HEADING>
<P>
<LINK REF="STD-Barkham-2010" TYPE="STUDY">Barkham 2010</LINK>, <LINK REF="STD-Braun-2002" TYPE="STUDY">Braun 2002</LINK>, <LINK REF="STD-Brandt-2003" TYPE="STUDY">Brandt 2003</LINK>, <LINK REF="STD-Davis-2003" TYPE="STUDY">Davis 2003</LINK>, <LINK REF="STD-Gorman-2002" TYPE="STUDY">Gorman 2002</LINK>, <LINK REF="STD-Hu-2012" TYPE="STUDY">Hu 2012</LINK>, <LINK REF="STD-Huang-2014" TYPE="STUDY">Huang 2014</LINK>, <LINK REF="STD-Inman-2008" TYPE="STUDY">Inman 2008</LINK>, <LINK REF="STD-Lambert-2007" TYPE="STUDY">Lambert 2007</LINK>, <LINK REF="STD-van-der-Heijde-2005" TYPE="STUDY">van der Heijde 2005</LINK>, and <LINK REF="STD-van-der-Heijde-2006a" TYPE="STUDY">van der Heijde 2006a</LINK> reported that the investigator was blinded. <LINK REF="STD-Calin-2004" TYPE="STUDY">Calin 2004</LINK> did not specify who other than the patient was blinded and physician/investigator blinding was unclear in <LINK REF="STD-Dougados-2011" TYPE="STUDY">Dougados 2011</LINK>, <LINK REF="STD-Marzo_x002d_Ortega-2005" TYPE="STUDY">Marzo-Ortega 2005</LINK>, and <LINK REF="STD-van-der-Heijde-2006b" TYPE="STUDY">van der Heijde 2006b</LINK>. There was no blinding in <LINK REF="STD-Giardina-2009" TYPE="STUDY">Giardina 2009 </LINK>which places it at a high risk of bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Incomplete outcome data</HEADING>
<P>We judged all trials but five trials to be at low risk of incomplete outcome data bias for beneficial outcomes as there was a low rate of missing data and most conducted an intention-to-treat analysis. Five were judged as unclear.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Selective outcome reporting</HEADING>
<P>We judged most of the trials to be at low risk of selective outcome reporting bias as they reported on outcomes recommended by the Assessment of SpondyloArthritis international Society, with the exception of <LINK REF="STD-Giardina-2009" TYPE="STUDY">Giardina 2009</LINK> and <LINK REF="STD-Hu-2012" TYPE="STUDY">Hu 2012</LINK> which we judged as 'high risk'. In <LINK REF="STD-Giardina-2009" TYPE="STUDY">Giardina 2009</LINK>, the abstract we found first for this trial had the primary outcome listed as the proportion of people achieving a 50% response in BASDAI. However, the full-text article did not report this outcome. We could not find a protocol for this trial. <LINK REF="STD-Hu-2012" TYPE="STUDY">Hu 2012</LINK> did not state their primary outcome nor any adverse event data. In terms of risk of bias for selective adverse event reporting, we judged <LINK REF="STD-Inman-2010" TYPE="STUDY">Inman 2010</LINK> and <LINK REF="STD-Lambert-2007" TYPE="STUDY">Lambert 2007</LINK> as &#8216;unclear&#8217; given the lack of specifics provided on harms data. In <LINK REF="STD-Lambert-2007" TYPE="STUDY">Lambert 2007</LINK>, the primary outcome was reported in an abstract but not in the full-text article.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Method of adverse event monitoring</HEADING>
<P>The following studies stated that the patients were actively monitored (though few details were provided on the specifics of the monitoring) for adverse events. These were judged to be at low risk of bias: <LINK REF="STD-Calin-2004" TYPE="STUDY">Calin 2004</LINK>, <LINK REF="STD-Davis-2003" TYPE="STUDY">Davis 2003</LINK>, <LINK REF="STD-Giardina-2009" TYPE="STUDY">Giardina 2009</LINK>, <LINK REF="STD-Gorman-2002" TYPE="STUDY">Gorman 2002</LINK>, <LINK REF="STD-Huang-2008" TYPE="STUDY">Huang 2008</LINK>, <LINK REF="STD-Navarro_x002d_Sarabia-2011" TYPE="STUDY">Navarro-Sarabia 2011</LINK>, <LINK REF="STD-van-der-Heijde-2005" TYPE="STUDY">van der Heijde 2005</LINK>, <LINK REF="STD-van-der-Heijde-2006a" TYPE="STUDY">van der Heijde 2006a</LINK>, and <LINK REF="STD-van-der-Heijde-2006b" TYPE="STUDY">van der Heijde 2006b</LINK>. The rest of the studies did not mention how the patients were monitored for adverse events and were judged as 'unclear' risk of bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Definition of serious adverse event provided</HEADING>
<P>The following studies used a common grading system, though the specific definition of serious adverse events was not provided in the articles: <LINK REF="STD-Davis-2003" TYPE="STUDY">Davis 2003</LINK>, <LINK REF="STD-Gorman-2002" TYPE="STUDY">Gorman 2002</LINK>, <LINK REF="STD-Inman-2010" TYPE="STUDY">Inman 2010</LINK>; we judged these to be at low risk of bias. <LINK REF="STD-van-der-Heijde-2005" TYPE="STUDY">van der Heijde 2005</LINK> and <LINK REF="STD-van-der-Heijde-2006a" TYPE="STUDY">van der Heijde 2006a</LINK> did not provide general serious adverse events definitions, but each serious adverse event was clearly explained in the published report. The other studies did not report their definition of 'serious adverse events' and we judged them to be at unclear risk of bias.</P>
</SUBSECTION>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2015-03-26 05:00:56 -0400" MODIFIED_BY="[Empty name]">
<P>The review prespecified that outcomes measured at six months or less would assess short-term results and greater than six months would assess long-term results; however, all outcomes in the placebo-controlled trials were reported at six months or less.</P>
<P>
<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK> provides an overview of the mixed treatment comparison refined placebo estimates for the major outcomes of ASAS40, physical function, ASAS partial remission, withdrawals due to adverse events and serious adverse events for the individual biologics and for the class-effect analysis for the two adverse event outcomes. We did not pool data from magnetic resonance imaging and radiographic progression outcomes. <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> shows the network diagram for ASAS40. <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK> and <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK> show the forest plots for the biologic versus placebo and head-to-head mixed treatment comparison estimates for the outcomes ASAS40 and withdrawals due to adverse events, respectively. The pairwise data for the individual trials that was used in the mixed treatment comparison analysis is available in the Data and Analyses section. Trace plots and Brooks&#8211;Gelman&#8211;Rubin statistic indicated convergence of the model in all analyses.</P>
<SUBSECTION>
<HEADING LEVEL="3">Individual biologics</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Adalimumab (40 mg every other week) versus placebo</HEADING>
<P>Four studies assessed the effect of adalimumab versus placebo (<LINK REF="STD-Hu-2012" TYPE="STUDY">Hu 2012</LINK>; <LINK REF="STD-Huang-2014" TYPE="STUDY">Huang 2014</LINK>; <LINK REF="STD-Lambert-2007" TYPE="STUDY">Lambert 2007</LINK>; <LINK REF="STD-van-der-Heijde-2006a" TYPE="STUDY">van der Heijde 2006a</LINK>). <LINK REF="STD-Lambert-2007" TYPE="STUDY">Lambert 2007</LINK> did not report all benefits and adverse events in the published article but they were reported in an abstract and other publications of the same trial (<LINK REF="REF-Maksymowych-2005" TYPE="REFERENCE">Maksymowych 2005</LINK>; <LINK REF="REF-Maksymowych-2008" TYPE="REFERENCE">Maksymowych 2008</LINK>). <LINK REF="STD-Hu-2012" TYPE="STUDY">Hu 2012</LINK> did not report on any adverse outcomes.</P>
<SUBSECTION>
<HEADING LEVEL="5">Major outcomes</HEADING>
<P>
<B>ASAS40</B>: There was high quality evidence that the adalimumab group was more likely than placebo to achieve the ASAS40 criteria (risk ratio (RR) 3.53, 95% credible interval (Crl) 2.49 to 4.91, with an absolute improvement of 33% (95% Crl 19% to 51%) and a NNT = 4 (95% confidence interval (CI) 2 to 6)).</P>
<P>
<B>Physical function (BASFI 0 to 10 scale, lower is better)</B>: There was high quality evidence of a clinically important improvement in physical function (mean difference (MD) -1.6, 95% CrI -2.2 to -0.9), with an absolute increased benefit of -16% (95% Crl -22% to -9%)); relative percentage change from baseline = -32% (95% CrI -44% to -18%); and NNT to achieve the minimally important difference (MCID) of 0.7 points = 4 (95% CI 3 to 5).</P>
<P>
<B>ASAS partial remission</B>: There was moderate quality evidence (downgraded for imprecision) that the adalimumab group was more likely than placebo to meet the criteria for partial remission (RR 6.28, 95% Crl 3.13 to 12.78), with an absolute improvement of 16% (95% Crl 6% to 35%) and a NNT = 7 (95% CI 3 to 16).</P>
<P>
<B>Magnetic resonance imaging (MRI)</B>: There was moderate quality evidence of a small absolute improvement on spinal inflammation with unclear clinical relevance. <LINK REF="STD-Hu-2012" TYPE="STUDY">Hu 2012</LINK> (N = 46) assessed spinal inflammation using the Spondyloarthritis Research Consortium of Canada (SPARCC) scoring method. SPARCC scores for the spine can range from 0 to 108 and SPARCC sacroiliac joint scores can range from 0 to 72. The MD for the lumbar spine was -6.5 (95% CI -13.06 to 0.06), with a small absolute benefit of -6% (95% CI -12% to 0.05%) and relative percentage change = -33% (95% CI -66% to 0%). The MD for the sacroiliac joint was -3.00 (95% CI -7.46 to 1.46).</P>
<P>
<LINK REF="STD-Lambert-2007" TYPE="STUDY">Lambert 2007</LINK> used MRI to assess the effect of adalimumab compared to placebo in reducing spinal and sacroiliac joint inflammation using the SPARCC scoring method. MRIs were obtained for all participants (N = 82) at baseline and week 12. There was high quality evidence of a statistically significantly greater reduction in the mean spine SPARCC score of adalimumab-treated patients (median change 6.3, range 34.0 to 2.0) compared with placebo-treated patients (median change 0.5, range 26.0 to 13.5) (P &lt; 0.001). The mean sacroiliac joint SPARCC score also decreased significantly between the adalimumab (median change 0.5, range 22.5 to 2.5) and placebo groups (median change 0.0, range 13.5 to 16.0) (P &lt; 0.001). In terms of percentage change from baseline, placebo-treated patients had a 9.4% mean increase in spine SPARCC scores compared to a 53.6% mean reduction in scores in adalimumab-treated patients (P &lt; 0.001). There was also a significant difference in the mean percentage reduction in adalimumab (52.9%) and placebo-treated (12.7%) patients in the sacroiliac joint SPARCC score (P = 0.017).</P>
<P>
<B>Radiographic progression:</B> Not reported.</P>
<P>
<B>Withdrawals due to adverse events</B>: Based on moderate quality evidence, we are uncertain of the effect on withdrawals due to adverse events (RR 1.69, 95% CI 0.35 to 10.84) but the absolute numbers were low: 6/437 in the adalimumab group versus 2/222 in the placebo (absolute increased harm = 0.6% (95% Crl -0.4% to 7%); relative percentage change = 69% (95% CI -65% to 984%). We downgraded the evidence due to the low event rates and resulting imprecision.</P>
<P>
<B>Serious adverse events</B>: Based moderate quality evidence, we are uncertain of the effect on serious adverse events (RR 0.92, 95% CI 0.26 to 3.93) but the absolute numbers were low: 7/437 in the adalimumab group versus 4/222 in the placebo (absolute increased harm = -0.2% (95% Crl -1.1% to 4.4%); relative percentage change = -8% (95% CI -74% to 293%)). We downgraded the evidence due to the low event rates and resulting imprecision.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Etanercept (25 mg twice weekly or 50 mg once weekly) versus placebo</HEADING>
<P>Five studies assessed the effect of etanercept 25 mg twice weekly versus placebo (<LINK REF="STD-Barkham-2010" TYPE="STUDY">Barkham 2010</LINK>; <LINK REF="STD-Brandt-2003" TYPE="STUDY">Brandt 2003</LINK>; <LINK REF="STD-Calin-2004" TYPE="STUDY">Calin 2004</LINK>; <LINK REF="STD-Davis-2003" TYPE="STUDY">Davis 2003</LINK>; <LINK REF="STD-Gorman-2002" TYPE="STUDY">Gorman 2002</LINK>). Two studies assessed the effect of 50 mg of etanercept once weekly versus placebo (<LINK REF="STD-Dougados-2011" TYPE="STUDY">Dougados 2011</LINK>; <LINK REF="STD-Huang-2008" TYPE="STUDY">Huang 2008</LINK>).</P>
<P>
<LINK REF="STD-van-der-Heijde-2006b" TYPE="STUDY">van der Heijde 2006b</LINK> performed a double-blind, placebo-controlled non-inferiority trial with 356 patients to compare the benefit of 25 mg twice weekly and 50 mg once weekly. Both dosing regimens were found to be statistically significantly better than placebo in terms of ASAS20, ASAS5/6, ASAS40, BASDAI, BASFI, and other clinical measures. The study also showed that 50 mg once weekly was not inferior to the usual standard of 25 mg twice weekly in terms of the primary outcome of ASAS20 response at 12 weeks. As well, patient-reported outcomes such as fatigue, EuroQOL-5D, and SF-36 scores were similar between the two doses. Injection site reactions were similar in the 50 mg once weekly and 25 mg twice weekly groups (20.7% versus 22.7%). Infections were also similar between the two groups (22.6% and 22.0%). The percentage of non-infectious serious adverse events was 5.2% and 4.0% in the 50 mg once- and 25 mg twice-per-week groups, respectively. One serious infection occurred in each group.The authors concluded that "the efficacy and safety of etanercept 50 mg once weekly was comparable with that of the standard regimen of 25 mg twice weekly in patients with ankylosing spondylitis." Based on this result, we combined studies with the two dosing regimens in the standard and network meta-analyses.</P>
<P>
<LINK REF="STD-Dougados-2011" TYPE="STUDY">Dougados 2011</LINK> assessed the effect of 50 mg of etanercept once weekly versus placebo in a population with advanced and active ankylosing spondylitis. We pooled this results of this study with the ones above given the lack of heterogeneity of the results, even though the population had a longer disease duration than the other included studies. The majority of clinical outcomes showed statistically and clinically important improvements in this population.</P>
<SUBSECTION>
<HEADING LEVEL="5">Major outcomes</HEADING>
<P>
<B>ASAS40</B>: There was high quality evidence that the etanercept group participants were more likely than placebo to achieve the ASAS40 criteria (RR 3.31, 95% Crl 2.38 to 4.53), with an absolute improvement of 30% (95% CI 18% to 46%) and a NNT = 4 (95% CI 2 to 6).</P>
<P>
<B>Physical function (BASFI 0 to 10 scale, lower is better)</B>: There was high quality evidence of a clinically important improvement in physical function (MD -1.1, 95% CI -1.6 to -0.6), with an absolute increased benefit percentage = -11% (95% Crl -16% to -6%); relative percentage change from baseline = -22% (95% CI -32% to -12%); and NNT to achieve the MCID of 0.7 points = 4 (95% CI 4 to 6).</P>
<P>
<B>ASAS partial remission</B>: There was moderate quality evidence (downgraded for imprecision) that the etanercept group participants were more likely than placebo to meet the criteria for partial remission (RR 4.24, 95% Crl 2.31 to 8.09), with an absolute improvement of 10% (95% Crl 4% to 21%) and a NNT = 11 (95% CI 5 to 26).</P>
<P>
<B>MRI and radiographic outcomes:</B> Not assessed in these studies.</P>
<P>
<B>Withdrawals due to adverse events</B>: There was moderate quality evidence of increased withdrawals due to adverse events in the etanercept versus placebo group (RR 3.65, 95% CI 1.27 to 11.79) although the absolute numbers were low: 22/655 in the etanercept group versus 1/402 in the placebo (absolute increased harm: 2% (95% Crl 0.2% to 8%; NNTH: 54 (95% CI 14 to 530). The evidence was downgraded due to the low event rates and resulting imprecision.</P>
<P>
<B>Serious adverse events:</B> Based on moderate quality evidence, we are uncertain of the effect of etanercept on serious adverse events (RR 1.69, 95% CI 0.76 to 3.72) but the absolute numbers were low: 28/655 in the etanercept group versus 8/406 in the placebo (absolute increased harm = 1% (95% Crl -0.4% to 4.1%); relative percentage change = 67% (95% CI -27% to 282%)). The evidence was downgraded due to the low event rates and resulting imprecision.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Etanercept (50 mg twice weekly) versus Etanercept (50 mg once weekly)</HEADING>
<P>
<LINK REF="STD-Navarro_x002d_Sarabia-2011" TYPE="STUDY">Navarro-Sarabia 2011</LINK> investigated a high-dose (100 mg per week) versus a standard-dose (50 mg per week) of etanercept. There was no evidence of a difference between the two doses in the major clinical beneficial outcomes and most results were precise in the estimate around a null effect. The evidence for the harms outcomes was inconclusive due to the low number of events and the wide confidence intervals. The authors concluded that the higher dose does not significantly increase the benefit of etanercept.<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Etanercept 50 mg weekly versus sulphasalazine (3 g) daily</HEADING>
<P>
<LINK REF="STD-Braun-2011" TYPE="STUDY">Braun 2011</LINK> (ASCEND study) found a statistically and clinically important improvement for ASAS40 (RR 1.84, 95% CI 1.47 to 2.29) (<LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>) and ASAS Partial Remission RR 2.14 (1.49 to 3.08) (<LINK REF="CMP-006.03" TYPE="ANALYSIS">Analysis 6.3</LINK>) at 16 weeks in the etanercept compared to sulphasalazine group. BASFI was statistically significantly improved in the etanercept versus the sulphasalazine group (MD -10.63, 95% CI -15.22 to -6.04) . There was no evidence of a difference in the risk of serious adverse events between etanercept and sulphasalazine (Peto OR 0.86, 95% CI 0.24 to 3.05) <LINK REF="CMP-006.05" TYPE="ANALYSIS">Analysis 6.5</LINK>).</P>
<P>A subanalysis of the ASCEND study was undertaken to investigate the benefit of etanercept versus sulphasalazine in patients with peripheral joint involvement (<LINK REF="REF-Braun-2012a" TYPE="REFERENCE">Braun 2012a</LINK>). Of 566 subjects included in original study, 181 (etanercept 121; sulphasalazine 60) had &#8805; 1 swollen peripheral joint and 364 (etanercept 250; sulphasalazine 124) had none at baseline. Ankylosing spondylitis patients treated with etanercept showed significantly greater improvement than those treated with sulphasalazine in all joint assessments regardless of swollen joint involvement. The authors noted that,"These findings support the role of etanercept as a key therapy for the management of subjects with ankylosing spondylitis regardless of peripheral joint involvement."</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Golimumab (50 mg every 4 weeks) versus placebo</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Major outcomes</HEADING>
<P>
<B>ASAS40</B>: There was high quality evidence that the golimumab group participants were more likely than placebo to achieve the ASAS40 criteria (RR 2.90, 95% Crl 1.90 to 4.23), with an absolute improvement of 25% (95% Crl 12% to 42%) and a NNT = 5 (95% CI 3 to 9).</P>
<P>
<B>Physical function (BASFI 0 to 10 scale, lower is better)</B>: There was high quality evidence of a clinically important improvement in physical function (MD -1.5, 95% Crl -2.3 to -0.7), with an absolute increased benefit percentage of -15% (95% Crl -23% to -7%); relative percentage change from baseline of -30% (95% CI -46% to -14%); and NNT to achieve the MCID of 0.7 points = 4 (95% CI 3 to 5).</P>
<P>
<B>ASAS partial remission</B>: There was moderate quality evidence (downgraded for imprecision) that people in the golimumab group were more likely than those in the placebo group to meet the criteria for partial remission (RR 5.18, 95% Crl 1.90 to 14.79), with an absolute improvement of 13% (95% Crl 3% to 41%) and a NNT = 8 (95% CI 3 to 38).</P>
<P>
<B>MRI</B>: A MRI substudy conducted at 10/57 participating sites (N = 60 for placebo and 50 mg golimumab arms) of <LINK REF="STD-Inman-2008" TYPE="STUDY">Inman 2008</LINK> was reported in <LINK REF="REF-Braun-2012b" TYPE="REFERENCE">Braun 2012b</LINK>. Evidence was downgraded to low quality due to concerns about missing data and the modest level of agreement between outcome assessors. The mean change from baseline in the golimumab group was 3.4 points lower (95% CI 7.7 to 0.90 points lower) than placebo, as measured by the ankylosing spondylitis spine MRI activity score (0 to 138; lower means less erosions or edema). This translated to a small absolute increased benefit of 2.5% (95% CI -5.6% to 0.7%) and a relative percentage change of -35% (95% CI -80% to 9%).<BR/>
</P>
<P>
<B>Radiographic progression:</B> Not reported.</P>
<P>
<B>Withdrawals due to adverse events</B>: Based on moderate quality evidence, we are uncertain of the effect of golimumab on withdrawals due to adverse events (RR 1.97, 95% CI 0.36 to 17.51) but the absolute numbers were low: 5/246 in the golimumab group versus 2/183 in the placebo (absolute increased harm = 1.6% (95% Crl -0.4% to 11.6%); relative percentage change of 97% (95% CI -64% to 1651%)). The evidence was downgraded due to the low event rates and resulting imprecision.</P>
<P>
<B>Serious adverse events</B>: Based on moderate quality evidence, we are uncertain of the effect of golimumab on serious adverse events (RR 0.69, 95% CI 0.15 to 3.32) but the absolute numbers were low: 5<B>/</B>138 in the golimumab group versus 4/78 in the placebo group (absolute increased harm was -0.5% (95% Crl -1.3% to 3.5%); relative percentage change was -31% (95% CI -85% to 232%). The evidence was downgraded due to the low event rates and resulting imprecision. The total number of serious adverse events were not clearly reported in <LINK REF="STD-Bao-2014" TYPE="STUDY">Bao 2014</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Infliximab versus placebo (pooled 3 mg/kg and 5 mg/kg)</HEADING>
<P>Two studies assessed the effect of infliximab 5 mg/kg versus placebo; <LINK REF="STD-Braun-2002" TYPE="STUDY">Braun 2002</LINK> at 12 weeks and <LINK REF="STD-van-der-Heijde-2005" TYPE="STUDY">van der Heijde 2005</LINK> at 24 weeks. <LINK REF="STD-Inman-2010" TYPE="STUDY">Inman 2010</LINK> evaluated a 12-week RCT of a lower dose of 3 mg/kg against placebo. There was no significant heterogeneity of including the 3 mg/kg dose with the 5 mg/kg dose results, so they were pooled together. Separate details for the lower dose are also reported below.</P>
<SUBSECTION>
<HEADING LEVEL="5">Major outcomes</HEADING>
<P>
<B>ASAS40</B>: There was high quality evidence that the infliximab group participants were more likely than placebo to achieve the ASAS40 criteria (RR 4.07, 95% Crl 2.80 to 5.74), with an absolute improvement of 40% (95% Crl 23% to 62%) and a NNT = 3 (95% CI 2 to 5).</P>
<P>
<B>Physical function (BASFI 0 to 10 scale, lower is better)</B>: There was high quality evidence of a clinically important improvement in physical function (MD -2.1, 95% CrI -2.7 to -1.4), with an absolute increased benefit percentage of -21% (95% Crl -27% to -14%); relative percentage change from baseline was -42% (95% CI -54% to -28%); and NNT to achieve the MCID of 0.7 points = 2 (95% CI 2 to 3).</P>
<P>
<B>ASAS Partial remission</B>: There was moderate quality evidence (downgraded for imprecision) that participants in the infliximab group were more likely than placebo to meet the criteria for partial remission (RR 15.41, 95% Crl 5.09 to 47.98), with an absolute improvement of 44% (95% Crl 13% to 87%) and a NNT = 3 (95% CI 2 to 8).</P>
<P>
<B>Withdrawals due to adverse events</B>: Based on moderate quality evidence, we are uncertain of the effect of infliximab on withdrawals due to adverse events (RR 1.77, 95% CI 0.43 to 8.46) but the absolute numbers were low: 5/274 in the infliximab group versus 2/150 in the placebo (absolute increased harm was 0.5% (95% Crl -0.4% to 5.6%); relative percentage change was 77% (95% CI -43% to 746%). The evidence was downgraded due to the low event rates and resulting imprecision.</P>
<P>
<B>Serious adverse events</B>: Based on moderate quality evidence, we are uncertain of the effect of infliximab on serious adverse events (RR 2.53, 95% CI 0.76 to 11.09) but the absolute numbers were low: 11/275 in the infliximab group versus 2/147 in the placebo (absolute increased harm: 2.3% (95% Crl -0.4% to 15.1%); relative percentage change was 153% (95% CI -24% to 1009%). The evidence was downgraded due to the low event rates and resulting imprecision.</P>
<P>
<B>MRI:</B> Data was reported in a secondary publication of <LINK REF="STD-van-der-Heijde-2005" TYPE="STUDY">van der Heijde 2005</LINK> (<LINK REF="REF-Braun-2006" TYPE="REFERENCE">Braun 2006</LINK>). The MRI Activity Score was used to assess spinal inflammation as detected by MRI. There was high quality evidence of a greater reduction in MRI Activity Score from baseline to week 24 in the infliximab-treated group (MD -4.42, 95% CI -5.59 to -3.25 on a 0 to 138 scale, lower means less erosions or edema), though the absolute increase in benefit was small: -3% (95% CI -4% to -2.4%); NNT = 3 (95% CI 3 to 5) with a relative percentage change of -62% (95% CI -79% to -46%). As well, evidence of some ("some" defined as MRI Activity score &gt; 1 where each vertebral unit is scored from 0 to 6 with 0 = no inflammation) spinal inflammation by week 24 was 37% in the infliximab group compared to 73.6% in the placebo group (P &lt; 0.001).</P>
<P>A separate publication (<LINK REF="REF-Maksymowych-2010" TYPE="REFERENCE">Maksymowych 2010</LINK>) reported on spinal inflammation as measured by the SPARCC MRI method in a subset of the <LINK REF="STD-Inman-2010" TYPE="STUDY">Inman 2010</LINK> trial participants. Thirty-six patients at two of the sites involved in the trial participated in the MRI investigation. They found a large treatment effect in favor of infliximab (mean percentage change based on evaluation of the most severely affected discovertebral units (6 DVU score) in the infliximab group was -55.1% compared to +5.8% in the placebo group (P &lt; 0.001). When the evaluation was based on the entire spine (23 DVU score), the infliximab group had a mean reduction of 57.2% compared to 3.4% in the placebo group (P &lt; 0.001).</P>
<P>
<B>Radiographic progression:</B> Radiological change was assessed using the Bath ankylosing spondylitis radiology index (BASRI) in <LINK REF="STD-Braun-2002" TYPE="STUDY">Braun 2002</LINK> though data were not shown. They found that the "initial degree of radiological axial changes assessed by the BASRIs was similar in both groups." Interestingly, the study stated that there was "no less benefit in patients with higher BASRI scores than those with lower scores"; indicating that the amount of ankylosis did not impact the benefit of infliximab. Radiographic outcome data was not reported in <LINK REF="STD-van-der-Heijde-2005" TYPE="STUDY">van der Heijde 2005</LINK> or <LINK REF="STD-Inman-2010" TYPE="STUDY">Inman 2010</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Low dose infliximab (3 mg/kg) versus placebo</HEADING>
<P>
<LINK REF="STD-Inman-2010" TYPE="STUDY">Inman 2010</LINK> conducted a study on 76 patients to compare the benefit of infliximab at 3 mg/kg versus placebo. The first 12 weeks were a double-blind placebo phase and then there was an open-label phase where placebo patients switched to 3 mg/kg infliximab and received infusions at weeks 14, 16, 22 and every 8 weeks afterwards. Patients were eligible for a dose escalation to 5 mg/kg at weeks 22 or 38 if they were not responding adequately.</P>
<P>Significantly more participants in the infliximab group than placebo achieved an ASAS40 response at 12 weeks (RR 5.69 (1.83 to 17.74). However, after the 12-week double-blind placebo phase, 68% of patients in the 3 mg/kg infliximab group switched to the 5 mg/kg by 38 weeks because of lack of benefit.</P>
<P>Adverse event data were not presented separately for the placebo-controlled, 12-week phase, with the exception of one serious adverse event of arthralgia in an infliximab-treated patient.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Infliximab + methotrexate versus placebo + methotrexate</HEADING>
<P>
<LINK REF="STD-Marzo_x002d_Ortega-2005" TYPE="STUDY">Marzo-Ortega 2005</LINK> assessed the benefit and harms of adding infliximab (5 mg/kg) or placebo to methotrexate therapy. The final infliximab or placebo treatment was given at 22 weeks. At 30 weeks, neither the change in BASDAI (MD -1.14, 95% CI -2.76 to 0.48) (<LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>), nor the ASAS20 response (RR 2.33, 95% CI 0.80 to 6.80) (<LINK REF="CMP-007.02" TYPE="ANALYSIS">Analysis 7.2</LINK>) or a 50% improvement in BASDAI (RR 2.50, 95% CI 0.87 to 7.22) (<LINK REF="CMP-007.03" TYPE="ANALYSIS">Analysis 7.3</LINK>) were statistically significantly different between the two groups. There was a statistically significant difference at 10 weeks, but this did not extend to 30 weeks. The last dosing of infliximab was at 22 weeks, so the authors concluded that the addition of methotrexate to the treatment regimen did not lengthen the beneficial period of infliximab. There was a significantly greater reduction in the number of lesions in the sacroiliac joints and spine resolving completely in the combination group versus the methotrexate monotherapy group, as assessed by MRI. No serious adverse events were seen in either group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse events - pooled results from all four anti-TNF agents versus placebo</HEADING>
<P>We pooled the results from adalimumab, etanercept, golimumab, and infliximab to assess for a class-effect of adverse effects of TNF-inhibitors. Given our interest in adverse events was prespecified in short-term (less than or equal to 6 months) and long-term (greater than 6 months) periods, and that all time points reported were six months or less, we pooled all trials together for an assessment of short-term effects. The adverse events reported for the 50 mg once weekly and 25 mg twice weekly groups in the trial of etanercept (<LINK REF="STD-van-der-Heijde-2006b" TYPE="STUDY">van der Heijde 2006b</LINK>) and infliximab 3mg/kg and 5mg/kg doses were pooled together for this analysis .</P>
<P>
<B>Withdrawals due to adverse events</B>: Based on 16 studies (N = 2623 participants), there is moderate quality evidence (downgraded for imprecision) of an increase in withdrawals due to adverse events in the anti-TNF group versus placebo (Peto OR 2.44, 95% CI 1.26 to 4.72) though the absolute increase was small (1%, 95% CI 0% to 2%) with 38/1637 in the biologic group and 7/986 in the placebo group (<LINK REF="CMP-008.01" TYPE="ANALYSIS">Analysis 8.1</LINK>).</P>
<P>
<B>Serious adverse events</B>: Based on 15 studies (N = 2408 participants) and moderate quality evidence, results were inconclusive for evidence of a difference in serious adverse events in the anti-TNF group versus placebo (Peto OR 1.45, 95% CI 0.85 to 2.48) though the absolute increase was small (1%, 95% CI 0% to 2%) with 51/1530 in the biologic group and 18/878 in the placebo group (<LINK REF="CMP-008.02" TYPE="ANALYSIS">Analysis 8.2</LINK>).</P>
<P>Most studies did not provide a definition of a 'serious adverse event'. Two studies (<LINK REF="STD-Davis-2003" TYPE="STUDY">Davis 2003</LINK>; <LINK REF="STD-Gorman-2002" TYPE="STUDY">Gorman 2002</LINK>) stated that the National Cancer Institute Common Toxicity criteria scale was used to grade adverse events and abnormal laboratory values and <LINK REF="STD-Inman-2010" TYPE="STUDY">Inman 2010</LINK> used MedDRA ver9.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Head-to-head comparisons</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Direct evidence: Etanercept versus infliximab</HEADING>
<P>One RCT (<LINK REF="STD-Giardina-2009" TYPE="STUDY">Giardina 2009</LINK>) assessed the benefit and harm of etanercept compared to infliximab over a two-year period. The trial was reported first in a conference abstract and later a full-text article was published. The risk of bias for this study is high given the lack of blinding of participants and outcome assessors and there were no details provided about the method of sequence generation and allocation concealment.</P>
<P>Fifty patients were enrolled in the trial. To calculate the proportion of responders reported in the abstract for entry into RevMan, the number of participants in each treatment group was assumed to be the denominators at end of study. However, there is a slight discrepancy in the number of people in each group; the full-text article states that there were 25 people in each group, while the abstract states there were 26 people in the etanercept group and 24 people in the infliximab group. We used the numbers from the full-text article.</P>
<SUBSECTION>
<HEADING LEVEL="5">Major outcomes</HEADING>
<P>
<B>ASAS40</B>: We are uncertain whether there is a difference between etanercept and infliximab at 12 weeks (RR 0.79, 95% CI 0.45 to 1.38) (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>).</P>
<P>
<B>BASFI (0 to 10 scale):</B> A statistically significant MD of 1.50 (95% CI 0.94 to 2.06) in favour of infliximab was found.<BR/>
</P>
<P>
<B>Partial remission:</B> Not reported.</P>
<P>
<B>MRI and radiographic data: </B>Not reported.</P>
<P>
<B>Withdrawals due to adverse events</B>: The abstract states that "no patients discontinued therapy".</P>
<P>
<B>Serious adverse events</B>: Although two "severe infections" were reported in the infliximab group and one in the etanercept group, the text stated that there were no discontinuations due to adverse events, so we considered there to be no serious adverse events.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Indirect evidence from mixed treatment comparison (MTC) analysis</HEADING>
<P>Indirect comparisons of one treatment versus another are useful when there is no, or limited, direct evidence from head-to-head RCTs comparing treatments of interest to practitioners who must make choices as to which treatment to prescribe to their patient. In the case of the four anti-TNF agents for use in ankylosing spondylitis, the majority of RCTs assess each of adalimumab, etanercept, golimumab and infliximab against placebo and we also found one open-label RCT comparing etanercept to infliximab over a two year period (<LINK REF="STD-Giardina-2009" TYPE="STUDY">Giardina 2009</LINK>). The lack of direct comparisons between anti-TNF agents provides a compelling reason to undertake a mixed treatment comparison analysis. <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> describes the relationship of trials in this systematic review. It is a network with one closed loop (<LINK REF="REF-Wells-2009" TYPE="REFERENCE">Wells 2009</LINK>).</P>
<P>We used the direct evidence from the <LINK REF="STD-Giardina-2009" TYPE="STUDY">Giardina 2009</LINK> study in the mixed treatment comparison analysis to give refined estimates of the comparison of etanercept versus infliximab and refined estimates of the four anti-TNF agents versus placebo. As well, the mixed treatment comparison analysis provided us with new indirect estimates of adalimumab versus etanercept, golimumab versus etanercept, adalimumab versus infliximab, golimumab versus infliximab, and adalimumab versus golimumab. We performed indirect comparisons on the following outcomes: ASAS40, ASAS partial remission, withdrawals due to adverse events, and serious adverse events. <LINK REF="STD-Giardina-2009" TYPE="STUDY">Giardina 2009</LINK> was able to contribute data to all the outcomes except ASAS partial remission. The outcomes of withdrawals due to adverse events and serious adverse events had rare events, so in the mixed treatment comparison analysis, a random-effects model was used and the zero events were adjusted for by adding 0.5.</P>
<P>
<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>, <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>, <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>, <LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK> and <LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK> provide results for the mixed treatment comparison placebo estimates and also show the new estimates for the different biologics against each other. For the mixed treatment comparison-derived head-to-head estimates, there were wide confidence intervals and no consistency as to which biologic was favored in terms of ASAS40, partial remission, BASFI, withdrawals due to adverse events, and serious adverse events.</P>
<P>As already noted, we had direct estimates of the benefit and harm of etanercept versus infliximab from the <LINK REF="STD-Giardina-2009" TYPE="STUDY">Giardina 2009</LINK> study. We found the indirect mixed treatment comparison estimate and direct estimates to be similar in terms of magnitude and direction of effect. 
</P>
<P>With respect to the homogeneity assumption, statistical heterogeneity (as assessed by I<SUP>2</SUP> values) for the individual pairwise meta-analyses (e.g. adalimumab versus placebo, etanercept versus placebo, golimumab versus placebo and infliximab versus placebo) used in the indirect comparison meta-analyses were all very low (see Data and analyses 1 to 4).</P>
<P>For the assumption of trial similarity, <LINK REF="TBL-07" TYPE="TABLE">Table 7</LINK> shows key potential effect modifiers for the individual anti-TNFs versus placebo comparisons included in the network meta-analysis. We compared the distribution of mean age, disease duration, baseline BASDAI and BASFI for trials of adalimumab versus placebo to etanercept versus placebo to golimumab versus placebo and to infliximab versus placebo. The results for the modifiers are similar and overlap across comparisons.</P>
<P>As noted in the paper by <LINK REF="REF-Hochberg-2003" TYPE="REFERENCE">Hochberg 2003</LINK> et al, &#8220;another method of assessing the validity of this assumption is to compare the proportion of patients randomly allocated to receive placebo who develop the study outcome&#8221;. For ASAS40, the range of responses was 12% to 21%; for partial remission the range was 1% to 6%. Thus, it seems that it is likely that the patients in these trials are drawn from similar patient populations.</P>
<P>With respect to methodological risk of bias, most of the studies are similar in terms of sequence generation and allocation concealment, being either at low or unclear risk of bias due to lack of details in the published reports. However, all but the etanercept versus infliximab <LINK REF="STD-Giardina-2009" TYPE="STUDY">Giardina 2009</LINK> study were reported to be &#8220;double-blind&#8221;, though details of the methods of blinding were not always clearly reported in the other studies. <LINK REF="STD-Giardina-2009" TYPE="STUDY">Giardina 2009</LINK> was an unblinded study, presumably because it was difficult to blind treatments with different routes of administration; i.e. subcutaneous versus infusion. This puts it at a higher risk of bias than the other studies. As well, the length of outcome assessment was quite different in the <LINK REF="STD-Giardina-2009" TYPE="STUDY">Giardina 2009</LINK> study as the full duration of the trial was 104 weeks. As all other studies reported results at 24 weeks or less, and we used the 12 week data from <LINK REF="STD-Giardina-2009" TYPE="STUDY">Giardina 2009</LINK>.</P>
<P>However, there was no significant inconsistency evident in the consistency plot for ASAS40 (<LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>). The other major outcomes had similar consistency plots.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse effect warnings from regulatory websites</HEADING>
<P>
<LINK REF="TBL-08" TYPE="TABLE">Table 8</LINK> summarizes the warnings on the use of TNF-inhibitors from the websites of FDA MedWatch, European Medicines Evaluation Agency, Australian Adverse Drug Reactions Bulletin, and UK Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Updates. Most warnings concerned tuberculosis and other serious infections as well as lymphoma and other malignancies, and recommended avoiding the concomitant use of biologics.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sensitivity analyses</HEADING>
<P>As <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> shows, there were few concerns about studies with high risk of bias, with the exception of <LINK REF="STD-Giardina-2009" TYPE="STUDY">Giardina 2009</LINK> which did not blind patients or investigators. The results of the network meta-analyses showed good consistency so we did not perform a sensitivity analysis around study quality.</P>
<SUBSECTION>
<HEADING LEVEL="4">Mantel-Haenzsal versus Peto OR for rare events</HEADING>
<P>Although using the Mantel-Haenszel method changed the width of some confidence intervals, none of the point estimates changed significantly, nor did any estimates change in their statistical significance. Therefore, we feel our estimates of outcomes with rare events using the Peto OR are robust.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subgroup analyses</HEADING>
<P>We explored the characteristics of the studies as described below and found them sufficiently similar and did not conduct subgroup analyses.</P>
<SUBSECTION>
<HEADING LEVEL="4">Dose</HEADING>
<P>We pooled the 5 mg/kg dose and 3 mg/kg dose of infliximab for major outcomes in a standard meta-analysis. There was very little heterogeneity when these doses were pooled. We investigated the effect estimates in the low-dose and high-dose groups separately and found them to be quite similar.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Trial duration</HEADING>
<P>All RCT portions of the studies were six months or less duration and we had specified a priori that trials shorter than or equal to six months would be used to assess short-term benefits and harms.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Patient characteristics</HEADING>
<P>Overall, the studies were quite homogeneous (<LINK REF="TBL-07" TYPE="TABLE">Table 7</LINK>). <LINK REF="STD-Barkham-2010" TYPE="STUDY">Barkham 2010</LINK> and <LINK REF="STD-Huang-2008" TYPE="STUDY">Huang 2008</LINK> were reported in abstracts, so details of patient characteristics are not available. All studies included patients meeting the modified New York classification criteria. Patients were similar across trials in terms of age (range of mean age in treatment group 30 to 45 years). <LINK REF="STD-Calin-2004" TYPE="STUDY">Calin 2004 </LINK>included the oldest patients but the effect estimates were similar to the other studies for BASFI. All studies included a majority of men (% male in treatment group range: 65% to 83%, with the exception of <LINK REF="STD-Dougados-2011" TYPE="STUDY">Dougados 2011</LINK> which focused on people with advanced ankylosing spondylitis. We included and excluded <LINK REF="STD-Dougados-2011" TYPE="STUDY">Dougados 2011</LINK> from a standard meta-analysis of the major outcomes for trials of etanercept and found that the study introduced very little heterogeneity and the effect estimates were very similar: BASFI went from I<SUP>2 </SUP>= 24% to 0% and both ASAS40 and withdrawals due to adverse events stayed at I<SUP>2 </SUP>= 0% when <LINK REF="STD-Dougados-2011" TYPE="STUDY">Dougados 2011</LINK> was removed. Therefore we decided it was appropriate to pool it with the other studies.</P>
<P>BASDAI and BASFI baseline scores were similar across studies (BASDAI range: 5.8 to 6.6 and BASFI range: 4.5 to 6.5). Disease duration was similar, with almost all ranging from 10 to 15 years in the treatment groups across studies. The two exceptions were <LINK REF="STD-Dougados-2011" TYPE="STUDY">Dougados 2011</LINK> at 19 years but as explained above, we felt it was appropriate to use it in the analyses with the other studies. <LINK REF="STD-Bao-2014" TYPE="STUDY">Bao 2014</LINK> had the shortest disease duration at 6.1 years, but its results were very similar to the other golimumab study for the major outcomes (ASAS40 and withdrawals due to adverse events both had I<SUP>2 </SUP>= 0%).</P>
<P>Only <LINK REF="STD-Brandt-2003" TYPE="STUDY">Brandt 2003</LINK> did not allow concomitant disease-modifying anti-rheumatic drug therapy but in terms of the BASDAI, the result from this study was very similar to the other studies of etanercept.</P>
<P>Almost all included studies excluded patients with complete ankylosis (fusion) (exclusion criteria not reported in <LINK REF="STD-Lambert-2007" TYPE="STUDY">Lambert 2007</LINK> and <LINK REF="STD-van-der-Heijde-2006a" TYPE="STUDY">van der Heijde 2006a</LINK> restricted a priori to &lt; 10% of recruited patients could have complete ankylosis).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of publication bias</HEADING>
<P>We had planned to assess publication bias by visual inspection of funnel plots. However, it was very difficult to assess plots with few studies in them. According to the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>), when assessing publication bias using statistical tests for funnel plot asymmetry, at least 10 studies should be included in the meta-analysis, otherwise the power of the test is too low. There is no guidance regarding the minimum number of studies needed for visual inspection. We decided to look at plots with more than 10 studies and there were two analyses that met this criteria. Both appear to have a funnel shape (and it is more apparent when the treatment effect is a risk ratio rather than Peto OR) with the studies distributed fairly symmetrically around the mean effect size. There is not strong evidence of small-study bias when assessing these plots.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2015-03-26 05:01:48 -0400" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2015-03-26 05:01:39 -0400" MODIFIED_BY="[Empty name]">
<P>Twenty-one RCTs with a total of 3308 participants met the inclusion criteria for this review. The major beneficial outcomes were based on those recommended by the Assessment of SpondyloArthritis international Society (ASAS), and the primary analysis results were based on mixed treatment comparison refined placebo estimates.</P>
<P>High quality evidence showed that in the short-term (less than 24 weeks), each biologic - adalimumab, etanercept, golimumab, and infliximab - when compared to placebo, improved ankylosing spondylitis symptoms of pain, function, stiffness and global well-being. Moderate quality evidence showed a greater number of participants met the partial responder criteria. There was low to moderate quality evidence for less erosions and edema in spine and sacroiliac joints as measured by magnetic resonance imaging (MRI) in trials of adalimumab, golimumab, and infliximab, though the absolute improvement was small and we are not sure of the clinical relevance.</P>
<P>Radiological progression was measured in only one study of etanercept versus placebo and changes were similar in both groups. Given that all trials were 24 weeks or less, it is not surprising that most did not measure radiographic progression.</P>
<P>We pooled adverse event data from the four anti-TNF agents to investigate a class effect of the TNF-inhibitors. When all the anti-TNF agents were combined against placebo, there was moderate quality evidence from 16 studies of an increased risk of withdrawals due to adverse events in the anti-TNF group, but results were inconclusive for evidence of a difference between groups in terms of risk of serious adverse events in the anti-TNF group versus placebo. We downgraded the evidence to moderate, given the low number of events.</P>
<P>Our search of major regulatory agency websites for warnings of adverse effects highlighted concerns of serious infections, including tuberculosis, as well as lymphoma, and malignancies associated with anti-TNF use.</P>
<P>Indirect comparisons can be useful when there is limited direct evidence for a clinically-important question. Appropriate methods should be employed to undertake indirect comparisons; for example, &#8220;naive&#8221; pooling methods should be avoided, and in this analysis, we have undertaken a suitable methodology, mixed treatment comparisons, for our indirect comparisons. The direct estimates from the one head-to-head study of etanercept versus infliximab (<LINK REF="STD-Giardina-2009" TYPE="STUDY">Giardina 2009</LINK>) were comparable in terms of the magnitude and direction of effect with the refined estimates obtained from the MTC analysis, thereby increasing our confidence in the indirect comparison estimates. For the mixed treatment comparison-derived head-to-head estimates, there were wide confidence intervals and no consistency as to which biologic was favored in terms of the major outcomes. Therefore, we do not have evidence that one anti-TNF agent appears to confer more benefit or harm than another.</P>
<P>One RCT (<LINK REF="STD-Braun-2011" TYPE="STUDY">Braun 2011</LINK>) assessed etanercept (50 mg once a week) compared to sulphasalazine. Etanercept was found to have a statistically significantly better response in terms of ASAS20, ASAS40, and ASAS5/6 at 16 weeks. As well, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Metrology Index (BASMI), nocturnal back pain, and Modified Schobers response were all greater in the etanercept versus the sulphasalazine groups.</P>
<P>Infliximab in combination with methotrexate versus placebo plus methotrexate was assessed in <LINK REF="STD-Marzo_x002d_Ortega-2005" TYPE="STUDY">Marzo-Ortega 2005</LINK>. At 30 weeks, there was no statistically significant difference between the two groups in terms of ASAS20, &gt; 50% BASDAI response, or change in BASDAI, though there had been at 10 weeks. The assessment at 30 weeks was 8 weeks after the last dose of infliximab had been given and the authors concluded that the addition of methotrexate did not confer a longer benefit of infliximab. Caution is needed though, as this is based on only one small study.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2015-03-26 05:01:48 -0400" MODIFIED_BY="[Empty name]">
<P>In total, twenty-one trials addressed the use of anti-TNF agents: adalimumab (three trials), etanercept (eight trials versus placebo; one versus sulphasalazine, one a high versus low dose), golimumab (2 trials), infliximab (4 trials, one assessed the benefit of infliximab in combination with methotrexate), and one trial of etanercept versus infliximab, for the treatment of ankylosing spondylitis. The RCTs were between six and 24 weeks duration, so all data about benefit and harm is based on short-term studies. We assessed appropriate outcomes based on Assessment of SpondyloArthritis international Society recommendations to establish short-term benefit of the anti-TNF agents against placebo.</P>
<P>Participants in the included studies had high disease activity (entry criteria was a BASDAI &#8805; 4). The high levels of disease activity seen in the patients included in these trials may not be typical of patients seen in daily clinical practice. In addition, patients selected for RCTs generally have few major comorbidities. Almost all studies excluded patients with complete ankylosis of the spine, and many excluded patients with conditions related to the concerns of potential harms with biologics, i.e. recent serious infections, history of infectious diseases or malignancies in last five years, and signs of severe renal, cardiac, hepatic, demyelinating, or other diseases. This may impact the generalizability of these results to clinical practice.</P>
<P>As disease duration of the participants enrolled in these studies was mainly 10 years and longer, the applicability of this evidence to those with shorter disease duration is unclear. However, in <LINK REF="REF-Rudwaleit-2004" TYPE="REFERENCE">Rudwaleit 2004</LINK>, a shorter disease duration (&#8804; 10 years) and a lower BASFI (&lt; 4.5) were both found to be strong predictors of a major clinical response (as assessed by &gt; 50% BASDAI response). Therefore, it is of interest to conduct trials of anti-TNF agents in populations with early disease to determine if there is indeed a better response and any effect on the progression of ankylosis spondylitis in this population and to determine when it is appropriate to start anti-TNF therapy (<LINK REF="REF-Haibel-2010" TYPE="REFERENCE">Haibel 2010</LINK>).</P>
<P>Most trials used a standard dose for each of the biologics. One trial (<LINK REF="STD-van-der-Heijde-2006b" TYPE="STUDY">van der Heijde 2006b</LINK>) assessed the benefit of giving 50 mg of etanercept once a week versus 25 mg twice a week and concluded that the benefit and safety outcomes were similar between the two groups. Another trial (<LINK REF="STD-Inman-2010" TYPE="STUDY">Inman 2010</LINK>) evaluated the effect of a lower dose of infliximab (3 mg/kg) compared to the standard dose of 5 mg/kg. Although a previous open-label study of lower dose infliximab showed sustained benefit in the majority of patients, in the extension phase of this RCT (the double-blind phase was to 12 weeks), by week 38, most participants (68%) required an increase to 5 mg/kg to maintain benefit.</P>
<P>A limitation of this review is that we did not include non-RCT data to assess changes in the radiological progression of patients exposed to anti-TNF therapy. It is unlikely that changes in radiological progression will be seen in RCTs of six months or less duration. In addition, the lack of including non-RCT data limits the assessment of rare or delayed harms which are unlikely to be found in short-term RCTs.</P>
<P>An editorial on the study of abatacept in rheumatoid arthritis (<LINK REF="REF-Boers-2006" TYPE="REFERENCE">Boers 2006</LINK>) highlights the desire of clinicians for active comparator trials, once the benefit of a treatment has been established against placebo. As described above in the summary of results section, only one head-to-head study of anti-TNF agents (<LINK REF="STD-Giardina-2009" TYPE="STUDY">Giardina 2009</LINK>) was found in our systematic search. We therefore performed indirect comparisons using mixed treatment comparison methodology to explore the evidence base and test the robustness of the results. However, additional large, well conducted, head-to-head studies would be helpful to provide clinicians with a stronger evidence base regarding differences between the various biologics.</P>
<P>Certolizumab pegol, another TNF-inhibitor, has been approved for use in ankylosing spondylitis and it will be included in our update of this review. As well, we may need to consider whether a new disease activity measure, the Ankylosing Spondylitis Disease Activity Score (ASDAS) should be included as a major outcome. A further consideration for future updates is that new studies also apply the new ASAS axial spondyloarthropathy (axSpA) criteria and we will need discussion on including more heterogeneous populations of radiographic axSpA (ankylosing spondylitis) and non-radiographic axSpA.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2015-03-25 09:23:22 -0400" MODIFIED_BY="[Empty name]">
<P>Adequate allocation concealment can avoid selection bias in controlled trials and there is evidence that inadequate allocation concealment leads to an overestimation of the treatment effect (<LINK REF="REF-Schultz-1995" TYPE="REFERENCE">Schultz 1995</LINK>). We obtained additional information from the authors for some studies to clarify the method of allocation. Still, there were eleven studies which did not provide enough information on this domain and we had to mark it as unclear.</P>
<P>Blinding of participants was not clearly reported in seven studies. <LINK REF="STD-Giardina-2009" TYPE="STUDY">Giardina 2009</LINK> was clearly not blinded; this two-year study compared etanercept (given subcutaneously) with infliximab (given as an infusion), so it is evident why the patients were not blinded. Given that the primary outcome measured in most trials was the BASDAI or ASAS20, both self reported measures, it is necessary for patients to be blinded to ensure detection bias has not been introduced in these studies.</P>
<P>Risk of bias due to attrition bias was unclear in five studies, and completion rates were greater than 80% in all but one study, <LINK REF="STD-Marzo_x002d_Ortega-2005" TYPE="STUDY">Marzo-Ortega 2005</LINK>, which had a large imbalance in withdrawals in the treatment and placebo arms, mostly due to lack of benefit in the placebo group (93% versus 64%). All the trials reported the numbers of patients who dropped out in the treatment and placebo groups. The drop-out rates were generally higher in the placebo group than the treatment group in all trials and there was a much higher rate of withdrawal due to lack of benefit in the placebo groups. In most trials the missing data were imputed using last observation carried forward analysis for continuous data and 'non-responders' for dichotomous outcomes like ASAS20. Most trials reported a proper intention-to-treat analysis. The other trials (<LINK REF="STD-Braun-2002" TYPE="STUDY">Braun 2002</LINK>; <LINK REF="STD-Inman-2010" TYPE="STUDY">Inman 2010</LINK>; <LINK REF="STD-van-der-Heijde-2006b" TYPE="STUDY">van der Heijde 2006b</LINK>) reported a 'modified' intention-to-treat analysis as one defined by those subjects who received at least one infusion of study medication. Although fewer than 3% of participants were affected, it is of interest to know why patients who were randomized did not receive the study drug.</P>
<P>The Assessment of SpondyloArthritis international Society (ASAS) and OMERACT groups have had great success in standardizing outcomes that should be measured in trials of interventions for ankylosing spondylitis. The ASAS response criteria were developed for use in clinical trials and the ASAS40 and ASAS5/6 response criteria have both shown good discrimination in anti-TNF studies (<LINK REF="REF-Brandt-2004" TYPE="REFERENCE">Brandt 2004</LINK>). The trials included in this systematic review usually reported outcome measures as recommended by ASAS and OMERACT for trials on ankylosing spondylitis patients. There is little risk of bias due to selective reporting in these trials in terms of beneficial outcomes; however, adverse events were less clearly reported.</P>
<P>Heterogeneity was low in pooled analyses of the major outcomes. The low event rates in the outcomes of partial remission, withdrawals due to side effects, and serious adverse events led to downgrading the quality of evidence for the resulting imprecise estimates.</P>
<P>When combining studies it is important that the outcome measures are comparable. Of note, different definitions of serious adverse events were used in the assessment of these events across the trials. Most trials did not provide a specific definition, two stated they used the National Cancer Institute Common Toxicity Criteria, and another MedDRA version 9. We assumed for the purpose of this review that the definitions were similar enough to warrant combining.</P>
<P>Only two outcomes had enough studies in which to visually inspect a funnel plot for publication bias. These plots did not indicate a potential lack of publication of smaller, 'negative' studies but overall we do not have much evidence whether publication bias is an issue in this systematic review.</P>
<P>With regards to detecting adverse events in RCTs, it was noted in <LINK REF="REF-Yazici-2008" TYPE="REFERENCE">Yazici 2008</LINK> that an inadequate sample size (Type II error) is a possible reason that a significant difference in the number of adverse events between treatment and placebo groups is often not observed. All the included studies termed themselves 'efficacy and safety' studies. But in none of the trials was there a discussion of necessary sample sizes to detect adverse events.</P>
<P>We concluded that there is moderate (downgraded for concerns about imprecision due to low event rates) to high level evidence for the short-term outcomes of ASAS40 response, achievement of partial remission, physical function, and disease activity. Evidence for improvement in inflammation as measured by MRI results was low to moderate due to small population and concerns about missing data in one study. Harms outcomes were downgraded to moderate due to low event rates and resulting imprecise estimates.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2015-03-25 09:26:42 -0400" MODIFIED_BY="[Empty name]">
<P>We undertook a systematic, thorough search of the electronic literature and searched key conference proceedings to identify all studies meeting the inclusion criteria for this review. However, we did not approach pharmaceutical companies for additional data and it is possible that additional data from this source could contribute to this review. Study selection, data extraction, and risk of bias assessments were done in duplicate and independently and we reached consensus by discussing any discrepancies.</P>
<P>Published trial reports did not provide enough details to adequately assess risk of bias and some variance measures necessary for meta-analysis were missing from the report. We contacted some authors for further information and while some of the requested data was provided, it is a limitation of this review that not all the data were available. For some trials we had to undertake transformations and assumptions in order to enter continuous data into our mixed treatment comparison spreadsheets and this may reduce the accuracy of our estimates.</P>
<P>Some adverse event outcomes consisted of sparse data, with few events in the groups. In cases where there were no events in either study arm (zero total event studies), the study did not contribute to the meta-analysis. The rationale for this method is that no information on the magnitude of the treatment effect can be obtained from these studies. An investigation by <LINK REF="REF-Sweeting-2004" TYPE="REFERENCE">Sweeting 2004</LINK> confirmed that "zero total event studies do not contribute to a fixed meta-analysis" and so we felt it appropriate not to include these in our meta-analysis. The Peto OR was shown to be one of the least biased estimators of a treatment effect when using sparse data. However, in the case of unbalanced study arms with four times as many participants in one arm as another, there is concern that the estimate will be biased (<LINK REF="REF-Bradburn-2007" TYPE="REFERENCE">Bradburn 2007</LINK>). Given that none of our included studies were unbalanced by more than 4:1, we decided the Peto OR was a suitable method. When analyzing rare data in a meta-analysis, it is recommended that various methods are used to determine the treatment effect estimate and sensitivity analyses are undertaken (<LINK REF="REF-Sweeting-2004" TYPE="REFERENCE">Sweeting 2004</LINK>). For those analyses in which studies had zero events in one arm, or an event rate &lt; 10%, we used the Peto OR. We also performed the Mantel-Haenszel method with the standard continuity correction of 0.5 to check the robustness of our results and found that results did not change significantly. We did not perform other sensitivity analyses with other continuity corrections, but given that there was consistency of results with the standard continuity correction, we are confident that our estimates are robust.</P>
<P>For the indirect comparison results to be considered robust, it must be investigated whether the trials included in each standard meta-analysis comparison (e.g. A-B and C-B) are homogeneous; whether the effect of the linking treatment is similar across comparisons; and whether there is consistency of evidence. To judge the likelihood of these assumptions being true, the comparability of the linking treatment, the patient population, the methodological risk of bias, the study design, and the date of publication must be assessed (<LINK REF="REF-Song-2009" TYPE="REFERENCE">Song 2009</LINK>; <LINK REF="REF-Wells-2009" TYPE="REFERENCE">Wells 2009</LINK>). We did assess the studies included in terms of the criteria noted above. As noted in <LINK REF="TBL-07" TYPE="TABLE">Table 7</LINK> and the Results section, the patient populations were fairly similar in terms of length of disease duration, severity of disease, inclusion/exclusion trial criteria, and trial duration. The one head-to head study of etanercept versus infliximab (<LINK REF="STD-Giardina-2009" TYPE="STUDY">Giardina 2009</LINK>) did not blind the participants (given the difference in route of administration of the two biologics) and it was measured at a longer follow-up time than the other included studies (two years versus six months, though interim results were available). However, since the treatment effect observed for etanercept and infliximab was similar to that seen in other placebo-controlled studies, and including this study allowed us to have a closed loop in our network meta-analysis for evaluating the consistency of the direct and indirect evidence, we decided it was appropriate to include this in our indirect comparison analysis.</P>
<P>However, it must be cautioned that while we assessed the necessary assumptions for undertaking indirect comparisons, indirect comparisons may not provide the same strength of validity of results that a well conducted, head-to-head, RCT may.</P>
<P>A protocol was published for this review (<LINK REF="REF-Zochling-2005" TYPE="REFERENCE">Zochling 2005</LINK>) and outcomes and analyses were specified a priori. However, since this time, there have been significant changes to the methodology recommended in the <I>Cocharane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>), specifically around assessing the risk of bias, grading the quality of evidence, and providing 'Summary of findings' tables. Our protocol listed outcomes recommended by the Assessment of SpondyloArthritis international Society (ASAS) but for the 'Summary of findings' table, we had to choose a maximum of seven outcomes, representing both benefit and harm. In discussion with ASAS members we decided on our seven major outcomes and we do not think that any selection bias was introduced when making this choice.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2015-03-25 09:27:06 -0400" MODIFIED_BY="[Empty name]">
<P>The National Institute for Health and Clinical Excellence (NICE) undertook a technology appraisal report to provide guidance on the use of adalimumab, etanercept and infliximab for ankylosing spondylitis for the UK National Health Service (<LINK REF="REF-NICE-2008" TYPE="REFERENCE">NICE 2008</LINK>). The report was issued in May 2008 and the results are very similar to this review. This Cochrane review includes some newer information on the benefit of low-dose infliximab and use of 50 mg once per week of etanercept. The NICE report also conducted indirect comparisons of the anti-TNF inhibitors and as this review did, found no statistically significant difference between the three biologics in terms of ASAS response rates. The <LINK REF="REF-NICE-2008" TYPE="REFERENCE">NICE 2008</LINK> review assessed cost-effectiveness of three biologics in detail and recommended that the high cost of infliximab precluded its recommendation for use in people with ankylosing spondylitis. Both adalimumab and etanercept were recommended for use subject to the conditions outlined in the report. Golimumab was recommended for use in the <LINK REF="REF-NICE-2011" TYPE="REFERENCE">NICE 2011</LINK> report.</P>
<P>A recent meta-analysis (<LINK REF="REF-Callhoff-2014" TYPE="REFERENCE">Callhoff 2014</LINK>) of RCTs assessed the benefit of anti-TNF agents adalimumab, certolizumab, etanercept, golimumab or infliximab against placebo for both ankylosing spondylitis and non-radiographic axial spondyloarthritis. Like this review, they found that anti-TNF agents showed improved benefit compared to placebo. Effect sizes were greater in the ankylosing spondylitis population compared to the non-radiographic axial spondyloarthritis trials, though when they adjusted the estimates for the year of publication as a proxy for disease severity, there was no longer a difference between the two populations.</P>
<P>While the data for this systematic review is based on RCTs, a study based on the British Society for Rheumatology Biologic Register assessed the use of anti-TNF therapy for ankylosing spondylitis in the UK in routine care. They found the mean improvement in BASDAI was 3.6 (0 to 10 scale), 52% of patients achieved a BASDAI &gt; 50 and concluded that "routine clinical use improves disease activity and functional impairment in patients with ankylosing spondylitis" (<LINK REF="REF-Lord-2010" TYPE="REFERENCE">Lord 2010</LINK>).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2015-03-22 05:47:25 -0400" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2015-03-22 05:47:25 -0400" MODIFIED_BY="[Empty name]">
<P>There is moderate to high level quality of evidence for a clinically important benefit of adalimumab, etanercept, golimumab, and infliximab compared to placebo in improving disease activity and function, and achieving partial remission in ankylosing spondylitis in the short-term. Reduction in spinal inflammation, as measured by magnetic resonance imaging (MRI), was based on low to moderate quality evidence and the clinical relevance of the small absolute changes is unclear. There is little evidence on radiographic progression from these short-term RCTs. There is moderate quality evidence for a small increased risk of withdrawals due to adverse events for the anti-tumor necrosis factor (TNF) agents as a group against placebo, but results were inconclusive for evidence of a difference between groups in terms of risk of serious adverse events. We downgraded evidence given the low number of events in the harm outcomes. For the indirect head-to-head estimates, there were wide confidence intervals and no consistency as to which biologic was favored in terms of the major outcomes. Therefore, we do not find evidence that one treatment appears to confer more benefit than another. Given that the included studies were all six months or less in duration, we did not assess evidence on the long-term benefit or effectiveness of anti-TNF therapy for ankylosing spondylitis.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2015-02-21 00:27:41 -0500" MODIFIED_BY="[Empty name]">
<P>Future trials of anti-TNF agents should focus on populations with early disease to determine if there is indeed a better response, the effect on the progression of ankylosis in this population, and to determine when it is appropriate to start anti-TNF therapy. Given the paucity of head-to-head study data, we performed a network meta-analysis to estimate effects of one anti-TNF agent versus another. However, we recommend that large, well-conducted randomized trials of anti-TNF agents versus each other are needed to clearly address issues of effectiveness among these agents. Studies based on biologic registry and other observational data will be useful to assess rare and delayed adverse effects.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2015-03-26 05:02:00 -0400" MODIFIED_BY="[Empty name]">
<P>Many thanks to Tamara Rader, Louise Falzon, Jessie McGowan and Nancy Santesso for their assistance with the literature searching. Thanks to Bharbhoor Dhaliwal for assistance with screening the searches. Colin McCann assisted with screening search results and data extraction. Thanks to Lily Chen for her statistical expertise in running the mixed treatment comparison analyses. Thank you to the authors of primary trials who provided us with additional information.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2015-03-23 06:05:48 -0400" MODIFIED_BY="[Empty name]">
<P>We received a National Institute for Health Research (NIHR) Cochrane Incentive Award to assist with the completion of this review.</P>
<UL>
<LI>LJM: was an associate member of the Assessment of SpondyloArthritis international Society from 2005 to 2014.</LI>
<LI>JZ: none known</LI>
<LI>AB: Grants: to department only: Abbvie, Pfizer, Merck, Amgen Travel support to department: Janssen-Cilag; Honorarium: part to department, part personally: Pfizer, UCB, Janssen-Cilag, Abbvie</LI>
<LI>JAS: received research grants from Takeda and Savient and consultant fees from Savient, Takeda, Regeneron and Allergan. JAS is a member of the executive of OMERACT, an organization that develops outcome measures in rheumatology and receives arms-length funding from 36 companies; a member of the American College of Rheumatology's Guidelines Subcommittee of the Quality of Care Committee; and a member of the Veterans Affairs Rheumatology Field Advisory Committee.</LI>
<LI>ETG: none known.</LI>
<LI>MV: none known.</LI>
<LI>MBJ: none known.</LI>
<LI>PT: grants/honoraria from Bristol Myers, Chiltern International, and UCB.</LI>
<LI>GW: none known</LI>
</UL>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2015-03-26 04:55:36 -0400" MODIFIED_BY="[Empty name]">
<UL>
<LI>LM: conceptualized the idea, performed screening and data extraction, entered data into Review Manager and Excel, performed analyses, and wrote the review.</LI>
<LI>JZ: conceptualized the idea, performed screening and data extraction, entered data into Review Manager, and wrote and commented on drafts of the review.</LI>
<LI>AB: conceptualized the idea, provided clinical expertise, and commented on drafts of the review.</LI>
<LI>JAS: performed screening and data extraction, and commented on drafts of the review.</LI>
<LI>MV: performed screening and data extraction, and commented on drafts of the review.</LI>
<LI>MJB: performed screening and data extraction, and commented on drafts of the review.</LI>
<LI>ETG: performed screening, risk of bias and GRADE assessments, and commented on drafts of the review.</LI>
<LI>GW: conceptualized the idea, provided statistical expertise, and commented on drafts of the review.</LI>
<LI>PT: conceptualized the idea, provided clinical expertise, and commented on drafts of the review.</LI>
</UL>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2015-03-26 05:02:07 -0400" MODIFIED_BY="[Empty name]">
<P>For the primary analysis of the major outcomes in this review, we conducted Bayesian mixed treatment comparison meta-analyses using WinBUGS software. We added golimumab to the included interventions. We selected seven major outcomes for inclusion in the 'Summary of findings' table after discussions with ankylosing spondylitis experts in the Assessment of SpondyloArthritis international Society and reported on only these seven. The original protocol outcomes are listed below.</P>
<P>Primary and secondary outcome measures will be based on the DC-ART Ankylosing Spondylitis Working Group Core Set (<LINK REF="REF-van-der-Heijde-1997" TYPE="REFERENCE">van der Heijde 1997</LINK>) and the International ASAS consensus statement for the use of TNF-alpha inhibitors in patients with AS (<A HREF="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005468/full#CD005468-bbs2-0008">Braun 2003</A>). Secondary outcomes will be proportion of responders based on either the ASAS measures (ASAS20 (<A HREF="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005468/full#CD005468-bbs2-0001">Anderson 2001</A>), ASAS40 and/or ASAS 5 of 6 (<A HREF="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005468/full#CD005468-bbs2-0005">Brandt 2004</A>)), or on any alternative response criteria formulated by the authors. Additional outcomes including quality of life measures, other imaging outcomes and reduction of other medications will also be recorded. Finally, adverse events will be reported separately, distinguishing between withdrawal due to adverse events and withdrawal due to inefficacy of therapy.</P>
<P>Primary outcomes:<BR/>Physical function<BR/>Spinal Pain<BR/>Spinal stiffness (duration of morning stiffness)<BR/>Spinal mobility<BR/>Patient global assessment<BR/>Peripheral joint/enthesis inflammation<BR/>Changes in spine radiographs<BR/>Fatigue<BR/>Acute phase reactants (erthyrocyte sedimentation rate (ESR), C-reactive protein (CRP))<BR/>Disease activity (BASDAI)Secondary outcomes:<BR/>ASAS20 response<BR/>ASAS40 response<BR/>ASAS 5 out of 6 responseOther:<BR/>Changes in hip radiograph<BR/>Physician global assessement<BR/>Quality of life<BR/>MRI evidence of suppression of inflammation<BR/>Reduction of steroid or NSAID use<BR/>
</P>
<P>Adverse effects:<BR/>Data will be collected on:<BR/>a) Total withdrawals<BR/>b) Withdrawals due to adverse effects<BR/>c) Withdrawals due to inefficacy<BR/>d) Any reported adverse effects such as infections, allergic reactions</P>
<P>We followed the latest methods as outlined in the Cochrane Handbook (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) and therefore used the GRADE criteria to assess the quality of the evidence rather than the grading system described in the 2004 book Evidence-based Rheumatology (<A HREF="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005468/full#CD005468-bbs2-0021">Tugwell 2004</A>) as stated in the protocol.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2015-03-26 04:38:45 -0400" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2015-03-23 08:08:03 -0400" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2015-03-23 08:08:03 -0400" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Bao-2014" MODIFIED="2015-02-18 23:34:44 -0500" MODIFIED_BY="[Empty name]" NAME="Bao 2014" YEAR="2014">
<REFERENCE MODIFIED="2015-02-18 23:34:44 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bao C, Huang F, Khan MA, Fei K, Zhong W, Han C, et al</AU>
<TI>Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial</TI>
<SO>Rheumatology</SO>
<YR>2014</YR>
<VL>53</VL>
<PG>1654-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-10-10 05:27:55 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-10-10 05:27:55 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1093/rheumatology/keu132"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barkham-2010" MODIFIED="2015-02-18 23:35:16 -0500" MODIFIED_BY="[Empty name]" NAME="Barkham 2010" YEAR="2008">
<REFERENCE MODIFIED="2014-10-08 03:43:02 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barkham N, Coates L, Keen H, Hensor E, Fraser A, Redmond A, et al</AU>
<TI>A double blind placebo controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis</TI>
<SO>Rheumatology</SO>
<YR>2008</YR>
<VL>47</VL>
<PG>ii72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-18 23:35:16 -0500" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Barkham N, Coates LC, Keen H, Hensor E, Fraser A, Redmond A, et al</AU>
<TI>Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2010</YR>
<VL>69</VL>
<NO>11</NO>
<PG>1926-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Brandt-2003" MODIFIED="2015-02-18 23:38:03 -0500" MODIFIED_BY="[Empty name]" NAME="Brandt 2003" YEAR="">
<REFERENCE MODIFIED="2015-02-18 23:38:03 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Grassnickel L</AU>
<TI>Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2003</YR>
<VL>48</VL>
<PG>1667-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Braun-2002" MODIFIED="2015-02-18 23:38:12 -0500" MODIFIED_BY="[Empty name]" NAME="Braun 2002" YEAR="2002">
<REFERENCE MODIFIED="2015-02-18 23:38:12 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Braun J, Brandt J, Listing J, Zink A, Alten R, Krause A, et al</AU>
<TI>Treatment of active ankylosing spondylitis with infliximab, a double-blind placebo controlled multicenter trial</TI>
<SO>Lancet</SO>
<YR>2002</YR>
<VL>359</VL>
<PG>1187-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Braun-2011" MODIFIED="2015-02-18 23:42:09 -0500" MODIFIED_BY="[Empty name]" NAME="Braun 2011" YEAR="2008">
<REFERENCE MODIFIED="2015-02-18 23:38:45 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Braun J, Burgos-Vargas R, van der Horst-Bruinsma IE, Freundlich B, Vlahos B, Koenig AS, et al</AU>
<TI>Assessment of clinical efficacy in a randomized, double-blind study of etanercept and sulphasalazine in patients with ankylosing spondylitis</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2008</YR>
<VL>58</VL>
<PG>S415</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-10-08 11:18:13 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Braun J, Pavelka K, Ramos-Remus C, Dimic A, Vlahos B, Freundlich B, et al</AU>
<TI>Clinical efficacy of etanercept versus sulfasalazine in ankylosing spondylitis subjects with peripheral joint involvement</TI>
<SO>Journal of Rheumatology</SO>
<YR>2012</YR>
<VL>39</VL>
<NO>4</NO>
<PG>836-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-18 23:41:28 -0500" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Braun J, van der Horst-Bruinsma IE, Huang F, Burgos-Vargas R, Vlahos B, Koenig AS, et al</AU>
<TI>Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: A randomized, double-blind trial</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2011</YR>
<VL>63</VL>
<NO>6</NO>
<PG>1543-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-18 23:42:09 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sieper J, Moots R, Taylor A, Sato R, Singh A, Roberson D, et al</AU>
<TI>Assessment of patient-reported outcomes from a randomized, double-blind study of etanercept and sulphasalazine in patients with ankylosing spondylitis</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2008</YR>
<VL>58</VL>
<PG>S580</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Calin-2004" MODIFIED="2015-02-18 23:42:42 -0500" MODIFIED_BY="[Empty name]" NAME="Calin 2004" YEAR="">
<REFERENCE MODIFIED="2015-02-18 23:42:42 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Calin A, Dijkmans B, Emery P, Hakala M, Kalden J, Leirsalo-Repo M, et al</AU>
<TI>Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2004</YR>
<VL>63</VL>
<PG>1595-1600</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Davis-2003" MODIFIED="2015-02-18 23:43:50 -0500" MODIFIED_BY="[Empty name]" NAME="Davis 2003" YEAR="">
<REFERENCE MODIFIED="2015-02-18 23:42:57 -0500" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Davis J, van der Heijde D, Braun J, Dougados M, Cush J, Clegg D, et al</AU>
<TI>Recombinant Human Tumor Necrosis Factor Receptor (Etanercept) for Treating Ankylosing Spondylitis</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2003</YR>
<VL>48</VL>
<NO>11</NO>
<PG>3230-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-18 23:43:24 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Davis J, van der Heijde, Braun J, Dougados M, Clegg DO, Kivits A, et al</AU>
<TI>Effiacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2008</YR>
<VL>67</VL>
<PG>346-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-18 23:43:50 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davis JC, van der Heijde DM, Braun J, Dougados M, Cush J, Clegg D, et al</AU>
<TI>Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2005</YR>
<VL>64</VL>
<PG>1557-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dougados-2011" MODIFIED="2014-10-08 11:27:45 -0400" MODIFIED_BY="[Empty name]" NAME="Dougados 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-10-08 11:27:44 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dougados M, Braun J, Szanto S, Combe B, Elbaz M, Geher P, et al</AU>
<TI>Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: Results of a randomised double-blind placebo-controlled study (SPINE)</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2011</YR>
<VL>70</VL>
<PG>799-804</PG>
<IDENTIFIERS MODIFIED="2014-10-08 11:27:44 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-10-08 11:27:44 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1136/ard.2010.139261"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Giardina-2009" MODIFIED="2015-02-18 23:48:49 -0500" MODIFIED_BY="[Empty name]" NAME="Giardina 2009" YEAR="2009">
<REFERENCE MODIFIED="2015-02-18 23:45:07 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Braun J, Baraliakos X, Hermann KG, van der Heijde D, Inman RD, Deodhar AA, et al</AU>
<TI>Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo-controlled GO-RAISE study</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2012</YR>
<VL>71</VL>
<NO>6</NO>
<PG>878-84</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="DOI: 10.1136/annrheumdis-2011-200308"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-18 23:47:36 -0500" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="OTHER">
<AU>Giardina AR, Ferrante A, Ciccia F, Impastato R, Miceli M, Principato A, et al</AU>
<TI>A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis</TI>
<SO>Rheumatology International</SO>
<YR>2009 October 23 [Epub ahead of print]</YR>
<IDENTIFIERS MODIFIED="2010-04-11 12:12:26 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-04-11 12:12:26 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1007/s00296-009-1157-3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-18 23:48:49 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Impastato R, Ciccia F, Ferrante A, Principato A, Giardina A, Cadelo M, et al</AU>
<TI>Infliximab and etanercept are both effective and safe in patients with ankylosing spondylitis. A two-year randomised study</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2007</YR>
<VL>66</VL>
<NO>Suppl II</NO>
<PG>399</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gorman-2002" MODIFIED="2015-02-18 23:51:10 -0500" MODIFIED_BY="[Empty name]" NAME="Gorman 2002" YEAR="2002">
<REFERENCE MODIFIED="2015-02-18 23:51:10 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gorman JD, Sack KE, Davis JC</AU>
<TI>Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha</TI>
<SO>New England Journal of Medicine</SO>
<YR>2002</YR>
<VL>346</VL>
<PG>1349-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hu-2012" MODIFIED="2014-12-12 06:33:55 -0500" MODIFIED_BY="[Empty name]" NAME="Hu 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-12-12 06:33:52 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hu Z, Xu M, Qiuxia L, Zhiming L, Liao Z, Cao S, et al</AU>
<TI>Adalimumab significantly reduces inflammation and serumDKK-1 level but increases fatty deposition in lumbar spine inactive ankylosing spondylitis</TI>
<SO>International Journal of Rheumatic Diseases</SO>
<YR>2012</YR>
<VL>15</VL>
<PG>358-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-2008" MODIFIED="2015-03-23 08:06:09 -0400" MODIFIED_BY="[Empty name]" NAME="Huang 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-03-15 14:27:53 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Huang F, MacPeek D, Shunle C, Li Z, Gu J, Wu D, et al</AU>
<TI>Etanercept is effective and well tolerated in Chinese patients with ankylosing spondylitis: 6-week placebo-controlled trial followed by 6-week open-label treatment</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2008</YR>
<VL>67</VL>
<PG>Suppl II: 521</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-03-23 08:06:09 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Huang F, Zhang J, Huang JL, Wu DH, Li ZG, Chen SL, et al</AU>
<TI>A multicenter, double-blind, placebo-controlled, randomized, phase III clinical study of etanercept in treatment of ankylosing spondylitis</TI>
<SO>Zhonghua Nei Ke Za Zhi (Chinese Journal of Internal Medicine)</SO>
<YR>2010</YR>
<VL>49</VL>
<PG>741&#8211;5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-2014" MODIFIED="2015-02-19 01:01:45 -0500" MODIFIED_BY="[Empty name]" NAME="Huang 2014" YEAR="2014">
<REFERENCE MODIFIED="2015-02-19 01:01:45 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang F, Gu J, Zhu P, Bao C, Xu, J, Xu H, et al</AU>
<TI>Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2014</YR>
<VL>73</VL>
<PG>587-94</PG>
<IDENTIFIERS MODIFIED="2014-10-10 15:03:01 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-10-10 15:03:01 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1136/annrheumdis-2012-202533"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Inman-2008" MODIFIED="2015-03-23 08:08:03 -0400" MODIFIED_BY="[Empty name]" NAME="Inman 2008" YEAR="2008">
<REFERENCE MODIFIED="2015-02-19 01:04:06 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Braun J, Baraliakos X, Hermann KG, van der Heijde D, Inman RD, Deodhar AA, et al</AU>
<TI>Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo-controlled GO-RAISE study</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2012</YR>
<VL>71</VL>
<NO>6</NO>
<PG>878-84</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1136/annrheumdis-2011-200308"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-03-23 08:08:03 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Inman RD, Davis JC Jr, Heijde Dv, Diekman L, Sieper J, Kim SI, et al</AU>
<TI>Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2008</YR>
<VL>58</VL>
<NO>11</NO>
<PG>3402-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Inman-2010" MODIFIED="2015-02-19 01:16:12 -0500" MODIFIED_BY="[Empty name]" NAME="Inman 2010" YEAR="2008">
<REFERENCE MODIFIED="2015-02-19 01:08:12 -0500" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Inman R, Maksymowych W; CANDLE group</AU>
<TI>A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis</TI>
<SO>Journal of Rheumatology</SO>
<YR>2010</YR>
<VL>37</VL>
<NO>6</NO>
<PG>1-8</PG>
<IDENTIFIERS MODIFIED="2010-04-16 06:58:26 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-04-16 06:58:26 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="doi:10.3899/jrheum.091042"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-19 01:15:13 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Inman R, Shojania K, Keystone E, Haraoui B, Mitchell C, Maksymowych W</AU>
<TI>CANaDian evaluation of Low dosE infliximab in ankylosing spondylitis (CANDLE)</TI>
<SO>Journal of Rheumatology</SO>
<YR>2008</YR>
<VL>35</VL>
<NO>6</NO>
<PG>1213-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-19 01:16:12 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maksymowych W, Salonen D, Inman R, Paul FL, Lambert RG</AU>
<TI>CANaDian evaluation of Low dosE Infliximab in Ankylosing Spondylitis (CANDLE) - 12 week magnetic resonance imaging evaluation of spinal inflammation with the SPARCC MRI method</TI>
<SO>Journal of Rheumatology</SO>
<YR>2008</YR>
<VL>35</VL>
<NO>6</NO>
<PG>1211-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-10-09 12:19:06 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maksymowych WP, Salonen D, Inman RD, Rahman P, Lambert RGW</AU>
<TI>Low-dose infliximab (3 mg/kg) significantly reduces spinal inflammation on magnetic resonance imaging in patients with ankylosing spondylitis: a randomized placebo-controlled study</TI>
<SO>Journal of Rheumatology</SO>
<YR>2010</YR>
<VL>37</VL>
<NO>8</NO>
<PG>1728-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lambert-2007" MODIFIED="2015-02-19 01:16:47 -0500" MODIFIED_BY="[Empty name]" NAME="Lambert 2007" YEAR="2007">
<REFERENCE MODIFIED="2015-02-19 01:16:39 -0500" MODIFIED_BY="[Empty name]" NOTES="1693" NOTES_MODIFIED="2015-02-19 01:16:39 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lambert RGW, Salonen D, Rahman P, Inman RD, Wong RL, Einstein SG, et al</AU>
<TI>Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2007</YR>
<VL>56</VL>
<NO>12</NO>
<PG>4005-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-19 01:16:47 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Maksymowych W, Rahman P, Keystone E, Wong R, Inman R; M03-606 Study Group</AU>
<TI>Efficacy of adalimumab in active AS: Results from the Canadian AS study</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2005</YR>
<PG>S217</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-04-02 16:00:08 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maksymowych W, Rahman P, Shojania K, Olszynski W, Thomson G, Ballal S, et al</AU>
<TI>Beneficial effects of adalimumab on biomarkers reflecting structural damage in patients with ankylosing spondylitis</TI>
<SO>Journal of Rheumatology</SO>
<YR>2008</YR>
<VL>35</VL>
<NO>10</NO>
<PG>2030-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marzo_x002d_Ortega-2005" MODIFIED="2010-07-07 09:27:18 -0400" MODIFIED_BY="[Empty name]" NAME="Marzo-Ortega 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-07-07 09:27:18 -0400" MODIFIED_BY="[Empty name]" NOTES="128" NOTES_MODIFIED="2010-07-07 09:27:18 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marzo-Ortega H, McGonagle D, Jarrett S, Haugeberg G, Hensor E, O'Connor P, et al</AU>
<TI>Infliximab in combination with methotrexate in active ankylosing spondylitis: A clinical and imaging study</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2005</YR>
<VL>64</VL>
<NO>11</NO>
<PG>1568-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Navarro_x002d_Sarabia-2011" MODIFIED="2015-02-19 01:17:24 -0500" MODIFIED_BY="[Empty name]" NAME="Navarro-Sarabia 2011" YEAR="2011">
<REFERENCE MODIFIED="2015-02-19 01:17:24 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Navarro-Sarabia F, Fernandez-Sueiro JL, Torre-Alonso JC, Gratacos J, Queiro R, Gonzalez C, et al</AU>
<TI>High-dose etanercept in ankylosing spondylitis: results of a 12-week randomized, double blind, controlled multicentre study (LOADET study)</TI>
<SO>Rheumatology</SO>
<YR>2011</YR>
<VL>50</VL>
<NO>10</NO>
<PG>1828-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-der-Heijde-2005" MODIFIED="2015-02-19 01:18:41 -0500" MODIFIED_BY="[Empty name]" NAME="van der Heijde 2005" YEAR="">
<REFERENCE MODIFIED="2015-02-19 01:17:37 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Braun J, Deodhar A, Dijkmans B, Geusens P, Sieper J, Williamson P, et al</AU>
<TI>Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2008</YR>
<VL>59</VL>
<PG>1270-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-19 01:17:49 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Braun J, Landewe R, Hermann KGA, Han J, Yan S, Williamson P, et al</AU>
<TI>Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab - Results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2006</YR>
<VL>54</VL>
<NO>5</NO>
<PG>1646-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-19 01:18:07 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Heldmann F, Brandt J, Braun J; EASIC Study Group</AU>
<TI>European ankylosing spondylitis infliximab cohort (EASIC): safety of longterm therapy with infliximab in patients with ankylosing spondylitis</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2008</YR>
<VL>67</VL>
<PG>Suppl II:386</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-19 01:18:27 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Heldmann F, Brandt J, van der Horst-Bruinsma, Landewe R, Sieper J, Burmester G, et al</AU>
<TI>European Ankylosing Spondylitis Infliximab Cohort (EASIC): Safety of longterm therapy in patients with ankylosing spondylitis</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2009</YR>
<VL>68 (Suppl 3)</VL>
<PG>626</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-19 01:18:41 -0500" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, et al</AU>
<TI>Efficacy and Safety of Infliximab in Patients with Ankylosing Spondylitis. Results of a Randomized, Placebo-Controlled Trial (ASSERT)</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2005</YR>
<VL>52</VL>
<NO>2</NO>
<PG>582-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-06-05 16:00:21 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>van der Heijde D, Han C, Bala M, Williamson P, Han J, Braun J</AU>
<TI>Infliximab improves fatigue and pain in patients with ankylosing spondylitis: Results of a randomized, placebo-controlled trial (ASSERT)</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2005</YR>
<VL>64</VL>
<PG>318-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-06-05 16:01:40 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>van der Heijde D, Han C, Bala M, Williamson P, Han J, Braun J</AU>
<TI>Infliximab improves fatigue and pain in patients with ankylosing spondylitis: Results of a randomized, placebo-controlled trial</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2005</YR>
<VL>52 (9)</VL>
<PG>s35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-van-der-Heijde-2006a" MODIFIED="2015-02-19 01:20:21 -0500" MODIFIED_BY="[Empty name]" NAME="van der Heijde 2006a" YEAR="2006">
<REFERENCE MODIFIED="2015-02-19 01:19:20 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Davis Jr JC, Revicki D, van der Heijde DMF, Rentz AM, Wong RL, Kupper H, et al</AU>
<TI>Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: Results from a randomized controlled study</TI>
<SO>Arthritis Care and Research</SO>
<YR>2007</YR>
<VL>57</VL>
<NO>6</NO>
<PG>1050-7</PG>
<IDENTIFIERS MODIFIED="2009-04-27 12:20:58 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="DOI" VALUE="10.1002/art.22887"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-29 10:50:59 -0400" MODIFIED_BY="[Empty name]" NOTES="22" NOTES_MODIFIED="2009-04-29 10:50:59 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Revicki DA, Luo MP, Wordsworth P, Wong RL, Chen N, Davis Jr J</AU>
<TI>Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: Results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS)</TI>
<SO>Journal of Rheumatology</SO>
<YR>2008</YR>
<VL>35</VL>
<NO>7</NO>
<PG>1346-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-19 01:19:34 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>van der Heijde D, Dijkmans B, Schiff M, Kivitz A, de Vlam K, Wordsworth P, et al</AU>
<TI>Maintenance of reduction in disease activity and partial remission in patients with ankylosing spondylitis (AS) - 3 year results from the adalimumab (Humira) trial evaluating long-term efficacy and safety in AS (ATLAS)</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2008</YR>
<PG>S579</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-19 01:20:21 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Requested information regarding blinding and standard deviations for Table 2, 14/09/06&lt;/p&gt;" NOTES_MODIFIED="2015-02-19 01:20:21 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BAC, Braun J; ATLAS study group</AU>
<TI>Efficacy and safety of adalimumab in patients with ankylosing spondylitis</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2006</YR>
<VL>54</VL>
<NO>7</NO>
<PG>2136-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-06-05 20:02:12 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van der Heijde D, Schiff M, Sieper J, Kivitz A, Wong R, Kupper H, et al</AU>
<TI>Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2009</YR>
<VL>68</VL>
<PG>922-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-der-Heijde-2006b" MODIFIED="2009-04-28 11:00:30 -0400" MODIFIED_BY="[Empty name]" NAME="van der Heijde 2006b" YEAR="2006">
<REFERENCE MODIFIED="2009-04-28 11:00:24 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Braun J, McHugh N, Singh A, Wajdula JS, Sato R</AU>
<TI>Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly</TI>
<SO>Rheumatology</SO>
<YR>2007</YR>
<VL>46</VL>
<NO>6</NO>
<PG>999-1004</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-28 11:00:30 -0400" MODIFIED_BY="[Empty name]" NOTES="86" NOTES_MODIFIED="2009-04-28 11:00:30 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>van der Heijde D, Da Silva JC, Dougados M, Geher P, Van DH-B, Juanola X, et al</AU>
<TI>Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2006</YR>
<VL>65</VL>
<NO>12</NO>
<PG>1572-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2015-03-23 07:39:54 -0400" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Barkham-2008b" MODIFIED="2010-03-14 22:17:35 -0400" MODIFIED_BY="[Empty name]" NAME="Barkham 2008b" YEAR="2008">
<REFERENCE MODIFIED="2010-03-14 22:17:27 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Barkham N, Keen HI, Coates P, O'Connor EMA, Hensor AD, Fraser LS, et al</AU>
<TI>A randomized controlled trial of infliximab shows clinical and MRI efficacy in HLA B27 positive very early ankylosing spondylitis</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2008</YR>
<VL>67</VL>
<PG>Suppl II:382</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Breban-2008" MODIFIED="2015-02-19 01:21:48 -0500" MODIFIED_BY="[Empty name]" NAME="Breban 2008" YEAR="2008">
<REFERENCE MODIFIED="2015-02-19 01:21:48 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Breban M, Ravaud P, Claudepierre P, Baron G, Henry Y-D, Hudry C, et al</AU>
<TI>Maintenance of infliximab treatment in ankylosing spondylitis: Results of a one-year randomized controlled trial comparing systematic versus on-demand treatment</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2008</YR>
<VL>58</VL>
<NO>1</NO>
<PG>88-97</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/art.23167"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Haibel-2008" MODIFIED="2015-02-19 01:23:34 -0500" MODIFIED_BY="[Empty name]" NAME="Haibel 2008" YEAR="2008">
<REFERENCE MODIFIED="2015-02-19 01:23:34 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Haibel H, Rudwaleit M, Listing J, Heldmann F, Wong RL, Kupper H, et al</AU>
<TI>Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: Results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2008</YR>
<VL>58</VL>
<NO>7</NO>
<PG>1981-91</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/art.23606"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2008" MODIFIED="2015-02-19 01:23:42 -0500" MODIFIED_BY="[Empty name]" NAME="Li 2008" YEAR="2008">
<REFERENCE MODIFIED="2015-02-19 01:23:42 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li EK, Griffth JF, Lee VW, Wang YX, Li TK, Lee KK, et al</AU>
<TI>Short-term effiacy of combination methotrexate and infliximab in patients with ankylosing spondylitis: a clinical and magnetic resonance imaging correlation</TI>
<SO>Rheumatology</SO>
<YR>2008</YR>
<VL>47</VL>
<NO>9</NO>
<PG>1358-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morency-2011" MODIFIED="2015-02-19 01:23:59 -0500" MODIFIED_BY="[Empty name]" NAME="Morency 2011" YEAR="2011">
<REFERENCE MODIFIED="2015-02-19 01:23:59 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morency N, Lambert R, Maksymowych W</AU>
<TI>Direct imaging evidence that adalimumab induces resolution of inflammatory lesions in AS patients at sites of complete spinal ankylosis</TI>
<SO>Journal of Rheumatology</SO>
<YR>2011</YR>
<VL>38</VL>
<NO>6</NO>
<PG>1138</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-den-Bosch-2002" MODIFIED="2015-02-19 01:27:19 -0500" MODIFIED_BY="[Empty name]" NAME="Van den Bosch 2002" YEAR="2002">
<REFERENCE MODIFIED="2015-02-19 01:27:19 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kruithof E, Van den Bosch F, Baeten D, Herssens A, De Keyser F, Mielants H, et al</AU>
<TI>Repeated infusions of infliximab, a chimeric anti-TNF alpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up</TI>
<SO>Annals of Rheumatic Diseases</SO>
<YR>2002</YR>
<VL>61</VL>
<PG>207-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-19 01:27:14 -0500" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Van den Bosch F, Kruithof E, Baeten D, Herssens A, de Keyser F, Mielants H, et al</AU>
<TI>Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondyloarthropathy</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2002</YR>
<VL>46</VL>
<NO>3</NO>
<PG>755-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2015-02-19 01:28:28 -0500" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2009" MODIFIED="2015-02-19 01:28:28 -0500" MODIFIED_BY="[Empty name]" NAME="Zhang 2009" YEAR="2009">
<REFERENCE MODIFIED="2015-02-19 01:28:28 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang J, Zhang YM, Zhang J-L, Deng X-H, Huang F</AU>
<TI>Efficacy of etanercept in patients with ankylosing spondylitis: A double-blind, randomized, placebo controlled trial. [Chinese]</TI>
<SO>Chinese Journal of New Drugs</SO>
<YR>2009</YR>
<VL>18</VL>
<NO>19</NO>
<PG>1846</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2015-03-26 04:38:45 -0400" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2015-03-26 04:38:45 -0400" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Ades-2008" MODIFIED="2014-11-27 05:07:52 -0500" MODIFIED_BY="[Empty name]" NAME="Ades 2008" TYPE="JOURNAL_ARTICLE">
<AU>Ades AE, Welton NJ, Caldwell D, Price M, Goubar A, Lu G</AU>
<TI>Multiparameter evidence synthesis in epidemiology and medical decision-making</TI>
<SO>Journal of Health Services Research Policy</SO>
<YR>2008</YR>
<VL>13 Suppl 3</VL>
<PG>12-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Anderson-2001" MODIFIED="2015-02-19 01:29:14 -0500" MODIFIED_BY="[Empty name]" NAME="Anderson 2001" TYPE="JOURNAL_ARTICLE">
<AU>Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M</AU>
<TI>Ankylosing Spondylitis Assessment group preliminary definition of short-term improvement in ankylosing spondylitis</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2001</YR>
<VL>44</VL>
<NO>8</NO>
<PG>1876-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boers-2006" MODIFIED="2010-08-22 11:37:24 -0400" MODIFIED_BY="[Empty name]" NAME="Boers 2006" TYPE="JOURNAL_ARTICLE">
<AU>Boers M</AU>
<TI>Abatacept in rheumatoid arthritis: a new branch on the biologics tree (editorial)</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2006</YR>
<VL>144</VL>
<PG>933-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boonen-2001a" MODIFIED="2015-02-19 21:05:00 -0500" MODIFIED_BY="[Empty name]" NAME="Boonen 2001a" TYPE="JOURNAL_ARTICLE">
<AU>Boonen A, Chorus A, Miedema H, van der Heidje D, van der Temple H, van der Linden S</AU>
<TI>Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients</TI>
<SO>Annals of Rheumatic Diseases</SO>
<YR>2001</YR>
<VL>60</VL>
<PG>353-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boonen-2001b" MODIFIED="2015-02-19 21:04:54 -0500" MODIFIED_BY="[Empty name]" NAME="Boonen 2001b" TYPE="JOURNAL_ARTICLE">
<AU>Boonen A, Chorus A, Miedema H, van der Heijde D, Landewé R, Schouten H, et al</AU>
<TI>Withdrawal from labour force due to work disability in patients with ankylosing spondylitis</TI>
<SO>Annals of Rheumatic Diseases</SO>
<YR>2001</YR>
<VL>60</VL>
<PG>1033-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bradburn-2007" MODIFIED="2010-07-08 10:02:43 -0400" MODIFIED_BY="[Empty name]" NAME="Bradburn 2007" TYPE="JOURNAL_ARTICLE">
<AU>Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A</AU>
<TI>Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events</TI>
<SO>Statistics in Medicine</SO>
<YR>2007</YR>
<VL>26</VL>
<NO>1</NO>
<PG>53-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brandt-2000" MODIFIED="2015-02-19 01:30:27 -0500" MODIFIED_BY="[Empty name]" NAME="Brandt 2000" TYPE="JOURNAL_ARTICLE">
<AU>Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J, et al</AU>
<TI>Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2000</YR>
<VL>43</VL>
<NO>6</NO>
<PG>1346-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brandt-2004" MODIFIED="2015-02-19 01:31:15 -0500" MODIFIED_BY="[Empty name]" NAME="Brandt 2004" TYPE="JOURNAL_ARTICLE">
<AU>Brandt J, Listing J, Sieper J, Rudwaleit M, van der Heijde D, Braun J</AU>
<TI>Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2004</YR>
<VL>63</VL>
<NO>11</NO>
<PG>1438-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Braun-1995" MODIFIED="2015-02-19 01:31:56 -0500" MODIFIED_BY="[Empty name]" NAME="Braun 1995" TYPE="JOURNAL_ARTICLE">
<AU>Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H, et al</AU>
<TI>Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>1995</YR>
<VL>38</VL>
<NO>4</NO>
<PG>499-505</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Braun-2003" MODIFIED="2015-02-19 01:32:04 -0500" MODIFIED_BY="[Empty name]" NAME="Braun 2003" TYPE="JOURNAL_ARTICLE">
<AU>Braun J, Pham T, Sieper J, Davis J, van der Linden S, Dougados M, et al</AU>
<TI>International ASAS consensus statement for the use of anti-tumor necrosis factor agents in patients with ankylosing spondylitis</TI>
<SO>Annals of Rheumatic Diseases</SO>
<YR>2003</YR>
<VL>62</VL>
<PG>817-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Braun-2006" MODIFIED="2015-02-19 01:32:15 -0500" MODIFIED_BY="[Empty name]" NAME="Braun 2006" TYPE="JOURNAL_ARTICLE">
<AU>Braun J, Landewe R, Hermann KGA, Han J, Yan S, Williamson P, et al</AU>
<TI>Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab - Results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2006</YR>
<VL>54</VL>
<NO>5</NO>
<PG>1646-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Braun-2012a" MODIFIED="2015-02-19 01:33:53 -0500" MODIFIED_BY="[Empty name]" NAME="Braun 2012a" TYPE="JOURNAL_ARTICLE">
<AU>Braun J, Pavelka K, Ramos-Remus C, Dimic A, Vlahos B, Freundlich B, et al</AU>
<TI>Clinical efficacy of etanercept versus sulfasalazine in ankylosing spondylitis subjects with peripheral joint involvement</TI>
<SO>Journal of Rheumatology</SO>
<YR>2012</YR>
<VL>39</VL>
<NO>4</NO>
<PG>836-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Braun-2012b" MODIFIED="2015-02-19 01:33:47 -0500" MODIFIED_BY="[Empty name]" NAME="Braun 2012b" TYPE="JOURNAL_ARTICLE">
<AU>Braun J, Baraliakos X, Hermann K-G A, van der Heijde D, Inman RD, Deodhar AA, et al</AU>
<TI>Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2012</YR>
<VL>71</VL>
<PG>878-84</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1136/annrheumdis-2011-200308"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bucher-1997" MODIFIED="2010-07-08 10:33:59 -0400" MODIFIED_BY="[Empty name]" NAME="Bucher 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bucher HC, Guyatt GH, Griffith LE, Walter SD</AU>
<TI>The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>1997</YR>
<VL>50</VL>
<NO>6</NO>
<PG>683-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Calin-1994" MODIFIED="2014-11-17 14:34:32 -0500" MODIFIED_BY="[Empty name]" NAME="Calin 1994" TYPE="JOURNAL_ARTICLE">
<AU>Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al</AU>
<TI>A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index</TI>
<SO>Journal of Rheumatology</SO>
<YR>1994</YR>
<VL>21</VL>
<NO>12</NO>
<PG>2281-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Callhoff-2014" MODIFIED="2015-02-19 01:40:24 -0500" MODIFIED_BY="[Empty name]" NAME="Callhoff 2014" TYPE="OTHER">
<AU>Callhoff J, Sieper J, WeiB A, Zink A, Listing J</AU>
<TI>Efficacy of TNF&#945; blockers in patients with ankylosing spondylitis and non-radiographic axials spondyloarthritis: a meta-analysis</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2014 Apr 9 [Epub ahead of print]</YR>
<IDENTIFIERS MODIFIED="2014-12-11 06:04:47 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-12-11 06:04:47 -0500" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1136/annrheumdis-2014-205322"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cates-2008" MODIFIED="2015-03-20 07:27:39 -0400" MODIFIED_BY="[Empty name]" NAME="Cates 2008" TYPE="COMPUTER_PROGRAM">
<TI>Visual Rx3. Dr Chris Cates' EBM website www.nntonline.com</TI>
<YR>2008</YR>
<PB>Dr. Chris Cates</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chen-2014" MODIFIED="2015-01-29 14:57:09 -0500" MODIFIED_BY="[Empty name]" NAME="Chen 2014" TYPE="COCHRANE_REVIEW">
<AU>Chen J, Lin S, Liu C</AU>
<TI>Sulfasalazine for ankylosing spondylitis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2014</YR>
<NO>11</NO>
<IDENTIFIERS MODIFIED="2015-01-29 14:57:09 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-01-29 14:57:09 -0500" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004800"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cooper-2009" MODIFIED="2014-11-27 05:03:08 -0500" MODIFIED_BY="[Empty name]" NAME="Cooper 2009" TYPE="JOURNAL_ARTICLE">
<AU>Cooper NJ, Sutton AJ, Morris D, Ades AE, Welton NJ</AU>
<TI>Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons: application to stroke prevention treatments in individuals with non-rheumatic atrial fibrillation</TI>
<SO>Statistics in Medicine</SO>
<YR>2009</YR>
<VL>28</VL>
<NO>14</NO>
<PG>1861-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dagfinrud-2008" MODIFIED="2015-02-19 01:41:34 -0500" MODIFIED_BY="[Empty name]" NAME="Dagfinrud 2008" TYPE="COCHRANE_REVIEW">
<AU>Dagfinrud H, Kvien TK, Hagen KB</AU>
<TI>Physiotherapy interventions for ankylosing spondylitis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2015-01-13 10:10:17 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-01-13 10:10:17 -0500" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002822"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dias-2010" MODIFIED="2015-02-19 01:41:52 -0500" MODIFIED_BY="[Empty name]" NAME="Dias 2010" TYPE="JOURNAL_ARTICLE">
<AU>Dias S, Welton NJ, Caldwell DM, Ades AE</AU>
<TI>Checking consistency in mixed treatment comparison meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>2010</YR>
<VL>29</VL>
<PG>932-44</PG>
<IDENTIFIERS MODIFIED="2010-11-27 12:42:27 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-11-27 12:42:27 -0500" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="DOI: 10.1002/sim.3767"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dias-2011a" MODIFIED="2015-02-19 01:45:37 -0500" MODIFIED_BY="[Empty name]" NAME="Dias 2011a" TYPE="OTHER">
<AU>Dias S, Welton NJ, Sutton AJ, Ades AE; National Institute for Health and Clinical Excellence, Decision Support Unit</AU>
<TI>NICE DSU technical support document 1: introduction to evidence synthesis for decision making</TI>
<SO>www.cc-arcc.ca/common/pages/UserFile.aspx?fileId=282147</SO>
<YR>(accessed 22 Apr 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dias-2011b" MODIFIED="2015-02-19 01:48:02 -0500" MODIFIED_BY="[Empty name]" NAME="Dias 2011b" TYPE="OTHER">
<AU>Dias S, Welton NJ, Sutton AJ, Ades AE; National Institute for Health and Clinical Excellence, Decision Support Unit</AU>
<TI>NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials</TI>
<SO>www.nicedsu.org.uk/TSD2%20General%20meta%20analysis%20corrected%2015April2014.pdf</SO>
<YR>(accessed 22 Apr 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dias-2011c" MODIFIED="2015-02-19 01:49:28 -0500" MODIFIED_BY="[Empty name]" NAME="Dias 2011c" TYPE="OTHER">
<AU>Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE; National Institute for Health and Clinical Excellence, Decision Support Unit</AU>
<TI>NICE DSU technical support document 4: inconsistency in networks of evidence based on randomised controlled trials</TI>
<SO>www.nicedsu.org.uk/TSD4%20Inconsistency.final.15April2014.pdf</SO>
<YR>(accessed 22 Apr 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dougados-2002" MODIFIED="2015-02-19 01:49:52 -0500" MODIFIED_BY="[Empty name]" NAME="Dougados 2002" TYPE="JOURNAL_ARTICLE">
<AU>Dougados M, Kijkmans B, Khan M, Maksymowych W, van der Linden S, Brandt J</AU>
<TI>Conventional treatments for ankylosing spondylitis</TI>
<SO>Annals of Rheumatic Diseases</SO>
<YR>2002</YR>
<VL>61</VL>
<NO>Suppl iii</NO>
<PG>iii40-iii50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Edmunds-1991" MODIFIED="2015-02-19 01:51:54 -0500" MODIFIED_BY="[Empty name]" NAME="Edmunds 1991" TYPE="JOURNAL_ARTICLE">
<AU>Edmunds L, Elswood J, Kennedy LG, Calin A</AU>
<TI>Primary ankylosing spondylitis, psoriatic and enteropathic spondyloarthropathy: a controlled analysis</TI>
<SO>Journal of Rheumatology</SO>
<YR>1991</YR>
<VL>18</VL>
<NO>5</NO>
<PG>696-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GRADEpro-2014" MODIFIED="2015-03-22 05:00:20 -0400" MODIFIED_BY="[Empty name]" NAME="GRADEpro 2014" TYPE="COMPUTER_PROGRAM">
<TI>GRADEpro. [www.gradepro.org]</TI>
<YR>Version 3.6 [2014]</YR>
<PB>McMaster University</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Haibel-2004" MODIFIED="2015-02-19 01:56:03 -0500" MODIFIED_BY="[Empty name]" NAME="Haibel 2004" TYPE="JOURNAL_ARTICLE">
<AU>Haibel H, Brandt HC, Rudwaleit M, Listing J, Braun J, Kupper H, et al</AU>
<TI>Efficacy and safety of adalimumab in the treatment of active ankylosing spondylitis: Preliminary results of an open-label, 20-week trial</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2004</YR>
<VL>50</VL>
<NO>Suppl</NO>
<PG>S217</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Haibel-2010" MODIFIED="2015-02-19 01:56:41 -0500" MODIFIED_BY="[Empty name]" NAME="Haibel 2010" TYPE="JOURNAL_ARTICLE">
<AU>Haibel H, Sieper J</AU>
<TI>Editorial review: how early should ankylosing spondylitis be treated with a tumor necrosis factor-blocker?</TI>
<SO>Current Opinion in Rheumatology</SO>
<YR>2010</YR>
<VL>22</VL>
<PG>388-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins J, Thompson S, Deeks J, Altman D</AU>
<TI>Measuring inconsistency in meta-analysis</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2015-02-19 01:57:33 -0500" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hochberg-2003" MODIFIED="2015-02-19 18:26:28 -0500" MODIFIED_BY="[Empty name]" NAME="Hochberg 2003" TYPE="JOURNAL_ARTICLE">
<AU>Hochberg MC, Tracy JK, Hawkins-Holt M, Flores RH</AU>
<TI>Comparison of the efficacy of the tumour necrosis factor (alpha) blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2003</YR>
<VL>62</VL>
<NO>Suppl 2</NO>
<PG>ii13-ii16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Inman-2011" MODIFIED="2015-02-19 18:29:05 -0500" MODIFIED_BY="[Empty name]" NAME="Inman 2011" TYPE="BOOK_SECTION">
<AU>Inman RD</AU>
<TI>The spondyloarthropathies</TI>
<SO>Cecil Medicine</SO>
<YR>2011</YR>
<EN>24th</EN>
<ED>Goldman L, Schafer AI</ED>
<PB>Elsevier Saunders</PB>
<CY>Philadelphia, PA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Khan-2002" MODIFIED="2015-02-19 18:29:17 -0500" MODIFIED_BY="[Empty name]" NAME="Khan 2002" TYPE="JOURNAL_ARTICLE">
<AU>Khan M</AU>
<TI>Update on spondyloarthropathies</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2002</YR>
<VL>136</VL>
<PG>896-907</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lord-2010" MODIFIED="2015-02-19 18:30:14 -0500" MODIFIED_BY="[Empty name]" NAME="Lord 2010" TYPE="JOURNAL_ARTICLE">
<AU>Lord PAC, Farragher TM, Lunt M, Watson KD, Symmons DPM, Hyrich KL</AU>
<TI>Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register</TI>
<SO>Rheumatology</SO>
<YR>2010</YR>
<VL>49</VL>
<PG>563-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Maksymowych-2002" MODIFIED="2015-02-19 18:30:26 -0500" MODIFIED_BY="[Empty name]" NAME="Maksymowych 2002" TYPE="JOURNAL_ARTICLE">
<AU>Maksymowych W, Jhangri G, Lambert R, Mallon C, Buenviaje H, Pedryca E, et al</AU>
<TI>Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety</TI>
<SO>Journal of Rheumatology</SO>
<YR>2002</YR>
<VL>29</VL>
<PG>959-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Maksymowych-2003" MODIFIED="2015-02-19 18:30:37 -0500" MODIFIED_BY="[Empty name]" NAME="Maksymowych 2003" TYPE="JOURNAL_ARTICLE">
<AU>Maksymowych W, Inman R, Gladman D, Thompson G, Stone M, Karsh J, et al</AU>
<TI>Canadian Rheumatolgy Association Consensus on the use of anti-tumor necrosis factor-alpha directed therapies in the treatment of spondyloarthritis</TI>
<SO>Journal of Rheumatology</SO>
<YR>2003</YR>
<VL>30</VL>
<PG>1356-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Maksymowych-2005" MODIFIED="2015-02-19 18:30:50 -0500" MODIFIED_BY="[Empty name]" NAME="Maksymowych 2005" TYPE="CONFERENCE_PROC">
<AU>Maksymowych W, Rahman P, Keystone E, Wong R, Inman R; M03-606 Study Group</AU>
<TI>Efficacy of adalimumab in active AS: Results from the Canadian AS study</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2005</YR>
<PG>S217</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Maksymowych-2008" MODIFIED="2014-12-01 09:32:01 -0500" MODIFIED_BY="[Empty name]" NAME="Maksymowych 2008" TYPE="JOURNAL_ARTICLE">
<AU>Maksymowych W, Rahman P, Shojania K, Olszynski W, Thomson G, Ballal S, et al</AU>
<TI>Beneficial effects of adalimumab on biomarkers reflecting structural damage in patients with ankylosing spondylitis</TI>
<SO>Journal of Rheumatology</SO>
<YR>2008</YR>
<VL>35</VL>
<NO>10</NO>
<PG>2030-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Maksymowych-2010" MODIFIED="2014-10-09 12:20:11 -0400" MODIFIED_BY="[Empty name]" NAME="Maksymowych 2010" TYPE="JOURNAL_ARTICLE">
<AU>Maksymowych WP, Salonen D, Inman RD, Rahman P, Lambert RGW</AU>
<TI>Low-dose infliximab (3 mg/kg) significantly reduces spinal inflammation on magnetic resonance imaging in patients with ankylosing spondylitis: a randomized placebo-controlled study</TI>
<SO>Journal of Rheumatology</SO>
<YR>2010</YR>
<VL>37</VL>
<NO>8</NO>
<PG>1728-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marzo_x002d_Ortega-2001" MODIFIED="2015-02-19 18:32:12 -0500" MODIFIED_BY="[Empty name]" NAME="Marzo-Ortega 2001" TYPE="JOURNAL_ARTICLE">
<AU>Marzo-Ortega H, McGonagle D, O'Connor P, Emery P</AU>
<TI>Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2001</YR>
<VL>44</VL>
<NO>9</NO>
<PG>2112-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Montacer-2009" MODIFIED="2015-01-29 04:54:17 -0500" MODIFIED_BY="[Empty name]" NAME="Montacer 2009" TYPE="JOURNAL_ARTICLE">
<AU>Montacer KM, Mehdi Ghannouchi M, Hamdi W, Azzouz D, Kochbati S, Saadellaoui K, et al</AU>
<TI>Impact of the ankylosing spondylitis on the professional activity</TI>
<SO>Joint Bone Spine</SO>
<YR>2009</YR>
<VL>76</VL>
<NO>4</NO>
<PG>378-82</PG>
<IDENTIFIERS MODIFIED="2015-01-29 04:54:17 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-01-29 04:54:17 -0500" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/j.jbspin.2008.08.010"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-NICE-2008" MODIFIED="2015-02-19 18:33:13 -0500" MODIFIED_BY="[Empty name]" NAME="NICE 2008" TYPE="OTHER">
<AU>National Institute for Health and Clinical Excellence</AU>
<TI>Adalimumab, etanercept and infliximab for ankylosing spondylitis. NICE technology appraisal guidance 143</TI>
<SO>www.nice.org.uk/TA143</SO>
<YR>(accessed January 2010)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NICE-2011" MODIFIED="2015-02-19 18:33:28 -0500" MODIFIED_BY="[Empty name]" NAME="NICE 2011" TYPE="OTHER">
<AU>National Institute for Health and Clinical Excellence</AU>
<TI>Golimumab for the treatment of ankylosing spondylitis: NICE technology appraisal guidance 233</TI>
<SO>www.nice.org.uk/guidance/ta233/resources/guidance-golimumab-for-the-treatment-of-ankylosing-spondylitis-pdf</SO>
<YR>2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pavy-2005" MODIFIED="2015-02-19 18:33:40 -0500" MODIFIED_BY="[Empty name]" NAME="Pavy 2005" TYPE="JOURNAL_ARTICLE">
<AU>Pavy S, Brophy S, Calin A</AU>
<TI>Establishment of the minimum clinically important difference for the bath ankylosing spondylitis indices: a prospective study</TI>
<SO>Journal of Rheumatology</SO>
<YR>2005</YR>
<VL>32</VL>
<NO>1</NO>
<PG>80-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Plot-Digitizer-2014" MODIFIED="2015-02-20 17:05:43 -0500" MODIFIED_BY="[Empty name]" NAME="Plot Digitizer 2014" TYPE="COMPUTER_PROGRAM">
<AU>Huwaldt JA, Steinhorst S</AU>
<TI>Plot Digitizer</TI>
<YR>27 April 2014</YR>
<PB>Open source; http://plotdigitizer.sourceforge.net/</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2015-02-20 16:56:42 -0500" MODIFIED_BY="[Empty name]" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rudwaleit-2004" MODIFIED="2015-02-19 18:39:29 -0500" MODIFIED_BY="[Empty name]" NAME="Rudwaleit 2004" TYPE="JOURNAL_ARTICLE">
<AU>Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J</AU>
<TI>Prediction of a major clinical response (BASDAI 50) to TNF- blockers in ankylosing spondylitis?</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2004</YR>
<VL>63</VL>
<PG>665-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rudwaleit-2009a" MODIFIED="2015-03-11 09:12:29 -0400" MODIFIED_BY="[Empty name]" NAME="Rudwaleit 2009a" TYPE="JOURNAL_ARTICLE">
<AU>Rudwaleit M, Landewe R, van der Heijde D, Listing J, Brandt J, Braun J, et al</AU>
<TI>The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2009</YR>
<VL>68</VL>
<PG>770-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rudwaleit-2009b" MODIFIED="2015-03-11 09:14:32 -0400" MODIFIED_BY="[Empty name]" NAME="Rudwaleit 2009b" TYPE="JOURNAL_ARTICLE">
<AU>Rudwaleit M, van der Heijde D, Landewé R, Listing J, Akkoc N, Brandt J, et al</AU>
<TI>The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2009</YR>
<VL>68</VL>
<PG>777-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schultz-1995" MODIFIED="2010-08-22 12:08:16 -0400" MODIFIED_BY="[Empty name]" NAME="Schultz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schultz K, Chalmers I, Hayes R, Altman D</AU>
<TI>Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sch_x00fc_nemann-2009" MODIFIED="2015-03-22 05:22:02 -0400" MODIFIED_BY="[Empty name]" NAME="Schünemann 2009" TYPE="OTHER">
<AU>Schünemann H, Bro&#380;ek J, Oxman A, editors</AU>
<TI>GRADE handbook for grading quality of evidence and strength of recommendation. Version 3.2</TI>
<SO>The GRADE Working Group.</SO>
<YR>updated March 2009</YR>
<NO>Completing the Summary of Findings for an Outcome: Dichotomous outcomes - Corresponding risk</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sch_x00fc_nemann-2011" MODIFIED="2015-02-19 18:41:57 -0500" MODIFIED_BY="[Empty name]" NAME="Schünemann 2011" TYPE="OTHER">
<AU>Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH</AU>
<TI>Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Song-2009" MODIFIED="2009-09-25 14:46:08 -0400" MODIFIED_BY="[Empty name]" NAME="Song 2009" TYPE="JOURNAL_ARTICLE">
<AU>Song F, Loke YK, Walsh T, Glenny A-M, Eastwood AJ, Altman DG</AU>
<TI>Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews</TI>
<SO>BMJ</SO>
<YR>2009</YR>
<VL>338</VL>
<PG>b1147</PG>
<IDENTIFIERS MODIFIED="2009-09-25 14:46:08 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-09-25 14:46:08 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1136/bmj.b1147"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Spiegelhalter-2003" MODIFIED="2015-02-19 18:43:20 -0500" MODIFIED_BY="[Empty name]" NAME="Spiegelhalter 2003" TYPE="OTHER">
<AU>Spiegelhalter D, Thomas A, Best N, Lunn D</AU>
<TI>WinBUGS user manual [Internet]. Version 1.4</TI>
<SO>Cambridge, UK: MRC Biostatistics Unit, Institute of Public Health</SO>
<YR>(accessed 21 Apr 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stone-2001" NAME="Stone 2001" TYPE="JOURNAL_ARTICLE">
<AU>Stone M, Salonen D, Lax M, Payne U, Lapp V, Inman R</AU>
<TI>Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis</TI>
<SO>Journal of Rheumatology</SO>
<YR>2001</YR>
<VL>28</VL>
<PG>1605-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sweeting-2004" MODIFIED="2015-02-19 18:43:54 -0500" MODIFIED_BY="[Empty name]" NAME="Sweeting 2004" TYPE="JOURNAL_ARTICLE">
<AU>Sweeting MJ, Sutton AJ, Lambert PC</AU>
<TI>What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data</TI>
<SO>Statistics in Medicine</SO>
<YR>2004</YR>
<VL>23</VL>
<PG>1351-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Turner-2005" MODIFIED="2014-11-27 05:05:15 -0500" MODIFIED_BY="[Empty name]" NAME="Turner 2005" TYPE="JOURNAL_ARTICLE">
<AU>Turner RM, Thompson SG, Spiegelhalter DJ</AU>
<TI>Prior distributions for the intracluster correlation coefficient, based on multiple previous estimates, and their application in cluster randomized trials</TI>
<SO>Clinical Trials</SO>
<YR>2005</YR>
<VL>2</VL>
<NO>2</NO>
<PG>108-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-Den-Bosch-2002" MODIFIED="2015-02-19 18:44:11 -0500" MODIFIED_BY="[Empty name]" NAME="Van Den Bosch 2002" TYPE="JOURNAL_ARTICLE">
<AU>Van Den Bosch F, Kruithof E, Baeten D, Herssens A, de Keyser F, Mielants H, et al</AU>
<TI>Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2002</YR>
<VL>46</VL>
<PG>755-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-der-Heijde-1997" NAME="van der Heijde 1997" TYPE="JOURNAL_ARTICLE">
<AU>van der Heijde D, Bellamy N, Calin A, Dougados M, Khan MA, van der Linden S</AU>
<TI>Preliminary core sets for endpoints in ankylosing spondylitis</TI>
<SO>Journal of Rheumatology</SO>
<YR>1997</YR>
<VL>24</VL>
<PG>2225-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-der-Heijde-2011" MODIFIED="2015-02-19 18:44:48 -0500" MODIFIED_BY="[Empty name]" NAME="van der Heijde 2011" TYPE="JOURNAL_ARTICLE">
<AU>van der Heijde D, Sieper J, Maksymowych WP, Dougados M, Burgos-Vargas R, Landewé R, et al</AU>
<TI>Assessment of SpondyloArthritis international Society. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2011</YR>
<VL>70</VL>
<NO>6</NO>
<PG>905-8</PG>
<IDENTIFIERS MODIFIED="2014-11-17 14:45:24 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-11-17 14:45:24 -0500" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1136/ard.2011.151563"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wanders-2005" MODIFIED="2015-02-19 18:46:00 -0500" MODIFIED_BY="[Empty name]" NAME="Wanders 2005" TYPE="JOURNAL_ARTICLE">
<AU>Wanders A, van der Heijde D, Landewe R, Behier JM, Calin A, Olivieri I, et al</AU>
<TI>Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2005</YR>
<VL>52</VL>
<NO>6</NO>
<PG>1756-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wells-2009" MODIFIED="2015-02-19 18:49:34 -0500" MODIFIED_BY="[Empty name]" NAME="Wells 2009" TYPE="OTHER">
<AU>Wells GA, Sultan SA, Chen L, Khan M, Coyle D; Canadian Agency for Drugs and Technologies in Health</AU>
<TI>Indirect Evidence: Indirect Treatment Comparisons in Meta-Analysis</TI>
<SO>www.cadth.ca/media/pdf/H0462_itc_tr_e.pdf</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yazici-2008" MODIFIED="2010-08-22 13:03:47 -0400" MODIFIED_BY="[Empty name]" NAME="Yazici 2008" TYPE="JOURNAL_ARTICLE">
<AU>Yazici Y, Adler NM, Yazici H</AU>
<TI>Most tumour necrosis factor inhibitor trials in rheumatology are undeservedly called 'efficacy and safety' trials: a survey of power considerations</TI>
<SO>Rheumatology</SO>
<YR>2008</YR>
<VL>47</VL>
<NO>7</NO>
<PG>1054-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zink-2000" NAME="Zink 2000" TYPE="JOURNAL_ARTICLE">
<AU>Zink A, Braun J, Listing J, Wollenhaupt J</AU>
<TI>Disability and handicap in rheumatoid arthritis and ankylosing spondylitis - results from the German rheumatological database</TI>
<SO>Journal of Rheumatology</SO>
<YR>2000</YR>
<VL>27</VL>
<PG>613-32</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2015-03-23 08:09:44 -0400" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Zochling-2005" MODIFIED="2015-03-23 08:09:44 -0400" MODIFIED_BY="[Empty name]" NAME="Zochling 2005" TYPE="COCHRANE_PROTOCOL">
<AU>Zochling J, Maxwell L, Beardmore J, Boonen A</AU>
<TI>TNF-alpha inhibitors for ankylosing spondylitis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>3</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD005468"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2009-04-28 11:10:33 -0400" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2015-03-25 04:30:41 -0400" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2015-03-25 04:30:41 -0400" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2015-03-25 04:30:00 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bao-2014">
<CHAR_METHODS MODIFIED="2015-03-23 04:16:18 -0400" MODIFIED_BY="[Empty name]">
<P>Multicenter, 24-week, randomized, double-blind, placebo-controlled phase III trial followed by subcutaneous administration of golimumab 50mg to all patients from week 24 forward</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-22 06:05:38 -0400" MODIFIED_BY="[Empty name]">
<P>Golimumab 50 mg (N = 108) Placebo N = (105)</P>
<P>Age (mean (SD), years): Treatment group - 30.5 (10.27); Control group - 30.6 (8.60)<BR/>N (%) male: Treatment group - 90 (83.3); Control group - 87 (82.9)<BR/>Ethnicity: Chinese</P>
<P>
<BR/>Duration of symptoms (mean (SD), years): Treatment group - 6.1 (5.93); Control group -6.6 (5.67)</P>
<P>Duration since ankylosing spondylitis diagnosis: Treatment group 4.2 (5.22); control group 3.7 (3.88)</P>
<P>Inclusion: Diagnosis of ankylosing spondylitis for at least 3 months defined as definite by the 1984 modified New York criteria; BASDAI of &gt;=4 (0-10cm scale) and visual analogue scale score for total back pain of &gt;=4 (0-10cm scale)</P>
<P>Exclusion: prior biologic anti-TNF therapy; complete ankylosis of the spine, failed tuberculosis screening</P>
<P>Patients were allowed to continue receiving stable doses of MTX, SSZ and HCQ during study participation<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-22 20:52:51 -0500" MODIFIED_BY="[Empty name]">
<P>Subcutaneous injections of placebo (group 1) or golimumab 50 mg (group 2) every 4 weeks. At week 16, patients with &lt; 20% improvement from baseline in both total back pain and morning stiffness measures entered double-blind early escape, whereby those in group 1 were started on golimumab 50 mg and those in group 2 continued to receive golimumab 50 mg. At week 24, all patients still receiving placebo crossed over to golimumab 50 mg subcutaneous injections </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-03-23 04:19:42 -0400" MODIFIED_BY="[Empty name]">
<P>The primary study endpoint was the proportion of patients achieving ASAS20 at week 14. Other clinical assessments: BASFI, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Metrology Index (BASMI), ASAS40 response, ASAS5/6 response, ASAS partial remission, SF-36 health-related quality of life (HRQoL) questionnaire, Jenkins Sleep Evaluation Questionnaire (JSEQ)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-25 04:30:00 -0400" MODIFIED_BY="[Empty name]">
<P>NCT01248793. " This study was funded by Janssen Research &amp; Development, LLC, Spring House, PA, USA. Janssen statisticians and programmers performed the analyses. All authors reviewed and approved the content of the manuscript before submission and jointly agreed to submit the final version of the manuscript. The manuscript was prepared by C.B., F.H., M.A.K., K.F., Z.W., C.H., E.C.H., Michelle Perate (non-author; a paid consultant for Janssen Scientific Affairs), and Mary Whitman (non-author; Janssen Biotech)." Four authors are employees of Janssen Pharmaceuticals.<BR/>
</P>
<P>MTX = methotrexate, SSZ = sulphasalazine and HCQ = hydroxychloroquine</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-22 06:10:53 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Barkham-2010">
<CHAR_METHODS MODIFIED="2015-02-22 20:54:26 -0500" MODIFIED_BY="[Empty name]">
<P>"Double blind, placebo controlled trial". States that participants were randomized to etanercept or placebo in a 1 to 1 ratio</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-22 20:54:34 -0500" MODIFIED_BY="[Empty name]">
<P>N = 40, 20 per group. 32 (80%) male; mean age 40.1 years (range 20-61 years); mean duration of symptoms 17 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-22 20:54:41 -0500" MODIFIED_BY="[Empty name]">
<P>Etanercept (25 mg) or placebo twice weekly for 3 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-03-22 06:10:53 -0400" MODIFIED_BY="[Empty name]">
<P>Primary outcome was a change in the work instability of patients after 3 months as measured by the Ankylosing Spondylitis Work Instability Scale (AS WIS) scale. Secondary outcomes included changes in AS WIS score after 6 months, clinical response (BASDAI, BASFI, Ankylosing Spondylitis Quality of Life (ASQoL)) and gait analysis at 3 and 6 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-02-22 20:55:08 -0500" MODIFIED_BY="[Empty name]">
<P>Funding source not reported. First reference reported as an abstract from a conference proceeding</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-23 04:23:37 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brandt-2003">
<CHAR_METHODS>
<P>Multicenter, randomized, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-23 04:23:37 -0400" MODIFIED_BY="[Empty name]">
<P>N = 14 etanercept ; N = 16 placebo<BR/>Age (mean years): Treatment group - 40; Control group - 32<BR/>% male: Treatment group - 71%; Control group - 75%<BR/>% white: Not reported<BR/>Disease duration (years): Treatment group - 15; Control group -11<BR/>Patients fulfilled the modified NY criteria for ankylosing spondylitis and had active disease defined by BASDAI &gt;=4 and spinal pain of &gt;=4 on 0-10 scale</P>
<P>
<BR/>Excluded: active tuberculosis in past 3 years, serious infection in past 2 months, malignancies in past 5 years, multiple sclerosis or related disorder, current signs of severe disease. Disease-modifying, anti-rheumatic drugs (DMARDs) and corticosteroids withdrawn at least 4 weeks prior to screening. Also, widespread ankylosis. Non-steroidal, anti-inflammatory drugs (NSAIDs) at same or less dose at baseline were allowed</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Etanercept 25 mg twice weekly subcutaneously vs placebo for 6 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-03-23 04:21:54 -0400" MODIFIED_BY="[Empty name]">
<P>Primary: BASDAI &gt;= 50% by week 6. Others: BASDAI, BASFI, BASMI, ASAS20%, SF-36, Bath Ankylosing Spondylitis Radiology Index -spine (BASRI-s), adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-24 13:33:34 -0400" MODIFIED_BY="[Empty name]">
<P>"Supported by a grant (Kompentenznetz Rheuma) from the German MInistry of Research and by Wyeth Pharma who provided the study drug"</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-23 04:26:09 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Braun-2002">
<CHAR_METHODS>
<P>Multicenter, randomized placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-23 04:25:40 -0400" MODIFIED_BY="[Empty name]">
<P>N = 34 infliximab; N = 35 placebo<BR/>Age (mean years): Treatment group - 41; Control group - 39<BR/>% male: Treatment group - 68%; Control group - 63%<BR/>% white: Treatment group - not reported<BR/>Disease duration (years): Treatment group - 16; Control group -15<BR/>Patients fulfilled the modified NY criteria for AS and had active disease defined by BASDAI &gt;= 4 and spinal pain of &gt;= 4 on 0-10 scale</P>
<P>
<BR/>Excluded: The main reasons for exclusion were severe comorbidity, insufficient disease activity, complete ankylosis, incorrect diagnosis, and disease-modifying, anti-rheumatic drugs therapy. Also, active tuberculosis in past 3 years, specific changes in radiograph of chest at baseline, serious infection in past 2 months, malignancies in past 5 years, signs of severe renal, hepatic, haematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological, cerebral disease. Disease-modifying, anti-rheumatic drugs and corticosteroids withdrawn at least 4 weeks prior to screening. Patients allowed non-steroidal, anti-inflammatory drugs but dose could not increase from baseline dose</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-22 20:58:13 -0500" MODIFIED_BY="[Empty name]">
<P>Infliximab 5 mg/kg intravenous vs placebo administered at 0, 2, 6 weeks for 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-03-23 04:26:09 -0400" MODIFIED_BY="[Empty name]">
<P>Primary: BASDAI &gt;= 50% by week 12. Others BASDAI, BASFI, BASMI, ASAS20%, SF-36, spinal pain, serum C-reactive protein (CRP) level, erythrocyte sedimentation rate (ESR), adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-24 13:37:55 -0400" MODIFIED_BY="[Empty name]">
<P>"Funded by a grant (Kompentenznetz Rheuma) from the German MInistry of Research and by Essex Pharma, Munich, who provided the study drug"</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-25 04:30:41 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Braun-2011">
<CHAR_METHODS MODIFIED="2015-02-22 20:59:20 -0500" MODIFIED_BY="[Empty name]">
<P>RCT. Double-blind</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-25 04:30:41 -0400" MODIFIED_BY="[Empty name]">
<P>N = 566. AS patients had active disease based on BASDAI VAS&gt;=30; morning stiffness visual analogue scale (VAS)&gt;=30; VAS&gt;=30 for 2 of the following:patient global assessment of disease activity, pain, BASFI, and be a candidate for sulphasalazine or etanercept. All patients had failed &gt;= 1 non-steroidal, anti-inflammatory drug for &gt;= 3 months</P>
<P>Exclusion: complete ankylosis of the spine; previous etanercept treatment; sulphasalazine treatment within 6 months of screening</P>
<P>Mean age = 41 years; 74% male; average disease duration = 7.5 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-23 04:27:21 -0400" MODIFIED_BY="[Empty name]">
<P>Etanercept 50 mg once weekly (N = 379). Sulfasalzine 3 g daily (N =187)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-06-12 21:46:54 -0400" MODIFIED_BY="[Empty name]">
<P>Primary outcome: proportion of patients achieving ASAS20 at 16 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-25 04:30:41 -0400" MODIFIED_BY="[Empty name]">
<P>ASCEND (Ankylosing Spondylitis Study Comparing ENbrel with sulphasalazine Dosed Weekly) (NCT00247962). Funding source:"Supported by Wyeth Pharmaceuticals, which was acquired by Pfizer Inc. in October 2009"</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-23 04:29:03 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Calin-2004">
<CHAR_METHODS>
<P>Multicenter, randomized, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-23 04:28:35 -0400" MODIFIED_BY="[Empty name]">
<P>N = 45 etanercept; N = 39 placebo<BR/>Age (mean, years): Treatment group - 45; Control group - 41<BR/>% male: Treatment group - 80%; Control group - 77%<BR/>% white: Treatment group - 93%; Control group - 95%<BR/>Disease duration (years): Treatment group - 15; Control group -10</P>
<P>Patients fulfilled the modified NY criteria for AS and had active disease defined by score &gt;= 30 on visual analogue scale 0-100 for spinal inflammation and a score of &gt;= 30 on at least 2 of the 3 domains: back pain, patient global assessment and physical function. Patients were excluded if they had complete ankylosis (fusion) of the spine; previously used TNFa inhibitors, including etanercept; used disease-modifying anti-rheumatic drugs other than hydroxychloroquine, sulphasalazine, or methotrexate within 4 weeks of baseline; used multiple non-steroidal anti-inflammatory drugs (NSAIDs); used &gt; 10 mg prednisone daily; or changed doses of NSAIDs or prednisone within 2 weeks of baseline. Patients were permitted to continue prestudy physiotherapy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-22 21:01:23 -0500" MODIFIED_BY="[Empty name]">
<P>Etanercept 25 mg twice weekly subcutaneously vs placebo for 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-03-23 04:29:03 -0400" MODIFIED_BY="[Empty name]">
<P>Primary: ASAS20 by week 12. Others: BASDAI, BASFI, ASAS50, ASAS70, spinal inflammation, nocturnal and total pain, spinal mobility, serum C-reactive protein (CRP) level, erythrocyte sedimentation rate (ESR), adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-10-10 10:12:47 -0400" MODIFIED_BY="[Empty name]">
<P>NCT00421915. "Trial was funded by Wyeth Research"</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-23 04:30:39 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Davis-2003">
<CHAR_METHODS>
<P>Multicenter, randomized, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-23 04:30:24 -0400" MODIFIED_BY="[Empty name]">
<P>N = 138 etanercept; N = 139 placebo<BR/>Age (mean, years): Treatment group - 42; Control group - 42<BR/>% male: Treatment group - 76%; Control group - 76%<BR/>% white: Treatment group - 94%; Control group - 91%<BR/>Disease duration (years): Treatment group - 10; Control group -10</P>
<P>
<BR/>Patients fulfilled the modified NY criteria for AS and had active disease defined by score &gt;=30 on visual analogue scale 0-100 for morning stiffness and a score of &gt;= 30 on at least 2 of the 3 domains: back pain, patient global assessment and BASFI. Patients were excluded if they had complete ankylosis (fusion) of the spine based on radiographic assessment; previously used TNFa inhibitors, had a serious infection (requiring hospitalizations or IV antibiotics) within 4 weeks of screening or were pregnant. Patients were allowed to continue receiving hydroxychloroquine, sulphasalazine, or methotrexate at stable doses during the study but were excluded if they had received any other disease-modifying, anti-rheumatic drug within 4 weeks of baseline. Also allowed to continue on stable non-steroidal, anti-inflammatory drug, prednisone, and analgesics</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-22 21:02:56 -0500" MODIFIED_BY="[Empty name]">
<P>Etanercept 25 mg twice weekly subcutaneously vs placebo for 24 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-03-23 04:30:39 -0400" MODIFIED_BY="[Empty name]">
<P>Primary: ASAS20 by week 12 and 24. Others: ASAS50, ASAS70, partial remission (defined as value &lt; 20 mm (0-100mm scale) in each of 4 ASAS domains (patient global assessment, pain, BASFI, inflammation)). BASDAI, spinal mobility, peripheral joint count, serum C-reactive protein (CRP) level, erythrocyte sedimentation rate (ESR), assessor global assessment, adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-02-22 22:48:19 -0500" MODIFIED_BY="[Empty name]">
<P>"Supported by Immunex Corporation"</P>
<P>NCT00356356 for long-term extension</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-23 04:32:29 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dougados-2011">
<CHAR_METHODS MODIFIED="2015-02-22 23:10:18 -0500" MODIFIED_BY="[Empty name]">
<P>12-week randomized double-blind placebo-controlled multicenter study conducted in 21 centers in four European countries (France, Germany, The Netherlands and Hungary)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-23 04:31:47 -0400" MODIFIED_BY="[Empty name]">
<P>Etanercept (N = 39) Placebo (N = 43)</P>
<P>Inclusion criteria was patients with advanced and active ankylosing spondylitis<BR/>
</P>
<P>Age (mean, years): Treatment group - 46; Control group - 48<BR/>% male: Treatment group - 95%; Control group - 91%<BR/>Disease duration (years): Treatment group - 19; Control group -23</P>
<P>Inclusion criteria: Men and women aged 18&#8211;70 years were eligible if they had a current diagnosis of ankylosing spondylitis as defined by the modified New York criteria. Advanced ankylosing spondylitis and severe spinal ankylosis defined by having one of the following three criteria: (1) two intervertebral adjacent bridges and/or fusion at the lumbar spine; (2) three intervertebral adjacent bridges and/or fusion at the thoracic spine; or (3) two intervertebral adjacent bridges and/or fusion at the cervical spine. As well:</P>
<P>- radiologic evidence of spine and hip</P>
<P>- baseline pain with axial involvement of the overall level of ankylosing spondylitis neck, back or hip for a score &#8807; 30 on a 0-100 mm visual analogue scale (VAS). patients had to have an active refractory disease defined by a score &#8807; 40 on the BASDAI (0-100) despite optimal non-steroidal, antif-inflammatory drug treatment<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-22 06:00:30 -0400" MODIFIED_BY="[Empty name]">
<P>Etanercept 50 mg subcutaneous injection once weekly, with placebo (1:1 ratio)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-03-23 04:32:29 -0400" MODIFIED_BY="[Empty name]">
<P>The primary end point was the normalized net incremental area under the curve in the BASDAI between randomisation (baseline) and week 12 and was calculated as the area between baseline and the patient global assessment curve as a function of time, using the linear trapezoidal method, divided by the number of days the patient remained in the study</P>
<P>Secondary outcomes: ASAS20, ASAS40, ASAS5/6, ASAS partial remission, and improvement in BASDAI of at least 50% (BASDAI50), improvement in Ankylosing Spondylitis-Disease Activity State (AS-DAS) and AS-DAS status, BASFI, BASMI, Minimum Clinically Important Improvement (MCII) and Patient Acceptable Symptom State (PASS)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-02-22 21:05:56 -0500" MODIFIED_BY="[Empty name]">
<P>NCT00420238; "This study was sponsored by Wyeth Pharmaceuticals (Wyeth was acquired<BR/>by Pfizer in October 2009)"</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-23 04:33:58 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Giardina-2009">
<CHAR_METHODS MODIFIED="2010-03-17 20:04:04 -0400" MODIFIED_BY="[Empty name]">
<P>"Two year randomized study"</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-23 04:33:13 -0400" MODIFIED_BY="[Empty name]">
<P>N = 25 (abstract had N = 26) etanercept; N = 25 (abstract had N = 24) infliximab</P>
<P>Inclusion criteria: active disease for &gt; 3 months; BASDAI &gt; 4; visual analogue scale for spinal pain &gt; 4</P>
<P>Age (mean, years): Etanercept group - 32.6 SD 6.8; Infliximab group - 31.9 SD 9.2<BR/>% male: Etanercept group - 80%; Infliximab group - 76%<BR/>Disease duration (years): Etanercept group - 15.7 SD 6.5; Infliximab group -15.4 SD 10.6</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-22 21:07:22 -0500" MODIFIED_BY="[Empty name]">
<P>Etanercept 25 mg twice weekly or 5 mg/kg infliximab at week 0, 2, 6, and then every 6 weeks for a period of 102 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-03-23 04:33:50 -0400" MODIFIED_BY="[Empty name]">
<P>In the abstract, the primary outcome was stated to be the proportion of patients achieving a 50% BASDAI response at week 102; Secondary: ASAS50; BASFI, back pain, morning stiffness, C-reactive protein (CRP), spinal mobility. However, in the full-text article, the outcome defined as primary is not stated, and the 50% BASDAI response is not reported. ASAS20 and 40, BASDAI, BASFI and adverse events were reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-23 04:33:58 -0400" MODIFIED_BY="[Empty name]">
<P>Reported as a full-text and an abstract from a conference. Funding source not reported.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-23 05:00:17 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gorman-2002">
<CHAR_METHODS>
<P>Randomized, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-23 04:59:48 -0400" MODIFIED_BY="[Empty name]">
<P>N = 20 (etanercept); N = 20 (placebo)<BR/>Age (median, years): Treatment group - 38; Control group - 39<BR/>% male: Treatment group - 65%; Control group - 90%<BR/>% white: Treatment group - 75%; Control group - 70%<BR/>Disease duration (years): Treatment group - 15; Control group -12</P>
<P>Patients &gt;= 18 years of age and classified as having definite ankylosing spondylitis based on the modified New York criteria. Active spondylitis was defined as the presence of inflammatory back pain (stiffness and pain that worsened with rest and improved with exercise), morning stiffness for at least 45 minutes, and at least moderate disease activity as assessed by the patient and the physician. The patient&#8217;s global assessment of disease activity was based on a five-point scale (1, none; 2, mild; 3, moderate; 4, severe; and 5, very severe). The physician&#8217;s assessment was measured with the use of a visual analogue scale (0 mm absence of disease activity and 100 mm very severe activity); a moderate or higher level of disease activity was defined by the placement of a vertical line at 40 mm or higher.<BR/>
<BR/>Patients were excluded if they had a spondylitis other than ankylosing spondylitis, clinical or radiographic evidence of complete spinal ankylosis, a history of recurrent infections or cancer, or a serious liver, renal, hematologic, or neurologic disorder.</P>
<P>Patients continued to take drugs that had already been prescribed for ankylosing spondylitis if the doses had not been changed for at least four weeks before randomisation and if they remained unchanged throughout the trial. Acceptable medications included non-steroidal anti-inflammatory drugs,oral corticosteroids (« 10 mg per day), gold injections («50 mg per month), methotrexate («20 mg per week), and sulphasalazine(« 3 g per day)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-22 21:08:57 -0500" MODIFIED_BY="[Empty name]">
<P>Twice-weekly subcutaneous injections of etanercept (25 mg) versus placebo for four months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-03-23 05:00:17 -0400" MODIFIED_BY="[Empty name]">
<P>Primary: ASAS20<BR/>Secondary outcomes: physician&#8217;s global assessment of disease activity, measures of spinal mobility, the scores for enthesitis and peripheral-joint tenderness, erythrocyte sedimentation rate, C-reactive protein, adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-02-22 21:09:14 -0500" MODIFIED_BY="[Empty name]">
<P>NCT00000433. "The majority of funding for the study was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases. Immunex, the pharmaceutical funding source, supplied etanercept and placebo and provided partial funding. Immunex was not involved in the study design, data collection, statistical analysis, or manuscript preparation; these tasks were performed by the authors"</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-23 05:01:04 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hu-2012">
<CHAR_METHODS MODIFIED="2015-02-22 21:19:43 -0500" MODIFIED_BY="[Empty name]">
<P>This was a randomized, double-blind, placebo-controlled study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-23 05:01:04 -0400" MODIFIED_BY="[Empty name]">
<P>Patients were adults (18 and 65 years) diagnosed as having AS defined by the modified New York criteria who had been treated unsuccessfully (nonresponsive or lack of tolerance) with &#8805; 1 non-steroidal anti-inflammatory drug (NSAIDs). Active ankylosing spondylitis at baseline was defined by fulfilment of at least two of the following three criteria: a BASDAI score &#8805; 4, total back pain visual analog scale score &#8805; 40, or morning stiffness of &#8805; 1 h in duration. Patients could continue taking sulphasalazine ( &#8804; 3 g/day), methotrexate ( &#8804; 25 mg/week), prednisone and/or prednisone equivalents ( &#8804; 10 mg/day), and/or NSAIDs as long as these doses had remained stable for 4 weeks before</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-22 21:20:29 -0500" MODIFIED_BY="[Empty name]">
<P>40 mg adalimumab (n = 26) or placebo (n = 20) every other week during an initial 12-week double-blind period, and all switched to adalimumab treatment for another 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-22 21:20:49 -0500" MODIFIED_BY="[Empty name]">
<P>"Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Function Index (BASFI), C-reactive protein (CRP), Ankylosing Spondylitis Disease Activity Scores (ASDAS) and serum DKK-1 levels were measured and magnetic resonance imaging (MRI) of both the lumbar spine and sacroiliac joints were obtained at baseline, week 12 and week 24. Spinal and sacroiliac joint inflammations were evaluated using the Spondyloarthritis Research Consortium of Canada (SPARCC) MRI index, and fatty deposition lesions (FDL) were assessed in a dichotomous manner"</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-01-13 10:55:18 -0500" MODIFIED_BY="[Empty name]">
<P>No source of funding reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-23 05:01:30 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Huang-2008">
<CHAR_METHODS MODIFIED="2010-03-15 14:38:37 -0400" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, placebo-controlled study for 6 weeks with 6 week open label afterwards</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-23 05:01:30 -0400" MODIFIED_BY="[Empty name]">
<P>N = 74 etanercept; N = 78 placebo. Adult patients with ankylosing spondylitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-22 21:22:04 -0500" MODIFIED_BY="[Empty name]">
<P>Etanercept 50 mg once weekly for 6 weeks or placebo subcutaneously. Patients receiving hydrochloroquine, sulphasalazine, or methotrexate at screening continued on the medication</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-13 10:42:39 -0500" MODIFIED_BY="[Empty name]">
<P>Primary endpoint: ASAS20 week 6. Secondary ASAS40, ASAS5/6, adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-10-10 09:30:23 -0400" MODIFIED_BY="[Empty name]">
<P>Abstract from conference proceeding. Funding source not reported. NCT00434044</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-23 05:04:04 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Huang-2014">
<CHAR_METHODS MODIFIED="2015-03-23 05:01:48 -0400" MODIFIED_BY="[Empty name]">
<P>Placebo-controlled, double-blind, randomized, phase III trial conducted between January 2010 and February 2011 at nine study sites in the People&#8217;s Republic of China. 12-week double-blind phase was followed by a 12-week open-label phase, during which all patients received open-label adalimumab 40 mg every other week.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-23 05:03:04 -0400" MODIFIED_BY="[Empty name]">
<P>344 patients ; N = 115 placebo; N = 229 adalimumab</P>
<P>Age (mean (standard deviation (SD), years): Treatment group - 30.1 (8.7); Control group - 29.6 (7.5)<BR/>N (%) male: Treatment group - 185 (80.8); Control group - 95 (82.6)<BR/>Ethnicity: Chinese<BR/>Duration of AS symptoms (mean (SD), years): Treatment group - 8.1 (6.0); Control group -7.7 (4.7)<BR/>Duration since AS diagnosis, mean (SD), years: Treatment group 3.0 (3.2) ; Control group 3.0 (3.8)</P>
<P>Inclusion criteria: Adults (18 to 65 years) fulfilling modified New York Criteria for ankylosing spondylitis, active disease (as defined by &gt;= 2 of the following: BASDAI &gt;= 4; total back pain on a visual analogue scale (VAS) &gt;= 4 cm; and &gt;= 1 hour of morning stiffness; and had an inadequate response or were intolerant to &gt;=1 non-steroidal anti-inflammatory drug (NSAID).</P>
<P>Exclusion: Patients with latent or active tuberculosis; total spinal ankylosis; unstable extra-articular manifestations (e.g. psoriasis, uveitis, inflammatory bowel disease); surgery involving the spine or joints within the previous 2 months; intra-articular or spinal/paraspinal corticosteroid injections within the previous 28 days; positive serology for HIV antibody, hepatitis B surface antibody or hepatitis C virus antibody; recent<BR/>infection requiring anti-infectives; listeriosis; histoplasmosis; immunodeficiency syndrome; or chronic recurring infections. Patients with moderate to severe congestive heart failure, recent cerebrovascular accident, central nervous system demyelinating disease, or history of malignancy (except for successfully treated non-metastatic non-melanoma skin cancer or localized cervical carcinoma in situ) were also excluded.<BR/>Prior exposure to TNF inhibitors, natalizumab or efalizumab at any time, or use of traditional Chinese medicines within 28 days of baseline was not allowed</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-23 05:03:31 -0400" MODIFIED_BY="[Empty name]">
<P>Adalimumab 40 mg or matching placebo subcutaneously every other week (EOW)</P>
<P>Concomitant use of methotrexate (&lt;= 25 mg/week), sulphasalazine (&lt;= 3 g/day), prednisone (&lt;= 10 mg/day), NSAIDs and/or analgesics was allowed but dose adjustments, induction and/or discontinuation of these therapies were only permitted during the open-label period. Other pharmacological therapies for ankylosing spondylitis except for those listed above could not be initiated at any time during the study</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-03-23 05:04:04 -0400" MODIFIED_BY="[Empty name]">
<P>The primary efficacy endpoint was the percentage of patients achieving the ASAS20 response criteria at week 12. Secondary endpoints were ASAS40 and ASAS5/6 response, ASAS partial remission; BASDAI50; Ankylosing Spondylitis Disease Activity Score (ASDAS); disease activity, pain and spinal mobility by measuring changes from baseline in patient global assessment (VAS), total back pain (VAS), inflammation/morning stiffness,BASDAI, physician&#8217;s global assessment of disease activity (VAS),nocturnal pain (VAS), patient&#8217;s global assessment of pain (VAS), tender joint count, swollen joint count, Maastricht AS Enthesitis Score (MASES), BASMI-linear and chest expansion. All measures recorded on a VAS were reported on a 0&#8211;10 cm scale. Health-related quality of life, physical function and work productivity measures included the Health Assessment Questionnaire modified for spondyloarthropathies (HAQ-S), 36-Item Short-Form Health Survey, V.2 (SF-36v2), BASFI, Bath AS Patient Global Index (BAS-G) and Work Productivity and Activity Impairment-Specific Health Problem Questionnaire (WPAI-SHP)</P>
<P>Note: BASFI was measured on a 0-100 scale as per the result on clinicaltrials.gov. Converted to 0-10 scale for meta-analysis</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-02-22 21:26:24 -0500" MODIFIED_BY="[Empty name]">
<P>(NCT01114880). "This study was sponsored by AbbVie". FH is a consultant and has served on speakers bureaus for AbbVie China. Data extracted for efficacy from 12-week placebo-controlled phase</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-23 05:10:48 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Inman-2008">
<CHAR_METHODS MODIFIED="2014-10-09 15:28:28 -0400" MODIFIED_BY="[Empty name]">
<P>24-week, double-blind, placebo-controlled study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-23 05:10:03 -0400" MODIFIED_BY="[Empty name]">
<P>Placebo (N = 78) Golimumab 50 mg (N = 138) Golimumab 100 mg (N = 140)</P>
<P>Age (median (interquartile range, years) 41.0 (31.0&#8211;50.0) 38.0 (30.0&#8211;47.0) 38.0 (29.0&#8211;46.0)<BR/>Male, No (%) 55 (70.5) 102 (73.9) 98 (70.0)<BR/>White, No (%) 57 (73.1) 103 (74.6) 102 (72.9)</P>
<P>
<BR/>Years since symptoms occurred, median (interquartile range) 16 (5&#8211;25) 11( 6&#8211;18) 9.5 (14-18)</P>
<P>Inclusion criteria: Adult patients who had AS (diagnosed according to the modified New York Criteria for 3 months before the first administration of the study agent, a Bath AS Disease Activity Index (BASDAI) score of 4 (0&#8211;10-point scale), a spinal pain assessment score of 4 on a visual analogue scale (VAS); 0&#8211;10-cm scale), and an inadequate response to current or previous non-steroidal anti-inflammatory drugs (NSAIDs) or disease-modifying anti-rheumatic drugs (DMARDs). Failure to DMARDs for at least 3 months. Normal chest radiograph within 3 months before randomisation and to have undergone screening for latent tuberculosis (TB)</P>
<P>Exclusion criteria: any of the following: complete ankylosis of the spine, any other inflammatory rheumatic disease, a serious infection within 2 months before randomisation, active or latent TB or positive results of a tuberculin skin test before screening or recent contact with a person with active TB, an opportunistic infection within 6 months of screening, hepatitis, human immunodeficiency virus, a transplanted organ, malignancy, multiple sclerosis, or congestive heart failure</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-22 21:27:50 -0500" MODIFIED_BY="[Empty name]">
<P>3-arm study. Patients were randomly assigned in a 1:1.8:1.8 ratio to receive placebo or golimumab at a dose of 50 mg or 100 mg every 4 weeks.</P>
<P>Patients were allowed to continue concurrent treatment with methotrexate (MTX), sulphasalazine, hydroxychloroquine,<BR/>corticosteroids, and NSAIDs at stable doses during the study.</P>
<P>At week 16 there was an early-escape option for those patients who had not responded.</P>
<P>Note -only extracted 50 mg data (100 mg only indicated for patients &gt; 100 kg and who fail to achieve response to 50mg &#8211; not many in the trial and not standard dose) at week 14</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-03-23 05:10:48 -0400" MODIFIED_BY="[Empty name]">
<P>The primary end point was the proportion of patients who achieved ASAS20 at week 14. Secondary end points included ASAS40, ASAS partial remission, ASAS5/6. Disease activity was evaluated using the BASDAI, the back pain VAS, the night pain VAS, the patient&#8217;s global assessment, and the C-reactive protein level. Physical function was evaluated using the BASFI. Range of motion was assessed using the BASMI (3-point scale), and chest expansion. Health-related quality of life was measured using the Short Form 36 (SF-36) Health Survey. Sleep disturbance was assessed using the Jenkins Sleep Evaluation Questionnaire(JSEQ). Presence of antibodies to golimumab</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-02-22 21:27:55 -0500" MODIFIED_BY="[Empty name]">
<P>NCT00265083. Supported by Centocor Research and Development, Inc. and the Schering-Plough Research Institute, Inc</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-23 05:20:54 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Inman-2010">
<CHAR_METHODS MODIFIED="2015-02-22 23:10:23 -0500" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, placebo-controlled, multi-center trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-23 05:20:30 -0400" MODIFIED_BY="[Empty name]">
<P>N = 76; N = 39 infliximab, N = 37 placebo Note: one abstract assessing spinal inflammation with magnetic resonance imaging (MRI) indicates N=32 (16 infliximab and 16 placebo). The study protocol from clinicaltrials.gov indicates the study is complete and the sample is 76 participants</P>
<P>Age (mean, years): Treatment group - 42.9 (10.4); Control group - 39.3 (9)<BR/>% male: Treatment group - 82%; Control group - 78%<BR/>% white: Treatment group - 87%; Control group - 89%<BR/>Disease duration (years): Treatment group - 11.7 (10.6); Control group -11.1 (10.3)</P>
<P>Positive for HLA-B27: infliximab = 72%; placebo = 73%</P>
<P>Inclusion: Adults (&gt; 18 years) with active ankylosing spondylitis (BASDAI &gt;= 4)</P>
<P>In those patients taking non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs), analgesics, or corticosteroids, the dose must have been stable for at least 14 days (30 days for DMARD) prior to the first infusion of study drug. Patients were excluded from the study if they had a history of chronic/recurrent infectious disease, including tuberculosis, hepatitis B, or HIV, and/or a diagnosis of malignancy or lymphoproliferative disease currently or within the past 5 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-23 05:20:54 -0400" MODIFIED_BY="[Empty name]">
<P>Infliximab (IFX) 3 mg/kg or placebo intravenously at weeks 0, 2, and 6. An open-label phase followed after week 12 which lasted 46 weeks and the placebo group crossed over to receive infusions of IFX 3 mg/kg at Weeks 14, 16, and 22, and every 8 weeks thereafter. "All patients could receive dose-escalation of IFX to 5 mg/kg at Weeks 22 or 38 if the patient had an absolute BASDAI score &gt; 3 and a relative decrease of &lt; 50% in BASDAI from baseline". Follow-up was for 52 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-22 21:29:46 -0500" MODIFIED_BY="[Empty name]">
<P>Primary outcome listed in study protocol was ASAS 20 at week 12. Other clinical outcomes in the protocol: BASDAI, BASFI, BASGI, BASMI, ASAS 40/50/70 and ASAS 5/6 and MRI at week 12 were reported in the abstracts (though the number of participants is unclear)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-01-29 11:08:28 -0500" MODIFIED_BY="[Empty name]">
<P>NCT00202865. Study known as "CANaDian evaluation of Low DosE infliximab (CANDLE)."</P>
<P>Reported in one full-text article and 3 abstracts from conferences.</P>
<P>"Supported by Schering-Plough, Canada"</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-23 05:24:07 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lambert-2007">
<CHAR_METHODS MODIFIED="2010-03-15 21:02:33 -0400" MODIFIED_BY="[Empty name]">
<P>Randomized, multicenter, double-blind, placebo-controlled study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-23 05:24:07 -0400" MODIFIED_BY="[Empty name]">
<P>N = 38 adalimumab, N = 44 placebo</P>
<P>Age (mean (SD), years): Treatment group - 41.9(11.1); Control group - 40 (10.9)<BR/>% male: Treatment group - 76.3%; Control group - 81.8%<BR/>% white: Treatment group - not reported</P>
<P>
<BR/>Disease duration (years (SD)): Treatment group - 14.5 (9); Control group -12.1 (8.7)</P>
<P>Inclusion:Patients were adults (18 years of age) diagnosed as having ankylosing spondylitis as defined by the modified New York criteria, who had been treated unsuccessfully (nonresponse or lack of tolerance) with 1 non-steroidal anti-inflammatory drug (NSAIDs). Patients who had failed to respond to 1 disease-modifying anti-rheumatic drug (DMARD) (e.g., methotrexate,sulphasalazine) were also allowed to enrol. Active ankylosing spondylitis at baseline was defined by fulfilment of 2 of the following 3 criteria: a BASDAI score greater than or equal to 4, total back pain visual analog scale score greater than or equal to 40, or morning stiffness of 1 hour in duration. Patients could continue taking sulphasalazine (3 g/day), methotrexate (25 mg/week), hydroxychloroquine (400 mg/day), prednisone and/or prednisone equivalents (10 mg/day), and/or NSAIDs as long as these doses had remained stable for 4 weeks before baseline</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-22 21:31:46 -0500" MODIFIED_BY="[Empty name]">
<P>40 mg adalimumab or placebo every other week for 24 weeks (double-blind phase) but an early escape option to non-responders was available after week 12. Study visits occurred at baseline, week 2, week 4, every 4 weeks through week 24</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-22 21:31:51 -0500" MODIFIED_BY="[Empty name]">
<P>Primary endpoint was ASAS20 at 12 weeks but results were not provided in full-text Lambert article, but were reported in a conference abstract (Maksymowych 2005)</P>
<P>Secondary outcomes of MRI of spine and SI joints scored using SPARCC methodology at week 12 were reported in Lambert2007. Another publication from this trial, Maksymowych 2008, which was focused on biomarkers for structural damage, also reported BASDAI, total back pain, patient global, BASFI, BASMI</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-02-22 21:32:13 -0500" MODIFIED_BY="[Empty name]">
<P>NCT00195819; M03-606 study group</P>
<P>"ROLE OF THE STUDY SPONSOR An advisory committee, including authors from academic institutions and Abbott Laboratories, and members of the Abbott Laboratories clinical trial team designed the study, which was conducted at 11 centers in Canada. Clinical data were collected and analyzed by Abbott Laboratories. Data analyses were reviewed by members of the advisory committee. All authors reviewed and assisted in the manuscript preparation during its development, agreed to submit the manuscript, and approved the content of the submitted manuscript"</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-23 05:26:05 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Marzo_x002d_Ortega-2005">
<CHAR_METHODS MODIFIED="2015-02-22 23:10:28 -0500" MODIFIED_BY="[Empty name]">
<P>30 week, single-center, randomized, double-blind placebo controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-23 05:25:25 -0400" MODIFIED_BY="[Empty name]">
<P>N = 28 infliximab + methotrexate (MTX), N = 14 placebo + MTX</P>
<P>Age (mean (range), years): Treatment group - 41 (28&#8211;74); Control group - 39 (30&#8211;56)<BR/>% male: Treatment group - 82%; Control group - 79%<BR/>% white: - not reported</P>
<P>
<BR/>Disease duration (median years (range)): Treatment group - 8 (0-41) ; Control group - 10 (0-35)</P>
<P>Inclusion: fulfil the modified New York criteria for ankylosing spondylitis,14 be older than 18 years of age, and have active spinal disease. This was defined as persistent inflammatory back pain (defined as 3 cm or more on a 10 cm visual analogue scale (VAS)) and a raised inflammatory response in serum as shown by a C reactive protein (CRP) value of more than 10 mg/L despite treatment with conventional agents such as an optimal dose of non-steroidal anti-inflammatory drugs (NSAIDs) or disease-modifying anti-rheumatic drugs (DMARDs)</P>
<P>Exclusion: any history of tuberculosis, active infection, demyelinating disease, previous lymphoproliferative or malignant disorder, pregnancy, breast feeding, or uncontrolled concomitant disease in the opinion of the investigator.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-22 21:34:05 -0500" MODIFIED_BY="[Empty name]">
<P>Infusions of infliximab (5 mg/kg in 250 ml 0.9% NaCl) + MTX or placebo + MTX. The infusion regimen was weeks 0, 2, 6, 14, and 22. All subjects also received a dose of 7.5 mg with folic acid cover (5 mg twice a week), which was eventually increased to 10 mg a week</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-03-23 05:26:05 -0400" MODIFIED_BY="[Empty name]">
<P>The primary outcome was evaluation of change in the BASDAI score at weeks 4, 10, and 30. Secondary outcomes were ASAS 20 and BASDAI 50% response. Magnetic resonance imaging (MRI) also assessed</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-02-22 21:34:11 -0500" MODIFIED_BY="[Empty name]">
<P>This study was supported by a grant in aid from Schering-Plough, UK</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-23 05:30:40 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Navarro_x002d_Sarabia-2011">
<CHAR_METHODS MODIFIED="2015-03-23 05:27:18 -0400" MODIFIED_BY="[Empty name]">
<P>12-week double-blind, placebo-controlled randomized pilot study to evaluate the effect of etanercept 100 vs 50 mg/week to treat ankylosing spondylitis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-23 05:29:23 -0400" MODIFIED_BY="[Empty name]">
<P>N = 54 etanercept 100 mg/week; N = 54 etancercept 50 mg/week</P>
<P>Age (mean (SD), years): Treatment group - 40.22 (10.36); Control group - 42.63 (10.66)<BR/>% male: Treatment group - 79.6%; Control group - 79.6%<BR/>% white: - not reported<BR/>Disease duration (years since diagnosis, mean years (standard deviation (SD)): Treatment group - 7.03 (6.83) ; Control group - 7.28 (7.06)</P>
<P>Inclusion criteria: Adult outpatients with ankylosing spondylitis diagnosis as defined by the modified New York criteria for ankylosing spondylitis and with inflammatory activity maintained for &gt;12 weeks, who had failed treatment with at least two non-steroidal anti-inflammatory drugs (NSAIDs) at maximum recommended doses during at least 3 months</P>
<P>Exclusion criteria: Complete ankylosis, contraindications for anti-TNF alpha treatment, treatment with more than 10mg/day of disease-modifying anti-rheumatic drugs (DMARDs) or prednisone, NSAID use within 2 weeks of baseline, previous TNF inhibitors or biologics use, abnormal haematological profiles, psychiatric disease, history of alcohol or drug abuse</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-03-23 05:29:46 -0400" MODIFIED_BY="[Empty name]">
<P>Etanercept 50 mg twice a week or 50 mg once a week plus a second injection of placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-03-23 05:30:40 -0400" MODIFIED_BY="[Empty name]">
<P>The primary efficacy endpoint was the proportion of subjects who achieved ASAS20 response at Week 12.</P>
<P>Patients&#8217; global assessment of disease activity and pain were measured using a visual analogue scale (VAS), physical function was assessed using the BASFI score and inflammation was measured using the score of the morning-stiffness items of the BASDAI. Secondary endpoints were the proportion of subjects who achieved ASAS40, ASAS50, ASAS70, ASAS5/6 response and partial remission at Week 12, nocturnal and overall spine pain, physician global assessment of disease activity, activity index (BASDAI), spinal mobility (BASMI) score , complete peripheral joint count (ACR64/66 index), tenderness of enthesis [Maastricht Ankylosing Spondylitis Enthesis Score (MASES) index], C-reactive protein and erythrocyte sedimentation rate. Quality of life was assessed by the European Quality of Life Scale. (EuroQoL) and 36-item Short-Form Health Survey (SF-36) questionnaires</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-10-10 10:36:38 -0400" MODIFIED_BY="[Empty name]">
<P>NCT00873730; LOADET. This work was supported by Pfizer S.A.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-23 06:11:24 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-van-der-Heijde-2005">
<CHAR_METHODS MODIFIED="2010-12-11 16:38:14 -0500" MODIFIED_BY="[Empty name]">
<P>Multicenter, randomized, placebo-controlled study for 24 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-23 06:09:03 -0400" MODIFIED_BY="[Empty name]">
<P>N = 201 infliximab N = 78 placebo<BR/>Age (mean, years): Treatment group - 40; Control group - 41<BR/>% male: Treatment group - 78%; Control group - 87%<BR/>% white: Treatment group - 98%; Control group - 97%</P>
<P>
<BR/>Disease duration (years): Treatment group - 8; Control group -13<BR/>Patient fulfilling the modified New York criteria for at least 3 months prior to screening, with BASDAI &gt;= 4 (range 0&#8211;10) and spinal pain assessment score &gt;= 4 on a visual analogue scale (0&#8211;10 cm) were eligible for the study. Patients were also required to have a normal chest radiograph within 3 months prior to randomisation and either a negative tuberculosis (TB) test. Exclusion: total ankylosis of the spine (defined by syndesmophytes present on the lateral views of spinal radiographs at all intervertebral levels from T6 through S1), any other inflammatory rheumatic disease, fibromyalgia, a serious infection within 2 months prior to randomisation, TB (active or latent) or recent contact with a person with active TB, an opportunistic infection within 6 months of screening, hepatitis, human immunodeficiency virus, a transplanted organ, malignancy, multiple sclerosis, or congestive heart failure. Patients were allowed to receive concurrent stable doses of non-steroidal anti-inflammatory drugs, acetaminophen (paracetamol), or tramadol during the study. Patients were not permitted to receive sulphasalazine or methotrexate within 2 weeks prior to screening, systemic corticosteroids within 1 month prior to screening, anti-TNF therapy other than infliximab within 3 months prior to screening, infliximab at any time prior to screening, Disease-modifying anti-rheumatic drugs other than sulphasalazine or methotrexate within 6 months prior to screening, or cytotoxic drugs within 12 months prior to screening</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>5 mg/kg infliximab at weeks 0, 2, 6, 12, and 18 vs placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-03-23 06:09:31 -0400" MODIFIED_BY="[Empty name]">
<P>Primary end point: ASAS20 responders at week 24. Other: BASDAI, night pain, patient&#8217;s global assessment, BASF, BASMI, chest expansion, the Mander enthesis index, the total swollen joint index, the C-reactive protein level, SF-36, adverse events</P>
<P>Magnetic resonance imaging (MRI) reported in another publication (Braun 2006): MRI Activity Score based on the amount of bone marrow edema or erosions,as follows: 0 no erosions or bone marrow edema, 1 minor bone marrow edema involving 25% of the vertebral unit, 2 moderate bone marrow edema involving 20% but 50% of the vertebral unit, 3 major bone marrow edema involving 50% of the vertebral unit, 4 bone marrow edema and minor erosion involving 25% of the vertebral unit, 5 bone marrow edema and moderate erosion involving 20% but 50% of the vertebral unit, and 6 bone marrow edema and major erosion involving 50% of the vertebral unit. Thus, the MRI Activity Score for each vertebral unit ranged from 0 to 6. With 23 vertebral units assessed (from C2 to S1), the total MRI Activity Score for the spine ranged from 0 to 138</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-23 06:11:24 -0400" MODIFIED_BY="[Empty name]">
<P>NCT00207701 'Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy (ASSERT)' trial. "Supported by Centocor Inc"</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-23 06:19:52 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-van-der-Heijde-2006a">
<CHAR_METHODS>
<P>Multicenter, randomized (2:1 ratio) placebo-controlled study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-23 06:19:52 -0400" MODIFIED_BY="[Empty name]">
<P>N = 208 adalimumab; N = 107 placebo<BR/>Age (mean, years): Treatment group - 42; Control group - 43<BR/>% male: Treatment group - 76%; Control group - 74%<BR/>% white: Treatment group - 97%; Control group - 93%</P>
<P>
<BR/>Disease duration (years): Treatment group - 11; Control group -10<BR/>Patients &gt;= 18 years of age and classified as having definite ankylosing spondylitis based on the modified New York criteria. All had active disease, defined as fulfilment of at least 2 of the following 3 criteria: BASDAI &gt;= 4, a total back pain score &gt;4 (visual analogue scale 0&#8211;10 cm), or a duration of morning stiffness &gt; 1 hour</P>
<P>
<BR/>Patients with stable and well-controlled psoriasis, uveitis, inflammatory bowel disease (i.e., ulcerative colitis,Crohn&#8217;s disease), and reactive arthritis were allowed to participate. Inadequate response or intolerance to 1 or more non-steroidal anti-inflammatory (NSAIDs) was defined by the investigators. Patients in whom 1 or more disease-modifying anti-rheumatic drugs (DMARDs) had failed were also allowed to participate. Patients were allowed to continue any of the following medications if the dose had remained stable for at least 4 weeks before the baseline visit: sulphasalazine (&lt;=3gm/day), methotrexate (&lt;= 25 mg/week), hydroxychloroquine(&lt;= 400 mg/day), prednisone or prednisone equivalent (&lt;=10mg/day), and NSAIDs</P>
<P>
<BR/>Exclusions: "previously received anti-TNF therapy, cyclosporine, azathioprine, or DMARDs (other than the medications and doses listed above) at any time and patients who had received intraarticular injection(s) with corticosteroids within 4 weeks prior to baseline. Patients with latent tuberculosis (TB) were allowed to participate in the study if a documented history of treatment was available or if treatment for latent TB was initiated before the first dose of study medication. Patients with clinically active TB were excluded from the study. History of any recent infections requiring antibiotic treatment; hepatitis or human immunodeficiency virus; a significant history of cardiac, renal, neurologic, psychiatric, endocrinologic, metabolic, or hepatic disease; and a history of demyelinating disease or multiple sclerosis. History of cancer or lymphoproliferative disease other than a successfully treated nonmetastatic squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the cervix"</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-22 22:20:40 -0500" MODIFIED_BY="[Empty name]">
<P>Adalimumab 40 mg every other week or placebo for a 24-week period. Patients who did not achieve a 20% response according to the ASsessment in Ankylosing Spondylitis International Working Group criteria for improvement (ASAS20) at weeks 12, 16, or 20 were eligible for &#8220;early-escape&#8221; open label treatment with adalimumab 40 mg every other week</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-22 22:20:44 -0500" MODIFIED_BY="[Empty name]">
<P>Primary efficacy outcome: percentage of ASAS20 responders at week 12. Secondary: ASAS5/6, ASAS40</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-23 06:17:19 -0400" MODIFIED_BY="[Empty name]">
<P>NCT00085644. 'Adalimumab Trial Evaluating Long-term Efficacy and Safety for Ankylosing Spondylitis (ATLAS)'. "Supported by Abbott Laboratories"</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-03-23 06:21:49 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-van-der-Heijde-2006b">
<CHAR_METHODS MODIFIED="2015-02-22 23:10:39 -0500" MODIFIED_BY="[Empty name]">
<P>12-week, randomized, placebo-controlled, double-blind, multicenter study with three treatment groups in a 3:3:1 ratio (etanercept 50 mg once weekly: etanercept 25 mg twice weekly: placebo)</P>
<P>Study carried out in 38 centers in 11 European countries</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-03-23 06:21:49 -0400" MODIFIED_BY="[Empty name]">
<P>Etanercept 50mg once weekly:N=155; mean age (SD)=41.5 (11.0); 69.7% male; disease duration, years (SD) = 9.0 (8.7)</P>
<P>Etanercept 25mg twice weekly:N=150; mean age (SD)=39.8 (10.7); 76% male; disease duration, years (SD) = 10.0 (9.1)</P>
<P>Placebo: N = 51; mean age (SD) = 40.1 (10.9); 78.4% male; disease duration, years (SD) = 8.5 (6.8)</P>
<P>Inclusion - age 18 to 70 years with active AS based on the Modified New York Criteria for ankylosing spondylitis. Active ankylosing spondylitis defined by visual analogue scale (VAS) &gt;= 30 for duration and intensity of morning stiffness and two or more of the following:patient global assessment of disease activity VAS &gt;=30; mean of nocturnal and total pain VAS scores &gt;=30</P>
<P>"Concomitant oral non-steroidal anti-inflammatory drugs and oral corticosteroids ((10 mg/day), if stable for &gt;2 weeks before randomisation, and disease-modifying antirheumatic drugs (hydroxychloroquine, sulphasalazine and methotrexate), if stable for &gt;4 weeks before randomisation, were permitted"</P>
<P>Exclusion: "Patients previously treated with TNFa inhibitors, including etanercept or other biological agents, or disease-modifying antirheumatic drugs (other than hydrochloroquine, sulphasalazine and methotrexate) less than 4 weeks before baseline, were not eligible. Other important exclusion criteria included complete ankylosis (fusion) of the spine based on radiographic assessment and concurrent medical events, such as uncontrolled hypertension, unstable angina pectoris, congestive heart failure, severe pulmonary disease, cancer, demyelinating diseases of the central nervous system and serious infections"<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-22 22:22:18 -0500" MODIFIED_BY="[Empty name]">
<P>Etanercept 50 mg once weekly versus etanercept 25 mg twice weekly versus placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-22 22:22:52 -0500" MODIFIED_BY="[Empty name]">
<P>Non-inferiority design to compare etanercept 50 mg once weekly to 25 mg twice weekly. Primary outcome: ASAS20 at week 12. Secondary outcomes: Secondary outcomes: ASAS40 and ASAS5/6 criteria at all time points</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-02-22 22:22:46 -0500" MODIFIED_BY="[Empty name]">
<P>NCT00418548. "Study was supported by Wyeth Pharmaceuticals, Collegeville, Pennsylvania, USA (study drug and grants to investigational sites)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>AID: articular index according to Dougados<BR/>AS: Ankylosing Spondylitis<BR/>ASAS20 response: defined as 20% or greater improvement in at least three of five measures of disease activity, as recommended by the Assessment of SpondyloArthritis international Society (ASAS) (duration of morning stiffness, degree of nocturnal spinal pain, the BASFI, the patient&#8217;s global assessment of disease activity, and the score for joint swelling), one of which was required to be duration of morning stiffness or degree of nocturnal spinal pain, with no worsening in any of the measures. If the swollen-joint score was zero throughout the study, improvement was required in at least two of the four other outcome measures, with the aforementioned restrictions. Twenty per cent improvement is defined as improvement of at least 20% and absolute improvement of at least 10 units (on a scale of 0&#8211;100) in three or more of the following domains: patient global assessment, pain, function (from the BASFI score), and inflammation (measured by the mean of the two morning stiffness-related BASDAI and visual analogue scores). Furthermore, deterioration in the potentially remaining domain has to be absent, defined as a change for the worse of 20% or more, and net worsening of 10 units or more (on a scale of 0&#8211;100)<BR/>ASAS40 response: at least a 40% improvement with a minimum of 20 units (0 to 100 scale) improvement compared with baseline in at least three of four domains (spinal pain, function (BASFI), inflammation as measured by the mean of intensity and duration of morning stiffness in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), and patient global assessment), and with no worsening in the fourth domain.<BR/>ASAS50 response: at least a 50% with a minimum of 20 units (0 to 100 scale) improvement compared with baseline in at least three of four domains (spinal pain, function (BASFI), inflammation as measured by the mean of intensity and duration of morning stiffness in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), and patient global assessment), and with no worsening in the fourth domain.<BR/>ASAS70 response: at least a 70% with a minimum of 20 units (0 to 100 scale) improvement compared with baseline in at least three of four domains (spinal pain, function (BASFI), inflammation as measured by the mean of intensity and duration of morning stiffness in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), and patient global assessment), and with no worsening in the fourth domain.<BR/>ASAS Partial remission: a value of less than 2 on a 0 to 10 scale in each of the four domains as described above for the ASAS40.<BR/>ASAS 5/6 response criteria require at least 20% improvement in 5 of 6 domains: spinal mobility (according to the Bath Ankylosing Spondylitis Metrology Index [BASMI];other instruments may be used) and acute-phase reactants (the CRP concentration) in addition to the 4 domains included in the ASAS 20 response criteria.<BR/>BASDAI: Bath Ankylosing Spondylitis Disease Activity Index<BR/>BASDAI 50: 50% improvement of the initial BASDAI<BR/>BASFI: Bath Ankylosing Spondylitis Functional Index<BR/>BASMI: Bath Ankylosing Spondylitis Metrology index<BR/>BASRI-s: Bath Ankylosing Spondylitis Radiology Index for the spine<BR/>CRP: C-reactive protein level<BR/>DFI: Dougados Functional Index<BR/>DMARD: disease-modifying anti-rheumatic drug<BR/>ESR: erythrocyte sedimentation rate<BR/>NSAID: non-steroidal anti-inflammatory drug<BR/>SF-36: short form 36. A health-related assessment of quality of life<BR/>VAS: Visual analogue scale<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2015-03-23 07:39:54 -0400" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2015-02-22 22:30:55 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Barkham-2008b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-22 22:30:55 -0500" MODIFIED_BY="[Empty name]">
<P>Trial participant inclusion criteria does not meet review participant inclusion criteria (inflammatory back pain by Calin criteria &lt; 3yrs)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-23 06:52:59 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Breban-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-23 06:52:59 -0400" MODIFIED_BY="[Empty name]">
<P>Trial participants did not meet complete modified NY criteria for ankylosing spondylitis and the intervention was systematic versus on-demand treatment using infliximab</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-23 06:53:12 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Haibel-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-23 06:53:12 -0400" MODIFIED_BY="[Empty name]">
<P>The population included in this study "axial spondylarthritis without radiographically defined sacroiliitis" does not meet the review's inclusion criteria. This study is in early ankylosing spondylitis patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-22 22:31:13 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-22 22:31:13 -0500" MODIFIED_BY="[Empty name]">
<P>The intervention of infliximab + methotrexate vs infliximab + placebo assesses effect of methotrexate and does not meet the review's intervention inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-22 22:31:20 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Morency-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-22 22:31:20 -0500" MODIFIED_BY="[Empty name]">
<P>Open-label extension of Lambert 2007</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-23 06:54:07 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Van-den-Bosch-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-23 06:54:07 -0400" MODIFIED_BY="[Empty name]">
<P>Patients included ankylosing spondylitis, reactive arthritis, psoriatic arthritis, and undifferentiated spondyloarthritis. Results for ankylosing spondylitis patients only were not available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2015-02-22 22:33:19 -0500" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2015-02-22 22:33:19 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2009">
<CHAR_METHODS MODIFIED="2015-02-22 22:33:04 -0500" MODIFIED_BY="[Empty name]">
<P>Randomized, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-29 07:53:27 -0500" MODIFIED_BY="[Empty name]">
<P>86 Chinese patients with AS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-22 22:33:12 -0500" MODIFIED_BY="[Empty name]">
<P>Etanercept or placebo for 6 weeks followed by 6 week open-label extension</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-29 07:58:04 -0500" MODIFIED_BY="[Empty name]">
<P>ASAS20 and other ASAS responses, changes in BASDAI, BASFI, morning stiffness, nocturnal spinal pain</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-02-22 22:33:19 -0500" MODIFIED_BY="[Empty name]">
<P>Chinese paper; abstract in English. Same authors as Huang 2008 and same intervention so it might be a report from the same study, though only reports on 86 participants as opposed to 152 in Huang 2008. Awaiting translation and confirmation with authors</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2015-03-23 06:22:30 -0400" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2015-02-22 23:09:02 -0500" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-22 20:53:52 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bao-2014">
<DESCRIPTION>
<P>No details provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-22 20:55:11 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Barkham-2010">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-22 20:56:48 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brandt-2003">
<DESCRIPTION>
<P>"Initials and sex of the 33 remaining patients were reported to a central independent registration office by fax. Patients were randomly allocated to one of the treatment groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-22 20:58:26 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Braun-2002">
<DESCRIPTION>
<P>"The allocation schedule was generated by computer-generated random numbers, done in blocks of four for every centre. Thus, within each group of patients enrolled by a single centre, two were randomly assigned to placebo, and two to infliximab"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-22 23:07:56 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Braun-2011">
<DESCRIPTION>
<P>Computerized randomisation/enrolment system</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-22 21:01:31 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Calin-2004">
<DESCRIPTION>
<P>No details provided on sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-22 23:07:58 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Davis-2003">
<DESCRIPTION>
<P>"Patients, investigators, assessors, other study site personnel, and representatives of the sponsor were blinded to the randomisation schedule and to treatment assignment until completion of the trial"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-22 21:06:08 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dougados-2011">
<DESCRIPTION>
<P>"Randomised double-blind", no further details provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-22 21:18:07 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Giardina-2009">
<DESCRIPTION>
<P>"Patients were randomised to receive alternatively etanercept or<BR/>inXiximab with a ratio of 1:1"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-22 21:09:25 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gorman-2002">
<DESCRIPTION>
<P>"A statistician not otherwise involved with the study randomly assigned patients to the study groups, using computer-generated, random blocks of two and four"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-22 21:21:18 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hu-2012">
<DESCRIPTION>
<P>"Randomized, double-blind, placebo-controlled comparison..." No further details provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-22 21:22:28 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huang-2008">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-22 21:26:29 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huang-2014">
<DESCRIPTION>
<P>"Participants were centrally randomised using an interactive voice response or web-based system in a 2:1 ratio"<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-22 21:28:03 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Inman-2008">
<DESCRIPTION>
<P>"An interactive voice-response system with adaptive treatment allocation was used to assign patients to treatment"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-22 21:29:54 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Inman-2010">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-22 21:32:16 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lambert-2007">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-07 17:18:00 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marzo_x002d_Ortega-2005">
<DESCRIPTION>
<P>"A 2:1 randomisation list was generated by a statistician (who was unconnected with the final analysis of results)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-22 21:39:03 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Navarro_x002d_Sarabia-2011">
<DESCRIPTION>
<P>Patients were sequentially numbered at the screening visit</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-24 13:41:01 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-van-der-Heijde-2005">
<DESCRIPTION>
<P>"Randomly assigned in 3:8 ratio"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-22 23:09:02 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-der-Heijde-2006a">
<DESCRIPTION>
<P>From study author: "A random number generator was used to generate the randomisation numbers. All patients were centrally randomized using an Interactive Voice Response System (IVRS). Randomization occurred within each site"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-22 22:22:57 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-van-der-Heijde-2006b">
<DESCRIPTION>
<P>Not reported in article</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2015-02-22 23:07:58 -0500" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-22 20:53:55 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bao-2014">
<DESCRIPTION>
<P>No details provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-22 20:55:15 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Barkham-2010">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-22 20:56:51 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brandt-2003">
<DESCRIPTION>
<P>"Initials and sex of the 33 remaining patients were reported to a central independent registration office by fax. Patients were randomly allocated to one of the treatment groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-22 20:58:29 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Braun-2002">
<DESCRIPTION>
<P>"The allocation schedule was generated by computer-generated random numbers, done in blocks of four for every centre. Thus, within each group of patients enrolled by a single centre, two were randomly assigned to placebo, and two to infliximab." "Investigators were informed by fax about the randomisation, and were provided with the trial number of the patient." This information was kept in a sealed envelope that was only opened in case of a serious adverse event</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-22 23:07:56 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Braun-2011">
<DESCRIPTION>
<P>Computerized randomisation/enrolment system</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-22 21:01:34 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Calin-2004">
<DESCRIPTION>
<P>No details provided on allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-22 23:07:58 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Davis-2003">
<DESCRIPTION>
<P>"Patients, investigators, assessors, other study site personnel, and representatives of the sponsor were blinded to the randomisation schedule and to treatment assignment until completion of the trial"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-22 21:06:12 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dougados-2011">
<DESCRIPTION>
<P>"Randomised double-blind", no further details provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-22 21:07:42 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Giardina-2009">
<DESCRIPTION>
<P>No details on concealment of allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-22 21:09:31 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gorman-2002">
<DESCRIPTION>
<P>"Cards with the group assignments were placed in sequentially numbered envelopes that were opened by the study pharmacist as each patient was enrolled"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-22 21:21:26 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hu-2012">
<DESCRIPTION>
<P>"Randomized, double-blind, placebo-controlled comparison..." No further details provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-22 21:22:32 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huang-2008">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-22 21:26:32 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huang-2014">
<DESCRIPTION>
<P>"Participants were centrally randomised using an interactive voice response or web-based system in a 2:1 ratio"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-22 21:28:04 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Inman-2008">
<DESCRIPTION>
<P>"An interactive voice-response system with adaptive treatment allocation was used to assign patients to treatment"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-22 21:29:56 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Inman-2010">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-22 21:32:19 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lambert-2007">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-07 17:18:39 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marzo_x002d_Ortega-2005">
<DESCRIPTION>
<P>"Study participants, clinical observers, and metrologists were unaware of the randomisation code, which was kept in the hospital pharmacy"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-09 10:31:19 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Navarro_x002d_Sarabia-2011">
<DESCRIPTION>
<P>"Upon completion of the baseline evaluation, eligible subjects were randomly allocated to a treatment group." Method of concealment of allocation not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-29 19:56:53 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-van-der-Heijde-2005">
<DESCRIPTION>
<P>Unclear "Patients were allocated to treatment groups using an adaptive treatment allocation stratified by investigational site and C-reactive protein level..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-22 22:20:51 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-der-Heijde-2006a">
<DESCRIPTION>
<P>From study author: "The patient, sponsor and the study sites were blinded to treatment allocation." "The treatment allocation for each patient was provided to the site in a sealed envelope, to be opened in the case of an emergency in which the investigator believed that knowledge of study drug treatment was required. However, no patient was unblinded during the course of the double blind period"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-22 22:23:01 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-van-der-Heijde-2006b">
<DESCRIPTION>
<P>Not reported in article</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2014-11-17 17:33:48 -0500" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>Physician assessed outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>Patient assessed outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="GROUP" MODIFIED="2015-02-22 23:07:58 -0500" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-09.02" NO="2">
<NAME>Physician-assessed outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-09.01" NO="1">
<NAME>Patient-assessed outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-02-22 20:53:58 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bao-2014">
<DESCRIPTION>
<P>"Double-blind", no details provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.02" MODIFIED="2015-02-22 20:54:01 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bao-2014">
<DESCRIPTION>
<P>"Double-blind", no details provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-02-22 20:55:17 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barkham-2010">
<DESCRIPTION>
<P>"The site monitor, investigators, and patients remained blinded until after the data through week 12 had been finalised" ; although details not provided, probably done adequately</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.02" MODIFIED="2015-02-22 20:55:20 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barkham-2010">
<DESCRIPTION>
<P>"The site monitor, investigators, and patients remained blinded until after the data through week 12 had been finalised" ; although details not provided, probably done adequately</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-02-22 20:56:54 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brandt-2003">
<DESCRIPTION>
<P>"The pharmacist at each center prepared the medication, which was delivered in a blinded manner." "The placebo solution containing bacteriostatic water was supplied and administered identically." "Investigators and patients remained blinded until week 12, 6 weeks after the placebo controlled phase had finished"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.02" MODIFIED="2015-02-22 20:56:56 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brandt-2003">
<DESCRIPTION>
<P>"Investigators and patients remained blinded until week 12, 6 weeks after the placebo controlled phase had finished"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-02-22 20:58:31 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Braun-2002">
<DESCRIPTION>
<P>"Investigators and patients were unaware of treatment status until all case report forms had been completed"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.02" MODIFIED="2015-02-22 20:58:36 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Braun-2002">
<DESCRIPTION>
<P>"Investigators and patients were unaware of treatment status until all case report forms had been completed." "The information had to be sent back once the patient had completed the trial." (referring to the sealed envelope with the group assignment)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-02-22 20:59:58 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Braun-2011">
<DESCRIPTION>
<P>Double-blind; All patients treated with visually identical injections and tablets</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.02" MODIFIED="2015-02-22 21:00:01 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Braun-2011">
<DESCRIPTION>
<P>Double-blind; All patients treated with visually identical injections and tablets; probably investigator blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-02-22 21:01:36 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Calin-2004">
<DESCRIPTION>
<P>"To preserve the integrity of the blind study, placebo and etanercept supplies were similar in appearance"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.02" MODIFIED="2015-02-22 21:01:42 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Calin-2004">
<DESCRIPTION>
<P>No details provided other than 'double-blind'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-02-22 23:07:58 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Davis-2003">
<DESCRIPTION>
<P>"Patients, investigators, assessors, other study site personnel, and representatives of the sponsor were blinded to the randomisation schedule and to treatment assignment until completion of the trial"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.02" MODIFIED="2015-02-22 23:07:58 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Davis-2003">
<DESCRIPTION>
<P>"Patients, investigators, assessors, other study site personnel, and representatives of the sponsor were blinded to the randomisation schedule and to treatment assignment until completion of the trial"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-02-22 21:06:15 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dougados-2011">
<DESCRIPTION>
<P>"Matching placebo"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.02" MODIFIED="2015-02-22 21:06:18 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dougados-2011">
<DESCRIPTION>
<P>"Matching placebo" ; unclear if investigators were properly blinded and no details provided on allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-02-22 21:07:48 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Giardina-2009">
<DESCRIPTION>
<P>"Open-label"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.02" MODIFIED="2015-02-22 21:07:51 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Giardina-2009">
<DESCRIPTION>
<P>"Open-label"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-02-22 21:09:34 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gorman-2002">
<DESCRIPTION>
<P>"The patients and study investigators were unaware of the group assignments"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.02" MODIFIED="2015-02-22 21:09:36 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gorman-2002">
<DESCRIPTION>
<P>"The patients and study investigators were unaware of the group assignments"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-02-22 21:21:28 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hu-2012">
<DESCRIPTION>
<P>"Randomized, double-blind, placebo-controlled comparison..."No further details provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.02" MODIFIED="2015-02-22 21:21:32 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hu-2012">
<DESCRIPTION>
<P>"Randomized, double-blind, placebo-controlled comparison..." No further details provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-02-22 21:22:36 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huang-2008">
<DESCRIPTION>
<P>"Double blind"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.02" MODIFIED="2015-02-22 21:22:39 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huang-2008">
<DESCRIPTION>
<P>"Double blind"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2014-11-17 17:24:07 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huang-2014">
<DESCRIPTION>
<P>"Study overseers, investigators, study site personnel and patients remained blinded to treatment during this phase, which was followed by a 12-week open-label phase, during which all patients received open-label adalimumab 40 mg EOW"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.02" MODIFIED="2014-11-17 17:24:08 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huang-2014">
<DESCRIPTION>
<P>"Study overseers, investigators, study site personnel and patients remained blinded to treatment during this phase, which was followed by a 12-week open-label phase, during which all patients received open-label adalimumab 40 mg EOW"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-02-22 21:28:06 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Inman-2008">
<DESCRIPTION>
<P>"To maintain blinding, patients in the 50-mg group received active golimumab in the 0.5-ml syringe and placebo in the 1.0-ml syringe; patients in the 100-mg group received placebo in the 0.5-ml syringe and active golimumab in the 1.0-ml syringe; and patients in the placebo group received placebo in both syringes"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.02" MODIFIED="2015-02-22 21:28:09 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Inman-2008">
<DESCRIPTION>
<P>Matching placebo and adequate allocation concealment; investigators probably blinded adequately</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-02-22 21:29:59 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Inman-2010">
<DESCRIPTION>
<P>"Double-blind"; no further details reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.02" MODIFIED="2015-02-22 21:30:02 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Inman-2010">
<DESCRIPTION>
<P>"Double-blind"; no further details reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-02-22 21:32:22 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lambert-2007">
<DESCRIPTION>
<P>Trial protocol states "Double Blind (Subject, Investigator)" but no details provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.02" MODIFIED="2015-02-22 21:32:26 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lambert-2007">
<DESCRIPTION>
<P>"Readers were qualified, trained radiologists who were blinded to the patients' identities, treatments, and imaging time points"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-02-22 21:34:21 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marzo_x002d_Ortega-2005">
<DESCRIPTION>
<P>"Double-blind"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.02" MODIFIED="2015-02-22 21:34:24 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marzo_x002d_Ortega-2005">
<DESCRIPTION>
<P>"Double-blind"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-02-22 21:39:06 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Navarro_x002d_Sarabia-2011">
<DESCRIPTION>
<P>All study personnel and participants, including statisticians, were blinded to treatment assignment for the whole duration of the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.02" MODIFIED="2015-02-22 21:39:08 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Navarro_x002d_Sarabia-2011">
<DESCRIPTION>
<P>All study personnel and participants, including statisticians, were blinded to treatment assignment for the whole duration of the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-02-22 22:19:24 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-der-Heijde-2005">
<DESCRIPTION>
<P>"Double blind"; "both infliximab and placebo were supplied as sterile, white, lyophilized powders in single-use 20-ml vials"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.02" MODIFIED="2015-02-22 22:19:27 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-der-Heijde-2005">
<DESCRIPTION>
<P>"Double blind"; probably yes given the blinding of the study drug</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-02-22 22:20:53 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-der-Heijde-2006a">
<DESCRIPTION>
<P>From study author: "The patient, sponsor and the study sites were blinded to treatment allocation." "The treatment allocation for each patient was provided to the site in a sealed envelope, to be opened in the case of an emergency in which the investigator believed that knowledge of study drug treatment was required. However, no patient was unblinded during the course of the double blind period"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.02" MODIFIED="2015-02-22 22:20:56 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-der-Heijde-2006a">
<DESCRIPTION>
<P>From study author: "The patient, sponsor and the study sites were blinded to treatment allocation." "The treatment allocation for each patient was provided to the site in a sealed envelope, to be opened in the case of an emergency in which the investigator believed that knowledge of study drug treatment was required. However, no patient was unblinded during the course of the double blind period"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.01" MODIFIED="2015-02-22 22:23:03 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-van-der-Heijde-2006b">
<DESCRIPTION>
<P>"Double-blind", no further details reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-09.02" MODIFIED="2015-02-22 22:23:06 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-van-der-Heijde-2006b">
<DESCRIPTION>
<P>"Double-blind", no further details reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="GROUP" MODIFIED="2015-02-22 23:07:59 -0500" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-10.02" NO="2">
<NAME>Physician-assessed outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-10.01" NO="1">
<NAME>Patient-assessed outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2015-02-22 20:54:04 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bao-2014">
<DESCRIPTION>
<P>"Double-blind", no details provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.02" MODIFIED="2015-02-22 20:54:07 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bao-2014">
<DESCRIPTION>
<P>"Double-blind", no details provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2015-02-22 20:55:23 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barkham-2010">
<DESCRIPTION>
<P>"The site monitor, investigators, and patients remained blinded until after the data through week 12 had been finalised" ; although details not provided, probably done adequately</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.02" MODIFIED="2015-02-22 20:55:26 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barkham-2010">
<DESCRIPTION>
<P>"The site monitor, investigators, and patients remained blinded until after the data through week 12 had been finalised" ; although details not provided, probably done adequately</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2015-02-22 20:56:58 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brandt-2003">
<DESCRIPTION>
<P>"The pharmacist at each center prepared the medication, which was delivered in a blinded manner." "The placebo solution containing bacteriostatic water was supplied and administered identically." "Investigators and patients remained blinded until week 12, 6 weeks after the placebo controlled phase had finished"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.02" MODIFIED="2015-02-22 20:57:01 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brandt-2003">
<DESCRIPTION>
<P>Investigators and patients remained blinded until week 12, 6 weeks after the placebo controlled phase had finished"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2015-02-22 20:58:38 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Braun-2002">
<DESCRIPTION>
<P>"Investigators and patients were unaware of treatment status until all case report forms had been completed"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.02" MODIFIED="2015-02-22 20:58:50 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Braun-2002">
<DESCRIPTION>
<P>"Investigators and patients were unaware of treatment status until all case report forms had been completed." "The information had to be sent back once the patient had completed the trial."(referring to the sealed envelope with the group assignment)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2015-02-22 21:00:04 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Braun-2011">
<DESCRIPTION>
<P>Double-blind; All patients treated with visually identical injections and tablets</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.02" MODIFIED="2015-02-22 21:00:06 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Braun-2011">
<DESCRIPTION>
<P>Double-blind; All patients treated with visually identical injections and tablets; probably investigator blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2015-02-22 21:01:44 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Calin-2004">
<DESCRIPTION>
<P>"To preserve the integrity of the blind study, placebo and etanercept supplies were similar in appearance"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.02" MODIFIED="2015-02-22 21:01:50 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Calin-2004">
<DESCRIPTION>
<P>No details provided other than 'double-blind'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2015-02-22 23:07:59 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Davis-2003">
<DESCRIPTION>
<P>"Patients, investigators, assessors, other study site personnel, and representatives of the sponsor were blinded to the randomisation schedule and to treatment assignment until completion of the trial"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.02" MODIFIED="2015-02-22 23:07:59 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Davis-2003">
<DESCRIPTION>
<P>"Patients, investigators, assessors, other study site personnel, and representatives of the sponsor were blinded to the randomisation schedule and to treatment assignment until completion of the trial"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2015-02-22 21:06:21 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dougados-2011">
<DESCRIPTION>
<P>"Matching placebo"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.02" MODIFIED="2015-02-22 21:06:24 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dougados-2011">
<DESCRIPTION>
<P>"Matching placebo" ; unclear if investigators were properly blinded and no details provided on allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2015-02-22 21:07:53 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Giardina-2009">
<DESCRIPTION>
<P>"Open-label"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.02" MODIFIED="2015-02-22 21:07:55 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Giardina-2009">
<DESCRIPTION>
<P>"Open-label"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2015-02-22 21:09:39 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gorman-2002">
<DESCRIPTION>
<P>"The patients and study investigators were unaware of the group assignments"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.02" MODIFIED="2015-02-22 21:09:44 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gorman-2002">
<DESCRIPTION>
<P>"The patients and study investigators were unaware of the group assignments"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2015-02-22 21:21:35 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hu-2012">
<DESCRIPTION>
<P>"Randomized, double-blind, placebo-controlled comparison..."No further details provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.02" MODIFIED="2015-02-22 21:21:38 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hu-2012">
<DESCRIPTION>
<P>"Randomized, double-blind, placebo-controlled comparison..." "Each image was rated by two independent readers (XHD and ZYH) who were blinded to the patients&#8217; identities," Unclear if readers were blinded to the treatment group assignment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2015-02-22 21:22:41 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huang-2008">
<DESCRIPTION>
<P>"Double blind"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.02" MODIFIED="2015-02-22 21:22:45 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huang-2008">
<DESCRIPTION>
<P>"Double blind"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2014-11-17 17:24:10 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huang-2014">
<DESCRIPTION>
<P>"Study overseers, investigators, study site personnel and patients remained blinded to treatment during this phase, which was followed by a 12-week open-label phase, during which all patients received open-label adalimumab 40 mg EOW"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.02" MODIFIED="2014-11-17 17:24:11 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huang-2014">
<DESCRIPTION>
<P>"Study overseers, investigators, study site personnel and patients remained blinded to treatment during this phase, which was followed by a 12-week open-label phase, during which all patients received open-label adalimumab 40 mg EOW"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2015-02-22 21:28:11 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Inman-2008">
<DESCRIPTION>
<P>"To maintain blinding, patients in the 50-mg group received active golimumab in the 0.5-ml syringe and placebo in the 1.0-ml syringe; patients in the 100-mg group received placebo in the 0.5-ml syringe and active golimumab in the 1.0-ml syringe; and patients in the placebo group received placebo in both syringes"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.02" MODIFIED="2014-11-17 17:25:05 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Inman-2008">
<DESCRIPTION>
<P>matching placebo and adequate allocation concealment; investigators probably blinded adequately</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2015-02-22 21:30:05 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Inman-2010">
<DESCRIPTION>
<P>"Double-blind"; no further details reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.02" MODIFIED="2015-02-22 21:30:07 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Inman-2010">
<DESCRIPTION>
<P>"Double-blind"; no further details reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2015-02-22 21:32:32 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lambert-2007">
<DESCRIPTION>
<P>Trial protocol states "Double Blind (Subject, Investigator)" but no details provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.02" MODIFIED="2015-02-22 21:32:35 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lambert-2007">
<DESCRIPTION>
<P>"Readers were qualified, trained radiologists who were blinded to the patients' identities, treatments, and imaging time points"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2015-02-22 21:34:27 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marzo_x002d_Ortega-2005">
<DESCRIPTION>
<P>"Double-blind"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.02" MODIFIED="2015-02-22 21:34:30 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marzo_x002d_Ortega-2005">
<DESCRIPTION>
<P>"Double-blind"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2015-02-22 21:39:10 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Navarro_x002d_Sarabia-2011">
<DESCRIPTION>
<P>All study personnel and participants, including statisticians, were blinded to treatment assignment for the whole duration of the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.02" MODIFIED="2015-02-22 21:39:12 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Navarro_x002d_Sarabia-2011">
<DESCRIPTION>
<P>All study personnel and participants, including statisticians, were blinded to treatment assignment for the whole duration of the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2015-02-22 22:19:29 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-der-Heijde-2005">
<DESCRIPTION>
<P>"Double blind"; "both infliximab and placebo were supplied as sterile, white, lyophilized powders in single-use 20-ml vials"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.02" MODIFIED="2015-02-22 22:19:32 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-der-Heijde-2005">
<DESCRIPTION>
<P>"Double blind"; probably yes given the blinding of the study drug</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2015-02-22 22:20:58 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-der-Heijde-2006a">
<DESCRIPTION>
<P>From study author: "Yes, patients and assessors were blinded. In particular, the assessor who performed the tender and swollen joint counts, MASES, and the physical examination was blinded to information from the patient reported questionnaires at all visits"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.02" MODIFIED="2015-02-22 22:21:01 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-der-Heijde-2006a">
<DESCRIPTION>
<P>From study author: "Yes, patients and assessors were blinded. In particular, the assessor who performed the tender and swollen joint counts, MASES, and the physical examination was blinded to information from the patient reported questionnaires at all visits"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.01" MODIFIED="2015-02-22 22:23:08 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-van-der-Heijde-2006b">
<DESCRIPTION>
<P>"Double-blind", no further details reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-10.02" MODIFIED="2015-02-22 22:23:11 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-van-der-Heijde-2006b">
<DESCRIPTION>
<P>"Double-blind", no further details reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2015-03-23 06:22:19 -0400" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>Efficacy outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.02" NO="2">
<NAME>Safety outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-03-23 05:06:52 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bao-2014">
<DESCRIPTION>
<P>101/105 in golimumab group and 102/108 in placebo group completed 52 weeks; Intention-to-treat analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-03-23 05:06:58 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bao-2014">
<DESCRIPTION>
<P>101/105 in golimumab group and 102/108 in placebo group completed 52 weeks; Intention-to-treat analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-02-22 20:55:29 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Barkham-2010">
<DESCRIPTION>
<P>Unclear if all completed trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2014-10-08 05:06:31 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Barkham-2010">
<DESCRIPTION>
<P>unclear if all completed trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-02-22 20:57:09 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brandt-2003">
<DESCRIPTION>
<P>Reasons for withdrawal provided. &gt; 80% follow-up in both treatment and placebo groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-02-22 20:57:16 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brandt-2003">
<DESCRIPTION>
<P>Reasons for withdrawal provided. &gt; 80% follow-up in both treatment and placebo groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-02-22 20:58:57 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Braun-2002">
<DESCRIPTION>
<P>Greater than 80% follow-up. Reasons for withdrawal were provided. The last observation carried forward method was applied to the four infliximab group members that withdrew</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-02-22 20:59:04 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Braun-2002">
<DESCRIPTION>
<P>Greater than 80% follow-up. Reasons for withdrawal were provided. The last observation carried forward method was applied to the four infliximab group members that withdrew</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-03-23 05:06:22 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Braun-2011">
<DESCRIPTION>
<P>&lt; 10% withdrawals in each group; reasons provided; modified intention-to-treat analysis reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-03-23 05:06:17 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Braun-2011">
<DESCRIPTION>
<P>&lt; 10% withdrawals in each group; reasons provided; modified <B>i</B>ntention-to-treat analysis reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-02-22 21:01:56 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Calin-2004">
<DESCRIPTION>
<P>Reasons for withdrawal reported. Follow-up was greater than 80%. "Disease activity and safety analyses were based on the intention to treat population and included all patients who received at least one dose of the &#8216;&#8216;blinded&#8217;&#8217; test article. The last observation carried forward technique was used to handle missing data for continuous and ordinal end points"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-02-22 21:02:02 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Calin-2004">
<DESCRIPTION>
<P>Reasons for withdrawal reported. Follow-up was greater than 80%. "Disease activity and safety analyses were based on the intention to treat population and included all patients who received at least one dose of the &#8216;&#8216;blinded&#8217;&#8217; test article. The last observation carried forward technique was used to handle missing data for continuous and ordinal end points"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-03-23 05:05:50 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Davis-2003">
<DESCRIPTION>
<P>Completed study: 86% in placebo and 91% in treatment; 1 loss to follow-up in placebo and 2 loss to follow-up in treatment. Last observation carried forward (LOCF) used for missing data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-05-29 20:49:13 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Davis-2003">
<DESCRIPTION>
<P>Completed study: 86% in placebo and 91% in treatment; 1 loss to follow-up in placebo and 2 loss to follow-up in treatment. LOCF used for missing data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-03-23 05:05:29 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dougados-2011">
<DESCRIPTION>
<P>&lt; 10% drop out rate; Intention-to-treat analysis conducted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-03-23 05:16:07 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dougados-2011">
<DESCRIPTION>
<P>&lt; 10% drop out rate; Intention-to-treat analysis conducted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-04-11 12:33:21 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Giardina-2009">
<DESCRIPTION>
<P>"No patients discontinued therapy"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-04-11 12:33:23 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Giardina-2009">
<DESCRIPTION>
<P>"No patients discontinued therapy"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-03-23 05:05:13 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gorman-2002">
<DESCRIPTION>
<P>Reasons for withdrawal were provided. Follow-up was greater than 80% in both groups. Intention-to-treat analyses were performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-02-22 21:09:50 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gorman-2002">
<DESCRIPTION>
<P>Reasons for withdrawal were provided. Follow-up was greater than 80% in both groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-12-16 04:14:49 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hu-2012">
<DESCRIPTION>
<P>No details provided on number of patients completing the trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2014-12-16 04:15:08 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hu-2012">
<DESCRIPTION>
<P>No details provided on number of patients completing the trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-03-15 14:35:06 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huang-2008">
<DESCRIPTION>
<P>2/152 withdrew, no group or reason given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-03-15 14:35:59 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huang-2008">
<DESCRIPTION>
<P>2/152 withdrew, no group or reason given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-03-23 05:04:50 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huang-2014">
<DESCRIPTION>
<P>Completer of 12 week double-blind period: 113/115 placebo; 224/229 adalimumab; Intention-to-treat analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-03-23 05:04:59 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huang-2014">
<DESCRIPTION>
<P>Completer of 12 week double-blind period: 113/115 placebo; 224/229 adalimumab; Intention-to-treat analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-02-22 21:28:20 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Inman-2008">
<DESCRIPTION>
<P>&lt; 10% withdrawal; participants who entered early escape option were considered non-responders at week 24; "data from all randomized patients were analyzed according to their assigned treatment group"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-02-22 21:28:25 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Inman-2008">
<DESCRIPTION>
<P>&lt; 10% withdrawal;all participants who received study drug were assessed in the safety analyses ; "data from all randomized patients were analyzed according to their assigned treatment group"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-02-22 21:30:13 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Inman-2010">
<DESCRIPTION>
<P>Fig.1 shows the details of patient flow throughout the study. The number of people completing the study at week 12 (RCT phase) was not clearly reported, but the number of drop outs was low. ITT analysis performed, defined as those who received one dose of the study drug</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-08-21 17:25:20 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Inman-2010">
<DESCRIPTION>
<P>Safety outcomes reported for the combined RCT and open-label phase; not for RCT phase separately</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-02-22 21:32:39 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lambert-2007">
<DESCRIPTION>
<P>"At baseline and week 12, all 44 patients in the placebo group and 38 in the adalimumab group had evaluable MRIs"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-02-22 21:32:45 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lambert-2007">
<DESCRIPTION>
<P>Safety data not reported in primary publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-03-23 05:26:37 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marzo_x002d_Ortega-2005">
<DESCRIPTION>
<P>93% completed treatment, 64% completed in control group; an intention-to-treat analysis performed with last observation carried forward imputation for missing data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-03-23 05:27:00 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marzo_x002d_Ortega-2005">
<DESCRIPTION>
<P>93% completed treatment, 64% completed in control group; an intention-to-treat analysis performed with last observation carried forward imputation for missing data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-03-23 05:31:32 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Navarro_x002d_Sarabia-2011">
<DESCRIPTION>
<P>The intent-to-treat (ITT) population was defined as 'All randomized patients who had received at least one treatment dose and who had undergone at least one therapy evaluation'. This resulted in 48/54 of etanercept 100 mg/week and 49/54 etanercept 50 mg/week. Unclear what effect the 10% missing may have made to the estimate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2014-10-09 11:25:21 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Navarro_x002d_Sarabia-2011">
<DESCRIPTION>
<P>Analysis done on the number randomized</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-03-23 06:11:48 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-der-Heijde-2005">
<DESCRIPTION>
<P>Fairly complete follow up; 75/78 completed in placebo and 199/201 completed in infliximab group. Intention-to-treat analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-03-23 06:11:56 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-der-Heijde-2005">
<DESCRIPTION>
<P>Fairly complete follow up; 75/78 completed in placebo and 199/201 completed in infliximab group. Intention-to-treat analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-02-22 22:21:03 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-der-Heijde-2006a">
<DESCRIPTION>
<P>95% of participants completed 24 weeks. Intention-to-treat analysis performed using non-responder imputation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-02-22 22:21:08 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-der-Heijde-2006a">
<DESCRIPTION>
<P>95% of participants completed 24 weeks</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-03-23 06:22:19 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-der-Heijde-2006b">
<DESCRIPTION>
<P>Reasons for withdrawal were provided. Follow-up was greater than 80% in all groups. Modified intention-to-treat analyses were performed in which "all participants who received at least one dose of the test drugs" were included in the analyses (356/361 randomized). "A last-observation-carried-forward approach was used to impute missing data in the modified intent-to-treat population analysis"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-02-22 22:23:16 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-der-Heijde-2006b">
<DESCRIPTION>
<P>Same as efficacy outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2015-03-23 06:12:18 -0400" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-23 05:18:52 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bao-2014">
<DESCRIPTION>
<P>Reported on primary outcome as defined in protocol on clinicaltrials.gov and on Assessment of SpondyloArthritis international Society (ASAS)-recommended outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-23 05:18:41 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barkham-2010">
<DESCRIPTION>
<P>Assessment of SpondyloArthritis international Society (ASAS)-recommended clinical outcomes reported in addition to primary outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-23 05:18:19 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brandt-2003">
<DESCRIPTION>
<P>Assessment of SpondyloArthritis international Society (ASAS)-recommended outcomes reported. "As the primary end point of the study, an improvement in disease activity of 50% between baseline and week 6, measured by the BASDAI, was chosen. The secondary outcome parameters analyzed were improvements in numeric rating scale for spinal pain, BASFI, Bath Anyklosing Spondylitis Metrology Index (BASMI), SF-36, the ASAS response criteria, serum C-reactive protein (CRP) level, and erythrocyte sedimentation rate (ESR)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-23 05:18:00 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Braun-2002">
<DESCRIPTION>
<P>Assessment of SpondyloArthritis international Society (ASAS) recommended outcomes were reported. "The primary endpoint was improvement of disease activity by 50% between baseline and week 12, measured by BASDAI"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-23 05:17:32 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Braun-2011">
<DESCRIPTION>
<P>Assessment of SpondyloArthritis international Society (ASAS)-recommended outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-23 05:17:08 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Calin-2004">
<DESCRIPTION>
<P>Assessment of SpondyloArthritis international Society (ASAS)-recommended outcomes reported. "The primary efficacy end point was the percentage of ASAS 20 responders after 12 weeks of treatment"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-15 16:10:02 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Davis-2003">
<DESCRIPTION>
<P>ASAS20 was primary outcome; not stated that it was prespecified in the protocol, but it is an appropriate outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-23 05:16:22 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dougados-2011">
<DESCRIPTION>
<P>Important Assessment of SpondyloArthritis international Society (ASAS)-recommended outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-22 21:07:59 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Giardina-2009">
<DESCRIPTION>
<P>Primary outcome listed in abstract: proportion of people achieving a 50% response in BASDAI; full-text article does not state the primary outcome, but 50% BASDAI response not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-23 05:15:31 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gorman-2002">
<DESCRIPTION>
<P>"The primary outcome measure was a prespecified, composite treatment response, defined as 20 percent or greater improvement in at least three of five measures of disease activity, as recommended by the ASsessments in Ankylosing Spondylitis Working Group". Corresponds to the protocol on clinicaltrials.gov.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-22 21:21:46 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hu-2012">
<DESCRIPTION>
<P>While some recommended efficacy outcomes were reported (e.g. BASDAI, BASFI, ASDAS), no adverse outcomes were reported. No primary outcome stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-22 21:22:51 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huang-2008">
<DESCRIPTION>
<P>Primary outcome ASAS20 reported and appropriate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-23 05:14:41 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huang-2014">
<DESCRIPTION>
<P>Same primary outcome as listed on clinicaltrials.gov. Assessment of SpondyloArthritis international Society (ASAS)-recommended outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-23 05:14:08 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Inman-2008">
<DESCRIPTION>
<P>Outcomes recommended by Assessment of SpondyloArthritis international Society (ASAS) were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-23 05:39:18 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Inman-2010">
<DESCRIPTION>
<P>Harms data for RCT phase not reported separately</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-23 06:05:19 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lambert-2007">
<DESCRIPTION>
<P>Primary outcome and adverse events reported only in abstract. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-22 21:34:38 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Marzo_x002d_Ortega-2005">
<DESCRIPTION>
<P>Appropriate outcomes measured</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-09 11:25:42 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Navarro_x002d_Sarabia-2011">
<DESCRIPTION>
<P>ASAS-recommended outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-23 06:12:18 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-der-Heijde-2005">
<DESCRIPTION>
<P>ASAS-recommended outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-22 22:21:09 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-der-Heijde-2006a">
<DESCRIPTION>
<P>Outcomes reported as prespecified in trial protocol (ASAS20 at week 12). Appropriate outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-22 22:23:17 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-der-Heijde-2006b">
<DESCRIPTION>
<P>All appropriate outcomes were assessed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2014-11-17 17:33:48 -0500" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2015-03-23 06:22:30 -0400" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Method of adverse event monitoring</NAME>
<DESCRIPTION>
<P>Do the researchers actively monitor for adverse events (low risk of bias) or do they simply provide spontaneous reporting of AEs that arise (high risk of bias)?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>Safety outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-02-22 20:54:21 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bao-2014">
<DESCRIPTION>
<P>No details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-02-22 20:55:39 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Barkham-2010">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-02-22 20:57:26 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brandt-2003">
<DESCRIPTION>
<P>Method not reported; or efficacy, clinical questionnaires filled out every 3 weeks</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-02-22 20:59:10 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Braun-2002">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-02-22 21:00:34 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Braun-2011">
<DESCRIPTION>
<P>Safety was assessed by noting the rate of reported AEs and performing routine physical examinations and laboratory tests. Data on the occurrence of AEs were collected at each study visit and via telephone contact with patients 15 days after the 16-week treatment period</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-01-13 17:40:10 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Calin-2004">
<DESCRIPTION>
<P>"Patients were monitored for adverse events and abnormal laboratory tests" over the course of the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2010-08-21 17:12:46 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Davis-2003">
<DESCRIPTION>
<P>Patients used a diary to record presence of adverse events</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-02-22 21:06:34 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dougados-2011">
<DESCRIPTION>
<P>Not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-02-22 21:08:03 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Giardina-2009">
<DESCRIPTION>
<P>Patients were monitored for adverse events and abnormal lab values over the course of the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2010-08-21 17:14:27 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gorman-2002">
<DESCRIPTION>
<P>"Side effects monitored at each clinic visit by means of open ended questions..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-01-13 11:09:42 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hu-2012">
<DESCRIPTION>
<P>No adverse event data reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-02-22 21:22:55 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huang-2008">
<DESCRIPTION>
<P>"Safety evaluation included adverse event and routine lab monitoring"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-10-11 08:25:35 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huang-2014">
<DESCRIPTION>
<P>"Safety evaluations were conducted at every study visit and included adverse event (AE) monitoring and assessments of clinical laboratory and vital signs."-from published article. "Events were collected by non-systematic assessment" - from clinicaltrials.gov</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-02-22 21:28:30 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Inman-2008">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-01-13 17:45:09 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Inman-2010">
<DESCRIPTION>
<P>"Safety and tolerability were assessed by the incidence of treatment emergent adverse events"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-02-22 21:32:51 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lambert-2007">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-02-22 21:34:41 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marzo_x002d_Ortega-2005">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-03-23 06:07:16 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Navarro_x002d_Sarabia-2011">
<DESCRIPTION>
<P>Safety was assessed by the evaluation of the percentage and type of adverse events and serious adverse events, vital signs, physical examination, early withdrawals and laboratory results. Safety was assessed during all the study, until 15 days after the last study visit</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-01-13 17:52:52 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-der-Heijde-2005">
<DESCRIPTION>
<P>"Safety assessments included adverse events, infections, infusion reactions, premature discontinuations, and lab tests"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-01-14 05:14:42 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-der-Heijde-2006a">
<DESCRIPTION>
<P>"Adverse events and other safety assessments were completed throughout the study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-03-23 06:22:30 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-der-Heijde-2006b">
<DESCRIPTION>
<P>"Safety assessments were based on reports of adverse events, routine physical examinations and laboratory test results"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2015-03-23 06:20:33 -0400" MODIFIED_BY="[Empty name]" NO="8">
<NAME>'Serious adverse event' definitions provided?</NAME>
<DESCRIPTION>
<P>Does the study provide a definition for "serious adverse events" (low risk of bias)?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>Safety outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-02-22 20:54:24 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bao-2014">
<DESCRIPTION>
<P>No details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-02-22 20:55:42 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Barkham-2010">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-03-23 06:15:32 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brandt-2003">
<DESCRIPTION>
<P>Serious adverse event definition not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-02-22 20:59:13 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Braun-2002">
<DESCRIPTION>
<P>Not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-02-22 21:00:16 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Braun-2011">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-03-23 06:15:11 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Calin-2004">
<DESCRIPTION>
<P>Serious adverse event definition not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-13 17:40:50 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Davis-2003">
<DESCRIPTION>
<P>Adverse events graded on a scale derived from the National Cancer Institute Common Toxicity criteria</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-02-22 21:06:37 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dougados-2011">
<DESCRIPTION>
<P>Not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-03-23 06:14:51 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Giardina-2009">
<DESCRIPTION>
<P>No serious adverse event definition given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-13 17:43:08 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gorman-2002">
<DESCRIPTION>
<P>Adverse events graded on a scale derived from the National Cancer Institute Common Toxicity criteria</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-13 11:09:44 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hu-2012">
<DESCRIPTION>
<P>No adverse event data reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-03-23 06:14:30 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huang-2008">
<DESCRIPTION>
<P>No serious adverse event definition provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-02-22 21:26:45 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huang-2014">
<DESCRIPTION>
<P>Not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-02-22 21:28:33 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Inman-2008">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-02-22 21:30:21 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Inman-2010">
<DESCRIPTION>
<P>All adverse events were coded using the MedDRA dictionary of terms (version 9.0)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-02-22 21:32:54 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lambert-2007">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-02-22 21:34:44 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marzo_x002d_Ortega-2005">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-02-22 21:39:56 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Navarro_x002d_Sarabia-2011">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-03-23 06:13:56 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-van-der-Heijde-2005">
<DESCRIPTION>
<P>No general serious adverse event (SAE) definition provided; but all SAEs that occurred were explained</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-03-23 06:20:33 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-van-der-Heijde-2006a">
<DESCRIPTION>
<P>No general serious adverse event (SAE) definition provided; but each SAE that occurred was detailed in the report</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-02-22 22:23:21 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-van-der-Heijde-2006b">
<DESCRIPTION>
<P>Refers to "non-infectious serious adverse events" but no definition provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2015-03-25 08:13:15 -0400" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2015-03-25 08:13:15 -0400" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2010-12-01 15:03:02 -0500" MODIFIED_BY="[Empty name]">Summary of findings table</TITLE>
<TABLE COLS="8" ROWS="41">
<TR>
<TH COLSPAN="8">
<P>
<B>TNF-alpha inhibitors for ankylosing spondylitis (short-term results &lt; 24 weeks)</B>
</P>
</TH>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>
<B>Outcome</B>
</P>
</TH>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>
<B>Intervention and</B>
</P>
<P>
<B>comparison</B>
</P>
<P/>
</TH>
<TH COLSPAN="2" VALIGN="BOTTOM">
<P>
<B>Illustrative comparative risks</B>
</P>
</TH>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>
<B>Relative effect</B>
</P>
<P>
<B>(95% CrI)</B>
</P>
</TH>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>
<B>Number of participants</B>
</P>
<P>
<B>(studies)</B>
</P>
</TH>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>
<B>Quality of the evidence</B>
</P>
<P>
<B>(GRADE)</B>
</P>
</TH>
<TH ROWSPAN="3" VALIGN="BOTTOM">
<P>
<B>Comment</B>
</P>
</TH>
</TR>
<TR>
<TH VALIGN="BOTTOM">
<P>
<B>Assumed risk</B>
</P>
<P>
<B>with comparator<SUP>1</SUP>
</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>Corresponding risk</B>
</P>
<P>
<B>with intervention (95% CI or Crl)</B>
</P>
</TH>
</TR>
<TR>
<TH VALIGN="BOTTOM">
<P>
<B>Placebo</B>
</P>
</TH>
<TH VALIGN="BOTTOM">
<P>
<B>TNF-alpha inhibitor</B>
</P>
</TH>
</TR>
<TR>
<TD COLSPAN="8">
<P>
<B>ASAS40 </B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adalimumab versus placebo</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>13 per 100</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>46 per 100</B>
<BR/>(32 to 64)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>RR 3.53</B>
<BR/>(2.49 to 4.91)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>659<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Absolute increased benefit % = 33% (95% Crl 19% to 51%)</P>
<P/>
<P>Relative % change= 253% (95% CI 149% to 391%)</P>
<P/>
<P>NNT = 4 (95% CI 2 to 6)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Etanercept (25 mg twice weekly or 50 mg once weekly) versus placebo</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>13 per 100</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>43 per 100</B>
<BR/>(31 to 59)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>RR 3.31 </B>
<BR/>(2.38 to 4.53)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>584<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Absolute increased benefit % = 30% (95% Crl 18% to 46%)</P>
<P/>
<P>Relative % change = 231% (95% CI 138% to 353%)</P>
<P>
<BR/>NNT = 4 (95% Cl 3 to 6)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Golimumab versus placebo</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>13 per 100</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>38 per 100</B>
<BR/>(25 to 55)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>RR</B> <B>2.90</B> (1.90 to 4.23)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>429<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Absolute increased benefit % = 25% (95% Crl 12% to 42%)</P>
<P/>
<P>Relative % change = 190% (95% CI 90% to 323%)</P>
<P>
<BR/>NNT = 5 (95% CI 3 to 9)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Infliximab versus placebo</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>13 per 100</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>53 per 100</B>
<BR/>(36 to 75)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>RR 4.07 </B>
<BR/>(2.80 to 5.74)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>355<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Absolute increased benefit % = 40% (95% Crl 23% to 62%)</P>
<P/>
<P>Relative % change = 307% (95% CI 180% to 474%)</P>
<P>
<BR/>NNT= 3 (95% CI 2 to 5)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="8" VALIGN="TOP">
<P>
<B>BASFI (0 to 10 scale)</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adalimumab versus placebo</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean BASFI in the control groups was<BR/>
<B>5 points</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean BASFI in the intervention groups was<BR/>
<B>1.6 lower</B>
<BR/>(2.2 to 0.9 lower)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>786<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Absolute increased benefit % = -16% (95% Crl -22% to -9%);<BR/>Relative % change from baseline = -32% (-44% to -18%);<BR/>NNT to achieve the MCID of 0.7 points = 4 (95% CI 3 to 5)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Etanercept (25 mg twice weekly or 50 mg once weekly) versus placebo</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean BASFI in the control groups was<BR/>
<B>5 points</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean BASFI in the intervention groups was<BR/>
<B>1.1 lower</B>
<BR/>(1.6 to 0.6 lower)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>553<BR/>(6 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Absolute increased benefit % =-11% (95% Crl -16% to -6%);</P>
<P>Relative % change from baseline = -22% (-32% to -12%);<BR/>NNT to achieve the MCID of 0.7 points = 4 (4 to 6)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Golimumab versus placebo</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean BASFI in the control groups was<BR/>
<B>5 points</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean BASFI in the intervention groups was<BR/>
<B>1.5 lower</B>
<BR/>(2.3 to 0.7 lower)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>429<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Absolute increased benefit % =-15% (95% Crl -23% to -7%)</P>
<P/>
<P>Relative % change from baseline = -30% (-46% to -14%)</P>
<P>
<BR/>NNT to achieve the MCID of 0.7 points = 4 (3 to 5)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Infliximab versus placebo</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean BASFI in the control groups was<BR/>
<B>5 points</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean BASFI in the intervention groups was<BR/>
<B>2.1 lower</B>
<BR/>(2.7 to 1.4 lower)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>348<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Absolute increased benefit % = -21% (95% Crl -27% to -14%)</P>
<P/>
<P>Relative % change from baseline = -42% (-54% to -28%)</P>
<P>
<BR/>NNT to achieve the MCID of 0.7 points = 2 (2 to 3)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="8" VALIGN="TOP">
<P>
<B>ASAS partial remission</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adalimumab versus placebo</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>3 per 100</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>19 per 100</B>
<BR/>(9 to 38)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>RR 6.28 </B>
<BR/>(3.13 to 12.78)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>659<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8854;<BR/>
<B>moderate<SUP>2</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Absolute increased benefit % = 16% (95% Crl 6% to 35%)</P>
<P>
<BR/>Relative % change = 528% (95% CI 213% to 1178%)</P>
<P>
<BR/>NNT = 7 (95% CI 3 to 16)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Etanercept (25 mg twice weekly or 50 mg once weekly) versus placebo</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>3 per 100</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>13 per 100</B>
<BR/>(7 to 24)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>RR 4.24 </B>
<BR/>(2.31 to 8.09)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>785<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8854;<BR/>
<B>moderate<SUP>2</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Absolute increased benefit % = 10% (95% Crl 4% to 21%)<BR/>Relative % change = 324% (95% CI 131% to 709%);<BR/>NNT = 11 (95% CI 5 to 26)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Golimumab versus placebo</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>3 per 100</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>16 per 100</B>
<BR/>(6 to 44)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>RR 5.18</B> (1.90 to 14.79)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>216<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8854;<BR/>
<B>moderate<SUP>2</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Absolute increased benefit % = 13% (95% Crl 3% to 41%)<BR/>Relative % change = 418% (95% CI 90% to 1379%);<BR/>NNT = 8 (95% CI 3 to 38)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Infliximab versus placebo</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>3 per 100</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>47 per 100</B>
<BR/>(16 to 90)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>RR 15.41 </B>
<BR/>(5.09 to 47.98)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>348<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8854;<BR/>
<B>moderate<SUP>2</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Absolute increased benefit % = 44% (95% Crl 13% to 87%)</P>
<P>
<BR/>Relative % change = 1441% (95% CI 409% to 4698%)</P>
<P>
<BR/>NNT = 3 (95% CI 2 to 8)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="8" VALIGN="TOP">
<P>
<B>MRI of spinal inflammation</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adalimumab versus placebo</P>
<P>Lumbar spine MRI; SPARCC score (0 to 108)<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean SPARCC score in the control groups was<BR/>
<B>16.1</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean SPARCC score in the intervention groups was<BR/>
<B>6.5 lower</B>
<BR/>(13.06 to 0.06 higher)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>46<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8854;<BR/>
<B>moderate<SUP>3</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Absolute increased benefit % = -6% (95% CI -12% to 0.05%)</P>
<P>
<BR/>Relative % change = -33% (95% CI -66% to 0%)</P>
<P>
<BR/>NNT = n/a</P>
<P/>
<P>2nd study with MRI data: Lambert 2007 (N = 82): % change from baseline in SPARCC score, week 12 (no variance provided)</P>
<P/>
<P>1. Spine:<BR/>Adalimumab group = 53.6% mean decrease</P>
<P>
<BR/>Placebo group = 9.4% mean increase</P>
<P>
<BR/>Between group: P &lt; 0.001</P>
<P>
<BR/>2. Sacroiliac joint, % mean decrease:</P>
<P>Adalimumab group = 52.9%,<BR/>Placebo group = 12.7%</P>
<P>Between group: P = 0.017</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Etanercept (25 mg twice weekly or 50 mg once weekly) versus placebo</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No studies assessed this outcome</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Golimumab versus placebo</P>
<P>Change from baseline in AS spine MRI activity score (0 to 138; lower means less erosions or edema)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean change in the control group was<BR/>
<B>-2.5</B> <B>points</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean change in the golimumab group was<BR/>
<B>3.4</B> <B>points lower</B>
</P>
<P>
<B>(7.7 to 0.90 points lower)</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>60<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8854;&#8854;<BR/>
<B>low<SUP>3,4</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Absolute increased benefit % = -2.5% (95% CI -5.6% to -0.7%)</P>
<P>
<BR/>Relative % change = -35% (95% CI -80% to 9%)</P>
<P>
<BR/>NNT = n/a</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Infliximab versus placebo</P>
<P>Change from baseline in AS spine MRI activity score (0 to 138; lower means less erosions or edema)<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean change in the control group was<BR/>
<B>-0.6</B> <B>points</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The mean change in the infliximab group was<BR/>
<B>4.4</B> <B>points lower</B>
</P>
<P>
<B>(5.6 to 3.3 points lower)</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>266<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8854;<BR/>
<B>moderate<SUP>5</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Absolute increased benefit % = -3% (95% CI -4% to -2.4%)</P>
<P>
<BR/>Relative % change = -62% (95% CI -79% to -46%)</P>
<P>
<BR/>NNT = 3 (95% CI 3 to 5)</P>
<P/>
<P>Inman 2010 assessed MRI in a substudy (N = 26): "when the evaluation was based on the entire spine (23 DVU score), the infliximab group had a mean reduction of 57.2% compared to 3.4% in the placebo group (P &lt; 0.001)"</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="8" VALIGN="TOP">
<P>
<B>Radiographic progression</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adalimumab versus placebo</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No studies assessed this outcome</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Etanercept (25 mg twice weekly or 50 mg once weekly) versus placebo</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No studies measured this outcome</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Golimumab versus placebo</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No studies measured this outcome</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Infliximab versus placebo</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Braun 2002 (N = 60) used the Bath Ankylosing Spondylitis Radiology Index (BASRI) to measure radiographic progression but detailed data was not provided. The results stated the "initial degree of radiological axial changes assessed by the BASRIs was similar in both groups"</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Withdrawals due to adverse events</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Adalimumab versus placebo</P>
</TD>
<TD>
<P>
<B>7 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>12 per 1000</B>
<BR/>(3 to 80)</P>
</TD>
<TD>
<P>
<B>RR 1.69 </B>
<BR/>(0.35 to 10.84)</P>
<P>
<BR/>
</P>
</TD>
<TD>
<P>659<BR/>(2 studies)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8854;<BR/>
<B>moderate<SUP>2</SUP>
</B>
</P>
</TD>
<TD>
<P>Absolute increased harm % = 0.6% (95% Crl -0.4% to 7%)</P>
<P/>
<P>Relative % change = 69% (95% CI -65% to 984%)</P>
<P/>
<P>NNT = n/a</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Etanercept (25 mg twice weekly or 50 mg once weekly) versus placebo</P>
</TD>
<TD>
<P>
<B>7 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>26 per 1000</B>
<BR/>(9 to 83)</P>
</TD>
<TD>
<P>
<B>RR 3.65 </B>
<BR/>(1.27 to 11.79)</P>
</TD>
<TD>
<P>1061<BR/>(8 studies)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8854;<BR/>
<B>moderate<SUP>2</SUP>
</B>
</P>
</TD>
<TD>
<P>Absolute increased harm % = 2% (95% Crl 0.2% to 8%)</P>
<P>
<BR/>Relative % change = 265% (95% CI 27% to 1079%)</P>
<P>
<BR/>NNTH = 54 (95% CI 14 to 530)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Golimumab versus placebo</P>
</TD>
<TD>
<P>
<B>7 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>14 per 1000</B>
<BR/>(3 to 123)</P>
</TD>
<TD>
<P>
<B>RR 1.97</B> (0.36 to 17.51)</P>
</TD>
<TD>
<P>429<BR/>(2 studies)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8854;<BR/>
<B>moderate<SUP>2</SUP>
</B>
</P>
</TD>
<TD>
<P>Absolute increased harm % = 1.6% (95% Crl -0.4% to 11.6%)</P>
<P>
<BR/>Relative % change = 97% (95% CI -64% to 1651%)</P>
<P>
<BR/>NNTH = n/a</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Infliximab versus placebo</P>
</TD>
<TD>
<P>
<B>7 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>12 per 1000</B>
<BR/>(3 to 59)</P>
</TD>
<TD>
<P>
<B>RR 1.77 </B>
<BR/>(0.43 to 8.46)<BR/>
</P>
</TD>
<TD>
<P>424<BR/>(3 studies)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8854;<BR/>
<B>moderate<SUP>2</SUP>
</B>
</P>
</TD>
<TD>
<P>Absolute increased harm % = 0.5% (95% Crl -0.4% to 5.6%)</P>
<P>
<BR/>Relative % change = 77% (95% CI -43% to 746%)</P>
<P>
<BR/>NNT = n/a</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>All anti-TNF agents versus placebo</P>
</TD>
<TD>
<P>
<B>7 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>16 per 1000</B>
<BR/>(8 to 33)</P>
</TD>
<TD>
<P>
<B>Peto OR</B> <B>2.44</B> (1.26 to 4.72<BR/>
</P>
</TD>
<TD>
<P>2623<BR/>(16 studies)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8854;<BR/>
<B>moderate<SUP>2</SUP>
</B>
</P>
</TD>
<TD>
<P>Absolute increased harm % = 1% (95% CI 0% to 2%)</P>
<P>
<BR/>Relative % change = 130% (95% CI 12% to 371%)</P>
<P>
<BR/>NNTH = 101 (95% CI 555 to 40)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Serious adverse events</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Adalimumab versus placebo</P>
</TD>
<TD>
<P>
<B>15 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>14 per 1000</B>
<BR/>(4 to 59)</P>
</TD>
<TD>
<P>
<B>RR 0.92 </B>
<BR/>(0.26 to 3.93)<BR/>
</P>
</TD>
<TD>
<P>659<BR/>(2 studies)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8854;<BR/>
<B>moderate<SUP>2</SUP>
</B>
</P>
</TD>
<TD>
<P>Absolute increased harm %= -0.2% (95% Crl -1.1% to 4.4%);<BR/>Relative % change= -8% (95% CI -74% to 293%);<BR/>NNT = n/a</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Etanercept (25 mg twice weekly or 50 mg once weekly) versus placebo</P>
</TD>
<TD>
<P>
<B>15 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>25 per 1000</B>
<BR/>(11 to 56)</P>
</TD>
<TD>
<P>
<B>RR 1.69 </B>
<BR/>(0.76 to 3.72)</P>
</TD>
<TD>
<P>1061<BR/>(8 studies)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8854;<BR/>
<B>moderate<SUP>2</SUP>
</B>
</P>
</TD>
<TD>
<P>Absolute increased harm % = 1% (95% Crl -0.4% to 4.1%)</P>
<P>
<BR/>Relative % change = 67% (95% CI -27% to 282%)</P>
<P>
<BR/>NNT = n/a</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Golimumab versus placebo</P>
</TD>
<TD>
<P>
<B>15 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>10 per 1000</B>
<BR/>(2 to 50)</P>
</TD>
<TD>
<P>
<B>RR 0.69 </B>
<BR/>(0.15 to 3.32)</P>
</TD>
<TD>
<P>216<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8854;<BR/>
<B>moderate<SUP>2</SUP>
</B>
</P>
</TD>
<TD>
<P>Absolute increased harm % = -0.5% (95% Crl -1.3% to 3.5%);<BR/>Relative % change= -31% (95% CI -85% to 232%);<BR/>NNT = n/a</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Infliximab versus placebo</P>
</TD>
<TD>
<P>
<B>15 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>38 per 1000</B>
<BR/>(11 to 166)</P>
</TD>
<TD>
<P>
<B>RR 2.53 </B>
<BR/>(0.76 to 11.09)</P>
</TD>
<TD>
<P>422<BR/>(3 studies)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8854;<BR/>
<B>moderate<SUP>2</SUP>
</B>
</P>
</TD>
<TD>
<P>Absolute increased harm % = 2.3% (95% Crl -0.4% to 15.1%)</P>
<P/>
<P>Relative % change = 153% (95% CI -24% to 1009%)</P>
<P>
<BR/>NNT = n/a</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>All anti-TNF agents versus placebo</P>
</TD>
<TD>
<P>
<B>15 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>22 per 1000</B>
<BR/>(13 to 36)</P>
</TD>
<TD>
<P>
<B>Peto OR 1.45 </B>(0.85 to 2.48)<BR/>
</P>
</TD>
<TD>
<P>2408<BR/>(15 studies)</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8853;&#8854;<BR/>
<B>moderate<SUP>2</SUP>
</B>
</P>
</TD>
<TD>
<P>Absolute increased harm % = 1% (95% CI 0% to 2%)</P>
<P>
<BR/>Relative % change = 41% (95% CI -15% to 136%)</P>
<P>
<BR/>NNTH = n/a</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>95% CI = 95% confidence interval; 95% Crl = 95% credible interval; n/a = not applicable; NNTH = Number needed to treat for harm; RR = risk ratio; OR = odds ratio; SI = sacroiliac joint; SPARCC = Spondyloarthritis Research Consortium of Canada</P>
<P>NNT = not applicable for non-statistically significant results</P>
<P>Note: Results for ASAS40, BASFI, ASAS partial remission, withdrawals due to adverse events, and serious adverse events are based on the mixed treatment comparison analyses. The 'All anti-TNF agents versus placebo' results for withdrawals due to adverse events and serious adverse events are based on standard meta-analyses in Review Manager 5.3.</P>
<P>
<SUP>1</SUP> Assumed risk based on the placebo event rate as calculated in the mixed treatment comparison analysis.</P>
<P>
<SUP>2 </SUP>Downgraded for imprecision; fewer events than 300 (a threshold rule-of-thumb) and wide confidence interval.</P>
<P>
<SUP>3 </SUP>Downgraded for imprecision: total population is &lt; 400.</P>
<P>
<SUP>4 </SUP>MRI substudy (N = 60 for placebo and 50 mg golimumab arms) conducted at 10/57 participating sites; N = 216 in full RCT; readers were blinded but concerns regarding only modest level of agreement. Downgraded for concerns regarding missing data (12% did not have baseline and follow-up MRIs and imputed 7% of scores at week 14).</P>
<P>
<SUP>5 </SUP>Downgraded for imprecision; total population is &lt; 400. MRI data available for 194/201 in infliximab group; 72/78 in placebo group.</P>
<P>
<BR/>
<BR/>
</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2015-03-25 07:03:06 -0400" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2015-03-25 04:30:41 -0400" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2015-01-29 11:28:22 -0500" MODIFIED_BY="[Empty name]">Concomitant permitted therapy by study</TITLE>
<TABLE COLS="2" ROWS="18">
<TR>
<TH VALIGN="BOTTOM">
<P>Study ID</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Concomitant/Background treatment</P>
</TH>
</TR>
<TR>
<TD>
<P>
<I>Adalimumab</I>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Lambert-2007" TYPE="STUDY">Lambert 2007</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-van-der-Heijde-2006a" TYPE="STUDY">van der Heijde 2006a</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Allowed to continue sulphasalazine (3 g/day), methotrexate (25 mg/week), hydroxychloroquine (400 mg/day), prednisone or prednisone equivalent (10 mg/day), and NSAIDs, if the dose had remained stable for at least 4 weeks before the baseline visit</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Hu-2012" TYPE="STUDY">Hu 2012</LINK>, <LINK REF="STD-Huang-2014" TYPE="STUDY">Huang 2014</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Concomitant use of methotrexate (&#8806; 25 mg/week), sulphasalazine (&#8806; 3 g/day), prednisone (&#8806; 10 mg/day), NSAIDs and/or analgesics was allowed but dose adjustments, induction and/or discontinuation of these therapies was not permitted</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Etanercept</I>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Brandt-2003" TYPE="STUDY">Brandt 2003</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Allowed NSAIDs at the same or less dose at baseline</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Calin-2004" TYPE="STUDY">Calin 2004</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Allowed prestudy physiotherapy</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Davis-2003" TYPE="STUDY">Davis 2003</LINK>, <LINK REF="STD-Gorman-2002" TYPE="STUDY">Gorman 2002</LINK>, <LINK REF="STD-van-der-Heijde-2006b" TYPE="STUDY">van der Heijde 2006b</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Allowed stable doses of DMARDs, NSAIDs, and oral corticosteroids</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Huang-2008" TYPE="STUDY">Huang 2008</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Allowed stable DMARDs doses</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Barkham-2010" TYPE="STUDY">Barkham 2010</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Allowed stable doses of DMARDs (sulphasalazine or methotrexate) and/or a NSAID for the duration but not corticosteroids</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Golimumab</I>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Bao-2014" TYPE="STUDY">Bao 2014</LINK>, <LINK REF="STD-Inman-2008" TYPE="STUDY">Inman 2008</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Allowed to continue concurrent treatment with stable doses of methotrexate, sulphasalazine, and hydroxychloroquine</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Inman-2008" TYPE="STUDY">Inman 2008</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Allowed to continue concurrent treatment with stable doses of methotrexate, sulphasalazine, and hydroxychloroquine, corticosteroids, and NSAIDs</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Infliximab</I>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Braun-2002" TYPE="STUDY">Braun 2002</LINK>, <LINK REF="STD-van-der-Heijde-2005" TYPE="STUDY">van der Heijde 2005</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Allowed to continue on stable doses of NSAIDs</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Inman-2010" TYPE="STUDY">Inman 2010</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Concomitant therapy of NSAIDs, corticosteroids, analgesics, and DMARDs were allowed as long as doses remained stable in the study</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Marzo_x002d_Ortega-2005" TYPE="STUDY">Marzo-Ortega 2005</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Allowed concomitant use of NSAIDs or oral corticosteroids</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>DMARD - disease-modifying anti-rheumatic drug<BR/>NSAID - non-steroidal anti-inflammatory drug</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2015-02-20 20:46:46 -0500" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2015-02-20 20:40:30 -0500" MODIFIED_BY="[Empty name]">ASAS40: odds ratios, risk ratios and risk differences for all treatment comparisons (random-effects model)</TITLE>
<TABLE COLS="5" ROWS="15">
<TR>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Reference</P>
</TH>
<TH>
<P>OR (95% CrI)</P>
</TH>
<TH>
<P>RR (95% CrI)</P>
</TH>
<TH>
<P>RD% (95% CrI)</P>
</TH>
</TR>
<TR>
<TD>
<P>Etanercept</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>5.16 (3.14 to 8.62)</P>
</TD>
<TD>
<P>3.31 (2.38 to 4.53)</P>
</TD>
<TD>
<P>30.98 (20.08 to 42.47)</P>
</TD>
</TR>
<TR>
<TD>
<P>Infliximab</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>7.75 (4.11 to 15.45)</P>
</TD>
<TD>
<P>4.07 (2.80 to 5.74)</P>
</TD>
<TD>
<P>41.08 (26.62 to 55.88)</P>
</TD>
</TR>
<TR>
<TD>
<P>Adalimumab</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>5.84 (3.33 to 10.68)</P>
</TD>
<TD>
<P>3.53 (2.49 to 4.91)</P>
</TD>
<TD>
<P>34.00 (21.03 to 48.00)</P>
</TD>
</TR>
<TR>
<TD>
<P>Golimumab</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>4.12 (2.23 to 7.74)</P>
</TD>
<TD>
<P>2.90 (1.90 to 4.23)</P>
</TD>
<TD>
<P>25.50 (12.66 to 40.31)</P>
</TD>
</TR>
<TR>
<TD>
<P>Infliximab</P>
</TD>
<TD>
<P>Etanercept</P>
</TD>
<TD>
<P>1.50 (0.73 to 3.23)</P>
</TD>
<TD>
<P>1.23 (0.85 to 1.78)</P>
</TD>
<TD>
<P>10.01 (-7.67 to 28.21)</P>
</TD>
</TR>
<TR>
<TD>
<P>Adalimumab</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>1.13 (0.53 to 2.46)</P>
</TD>
<TD>
<P>1.07 (0.71 to 1.60)</P>
</TD>
<TD>
<P>3.09 (-15.40 to 21.89)</P>
</TD>
</TR>
<TR>
<TD>
<P>Golimumab</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>0.80 (0.36 to 1.78)</P>
</TD>
<TD>
<P>0.88 (0.55 to 1.38)</P>
</TD>
<TD>
<P>-5.45 (-23.60 to 13.99)</P>
</TD>
</TR>
<TR>
<TD>
<P>Adalimumab</P>
</TD>
<TD>
<P>Infliximab</P>
</TD>
<TD>
<P>0.76 (0.31 to 1.76)</P>
</TD>
<TD>
<P>0.87 (0.57 to 1.32)</P>
</TD>
<TD>
<P>-6.89 (-27.99 to 13.79)</P>
</TD>
</TR>
<TR>
<TD>
<P>Golimumab</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>0.53 (0.21 to 1.30)</P>
</TD>
<TD>
<P>0.71 (0.44 to 1.15)</P>
</TD>
<TD>
<P>-15.62 (-36.44 to 6.40)</P>
</TD>
</TR>
<TR>
<TD>
<P>Golimumab</P>
</TD>
<TD>
<P>Adalimumab</P>
</TD>
<TD>
<P>0.71 (0.30 to 1.62)</P>
</TD>
<TD>
<P>0.82 (0.50 to 1.31)</P>
</TD>
<TD>
<P>-8.45 (-28.45 to 11.78)</P>
</TD>
</TR>
<TR>
<TD>
<P>Random-effects model</P>
</TD>
<TD>
<P>Residual deviance</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>18.86 versus 20 data points</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Deviance information criteria</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>124.187</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Fixed-effect model</P>
</TD>
<TD>
<P>Residual deviance</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>19.51 versus 20 data points</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Deviance information criteria</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>123.44</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>CrL - credible interval<BR/>OR -odds ratio<BR/>RD -risk difference<BR/>RR -risk ratio</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2015-02-20 20:50:45 -0500" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2015-02-20 20:47:52 -0500" MODIFIED_BY="[Empty name]">BASFI: mean difference for all treatment comparisons (random-effects model)</TITLE>
<TABLE COLS="3" ROWS="15">
<TR>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Reference</P>
</TH>
<TH>
<P>Mean (SD)</P>
</TH>
</TR>
<TR>
<TD>
<P>Etanercept</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>-1.09 (-1.60 to -0.56)</P>
</TD>
</TR>
<TR>
<TD>
<P>Infliximab</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-2.07 (-2.71 to -1.35)</P>
</TD>
</TR>
<TR>
<TD>
<P>Adalimumab</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-1.57 (-2.21 to -0.89)</P>
</TD>
</TR>
<TR>
<TD>
<P>Golimumab</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-1.49 (-2.27 to -0.69)</P>
</TD>
</TR>
<TR>
<TD>
<P>Infliximab</P>
</TD>
<TD>
<P>Etanercept</P>
</TD>
<TD>
<P>-0.98 (-1.69 to -0.23)</P>
</TD>
</TR>
<TR>
<TD>
<P>Adalimumab</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-0.48 (-1.32 to 0.36)</P>
</TD>
</TR>
<TR>
<TD>
<P>Golimumab</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>-0.40 (-1.36 to 0.54)</P>
</TD>
</TR>
<TR>
<TD>
<P>Adalimumab</P>
</TD>
<TD>
<P>Infliximab</P>
</TD>
<TD>
<P>0.51 (-0.46 to 1.43)</P>
</TD>
</TR>
<TR>
<TD>
<P>Golimumab</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>0.59 (-0.49 to 1.61)</P>
</TD>
</TR>
<TR>
<TD>
<P>Golimumab</P>
</TD>
<TD>
<P>Adalimumab</P>
</TD>
<TD>
<P>0.08 (-0.95 to 1.10)</P>
</TD>
</TR>
<TR>
<TD>
<P>Random-effects model</P>
</TD>
<TD>
<P>Residual deviance</P>
</TD>
<TD>
<P>27.04 versus 28 data points</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Deviance information criteria</P>
</TD>
<TD>
<P>31.943</P>
</TD>
</TR>
<TR>
<TD>
<P>Fixed-effect model</P>
</TD>
<TD>
<P>Residual deviance</P>
</TD>
<TD>
<P>34.09 versus 28 data points</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Deviance information criteria</P>
</TD>
<TD>
<P>34.13</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>SD - standard deviation</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2015-02-20 20:59:27 -0500" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2015-02-20 20:52:39 -0500" MODIFIED_BY="[Empty name]">Partial remission: odds ratios, risk ratios and risk differences for all treatment comparisons (random-effects model)</TITLE>
<TABLE COLS="5" ROWS="15">
<TR>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Reference</P>
</TH>
<TH>
<P>OR (95% CrI)</P>
</TH>
<TH>
<P>RR (95% CrI)</P>
</TH>
<TH>
<P>RD% (95% CrI)</P>
</TH>
</TR>
<TR>
<TD>
<P>Etanercept</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>4.72 (2.43 to 9.72)</P>
</TD>
<TD>
<P>4.24 (2.31 to 8.09)</P>
</TD>
<TD>
<P>9.66 (3.79 to 19.10)</P>
</TD>
</TR>
<TR>
<TD>
<P>Infliximab</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>28.18 (6.25to 284.40)</P>
</TD>
<TD>
<P>15.41 (5.09 to 47.98)</P>
</TD>
<TD>
<P>43.61 (16.89 to 82.38)</P>
</TD>
</TR>
<TR>
<TD>
<P>Adalimumab</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>7.53 (3.39 to 18.33)</P>
</TD>
<TD>
<P>6.28 (3.13 to 12.78)</P>
</TD>
<TD>
<P>15.74 (6.11 to 32.38)</P>
</TD>
</TR>
<TR>
<TD>
<P>Golimumab</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>5.96 (1.97 to 23.86)</P>
</TD>
<TD>
<P>5.18 (1.90 to 14.79)</P>
</TD>
<TD>
<P>12.39 (2.69 to 38.31)</P>
</TD>
</TR>
<TR>
<TD>
<P>Infliximab</P>
</TD>
<TD>
<P>Etanercept</P>
</TD>
<TD>
<P>5.94 (1.12 to 65.22)</P>
</TD>
<TD>
<P>3.60 (1.09 to 12.19)</P>
</TD>
<TD>
<P>33.62 (1.91 to 76.29)</P>
</TD>
</TR>
<TR>
<TD>
<P>Adalimumab</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>1.59 (0.53 to 4.93)</P>
</TD>
<TD>
<P>1.47 (0.58 to 3.67)</P>
</TD>
<TD>
<P>5.83 (-7.73 to 24.11)</P>
</TD>
</TR>
<TR>
<TD>
<P>Golimumab</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>1.26 (0.34 to 5.71)</P>
</TD>
<TD>
<P>1.22 (0.38 to 4.00)</P>
</TD>
<TD>
<P>2.68 (-11.26 to 28.71)</P>
</TD>
</TR>
<TR>
<TD>
<P>Adalimumab</P>
</TD>
<TD>
<P>Infliximab</P>
</TD>
<TD>
<P>0.27 (0.02 to 1.52)</P>
</TD>
<TD>
<P>0.41 (0.12 to 1.35)</P>
</TD>
<TD>
<P>-26.97 (-72.15 to 7.93)</P>
</TD>
</TR>
<TR>
<TD>
<P>Golimumab</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>0.21 (0.02 to 1.56)</P>
</TD>
<TD>
<P>0.34 (0.08 to 1.35)</P>
</TD>
<TD>
<P>-29.87 (-74.54 to 9.13)</P>
</TD>
</TR>
<TR>
<TD>
<P>Golimumab</P>
</TD>
<TD>
<P>Adalimumab</P>
</TD>
<TD>
<P>0.78 (0.19 to 4.08)</P>
</TD>
<TD>
<P>0.82 (0.25 to 2.92)</P>
</TD>
<TD>
<P>-3.23 (-23.14 to 24.98)</P>
</TD>
</TR>
<TR>
<TD>
<P>Random-effects model</P>
</TD>
<TD>
<P>Residual deviance</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>12.93 versus 16 data points</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Deviance information criteria</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>88.137</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Fixed-effect model</P>
</TD>
<TD>
<P>Residual deviance</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>12.56 versus 16 data points</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Deviance information criteria</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>87.316</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>CrL - credible interval<BR/>OR - odds ratio<BR/>RD - risk difference<BR/>RR - risk ratio</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-05" MODIFIED="2015-02-20 21:03:53 -0500" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2015-02-20 20:58:46 -0500" MODIFIED_BY="[Empty name]">Serious adverse events: odds ratios, risk ratios and risk differences for all treatment comparisons (random-effects model)</TITLE>
<TABLE COLS="5" ROWS="15">
<TR>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Reference</P>
</TH>
<TH>
<P>OR (95% CrI)</P>
</TH>
<TH>
<P>RR (95% CrI)</P>
</TH>
<TH>
<P>RD% (95% CrI)</P>
</TH>
</TR>
<TR>
<TD>
<P>Etanercept</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>1.70 (0.76 to 3.84)</P>
</TD>
<TD>
<P>1.69 (0.76 to 3.72)</P>
</TD>
<TD>
<P>1.03 (-0.48 to 3.24)</P>
</TD>
</TR>
<TR>
<TD>
<P>Infliximab</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>2.60 (0.75 to 12.62)</P>
</TD>
<TD>
<P>2.53 (0.76 to 11.09)</P>
</TD>
<TD>
<P>2.34 (-0.45 to 12.84)</P>
</TD>
</TR>
<TR>
<TD>
<P>Adalimumab</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>0.92 (0.25 to 4.08)</P>
</TD>
<TD>
<P>0.92 (0.26 to 3.93)</P>
</TD>
<TD>
<P>-0.11 (-1.48 to 3.85)</P>
</TD>
</TR>
<TR>
<TD>
<P>Golimumab</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>0.69 (0.15 to 3.44)</P>
</TD>
<TD>
<P>0.69 (0.15 to 3.32)</P>
</TD>
<TD>
<P>-0.44 (-1.67 to 3.47)</P>
</TD>
</TR>
<TR>
<TD>
<P>Infliximab</P>
</TD>
<TD>
<P>Etanercept</P>
</TD>
<TD>
<P>1.53 (0.38 to 9.81)</P>
</TD>
<TD>
<P>1.51 (0.39 to 8.49)</P>
</TD>
<TD>
<P>1.27 (-2.48 to 12.27)</P>
</TD>
</TR>
<TR>
<TD>
<P>Adalimumab</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>0.54 (0.14 to 2.67)</P>
</TD>
<TD>
<P>0.55 (0.14 to 2.59)</P>
</TD>
<TD>
<P>-1.09 (-3.67 to 3.03)</P>
</TD>
</TR>
<TR>
<TD>
<P>Golimumab</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>0.40 (0.07 to 2.47)</P>
</TD>
<TD>
<P>0.41 (0.08 to 2.40)</P>
</TD>
<TD>
<P>-1.41 (-3.93 to 2.78)</P>
</TD>
</TR>
<TR>
<TD>
<P>Adalimumab</P>
</TD>
<TD>
<P>Infliximab</P>
</TD>
<TD>
<P>0.35 (0.05 to 2.28)</P>
</TD>
<TD>
<P>0.36 (0.05 to 2.22)</P>
</TD>
<TD>
<P>-2.33 (-13.00 to 2.47)</P>
</TD>
</TR>
<TR>
<TD>
<P>Golimumab</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>0.25 (0.03 to 2.03)</P>
</TD>
<TD>
<P>0.26 (0.03 to 1.99)</P>
</TD>
<TD>
<P>-2.68 (-13.32 to 2.04)</P>
</TD>
</TR>
<TR>
<TD>
<P>Golimumab</P>
</TD>
<TD>
<P>Adalimumab</P>
</TD>
<TD>
<P>0.74 (0.09 to 6.02)</P>
</TD>
<TD>
<P>0.75 (0.09 to 5.78)</P>
</TD>
<TD>
<P>-0.31 (-4.40 to 3.85)</P>
</TD>
</TR>
<TR>
<TD>
<P>Random-effect model</P>
</TD>
<TD>
<P>Residual deviance</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>21.86 versus 30 data points</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Deviance information criteria</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>109.922</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Fixed-effect model</P>
</TD>
<TD>
<P>Residual deviance</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>21.57 versus 30 data points</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Deviance information criteria</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>109.171</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>CrL - credible interval<BR/>OR - odds ratio<BR/>RD - risk difference<BR/>RR - risk ratio<BR/>
</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-06" MODIFIED="2015-02-20 21:09:11 -0500" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2015-02-20 21:05:54 -0500" MODIFIED_BY="[Empty name]">Withdrawal due to adverse events: odds ratios, risk ratios and risk differences for all treatment comparisons (random-effects model)</TITLE>
<TABLE COLS="5" ROWS="15">
<TR>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Reference</P>
</TH>
<TH>
<P>OR (95% CrI)</P>
</TH>
<TH>
<P>RR (95% CrI)</P>
</TH>
<TH>
<P>RD% (95% CrI)</P>
</TH>
</TR>
<TR>
<TD>
<P>Etanercept</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>3.73 (1.27 to 12.40)</P>
</TD>
<TD>
<P>3.65 (1.27 to 11.79)</P>
</TD>
<TD>
<P>1.94 (0.27 to 5.35)</P>
</TD>
</TR>
<TR>
<TD>
<P>Infliximab</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>1.78 (0.43 to 8.77)</P>
</TD>
<TD>
<P>1.77 (0.43 to 8.46)</P>
</TD>
<TD>
<P>0.55 (-0.55 to 4.45)</P>
</TD>
</TR>
<TR>
<TD>
<P>Adalimumab</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>1.70 (0.35 to 11.56)</P>
</TD>
<TD>
<P>1.69 (0.35 to 10.84)</P>
</TD>
<TD>
<P>0.49 (-0.61 to 6.14)</P>
</TD>
</TR>
<TR>
<TD>
<P>Golimumab</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>1.98 (0.36 to 19.49)</P>
</TD>
<TD>
<P>1.97 (0.36 to 17.51)</P>
</TD>
<TD>
<P>0.70 (-0.59 to 10.58)</P>
</TD>
</TR>
<TR>
<TD>
<P>Infliximab</P>
</TD>
<TD>
<P>Etanercept</P>
</TD>
<TD>
<P>0.49 (0.08 to 2.94)</P>
</TD>
<TD>
<P>0.49 (0.09 to 2.85)</P>
</TD>
<TD>
<P>-1.28 (-5.08 to 3.07)</P>
</TD>
</TR>
<TR>
<TD>
<P>Adalimumab</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>0.46 (0.07 to 3.72)</P>
</TD>
<TD>
<P>0.47 (0.07 to 3.54)</P>
</TD>
<TD>
<P>-1.33 (-5.10 to 4.63)</P>
</TD>
</TR>
<TR>
<TD>
<P>Golimumab</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>0.52 (0.06 to 7.31)</P>
</TD>
<TD>
<P>0.53 (0.06 to 6.59)</P>
</TD>
<TD>
<P>-1.16 (-5.16 to 9.25)</P>
</TD>
</TR>
<TR>
<TD>
<P>Adalimumab</P>
</TD>
<TD>
<P>Infliximab</P>
</TD>
<TD>
<P>0.94 (0.10 to 10.34)</P>
</TD>
<TD>
<P>0.94 (0.10 to 9.84)</P>
</TD>
<TD>
<P>-0.07 (-4.00 to 5.61)</P>
</TD>
</TR>
<TR>
<TD>
<P>Golimumab</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>1.11 (0.11 to 17.16)</P>
</TD>
<TD>
<P>1.11 (0.11 to 15.51)</P>
</TD>
<TD>
<P>0.12 (-3.92 to 10.05)</P>
</TD>
</TR>
<TR>
<TD>
<P>Golimumab</P>
</TD>
<TD>
<P>Adalimumab</P>
</TD>
<TD>
<P>1.19 (0.10 to 16.81)</P>
</TD>
<TD>
<P>1.19 (0.10 to 15.32)</P>
</TD>
<TD>
<P>0.19 (-5.13 to 9.86)</P>
</TD>
</TR>
<TR>
<TD>
<P>Random-effects model</P>
</TD>
<TD>
<P>Residual deviance</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>28.38 versus 32 data points</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Deviance information criteria</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>112.54</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Fixed-effect model</P>
</TD>
<TD>
<P>Residual deviance</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>28.92 versus 32 data points</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Deviance information criteria</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>112.474</P>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>CrL - credible interval<BR/>OR - odds ratio<BR/>RD - risk difference<BR/>RR - risk ratio</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-07" MODIFIED="2015-03-25 07:03:06 -0400" MODIFIED_BY="[Empty name]" NO="7">
<TITLE MODIFIED="2015-03-23 07:05:06 -0400" MODIFIED_BY="[Empty name]">Demographic and clinical characteristics of studies included in network meta-analysis</TITLE>
<TABLE COLS="9" ROWS="25">
<TR>
<TH VALIGN="BOTTOM">
<P>Study ID</P>
</TH>
<TH COLSPAN="2">
<P># of patients</P>
</TH>
<TH>
<P>Duration, weeks</P>
</TH>
<TH>
<P>Age (yrs, SD)</P>
</TH>
<TH>
<P>% male</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Disease duration (yrs, SD)</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Baseline BASDAI (SD)</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Baseline BASFI (SD)</P>
</TH>
</TR>
<TR>
<TH>
<P/>
</TH>
<TH>
<P>Tx</P>
</TH>
<TH>
<P>Control</P>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
</TR>
<TR>
<TD COLSPAN="4">
<P>
<B>Etanercept versus placebo</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Gorman-2002" TYPE="STUDY">Gorman 2002</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P>16</P>
</TD>
<TD VALIGN="TOP">
<P>38 (10)</P>
</TD>
<TD VALIGN="TOP">
<P>65</P>
</TD>
<TD VALIGN="TOP">
<P>15 (10)</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
<TD VALIGN="TOP">
<P>4.5 (2.1)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Brandt-2003" TYPE="STUDY">Brandt 2003</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>14</P>
</TD>
<TD VALIGN="TOP">
<P>16</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>39.8 (9.1)</P>
</TD>
<TD VALIGN="TOP">
<P>71.4</P>
</TD>
<TD VALIGN="TOP">
<P>14.9 (8.3)</P>
</TD>
<TD VALIGN="TOP">
<P>6.5 (1.2)</P>
</TD>
<TD VALIGN="TOP">
<P>6.2 (1.8)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Davis-2003" TYPE="STUDY">Davis 2003</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>138</P>
</TD>
<TD VALIGN="TOP">
<P>139</P>
</TD>
<TD VALIGN="TOP">
<P>24</P>
</TD>
<TD VALIGN="TOP">
<P>42.1</P>
</TD>
<TD VALIGN="TOP">
<P>76</P>
</TD>
<TD VALIGN="TOP">
<P>10.1</P>
</TD>
<TD VALIGN="TOP">
<P>58.1</P>
</TD>
<TD VALIGN="TOP">
<P>51.7</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Calin-2004" TYPE="STUDY">Calin 2004</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>45</P>
</TD>
<TD VALIGN="TOP">
<P>39</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>45.3 (9.5)</P>
</TD>
<TD VALIGN="TOP">
<P>80</P>
</TD>
<TD VALIGN="TOP">
<P>15 (8.8)</P>
</TD>
<TD VALIGN="TOP">
<P>61</P>
</TD>
<TD VALIGN="TOP">
<P>60.2</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-van-der-Heijde-2006b" TYPE="STUDY">van der Heijde 2006b</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>150</P>
</TD>
<TD VALIGN="TOP">
<P>51</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>39.8 (10.7)</P>
</TD>
<TD VALIGN="TOP">
<P>76</P>
</TD>
<TD VALIGN="TOP">
<P>10 (9.1)</P>
</TD>
<TD VALIGN="TOP">
<P>59.4 (16.7)</P>
</TD>
<TD VALIGN="TOP">
<P>57.7 (20.1)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Huang-2008" TYPE="STUDY">Huang 2008</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>74</P>
</TD>
<TD VALIGN="TOP">
<P>78</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD COLSPAN="5" VALIGN="TOP">
<P>abstract; no details reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Barkham-2010" TYPE="STUDY">Barkham 2010</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>40.8 (9.7)</P>
</TD>
<TD VALIGN="TOP">
<P>75</P>
</TD>
<TD VALIGN="TOP">
<P>11 (2&#8211;45)<SUP>#</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>6.05 (1.71)</P>
</TD>
<TD VALIGN="TOP">
<P>5.60 (1.98)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Dougados-2011" TYPE="STUDY">Dougados 2011</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>39</P>
</TD>
<TD VALIGN="TOP">
<P>43</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>46 (11)</P>
</TD>
<TD VALIGN="TOP">
<P>95</P>
</TD>
<TD VALIGN="TOP">
<P>19</P>
</TD>
<TD VALIGN="TOP">
<P>64 (12)</P>
</TD>
<TD VALIGN="TOP">
<P>63 (20)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="9" VALIGN="TOP">
<P>
<B>Infliximab versus placebo</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Braun-2002" TYPE="STUDY">Braun 2002</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>34</P>
</TD>
<TD VALIGN="TOP">
<P>35</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>40.6 (8)</P>
</TD>
<TD VALIGN="TOP">
<P>68</P>
</TD>
<TD VALIGN="TOP">
<P>16.4 (8.3)</P>
</TD>
<TD VALIGN="TOP">
<P>6.5(1.2)</P>
</TD>
<TD VALIGN="TOP">
<P>5.1 (2.2)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-van-der-Heijde-2005" TYPE="STUDY">van der Heijde 2005</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>201</P>
</TD>
<TD VALIGN="TOP">
<P>78</P>
</TD>
<TD VALIGN="TOP">
<P>24</P>
</TD>
<TD VALIGN="TOP">
<P>40 (32,47)*</P>
</TD>
<TD VALIGN="TOP">
<P>78</P>
</TD>
<TD VALIGN="TOP">
<P>10.1</P>
</TD>
<TD VALIGN="TOP">
<P>6.6 (5.3, 7.6)*</P>
</TD>
<TD VALIGN="TOP">
<P>5.7 (4.5, 7.1)*</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Inman-2010" TYPE="STUDY">Inman 2010</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>39</P>
</TD>
<TD VALIGN="TOP">
<P>37</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>42.9 (10.4)</P>
</TD>
<TD VALIGN="TOP">
<P>82</P>
</TD>
<TD VALIGN="TOP">
<P>11.7 (10.6)</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD COLSPAN="9" VALIGN="TOP">
<P>
<B>Adalimumab versus placebo</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-van-der-Heijde-2006a" TYPE="STUDY">van der Heijde 2006a</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>208</P>
</TD>
<TD VALIGN="TOP">
<P>107</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>41.7 (11.69)</P>
</TD>
<TD VALIGN="TOP">
<P>75.5</P>
</TD>
<TD VALIGN="TOP">
<P>11.3 (10)</P>
</TD>
<TD VALIGN="TOP">
<P>6.3 (1.7)</P>
</TD>
<TD VALIGN="TOP">
<P>5.2 (2.2)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Lambert-2007" TYPE="STUDY">Lambert 2007</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>38</P>
</TD>
<TD VALIGN="TOP">
<P>40</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>41.9 (11.1)</P>
</TD>
<TD VALIGN="TOP">
<P>76</P>
</TD>
<TD VALIGN="TOP">
<P>14.5 (9)</P>
</TD>
<TD VALIGN="TOP">
<P>6.2 (1.7)</P>
</TD>
<TD VALIGN="TOP">
<P>5.3 (2.0)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Hu-2012" TYPE="STUDY">Hu 2012</LINK>
</P>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>28.2 (6.9)</P>
</TD>
<TD>
<P>92</P>
</TD>
<TD>
<P>7.4 (5.7)</P>
</TD>
<TD>
<P>5.9 (1.4)</P>
</TD>
<TD>
<P>3.7 (2.1)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Huang-2014" TYPE="STUDY">Huang 2014</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>229</P>
</TD>
<TD VALIGN="TOP">
<P>115</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>30.1 (8.1)</P>
</TD>
<TD VALIGN="TOP">
<P>80.8</P>
</TD>
<TD VALIGN="TOP">
<P>8.1 (6.0)<SUP>+</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>6.0 (1.4)</P>
</TD>
<TD VALIGN="TOP">
<P>4.3 (2.3)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="9" VALIGN="TOP">
<P>
<B>Golimumab versus placebo</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Inman-2008" TYPE="STUDY">Inman 2008</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>138</P>
</TD>
<TD VALIGN="TOP">
<P>78</P>
</TD>
<TD VALIGN="TOP">
<P>14</P>
</TD>
<TD VALIGN="TOP">
<P>38 (30, 47)*</P>
</TD>
<TD VALIGN="TOP">
<P>73.9</P>
</TD>
<TD VALIGN="TOP">
<P>11 (6, 18)*<SUP>+</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>6.6 (5.6, 7.6)*</P>
</TD>
<TD VALIGN="TOP">
<P>5.0 (3.2, 6.7)*</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Bao-2014" TYPE="STUDY">Bao 2014</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>108</P>
</TD>
<TD VALIGN="TOP">
<P>105</P>
</TD>
<TD VALIGN="TOP">
<P>14</P>
</TD>
<TD VALIGN="TOP">
<P>30.5 (10.3)</P>
</TD>
<TD VALIGN="TOP">
<P>83.3</P>
</TD>
<TD VALIGN="TOP">
<P>6.1 (5.9)<SUP>+</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>6.6 (1.3)</P>
</TD>
<TD VALIGN="TOP">
<P>5.0 (2.4)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="9" VALIGN="TOP">
<P>
<B>Etanercept versus infliximab</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Giardina-2009" TYPE="STUDY">Giardina 2009</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>25</P>
</TD>
<TD VALIGN="TOP">
<P>25</P>
</TD>
<TD VALIGN="TOP">
<P>12**</P>
</TD>
<TD VALIGN="TOP">
<P>32.6 (6.8)</P>
</TD>
<TD VALIGN="TOP">
<P>80</P>
</TD>
<TD VALIGN="TOP">
<P>15.7 (6.5)</P>
</TD>
<TD VALIGN="TOP">
<P>6.6 (1.1)</P>
</TD>
<TD VALIGN="TOP">
<P>6.5 (1.1)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>Note: data from the treatment group provided in this table; for <LINK REF="STD-Giardina-2009" TYPE="STUDY">Giardina 2009</LINK>, the etanercept baseline data is provided (very similar to the infliximab group)<BR/>
<LINK REF="STD-Giardina-2009" TYPE="STUDY">Giardina 2009</LINK> is the only unblinded study. We did not include <LINK REF="STD-Braun-2011" TYPE="STUDY">Braun 2011</LINK> or <LINK REF="STD-Marzo_x002d_Ortega-2005" TYPE="STUDY">Marzo-Ortega 2005</LINK>
<BR/>*median (IQR)<BR/>
<SUP># </SUP>median (range)<BR/>
<SUP>+</SUP> years since symptoms occurred<BR/>**study ran for 104 weeks, but week 12 data used in the network meta-analysis<BR/>BASDAI: Bath Ankylosing Spondylitis Disease Activity Index<BR/>BASFI: Bath Ankylosing Spondylitis Functional Index<BR/>
</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-08" MODIFIED="2015-03-23 07:04:12 -0400" MODIFIED_BY="[Empty name]" NO="8">
<TITLE MODIFIED="2014-12-08 15:06:58 -0500" MODIFIED_BY="[Empty name]">Summary of warnings on the TNF-inhibitors from regulatory agencies</TITLE>
<TABLE COLS="2" ROWS="19">
<TR>
<TH>
<P>
<B>Summary of warning and conclusions</B>
</P>
</TH>
<TH>
<P>
<B>Date warning posted</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>
<B>MedWatch: The US Food and Drug Administration (FDA) Safety Information and Adverse Event Reporting Program</B>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Humira (adalimumab) injection: Postmarketing Experience: Hepato-biliary disorders: &#8230; added &#8230; hepatitis</P>
</TD>
<TD>
<P>May 2014</P>
</TD>
</TR>
<TR>
<TD>
<P>Humira (adalimumab)<BR/>5 WARNINGS AND PRECAUTIONS</P>
<P>5.1 Serious infections</P>
<UL>
<LI>Cases of reactivation of tuberculosis and new onset tuberculosis infections have been reported in patients receiving Humira, including patients who have previously received treatment for latent or active tuberculosis. Reports included cases of pulmonary and extrapulmonary (i.e. disseminated) tuberculosis. Evaluate....</LI>
<LI>Despite prophylactic treatment for tuberculosis, cases of reactivated tuberculosis have occurred in patients treated with Humira</LI>
</UL>
<P>5.2 Malignancies</P>
<UL>
<LI>The potential risk with the combination of azathioprine or 6-mercaptopurine and Humira should be carefully considered</LI>
</UL>
<P>5.3 Hypersensitivity reactions</P>
<UL>
<LI>Anaphylaxis and angioneurotic edema have been reported following Humira administration. If an anaphylactic or other serious allergic reaction occurs, ......</LI>
</UL>
<P>5.10 Immunizations</P>
<UL>
<LI>It is recommended that JIA patients, if possible, be brought up to date with all immunizations in agreement with current immunization.....</LI>
</UL>
<P>6 ADVERSE REACTIONS</P>
<P>6.2 Postmarketing experience</P>
<UL>
<LI>General disorders and administration site conditions: Pyrexia</LI>
<LI>Neoplasms benign, malignant and unspecified (including cysts and polyps): Merkel Cell Carcinoma (neuroendocrine carcinoma of the skin)</LI>
</UL>
<P>7 DRUG INTERACTIONS</P>
<P>7.2 Biologic products</P>
<UL>
<LI>Concomitant administration of Humira with other biologic DMARDS (e.g. anakinra and abatacept) or other TNF blockers is not recommended based upon the possible increased risk for infections and other potential pharmacological interactions</LI>
</UL>
</TD>
<TD>
<P>May 2013</P>
<P/>
<P/>
<P/>
<P/>
<P/>
<P/>
<P/>
<P/>
<P/>
<P/>
<P/>
<P/>
<P/>
<P/>
<P/>
<P/>
<P/>
<P/>
<P/>
<P/>
<P/>
<P/>
<P/>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Humira (adalimumab) 6.2 Postmarketing experience</P>
<UL>
<LI>added...liver failure, sarcoidosis, demyelinating disorders (e.g. optic neuritis, Guillain-Barré syndrome), cerebrovascular accident, pulmonary embolism, alopecia, and deep vein thrombosis</LI>
</UL>
<P/>
</TD>
<TD>
<P>May 2012</P>
</TD>
</TR>
<TR>
<TD>
<P>Humira (adalimumab) BOXED WARNING</P>
<P>Malignancy</P>
<UL>
<LI>Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which Humira is a member</LI>
</UL>
<P>WARNINGS and PRECAUTIONS</P>
<UL>
<LI>Malignancies, some fatal, have been reported among children, adolescents, and young adults who received treatment with TNF-blocking agents (initiation of therapy &#8804; 18 years of age), of which Humira is a member. Approximately half the cases were lymphomas, including Hodgkin's and non-Hodgkin's lymphoma. The other cases represented a variety of different malignancies and included rare malignancies usually associated with immunosuppression and malignancies that are not usually observed in children and adolescents. The malignancies occurred after a median of 30 months of therapy (range 1 to 84 months). Most of the patients were receiving concomitant immunosuppressants. These cases were reported postmarketing and are derived from a variety of sources including registries and spontaneous post marketing reports</LI>
</UL>
<P/>
<UL>
<LI>In the controlled portions of clinical trials of all the TNF-blocking agents, more cases of lymphoma have been observed among patients receiving TNF blockers compared to control patients. In controlled trials in patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn&#8217;s disease, and plaque psoriasis, 2 lymphomas were observed among 3853 Humira-treated patients versus 1 among 2183 control patients. In combining the controlled and uncontrolled open-label portions of these clinical trials with a median duration of approximately 2 years, including 6539 patients and over 16,000 patient-years of therapy, the observed rate of lymphomas is approximately 0.11/100 patient-years. This is approximately 3-fold higher than expected in the general population. Rates in clinical trials for Humira cannot be compared to rates of clinical trials of other TNF blockers and may not predict the rates observed in a broader patient population. Patients with rheumatoid arthritis, particularly those with highly active disease, are at a higher risk for the development of lymphoma. Cases of acute and chronic leukemia have been reported in association with postmarketing TNF-blocker use in rheumatoid arthritis and other indications. Even in the absence of TNF-blocker therapy, patients with rheumatoid arthritis may be at a higher risk (approximately 2-fold) than the general population for the development of leukemia</LI>
</UL>
<P>ADVERSE REACTIONS</P>
<P>Postmarketing experience</P>
<UL>
<LI>Skin reactions: new or worsening psoriasis (all subtypes including pustular and palmoplantar)</LI>
</UL>
</TD>
<TD>
<P>Nov 2009</P>
</TD>
</TR>
<TR>
<TD>
<P>Infliximab (Remicade) WARNINGS AND PRECAUTIONS</P>
<P>Skin cancer</P>
<UL>
<LI>Melanoma and merkel cell carcinoma have been reported in patients treated with TNF blocker therapy, including Remicade [see Adverse Reactions (6.2)]. Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer</LI>
</UL>
<P>Concurrent administration with other biological therapeutics</P>
<UL>
<LI>There is insufficient information regarding the concomitant use of Remicade with other biological therapeutics used to treat the same conditions as Remicade. The concomitant use of Remicade with these biologics is not recommended because of the possibility of an increased risk of infection</LI>
</UL>
<P>ADVERSE REACTIONS</P>
<P>Postmarketing experience</P>
<UL>
<LI>Serious infections and malignancies, including melanoma and merkel cell carcinoma</LI>
</UL>
</TD>
<TD>
<P>Mar 2013</P>
</TD>
</TR>
<TR>
<TD>
<P>Enbrel (Etanercept) Injection: ADVERSE REACTIONS- Postmarketing Experience: Sarcoidosis</P>
<P/>
</TD>
<TD>
<P>Dec 2012</P>
</TD>
</TR>
<TR>
<TD>
<P>Warning of ongoing safety review of TNF blockers and malignancy in children, adolescents, and young adults (30 years of age or younger). FDA is requiring the manufacturers of TNF blockers to perform enhanced safety surveillance for these products</P>
</TD>
<TD>
<P>03 Nov 2011</P>
</TD>
</TR>
<TR>
<TD>
<P>FDA notified healthcare professionals that the Boxed Warning for the entire class of Tumor Necrosis Factor-alpha (TNF&#945;) blockers has been updated to include the risk of infection from two bacterial pathogens, Legionella and Listeria. In addition, the Boxed Warning and Warnings and Precautions sections of the labels for all of the TNF&#945; blockers have been revised so that they contain consistent information about the risk for serious infections and the associated disease-causing pathogens</P>
<P/>
<P>Patients treated with TNF&#945; blockers are at increased risk for developing serious infections involving multiple organ systems and sites that may lead to hospitalizations or death due to bacterial, mycobacterial, fungal, viral, parasitic, and other opportunistic pathogens</P>
<P/>
</TD>
<TD>
<P>07 Sep 2011</P>
</TD>
</TR>
<TR>
<TD>
<P>FDA continues to receive reports of a rare cancer of white blood cells (known as Hepatosplenic T-Cell Lymphoma or HSTCL, primarily in adolescents and young adults being treated for Crohn&#8217;s disease and ulcerative colitis with medicines known as tumor necrosis factors (TNF) blockers, as well as with azathioprine, and/or mercaptopurine. TNF blockers include Remicade (infliximab), Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab pegol) and Simponi (golimumab)</P>
</TD>
<TD>
<P>04 Nov 2011</P>
<P>and 14 Apr 2011</P>
</TD>
</TR>
<TR>
<TD>
<P>Label warnings added since 2000 for infliximab: hepatotoxicity; infections (pneumonia specifically added), lymphoma, tuberculosis, and other serious opportunistic infections including histoplasmosis, listeriosis, and pneumocystosis, malignancies</P>
<P/>
<P>Label warnings added since 2000 for etanercept: serious infections leading to hospitalizations or death, including bacterial sepsis and tuberculosis; recommendation to screen for latent tuberculosis infection before beginning Enbrel; lymphoma and other malignancies, including acute and chronic leukemia</P>
<P/>
<P>Label warnings added since 2000 for adalimumab: lymphoma and other malignancies; skin reactions: new or worsening psoriasis (all sub-types including pustular and palmoplantar) ; serious infections with the combined use of Humira (adalimumab) and anakinra, hypersensitivity reactions, including anaphylaxis, and hematologic events, including pancytopenia and aplastic anemia</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>European Medicines Evaluation Agency (EMEA)</B>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>EPAR summary for the public: </B>Adalimumab: Humira must not be used in patients with active tuberculosis, other severe infections, or moderate to severe heart failure (an inability of the heart to pump enough blood around the body)</P>
<P/>
<P>
<B>EPAR summary for the public</B>: Etanercept: Enbrel must not be used in patients who have or are at risk of sepsis (when bacteria and toxins circulate in the blood and start to damage the organs), or in patients with infections. Patients developing a serious infection should stop Enbrel treatment</P>
<P>
<B>Revised public statement on Enbrel (etanercept) </B>- Serious haematological reactions</P>
<P/>
<P>
<B>EPAR summary for the public</B>: Golimumab: Simponi must not be used in people who are hypersensitive (allergic) to golimumab or any of the other ingredients. It must not be used in patients with tuberculosis, other severe infections, or moderate or severe heart failure (an inability of the heart to pump enough blood around the body). Due to an increased risk of infection, patients taking Simponi must be monitored closely for infections, including tuberculosis, during and for up to five months after treatment</P>
<P/>
<P>The most serious side effects include serious infections, such as sepsis (blood infection), pneumonia (lung infection), tuberculosis and infections due to fungi or yeasts, demyelinating disorders (disorders suggesting damage to the protective sheath around nerves, such as changes to vision and weak arms or legs), lymphoma (a type of cancer of the white blood cells), re-activation of hepatitis B (a liver disease), congestive heart failure (a heart disease), lupus-like syndrome and blood reactions</P>
<P/>
<P>
<B>EPAR summary for the public</B>: Infliximab: Remicade must not be used in patients who have experienced hypersensitivity (allergy) to infliximab in the past, or who are hypersensitive (allergic) to mouse proteins or any of the other ingredients of Remicade. Remicade must not be used in patients with tuberculosis, other severe infections, or moderate or severe heart failure (an inability of the heart to pump enough blood around the body)</P>
</TD>
<TD>
<P>14 Nov 2014</P>
<P/>
<P/>
<P>03 Sep 2014</P>
<P/>
<P>03 Nov 2000</P>
<P/>
<P/>
<P>23 Oct 2013</P>
<P/>
<P/>
<P/>
<P/>
<P/>
<P/>
<P>1 Mar 2012</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Australian Adverse Drug Reactions</B>
</P>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Bulletin</P>
<P>
<B>Golimumab: Infections </B>
</P>
<P>Serious and sometimes fatal infections due to bacterial (including sepsis and pneumonia), mycobacterial, invasive fungal, viral, protozoal, or other opportunistic pathogens have been reported in patients receiving TNF-blockers including SIMPONI. Among opportunistic infections, tuberculosis, histoplasmosis, aspergillosis, candidiasis, coccidioidomycosis, listeriosis, and pneumocystosis were the most commonly reported with TNF-blockers. Patients have frequently presented with disseminated rather than localized disease, and were often taking concomitant immunosuppressants such as methotrexate (MTX) or corticosteroids. The concomitant use of a TNF-blocker and abatacept or anakinra was associated with a higher risk of serious infections; therefore, the concomitant use of SIMPONI and these biologic products is not recommended</P>
<P/>
<P>
<B>Tuberculosis </B>
</P>
<P>Cases of reactivation of tuberculosis or new tuberculosis infections have been observed in patients receiving TNF-blockers, including Simponi</P>
<P/>
<P>
<B>Hepatitis B virus reactivation </B>
</P>
<P>The use of TNF-blockers including SIMPONI has been associated with reactivation of hepatitis B virus (HBV) in patients who are chronic hepatitis B carriers (i.e. surface antigen positive). Patients should be tested for Hepatitis B virus (HBV) infection before initiating treatment with immunosuppressants, including Simponi</P>
<P/>
<P>
<B>Malignancies </B>
</P>
<P>The potential role of TNF-blocking therapy in the development of malignancies is not known. Caution should be exercised when considering TNF-blocking therapy for patients with a history of malignancy or when considering continuing treatment in patients who develop malignancy</P>
<P/>
<P>
<I>
<B>Paediatric Malignancy </B>
</I>
</P>
<P>Post-marketing cases of malignancies, some fatal, have been reported among children, adolescents and young adults (up to 22 years of age) who received TNF-blocking agents (initiation of therapy &#8804; 18 years of age) to treat Juvenile Idiopathic Arthritis (JIA), Crohn&#8217;s disease or other conditions</P>
<P/>
<P>
<I>
<B>Lymphoma </B>
</I>
</P>
<P>In the controlled portions of clinical trials of all the TNF-blocking agents including Simponi, more cases of lymphoma have been observed among patients receiving anti-TNF treatment compared with control patients</P>
<P/>
<P>
<I>
<B>Leukaemia </B>
</I>
</P>
<P>Cases of acute and chronic leukaemia have been reported with postmarketing TNF-blocker use in rheumatoid arthritis and other indications</P>
<P/>
<P>
<I>
<B>Skin cancers </B>
</I>
</P>
<P>Melanoma has been reported in patients treated with TNF blocking agents, including Simponi. Merkel cell carcinoma has been reported in patients treated with other TNF-blocking agents</P>
<P/>
<P>
<B>Congestive Heart Failure </B>
</P>
<P>Cases of worsening congestive heart failure (CHF) and new onset CHF have been reported with TNF-blockers including SIMPONI. Cases of CHF in patients with known cardiovascular risk factors have been observed with Simponi</P>
<P/>
<P>
<B>Neurological events </B>
</P>
<P>Use of TNF-blocking agents has been associated with cases of new onset or exacerbation of clinical symptoms and/or radiographic evidence of central nervous system demyelinating disorders, including multiple sclerosis (MS) and peripheral demyelinating disorders, including Guillain-Barré syndrome</P>
<P/>
<P>
<B>Haematological cytopaenias </B>
</P>
<P>There have been post-marketing reports of pancytopaenia, leukopaenia, neutropaenia, aplastic anaemia, and thrombocytopaenia in patients receiving TNF-blockers. Cytopaenias including pancytopaenia, have been infrequently reported with Simponi in clinical trials</P>
<P/>
</TD>
<TD>
<P>16 Aug 2013</P>
</TD>
</TR>
<TR>
<TD>
<P>Drug-induced lupus erythematosus (June 2009): An emerging association with TNF inhibitors</P>
<P/>
<P>TNA-alpha inhibitors (Dec. 2006): While extremely effective, TNF inhibitors are associated with several serious reactions. These include:</P>
<P>· Hypersensitivity reactions - immediately post-injection or delayed</P>
<P>· Serious and life-threatening infection and sepsis</P>
<P>· Recrudescence of tuberculosis and other granulomatous diseases</P>
<P>· Reactivation of hepatitis B</P>
<P>· Malignancy, including lymphoma</P>
<P>· Haematological reactions such as pancytopenia and aplastic anaemia</P>
<P>· Autoimmunity - e.g. drug-induced lupus</P>
<P>· CNS reactions, including demyelinating disorders and seizures</P>
<P>· New-onset heart failure or worsening of advanced heart failure</P>
</TD>
<TD>
<P>June 2009</P>
<P/>
<P>Dec 2006</P>
<P/>
<P/>
<P/>
<P/>
<P/>
<P/>
<P/>
<P/>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>UK MHRA Medicines and Healthcare products Regulatory Agency: Drug Safety Updates (formerly Current Problems in Pharmacovigilance)</B>
</P>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>- letter to healthcare providers re: reports of hepatosplenic T-cell lymphoma in patients treated with Humira® (adalimumab)</P>
<P>- congestive cardiac failure, cardiomyopathy, the frequency of blood dyscrasias, demyelination, infections, adult respiratory distress syndrome and TB should be kept under close monitoring by the MA (marketing authorization) holder</P>
<P/>
<P>Highlight of the European Agency for the Evaluation of Medicinal Products (EMEA) public statement regarding tuberculosis (TB) or other opportunistic infections following infliximab (Remicade) therapy. &#8220;Prescribers and patients who are receiving Remicade need to be aware of the risk of developing infections upon starting therapy and to be especially vigilant for signs of infection throughout treatment. If active TB is suspected (persistent cough, wasting/weight loss, low grade fever), Remicade treatment should be withheld until the infection has been treated&#8221;</P>
</TD>
<TD>
<P>July 2008</P>
<P/>
<P/>
<P/>
<P>20 Dec 2000</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>DMARDs: Disease-modifying anti-rheumatic drugs<BR/>JIA: Juvenile idiopathic arthritis<BR/>TB: tuberculosis<BR/>
</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2015-03-26 09:23:50 -0400" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2015-03-23 08:27:52 -0400" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Adalimumab versus placebo</NAME>
<CONT_OUTCOME CHI2="3.1035567978175225" CI_END="-1.230318476344247" CI_START="-1.8888395301422476" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.5595790032432473" ESTIMABLE="YES" I2="3.3367134730817716" I2_Q="0.0" ID="CMP-001.01" MODIFIED="2015-03-23 08:11:06 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3759329782815001" P_Q="1.0" P_Z="1.6386725673462295E-20" Q="0.0" RANDOM="NO" SCALE="5.205589937345858" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="500" TOTAL_2="286" UNITS="" WEIGHT="100.0" Z="9.28358678821917">
<NAME>BASFI (0-10 VAS)</NAME>
<GROUP_LABEL_1>Adalimumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adalimumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.1035567978175225" CI_END="-1.230318476344247" CI_START="-1.8888395301422476" DF="3" EFFECT_SIZE="-1.5595790032432473" ESTIMABLE="YES" I2="3.3367134730817716" ID="CMP-001.01.01" MODIFIED="2015-03-12 08:00:12 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3759329782815001" P_Z="1.6386725673462295E-20" STUDIES="4" TAU2="0.0" TOTAL_1="500" TOTAL_2="286" WEIGHT="100.0" Z="9.28358678821917">
<NAME>12 weeks</NAME>
<CONT_DATA CI_END="-0.06480955251824261" CI_START="-2.135190447481757" EFFECT_SIZE="-1.0999999999999999" ESTIMABLE="YES" MEAN_1="1.8" MEAN_2="2.9" MODIFIED="2015-03-12 08:00:12 -0400" MODIFIED_BY="[Empty name]" ORDER="413" SD_1="1.6" SD_2="1.9" SE="0.5281680967850467" STUDY_ID="STD-Hu-2012" TOTAL_1="26" TOTAL_2="20" WEIGHT="10.116698939796457"/>
<CONT_DATA CI_END="-0.864407438190316" CI_START="-1.8955925618096847" EFFECT_SIZE="-1.3800000000000003" ESTIMABLE="YES" MEAN_1="2.55" MEAN_2="3.93" MODIFIED="2015-03-12 08:00:12 -0400" MODIFIED_BY="[Empty name]" ORDER="1081" SD_1="2.3" SD_2="2.3" SE="0.2630622633255574" STUDY_ID="STD-Huang-2014" TOTAL_1="228" TOTAL_2="115" WEIGHT="40.78176811324036"/>
<CONT_DATA CI_END="-0.12881798524691068" CI_START="-2.471182014753089" EFFECT_SIZE="-1.2999999999999998" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="5.3" MODIFIED="2015-03-12 08:00:12 -0400" MODIFIED_BY="[Empty name]" ORDER="253" SD_1="3.0" SD_2="2.3" SE="0.5975528244351546" STUDY_ID="STD-Lambert-2007" TOTAL_1="38" TOTAL_2="44" WEIGHT="7.903701841588522"/>
<CONT_DATA CI_END="-1.3870175677198069" CI_START="-2.412982432280194" EFFECT_SIZE="-1.9000000000000004" ESTIMABLE="YES" MEAN_1="3.3" MEAN_2="5.2" MODIFIED="2015-03-12 08:00:12 -0400" MODIFIED_BY="[Empty name]" ORDER="1838" SD_1="2.2" SD_2="2.2" SE="0.2617305401152947" STUDY_ID="STD-van-der-Heijde-2006a" TOTAL_1="208" TOTAL_2="107" WEIGHT="41.197831105374654"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.1540325711007806" CI_END="5.5293198075371315" CI_START="2.5568524611989125" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="3.760007308324973" ESTIMABLE="YES" EVENTS_1="185" EVENTS_2="25" I2="13.347333078637092" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.7426717096044908" LOG_CI_START="0.4077056685285565" LOG_EFFECT_SIZE="0.5751886890665235" METHOD="MH" MODIFIED="2015-03-12 08:30:41 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.28270662637025656" P_Q="1.0" P_Z="1.6835647023563087E-11" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="437" TOTAL_2="222" WEIGHT="100.0" Z="6.7311248105274775">
<NAME>ASAS 40</NAME>
<GROUP_LABEL_1>Adalimumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adalimumab</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.1540325711007806" CI_END="5.5293198075371315" CI_START="2.5568524611989125" DF="1" EFFECT_SIZE="3.760007308324973" ESTIMABLE="YES" EVENTS_1="185" EVENTS_2="25" I2="13.347333078637092" ID="CMP-001.02.01" LOG_CI_END="0.7426717096044908" LOG_CI_START="0.4077056685285565" LOG_EFFECT_SIZE="0.5751886890665235" MODIFIED="2015-03-12 08:00:12 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.28270662637025656" P_Z="1.6835647023563087E-11" STUDIES="2" TAU2="0.0" TOTAL_1="437" TOTAL_2="222" WEIGHT="100.0" Z="6.7311248105274775">
<NAME>12 weeks</NAME>
<DICH_DATA CI_END="8.31907751836719" CI_START="2.6065407447981475" EFFECT_SIZE="4.656609765780072" ESTIMABLE="YES" EVENTS_1="102" EVENTS_2="11" LOG_CI_END="0.9200751711351566" LOG_CI_START="0.416064518099676" LOG_EFFECT_SIZE="0.6680698446174163" MODIFIED="2015-03-12 08:00:12 -0400" MODIFIED_BY="[Empty name]" ORDER="1089" O_E="0.0" SE="0.2960583524860109" STUDY_ID="STD-Huang-2014" TOTAL_1="229" TOTAL_2="115" VAR="0.08765054807673107" WEIGHT="44.20004757095676"/>
<DICH_DATA CI_END="5.109589684681353" CI_START="1.820350311534319" EFFECT_SIZE="3.049793956043956" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="14" LOG_CI_END="0.7083860263903996" LOG_CI_START="0.26015497245016833" LOG_EFFECT_SIZE="0.484270499420284" MODIFIED="2015-03-12 08:00:12 -0400" MODIFIED_BY="[Empty name]" ORDER="1846" O_E="0.0" SE="0.26329313986399283" STUDY_ID="STD-van-der-Heijde-2006a" TOTAL_1="208" TOTAL_2="107" VAR="0.06932327749944009" WEIGHT="55.79995242904323"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.03115953258098539" CI_END="11.938885592996128" CI_START="2.920810711058472" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="5.905186272940488" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="1.0769637904952183" LOG_CI_START="0.4655034125687117" LOG_EFFECT_SIZE="0.7712336015319651" METHOD="MH" MODIFIED="2015-03-12 08:30:41 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8598849833684226" P_Q="1.0" P_Z="7.645861484029011E-7" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="437" TOTAL_2="222" WEIGHT="100.0" Z="4.9441963444815356">
<NAME>ASAS partial remission</NAME>
<GROUP_LABEL_1>Adalimumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adalimumab</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.03115953258098539" CI_END="11.938885592996128" CI_START="2.920810711058472" DF="1" EFFECT_SIZE="5.905186272940488" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="8" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="1.0769637904952183" LOG_CI_START="0.4655034125687117" LOG_EFFECT_SIZE="0.7712336015319651" MODIFIED="2015-03-12 08:00:12 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8598849833684226" P_Z="7.645861484029011E-7" STUDIES="2" TAU2="0.0" TOTAL_1="437" TOTAL_2="222" WEIGHT="100.0" Z="4.9441963444815356">
<NAME>12 weeks</NAME>
<DICH_DATA CI_END="16.952664786373433" CI_START="2.324378060117195" EFFECT_SIZE="6.277292576419214" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="4" LOG_CI_END="1.2292379745777213" LOG_CI_START="0.3663067674658386" LOG_EFFECT_SIZE="0.7977723710217801" MODIFIED="2015-03-12 08:00:12 -0400" MODIFIED_BY="[Empty name]" ORDER="1091" O_E="0.0" SE="0.5068900626358863" STUDY_ID="STD-Huang-2014" TOTAL_1="229" TOTAL_2="115" VAR="0.2569375355990127" WEIGHT="50.20287151934413"/>
<DICH_DATA CI_END="14.997135829361586" CI_START="2.0391514807252653" EFFECT_SIZE="5.530048076923077" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="4" LOG_CI_END="1.1760083249039444" LOG_CI_START="0.30944948904419994" LOG_EFFECT_SIZE="0.7427289069740722" MODIFIED="2015-03-12 08:00:12 -0400" MODIFIED_BY="[Empty name]" ORDER="1850" O_E="0.0" SE="0.5090209497194321" STUDY_ID="STD-van-der-Heijde-2006a" TOTAL_1="208" TOTAL_2="107" VAR="0.2591023272532727" WEIGHT="49.79712848065587"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.04" MODIFIED="2015-03-23 08:27:46 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="26" TOTAL_2="20" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>MRI SPARCC score (lumbar spine; scale 0-108)</NAME>
<GROUP_LABEL_1>Adalimumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adalimumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.060307626112547474" CI_START="-13.06030762611255" EFFECT_SIZE="-6.500000000000002" ESTIMABLE="YES" MEAN_1="9.6" MEAN_2="16.1" MODIFIED="2015-03-12 08:00:12 -0400" MODIFIED_BY="[Empty name]" ORDER="829" SD_1="12.7" SD_2="10.0" SE="3.3471572324080534" STUDY_ID="STD-Hu-2012" TOTAL_1="26" TOTAL_2="20" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.05" MODIFIED="2015-03-23 08:27:52 -0400" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="26" TOTAL_2="20" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>MRI SPARCC score (sacroiliac joint; scale 0-72))</NAME>
<GROUP_LABEL_1>Adalimumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adalimumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.4561130920810879" CI_START="-7.456113092081088" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="4.5" MEAN_2="7.5" MODIFIED="2015-03-12 08:00:12 -0400" MODIFIED_BY="[Empty name]" ORDER="829" SD_1="6.0" SD_2="8.7" SE="2.2735688651579005" STUDY_ID="STD-Hu-2012" TOTAL_1="26" TOTAL_2="20" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="2.2157501360417897" CI_END="6.460709975636318" CI_START="0.33965781800003764" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.4813610812545697" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" I2="54.86855743642659" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.8102802457905428" LOG_CI_START="-0.46895838467931894" LOG_EFFECT_SIZE="0.17066093055561188" METHOD="PETO" MODIFIED="2015-03-23 08:27:52 -0400" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.13660873726120226" P_Q="1.0" P_Z="0.6010086626629279" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="437" TOTAL_2="222" WEIGHT="100.0" Z="0.5229505574487433">
<NAME>Withdrawals due to adverse events</NAME>
<GROUP_LABEL_1>Adalimumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adalimumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.2157501360417897" CI_END="6.460709975636318" CI_START="0.33965781800003764" DF="1" EFFECT_SIZE="1.4813610812545697" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" I2="54.86855743642659" ID="CMP-001.06.01" LOG_CI_END="0.8102802457905428" LOG_CI_START="-0.46895838467931894" LOG_EFFECT_SIZE="0.17066093055561188" MODIFIED="2015-03-12 08:00:12 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.13660873726120226" P_Z="0.6010086626629279" STUDIES="2" TAU2="0.0" TOTAL_1="437" TOTAL_2="222" WEIGHT="100.0" Z="0.5229505574487433">
<NAME>12 weeks</NAME>
<DICH_DATA CI_END="36.66906884699879" CI_START="0.5649276224900655" EFFECT_SIZE="4.5514140530893865" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.56429988187921" LOG_CI_START="-0.24800718964369772" LOG_EFFECT_SIZE="0.6581463461177562" MODIFIED="2015-03-12 08:00:12 -0400" MODIFIED_BY="[Empty name]" ORDER="1094" O_E="1.3372093023255816" SE="1.0645581448772437" STUDY_ID="STD-Huang-2014" TOTAL_1="229" TOTAL_2="115" VAR="0.8823913170305594" WEIGHT="49.82411134633064"/>
<DICH_DATA CI_END="3.8865539330003505" CI_START="0.060760555838592765" EFFECT_SIZE="0.48595182607514725" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.5895646987086686" LOG_CI_START="-1.216378261857811" LOG_EFFECT_SIZE="-0.3134067815745712" MODIFIED="2015-03-12 08:00:12 -0400" MODIFIED_BY="[Empty name]" ORDER="1860" O_E="-0.6412698412698412" SE="1.0608198345985802" STUDY_ID="STD-van-der-Heijde-2006a" TOTAL_1="208" TOTAL_2="107" VAR="0.8886213376598575" WEIGHT="50.17588865366937"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.2179293909827764" CI_END="3.153465224444961" CI_START="0.25258719280119835" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.8924824528464151" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.4987880460745635" LOG_CI_START="-0.5975886737204199" LOG_EFFECT_SIZE="-0.049400313822928164" METHOD="PETO" MODIFIED="2015-03-23 08:27:50 -0400" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.6406221838685386" P_Q="1.0" P_Z="0.859804292900884" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="437" TOTAL_2="222" WEIGHT="99.99999999999999" Z="0.1766232977584944">
<NAME>Serious adverse events</NAME>
<GROUP_LABEL_1>Adalimumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adalimumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.2179293909827764" CI_END="3.153465224444961" CI_START="0.25258719280119835" DF="1" EFFECT_SIZE="0.8924824528464151" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" I2="0.0" ID="CMP-001.07.01" LOG_CI_END="0.4987880460745635" LOG_CI_START="-0.5975886737204199" LOG_EFFECT_SIZE="-0.049400313822928164" MODIFIED="2015-03-12 09:09:00 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6406221838685386" P_Z="0.859804292900884" STUDIES="2" TAU2="0.0" TOTAL_1="437" TOTAL_2="222" WEIGHT="99.99999999999999" Z="0.1766232977584944">
<NAME>12 weeks</NAME>
<DICH_DATA CI_END="8.983344790664294" CI_START="0.025000801850767813" EFFECT_SIZE="0.47391014239887846" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.9534380687013259" LOG_CI_START="-1.6020460619767956" LOG_EFFECT_SIZE="-0.32430399663773485" MODIFIED="2015-03-12 08:00:12 -0400" MODIFIED_BY="[Empty name]" ORDER="1093" O_E="-0.3313953488372092" SE="1.5011040282107897" STUDY_ID="STD-Huang-2014" TOTAL_1="229" TOTAL_2="115" VAR="0.44379092709478135" WEIGHT="18.40658555408808"/>
<DICH_DATA CI_END="4.163841284074374" CI_START="0.25452811341066645" EFFECT_SIZE="1.0294730042972944" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.6194941668604996" LOG_CI_START="-0.594264241520516" LOG_EFFECT_SIZE="0.012614962669991715" MODIFIED="2015-03-12 09:09:00 -0400" MODIFIED_BY="[Empty name]" ORDER="1859" O_E="0.05714285714285694" SE="0.7129676972840291" STUDY_ID="STD-van-der-Heijde-2006a" TOTAL_1="208" TOTAL_2="107" VAR="1.9672533471987521" WEIGHT="81.5934144459119"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2015-03-26 09:23:50 -0400" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Infliximab versus placebo</NAME>
<DICH_OUTCOME CHI2="0.08582025076888015" CI_END="6.458372152454372" CI_START="2.2848137676198954" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="3.84137704610478" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.8101230668658171" LOG_CI_START="0.3588508070355652" LOG_EFFECT_SIZE="0.5844869369506912" METHOD="MH" MODIFIED="2015-03-26 09:23:50 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7695596676711426" P_Q="0.7720671011521405" P_Z="3.8327359356545566E-7" Q="0.08390993547127226" RANDOM="NO" SCALE="38.8217879300869" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="240" TOTAL_2="115" WEIGHT="100.00000000000001" Z="5.077082940078793">
<NAME>ASAS 40</NAME>
<GROUP_LABEL_1>Infliximab</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours infliximab</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.25746286678516" CI_START="1.4126436000005096" DF="0" EFFECT_SIZE="3.4153846153846152" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="5" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="0.9168466293768868" LOG_CI_START="0.1500326062386793" LOG_EFFECT_SIZE="0.533439617807783" MODIFIED="2015-03-26 09:23:50 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.006392742933494677" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="37" WEIGHT="28.352328690023928" Z="2.726925714141838">
<NAME>12 weeks</NAME>
<DICH_DATA CI_END="8.25746286678516" CI_START="1.4126436000005096" EFFECT_SIZE="3.4153846153846152" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="5" LOG_CI_END="0.9168466293768868" LOG_CI_START="0.1500326062386793" LOG_EFFECT_SIZE="0.533439617807783" MODIFIED="2015-03-26 09:23:50 -0400" MODIFIED_BY="[Empty name]" ORDER="268" O_E="0.0" SE="0.4504303529820153" STUDY_ID="STD-Inman-2010" TOTAL_1="39" TOTAL_2="37" VAR="0.20288750288750287" WEIGHT="28.352328690023928"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.546284507825725" CI_START="2.130810332001786" DF="0" EFFECT_SIZE="4.009950248756219" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="9" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="0.8777331748180017" LOG_CI_START="0.328544793951202" LOG_EFFECT_SIZE="0.6031389843846018" MODIFIED="2015-03-12 08:01:44 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="1.669783264862955E-5" STUDIES="1" TAU2="0.0" TOTAL_1="201" TOTAL_2="78" WEIGHT="71.64767130997609" Z="4.305009822677222">
<NAME>24 weeks</NAME>
<DICH_DATA CI_END="7.546284507825725" CI_START="2.130810332001786" EFFECT_SIZE="4.009950248756219" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="9" LOG_CI_END="0.8777331748180017" LOG_CI_START="0.328544793951202" LOG_EFFECT_SIZE="0.6031389843846018" MODIFIED="2015-03-12 08:01:44 -0400" MODIFIED_BY="[Empty name]" ORDER="1806" O_E="0.0" SE="0.3225959734474872" STUDY_ID="STD-van-der-Heijde-2005" TOTAL_1="201" TOTAL_2="78" VAR="0.10406816208453185" WEIGHT="71.64767130997609"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="2.630884112293161" CI_END="-1.4923114406955655" CI_START="-2.183664034365246" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.837987737530406" ESTIMABLE="YES" I2="23.97992786323312" I2_Q="61.43490708398742" ID="CMP-002.02" MODIFIED="2015-03-23 08:12:13 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.2683558226571666" P_Q="0.10733599790349257" P_Z="1.982649159255632E-25" Q="2.593018515935666" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="274" TOTAL_2="150" UNITS="" WEIGHT="100.0" Z="10.421280841558625">
<NAME>BASFI</NAME>
<GROUP_LABEL_1>Infliximab</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours infliximab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.037865596357495035" CI_END="-0.6425083837421569" CI_START="-2.0377619576040424" DF="1" EFFECT_SIZE="-1.3401351706730997" ESTIMABLE="YES" I2="0.0" ID="CMP-002.02.01" MODIFIED="2015-03-12 08:01:44 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8457133510025749" P_Z="1.664995816557756E-4" STUDIES="2" TAU2="0.0" TOTAL_1="73" TOTAL_2="72" WEIGHT="24.55234091425298" Z="3.765074274871156">
<NAME>12 weeks</NAME>
<CONT_DATA CI_END="-0.1931550852254953" CI_START="-2.3268449147745054" EFFECT_SIZE="-1.2600000000000002" ESTIMABLE="YES" MEAN_1="3.44" MEAN_2="4.7" MODIFIED="2015-03-12 08:01:44 -0400" MODIFIED_BY="[Empty name]" ORDER="1800" SD_1="2.17" SD_2="2.35" SE="0.544318631969588" STUDY_ID="STD-Braun-2002" TOTAL_1="34" TOTAL_2="35" WEIGHT="10.498726417197325"/>
<CONT_DATA CI_END="-0.4779051792528516" CI_START="-2.3220948207471483" EFFECT_SIZE="-1.4" ESTIMABLE="YES" MEAN_1="-1.8" MEAN_2="-0.4" MODIFIED="2015-03-12 08:01:44 -0400" MODIFIED_BY="[Empty name]" ORDER="2428" SD_1="2.05" SD_2="2.05" SE="0.47046518610572163" STUDY_ID="STD-Inman-2010" TOTAL_1="39" TOTAL_2="37" WEIGHT="14.053614497055655"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.6020333162881892" CI_START="-2.397966683711811" DF="0" EFFECT_SIZE="-2.0" ESTIMABLE="YES" I2="0.0" ID="CMP-002.02.02" MODIFIED="2015-03-12 08:01:44 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="6.8619187309579E-23" STUDIES="1" TAU2="0.0" TOTAL_1="201" TOTAL_2="78" WEIGHT="75.44765908574702" Z="9.849889775996274">
<NAME>24 weeks</NAME>
<CONT_DATA CI_END="-1.6020333162881892" CI_START="-2.397966683711811" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="6.0" MODIFIED="2015-03-12 08:01:44 -0400" MODIFIED_BY="[Empty name]" ORDER="192" SD_1="1.3" SD_2="1.6" SE="0.20304795743744336" STUDY_ID="STD-van-der-Heijde-2005" TOTAL_1="201" TOTAL_2="78" WEIGHT="75.44765908574702"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="5.800169575678739E-7" CI_END="89.14281289465148" CI_START="3.4231640431562655" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="17.468556660662543" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="1.9500863340955803" LOG_CI_START="0.5344277116796522" LOG_EFFECT_SIZE="1.2422570228876162" METHOD="MH" MODIFIED="2015-03-12 08:29:16 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9993923405153173" P_Q="1.0" P_Z="5.821813985727179E-4" Q="0.0" RANDOM="NO" SCALE="179.42" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="235" TOTAL_2="113" WEIGHT="100.00000000000001" Z="3.439782707283687">
<NAME>ASAS partial remission</NAME>
<GROUP_LABEL_1>Infliximab</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours infliximab</GRAPH_LABEL_2>
<DICH_DATA CI_END="291.58972513048724" CI_START="1.048563024450907" EFFECT_SIZE="17.485714285714284" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" LOG_CI_END="2.4647722164986425" LOG_CI_START="0.020594539091928068" LOG_EFFECT_SIZE="1.2426833777952855" MODIFIED="2015-03-12 08:01:44 -0400" MODIFIED_BY="[Empty name]" ORDER="293" O_E="0.0" SE="1.4357220665833355" STUDY_ID="STD-Braun-2002" TOTAL_1="34" TOTAL_2="35" VAR="2.0612978524743233" WEIGHT="25.491424543817057"/>
<DICH_DATA CI_END="124.5072038580985" CI_START="2.4492191029409343" EFFECT_SIZE="17.46268656716418" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="1" LOG_CI_END="2.0951944799884634" LOG_CI_START="0.38902763810220664" LOG_EFFECT_SIZE="1.2421110590453353" MODIFIED="2015-03-12 08:01:44 -0400" MODIFIED_BY="[Empty name]" ORDER="294" O_E="0.0" SE="1.0022108485860646" STUDY_ID="STD-van-der-Heijde-2005" TOTAL_1="201" TOTAL_2="78" VAR="1.0044265850235998" WEIGHT="74.50857545618295"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.028876892845111" CI_END="8.139722825395504" CI_START="0.7501741325299935" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.471074565766007" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" I2="1.4232944811460084" I2_Q="50.62012731957246" ID="CMP-002.04" LOG_CI_END="0.9106096165045882" LOG_CI_START="-0.12483791524950456" LOG_EFFECT_SIZE="0.39288585062754183" METHOD="PETO" MODIFIED="2015-03-12 08:29:16 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.36260612230132816" P_Q="0.1547174467138438" P_Z="0.13691950215448276" Q="2.0251166026119893" RANDOM="NO" SCALE="621.81" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="275" TOTAL_2="147" WEIGHT="100.0" Z="1.4873609596825847">
<NAME>Serious adverse events</NAME>
<GROUP_LABEL_1>Infliximab</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours infliximab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0037602902331217714" CI_END="56.647540168170536" CI_START="1.0749740310899174" DF="1" EFFECT_SIZE="7.80350143242803" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-002.04.01" LOG_CI_END="1.7531810560425924" LOG_CI_START="0.03139797281853018" LOG_EFFECT_SIZE="0.8922895144305614" MODIFIED="2015-03-12 08:01:44 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9511034491630583" P_Z="0.042209697558088094" STUDIES="2" TAU2="0.0" TOTAL_1="73" TOTAL_2="72" WEIGHT="36.165903687349676" Z="2.0314467357779797">
<NAME>12 weeks</NAME>
<DICH_DATA CI_END="80.50798829669249" CI_START="0.8133951638037232" EFFECT_SIZE="8.092268429068355" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.9058389747908584" LOG_CI_START="-0.08969841410453225" LOG_EFFECT_SIZE="0.9080702803431631" MODIFIED="2015-03-12 08:01:44 -0400" MODIFIED_BY="[Empty name]" ORDER="1817" O_E="1.5217391304347827" SE="1.1721885403065389" STUDY_ID="STD-Braun-2002" TOTAL_1="34" TOTAL_2="35" VAR="0.7277882797731569" WEIGHT="26.923806205730397"/>
<DICH_DATA CI_END="354.250375643412" CI_START="0.13909918467159138" EFFECT_SIZE="7.019682216568182" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5493103194410915" LOG_CI_START="-0.8566754156130331" LOG_EFFECT_SIZE="0.8463174519140292" MODIFIED="2015-03-12 08:01:44 -0400" MODIFIED_BY="[Empty name]" ORDER="590" O_E="0.48684210526315785" SE="2.0006928806720943" STUDY_ID="STD-Inman-2010" TOTAL_1="39" TOTAL_2="37" VAR="0.24982686980609417" WEIGHT="9.242097481619277"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.727147785131137" CI_START="0.2896997517290256" DF="0" EFFECT_SIZE="1.288081244125513" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" I2="0.0" ID="CMP-002.04.02" LOG_CI_END="0.7579383899299633" LOG_CI_START="-0.5380518769838819" LOG_EFFECT_SIZE="0.10994325647304067" MODIFIED="2015-03-12 08:01:44 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7394809340145412" STUDIES="1" TAU2="0.0" TOTAL_1="202" TOTAL_2="75" WEIGHT="63.834096312650324" Z="0.3325408045591979">
<NAME>24 weeks</NAME>
<DICH_DATA CI_END="5.727147785131136" CI_START="0.2896997517290256" EFFECT_SIZE="1.288081244125513" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="0.7579383899299632" LOG_CI_START="-0.5380518769838819" LOG_EFFECT_SIZE="0.10994325647304067" MODIFIED="2015-03-12 08:01:44 -0400" MODIFIED_BY="[Empty name]" ORDER="1819" O_E="0.4368231046931408" SE="0.7612710980404778" STUDY_ID="STD-van-der-Heijde-2005" TOTAL_1="202" TOTAL_2="75" VAR="1.725525239309212" WEIGHT="63.834096312650324"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.3148236343748545" CI_END="5.616364840164365" CI_START="0.39240213736363727" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.484544902485095" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="13.60032918706035" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.7494553118930523" LOG_CI_START="-0.4062686357398326" LOG_EFFECT_SIZE="0.1715933380766099" METHOD="MH" MODIFIED="2015-03-12 08:29:16 -0400" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.31429863478214104" P_Q="0.5259214989564527" P_Z="0.560565408735221" Q="0.4022656672755641" RANDOM="NO" SCALE="217.81" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="274" TOTAL_2="150" WEIGHT="100.0" Z="0.5820018929364468">
<NAME>Withdrawals due to adverse events</NAME>
<GROUP_LABEL_1>Infliximab</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours infliximab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.033141234926159" CI_END="10.419243337641104" CI_START="0.3789389674143856" DF="1" EFFECT_SIZE="1.987022222222222" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="50.815025399043726" ID="CMP-002.05.01" LOG_CI_END="1.0178361809386405" LOG_CI_START="-0.4214307326429966" LOG_EFFECT_SIZE="0.298202724147822" MODIFIED="2015-03-12 08:01:44 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.15390264096868045" P_Z="0.4166925880375397" STUDIES="2" TAU2="0.0" TOTAL_1="73" TOTAL_2="72" WEIGHT="58.50391032587726" Z="0.8121726330344246">
<NAME>12 weeks</NAME>
<DICH_DATA CI_END="134.35891873202934" CI_START="0.3858322208099315" EFFECT_SIZE="7.2" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1282665001517445" LOG_CI_START="-0.4136015072892077" LOG_EFFECT_SIZE="0.8573324964312685" MODIFIED="2015-03-12 08:01:44 -0400" MODIFIED_BY="[Empty name]" ORDER="1820" O_E="0.0" SE="1.4931058500203793" STUDY_ID="STD-Braun-2002" TOTAL_1="34" TOTAL_2="35" VAR="2.2293650793650794" WEIGHT="14.196948905746215"/>
<DICH_DATA CI_END="7.536495490286037" CI_START="0.013305624332559893" EFFECT_SIZE="0.31666666666666665" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8771694436095382" LOG_CI_START="-1.8759647424711674" LOG_EFFECT_SIZE="-0.4993976494308147" MODIFIED="2015-03-12 08:01:44 -0400" MODIFIED_BY="[Empty name]" ORDER="678" O_E="0.0" SE="1.617204649137821" STUDY_ID="STD-Inman-2010" TOTAL_1="39" TOTAL_2="37" VAR="2.6153508771929825" WEIGHT="44.306961420131046"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.43783060793147" CI_START="0.07138817495621393" DF="0" EFFECT_SIZE="0.7761194029850746" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-002.05.02" LOG_CI_END="0.9262308025368475" LOG_CI_START="-1.146373720668902" LOG_EFFECT_SIZE="-0.11007145906602726" MODIFIED="2015-03-12 08:01:44 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.835089410790387" STUDIES="1" TAU2="0.0" TOTAL_1="201" TOTAL_2="78" WEIGHT="41.496089674122736" Z="0.20817873654111674">
<NAME>24 weeks</NAME>
<DICH_DATA CI_END="8.43783060793147" CI_START="0.07138817495621393" EFFECT_SIZE="0.7761194029850746" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="0.9262308025368475" LOG_CI_START="-1.146373720668902" LOG_EFFECT_SIZE="-0.11007145906602726" MODIFIED="2015-03-12 08:01:44 -0400" MODIFIED_BY="[Empty name]" ORDER="1822" O_E="0.0" SE="1.217458156488911" STUDY_ID="STD-van-der-Heijde-2005" TOTAL_1="201" TOTAL_2="78" VAR="1.4822043628013777" WEIGHT="41.496089674122736"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.06" MODIFIED="2015-03-23 08:12:41 -0400" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="12.200360925542757" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="194" TOTAL_2="72" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Spinal inflammation (MRI activity score (0-138))</NAME>
<GROUP_LABEL_1>Infliximab</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours infliximab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-3.2461470113539193" CI_START="-5.593852988646081" EFFECT_SIZE="-4.42" ESTIMABLE="YES" MEAN_1="-5.02" MEAN_2="-0.6" MODIFIED="2015-03-12 08:01:44 -0400" MODIFIED_BY="[Empty name]" ORDER="282" SD_1="6.2" SD_2="3.4" SE="0.5989155912584534" STUDY_ID="STD-van-der-Heijde-2005" TOTAL_1="194" TOTAL_2="72" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="72" EVENTS_2="53" I2="0.0" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2015-03-23 08:12:52 -0400" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="194" TOTAL_2="72" WEIGHT="0.0" Z="0.0">
<NAME>Spinal inflammation (MRI Activity score &gt;1)</NAME>
<GROUP_LABEL_1>Infliximab</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours infliximab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6342584698393927" CI_START="0.4007822796347299" EFFECT_SIZE="0.5041820657459638" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="53" LOG_CI_END="-0.19773372453200985" LOG_CI_START="-0.3970914888049465" LOG_EFFECT_SIZE="-0.2974126066684782" MODIFIED="2015-03-12 08:01:44 -0400" MODIFIED_BY="[Empty name]" ORDER="415" O_E="0.0" SE="0.11710373757077167" STUDY_ID="STD-van-der-Heijde-2005" TOTAL_1="194" TOTAL_2="72" VAR="0.013713285353044159" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2015-03-23 08:27:25 -0400" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Golimumab versus placebo</NAME>
<DICH_OUTCOME CHI2="0.03472113178870337" CI_END="4.35335522518678" CI_START="1.8941753494118485" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.871588089330025" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.6388241061751151" LOG_CI_START="0.2774201804523627" LOG_EFFECT_SIZE="0.4581221433137389" METHOD="MH" MODIFIED="2015-03-12 08:34:32 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8521812797717406" P_Q="1.0" P_Z="6.730896495923687E-7" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="246" TOTAL_2="183" WEIGHT="100.0" Z="4.968971488727231">
<NAME>ASAS40</NAME>
<GROUP_LABEL_1>Golimumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours golimumab</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.16113508255515" CI_START="1.454534003619404" EFFECT_SIZE="2.73989898989899" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="11" LOG_CI_END="0.7127452260222029" LOG_CI_START="0.16272387849586914" LOG_EFFECT_SIZE="0.437734552259036" MODIFIED="2015-03-12 08:01:24 -0400" MODIFIED_BY="[Empty name]" ORDER="1105" O_E="0.0" SE="0.3230852621865491" STUDY_ID="STD-Bao-2014" TOTAL_1="108" TOTAL_2="105" VAR="0.10438408664215115" WEIGHT="42.11272598369372"/>
<DICH_DATA CI_END="5.150300800320107" CI_START="1.7096887142148691" EFFECT_SIZE="2.967391304347826" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="12" LOG_CI_END="0.711832594498326" LOG_CI_START="0.2329170448920756" LOG_EFFECT_SIZE="0.4723748196952008" MODIFIED="2015-03-12 08:01:24 -0400" MODIFIED_BY="[Empty name]" ORDER="1098" O_E="0.0" SE="0.28131736450891576" STUDY_ID="STD-Inman-2008" TOTAL_1="138" TOTAL_2="78" VAR="0.07913945957424218" WEIGHT="57.88727401630628"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.2717172142630045" CI_END="-1.0159619436474179" CI_START="-1.9524564280707404" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.4842091858590791" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.02" MODIFIED="2015-03-23 08:27:18 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6021822226486337" P_Q="1.0" P_Z="5.214069593505065E-10" Q="0.0" RANDOM="YES" SCALE="5.778465028628871" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="246" TOTAL_2="183" UNITS="" WEIGHT="100.0" Z="6.212522546993157">
<NAME>BASFI</NAME>
<GROUP_LABEL_1>Golimumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours golimumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.7346543855625868" CI_START="-2.0053456144374135" EFFECT_SIZE="-1.37" ESTIMABLE="YES" MEAN_1="3.74" MEAN_2="5.11" MODIFIED="2015-03-12 08:01:24 -0400" MODIFIED_BY="[Empty name]" ORDER="1103" SD_1="2.35" SD_2="2.38" SE="0.324161882284031" STUDY_ID="STD-Bao-2014" TOTAL_1="108" TOTAL_2="105" WEIGHT="54.316325656368285"/>
<CONT_DATA CI_END="-0.9272209997417745" CI_START="-2.312779000258225" EFFECT_SIZE="-1.6199999999999997" ESTIMABLE="YES" MEAN_1="3.48" MEAN_2="5.1" MODIFIED="2015-03-12 08:01:24 -0400" MODIFIED_BY="[Empty name]" ORDER="1102" SD_1="2.59" SD_2="2.44" SE="0.35346516860655475" STUDY_ID="STD-Inman-2008" TOTAL_1="138" TOTAL_2="78" WEIGHT="45.68367434363172"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="32" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2015-03-23 08:27:18 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="24.69" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="138" TOTAL_2="78" WEIGHT="0.0" Z="0.0">
<NAME>ASAS partial remission</NAME>
<GROUP_LABEL_1>Golimumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours golimumab</GRAPH_LABEL_2>
<DICH_DATA CI_END="12.311790565779589" CI_START="1.6606946531834896" EFFECT_SIZE="4.521739130434782" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="4" LOG_CI_END="1.0903212191609903" LOG_CI_START="0.22028978740138447" LOG_EFFECT_SIZE="0.6553055032811874" MODIFIED="2015-03-12 08:01:24 -0400" MODIFIED_BY="[Empty name]" ORDER="1098" O_E="0.0" SE="0.5110607697406376" STUDY_ID="STD-Inman-2008" TOTAL_1="138" TOTAL_2="78" VAR="0.261183110367893" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.04" MODIFIED="2015-03-23 08:27:14 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="40.9" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="37" TOTAL_2="23" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>ASspiMRI-a change from baseline (spinal inflammation, score 0-138))</NAME>
<GROUP_LABEL_1>Golimumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours golimumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.8969033295782252" CI_START="-7.696903329578226" EFFECT_SIZE="-3.4000000000000004" ESTIMABLE="YES" MEAN_1="-5.9" MEAN_2="-2.5" MODIFIED="2015-03-12 08:01:24 -0400" MODIFIED_BY="[Empty name]" ORDER="417" SD_1="7.1" SD_2="8.9" SE="2.192337901855162" STUDY_ID="STD-Inman-2008" TOTAL_1="37" TOTAL_2="23" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.18920705448763284" CI_END="7.545951821915936" CI_START="0.35005636451119904" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.6252718115923108" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="0.8777140280657649" LOG_CI_START="-0.4558620218630102" LOG_EFFECT_SIZE="0.21092600310137744" METHOD="PETO" MODIFIED="2015-03-23 08:27:01 -0400" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.6635774075810349" P_Q="1.0" P_Z="0.5352589811841129" Q="0.0" RANDOM="NO" SCALE="23.881710280672817" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="246" TOTAL_2="183" WEIGHT="100.0" Z="0.6199981913348896">
<NAME>Withdrawals due to adverse events</NAME>
<GROUP_LABEL_1>Golimumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours golimumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="15.647882985486957" CI_START="0.060388783221392614" EFFECT_SIZE="0.9720887888893124" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1944555898114118" LOG_CI_START="-1.2190437209391023" LOG_EFFECT_SIZE="-0.012294065563845139" MODIFIED="2015-03-12 08:01:24 -0400" MODIFIED_BY="[Empty name]" ORDER="1117" O_E="-0.014084507042253502" SE="1.417701442149119" STUDY_ID="STD-Bao-2014" TOTAL_1="108" TOTAL_2="105" VAR="0.4975427906262983" WEIGHT="30.531013149654097"/>
<DICH_DATA CI_END="12.853859592995482" CI_START="0.32286799502892505" EFFECT_SIZE="2.037179391996141" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.1090335516565095" LOG_CI_START="-0.4909750032058835" LOG_EFFECT_SIZE="0.309029274225313" MODIFIED="2015-03-12 08:01:24 -0400" MODIFIED_BY="[Empty name]" ORDER="1115" O_E="0.8055555555555554" SE="0.9398529452962511" STUDY_ID="STD-Inman-2008" TOTAL_1="138" TOTAL_2="78" VAR="1.1320879988515649" WEIGHT="69.4689868503459"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2015-03-23 08:27:25 -0400" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="138" TOTAL_2="78" WEIGHT="0.0" Z="0.0">
<NAME>Serious adverse event</NAME>
<GROUP_LABEL_1>Golimumab</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours golimumab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.748464779224724" CI_START="0.17180938022537912" EFFECT_SIZE="0.6871768551762226" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.4390901759801709" LOG_CI_START="-0.7649531288114607" LOG_EFFECT_SIZE="-0.1629314764156449" MODIFIED="2015-03-12 08:01:24 -0400" MODIFIED_BY="[Empty name]" ORDER="1101" O_E="-0.75" SE="0.7072609973450865" STUDY_ID="STD-Inman-2008" TOTAL_1="138" TOTAL_2="78" VAR="1.999127906976744" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2015-03-23 08:28:09 -0400" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Etanercept (25 mg twice weekly or 50mg once weekly) versus placebo</NAME>
<DICH_OUTCOME CHI2="2.7201327426155153" CI_END="3.9083591089959806" CI_START="2.038495426568779" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="2.8226179637132502" ESTIMABLE="YES" EVENTS_1="235" EVENTS_2="34" I2="0.0" I2_Q="25.352644695704623" ID="CMP-004.01" LOG_CI_END="0.5919944608528253" LOG_CI_START="0.30930974143538154" LOG_EFFECT_SIZE="0.45065210114410337" METHOD="MH" MODIFIED="2015-03-23 08:28:09 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.43681685312555885" P_Q="0.24709899578689176" P_Z="4.128367487156854E-10" Q="1.3396321891426175" RANDOM="NO" SCALE="184.66597654949342" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="418" TOTAL_2="172" WEIGHT="100.0" Z="6.2490953852756475">
<NAME>ASAS 40</NAME>
<GROUP_LABEL_1>Etanercept</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.2687213323297948" CI_END="4.47538501318161" CI_START="2.113773525665099" DF="2" EFFECT_SIZE="3.075703229835681" ESTIMABLE="YES" EVENTS_1="217" EVENTS_2="24" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="0.650830403206703" LOG_CI_START="0.3250584541999692" LOG_EFFECT_SIZE="0.48794442870333615" MODIFIED="2015-03-12 08:00:42 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5302744282784707" P_Z="4.323736366409449E-9" STUDIES="2" TAU2="0.0" TOTAL_1="379" TOTAL_2="129" WEIGHT="76.80431807291087" Z="5.87130665873103">
<NAME>6-12 weeks</NAME>
<DICH_DATA CI_END="6.44474190331354" CI_START="2.253353082817168" EFFECT_SIZE="3.810810810810811" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="13" LOG_CI_END="0.8092055295697684" LOG_CI_START="0.35282924760700135" LOG_EFFECT_SIZE="0.5810173885883849" MODIFIED="2015-03-12 08:00:42 -0400" MODIFIED_BY="[Empty name]" ORDER="1535" O_E="0.0" SE="0.26807768712395935" STUDY_ID="STD-Huang-2008" TOTAL_1="74" TOTAL_2="78" VAR="0.07186564633373145" WEIGHT="30.866534634556313"/>
<DICH_DATA CI_END="6.43107493013359" CI_START="1.3106238342446945" EFFECT_SIZE="2.903225806451613" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="5" LOG_CI_END="0.8082835696906779" LOG_CI_START="0.11747806151942644" LOG_EFFECT_SIZE="0.46288081560505223" MODIFIED="2015-03-12 08:00:42 -0400" MODIFIED_BY="[Empty name]" ORDER="166" O_E="0.0" SE="0.40578257504220816" STUDY_ID="STD-van-der-Heijde-2006b" TOTAL_1="155" TOTAL_2="25" VAR="0.1646594982078853" WEIGHT="20.998370177585663"/>
<DICH_DATA CI_END="4.736488263004619" CI_START="1.1276782019328788" EFFECT_SIZE="2.311111111111111" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="6" LOG_CI_END="0.6754564654628822" LOG_CI_START="0.05218518558399104" LOG_EFFECT_SIZE="0.36382082552343664" MODIFIED="2015-03-12 08:00:42 -0400" MODIFIED_BY="[Empty name]" ORDER="143" O_E="0.0" SE="0.36611263504345426" STUDY_ID="STD-van-der-Heijde-2006b" TOTAL_1="150" TOTAL_2="26" VAR="0.13403846153846155" WEIGHT="24.939413260768898"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.1556441058769654E-31" CI_END="3.764152868548651" CI_START="1.046370421818368" DF="0" EFFECT_SIZE="1.984615384615385" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="10" I2="100.0" ID="CMP-004.01.02" LOG_CI_END="0.5756672525392292" LOG_CI_START="0.0196854547735576" LOG_EFFECT_SIZE="0.29767635365639344" MODIFIED="2015-03-12 08:51:27 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.03583845810352745" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="43" WEIGHT="23.195681927089122" Z="2.0987555152359074">
<NAME>Advanced AS</NAME>
<DICH_DATA CI_END="3.764152868548651" CI_START="1.046370421818368" EFFECT_SIZE="1.9846153846153847" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="10" LOG_CI_END="0.5756672525392292" LOG_CI_START="0.0196854547735576" LOG_EFFECT_SIZE="0.2976763536563934" MODIFIED="2015-03-12 08:51:27 -0400" MODIFIED_BY="[Empty name]" ORDER="1021" O_E="0.0" SE="0.3265864601618407" STUDY_ID="STD-Dougados-2011" TOTAL_1="39" TOTAL_2="43" VAR="0.10665871596104155" WEIGHT="23.195681927089122"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="6.567517389233716" CI_END="-0.9524177875289326" CI_START="-1.7454128123035832" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.348915299916258" ESTIMABLE="YES" I2="23.867731082119153" I2_Q="38.74494582078657" ID="CMP-004.02" MODIFIED="2015-03-23 08:28:09 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.25484168187534784" P_Q="0.1629054224009825" P_Z="2.5940192901335223E-11" Q="6.530073401449016" RANDOM="NO" SCALE="8.39" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="276" TOTAL_2="277" UNITS="" WEIGHT="99.99999999999997" Z="6.667949541757137">
<NAME>BASFI (0-10 scale, none to severe limitations)</NAME>
<GROUP_LABEL_1>Etanercept</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.8835818453050441" CI_START="-2.483581845305044" DF="0" EFFECT_SIZE="-0.7999999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-004.02.01" MODIFIED="2015-03-12 08:00:42 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.35168262038066544" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="16" WEIGHT="5.546416331048528" Z="0.9313305391149228">
<NAME>6 weeks</NAME>
<CONT_DATA CI_END="0.8835818453050441" CI_START="-2.483581845305044" EFFECT_SIZE="-0.7999999999999998" ESTIMABLE="YES" MEAN_1="4.3" MEAN_2="5.1" MODIFIED="2015-03-12 08:00:42 -0400" MODIFIED_BY="[Empty name]" ORDER="1742" SD_1="2.3" SD_2="2.4" SE="0.8589861133086744" STUDY_ID="STD-Brandt-2003" TOTAL_1="14" TOTAL_2="16" WEIGHT="5.546416331048528"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.03744398778469914" CI_END="-0.5443910969622973" CI_START="-2.1631801093711767" DF="1" EFFECT_SIZE="-1.353785603166737" ESTIMABLE="YES" I2="0.0" ID="CMP-004.02.02" MODIFIED="2015-03-12 08:00:42 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8465639658066578" P_Z="0.0010446496556645853" STUDIES="2" TAU2="0.0" TOTAL_1="65" TOTAL_2="59" WEIGHT="23.997192165194072" Z="3.278217240982163">
<NAME>12 weeks</NAME>
<CONT_DATA CI_END="-0.0972600087892832" CI_START="-2.4427399912107157" EFFECT_SIZE="-1.2699999999999996" ESTIMABLE="YES" MEAN_1="4.23" MEAN_2="5.5" MODIFIED="2015-03-12 08:00:42 -0400" MODIFIED_BY="[Empty name]" ORDER="333" SD_1="1.98" SD_2="1.8" SE="0.5983477249894078" STUDY_ID="STD-Barkham-2010" TOTAL_1="20" TOTAL_2="20" WEIGHT="11.430822041013528"/>
<CONT_DATA CI_END="-0.3115011462276267" CI_START="-2.5484988537723727" EFFECT_SIZE="-1.4299999999999997" ESTIMABLE="YES" MEAN_1="3.96" MEAN_2="5.39" MODIFIED="2015-03-12 08:00:42 -0400" MODIFIED_BY="[Empty name]" ORDER="1743" SD_1="2.83" SD_2="2.4" SE="0.5706731667494654" STUDY_ID="STD-Calin-2004" TOTAL_1="45" TOTAL_2="39" WEIGHT="12.566370124180544"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7048981709988369" CI_START="-2.5048981709988367" DF="0" EFFECT_SIZE="-0.8999999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-004.02.03" MODIFIED="2015-03-12 08:00:42 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.2717179434846364" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="6.103598668342526" Z="1.0991149581709674">
<NAME>16 weeks</NAME>
<CONT_DATA CI_END="0.7048981709988369" CI_START="-2.5048981709988367" EFFECT_SIZE="-0.8999999999999999" ESTIMABLE="YES" MEAN_1="2.2" MEAN_2="3.1" MODIFIED="2015-03-12 08:00:42 -0400" MODIFIED_BY="[Empty name]" ORDER="1744" SD_1="2.1" SD_2="3.0" SE="0.8188406438373709" STUDY_ID="STD-Gorman-2002" TOTAL_1="20" TOTAL_2="20" WEIGHT="6.103598668342526"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.2611653522118171" CI_START="-2.478834647788182" DF="0" EFFECT_SIZE="-1.8699999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-004.02.04" MODIFIED="2015-03-12 08:00:42 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="1.7450900051039968E-9" STUDIES="1" TAU2="0.0" TOTAL_1="138" TOTAL_2="139" WEIGHT="42.41136153886962" Z="6.0199147082132285">
<NAME>24 weeks</NAME>
<CONT_DATA CI_END="-1.2611653522118171" CI_START="-2.478834647788182" EFFECT_SIZE="-1.8699999999999997" ESTIMABLE="YES" MEAN_1="3.6" MEAN_2="5.47" MODIFIED="2015-03-12 08:00:42 -0400" MODIFIED_BY="[Empty name]" ORDER="1745" SD_1="2.58" SD_2="2.59" SE="0.3106356303435127" STUDY_ID="STD-Davis-2003" TOTAL_1="138" TOTAL_2="139" WEIGHT="42.41136153886962"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.24646302040695578" CI_START="-1.4464630204069568" DF="0" EFFECT_SIZE="-0.6000000000000005" ESTIMABLE="YES" I2="0.0" ID="CMP-004.02.05" MODIFIED="2015-03-12 08:00:42 -0400" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.16474609849486707" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="43" WEIGHT="21.941431296545236" Z="1.3892850158517915">
<NAME>Advanced AS</NAME>
<CONT_DATA CI_END="0.24646302040695578" CI_START="-1.4464630204069568" EFFECT_SIZE="-0.6000000000000005" ESTIMABLE="YES" MEAN_1="4.1" MEAN_2="4.7" MODIFIED="2015-03-12 08:00:42 -0400" MODIFIED_BY="[Empty name]" ORDER="1029" SD_1="2.0" SD_2="1.9" SE="0.431876823800717" STUDY_ID="STD-Dougados-2011" TOTAL_1="39" TOTAL_2="43" WEIGHT="21.941431296545236"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.26744954332498794" CI_END="7.197751097237225" CI_START="2.2124770591356375" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="3.9905963439072267" ESTIMABLE="YES" EVENTS_1="118" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.8571968244000523" LOG_CI_START="0.3448787762546289" LOG_EFFECT_SIZE="0.6010378003273407" METHOD="MH" MODIFIED="2015-03-12 08:34:29 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9660293915956445" P_Q="1.0" P_Z="4.250244568868205E-6" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="517" TOTAL_2="268" WEIGHT="100.0" Z="4.598754411456459">
<NAME>ASAS Partial remission</NAME>
<GROUP_LABEL_1>Etanercept</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept</GRAPH_LABEL_2>
<DICH_DATA CI_END="9.550088804455024" CI_START="1.699745892418187" EFFECT_SIZE="4.028985507246377" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="6" LOG_CI_END="0.9800074100241097" LOG_CI_START="0.23038400033753215" LOG_EFFECT_SIZE="0.605195705180821" MODIFIED="2015-03-12 08:00:42 -0400" MODIFIED_BY="[Empty name]" ORDER="290" O_E="0.0" SE="0.440332501545619" STUDY_ID="STD-Davis-2003" TOTAL_1="138" TOTAL_2="139" VAR="0.19389271191742255" WEIGHT="39.821677497747196"/>
<DICH_DATA CI_END="9.367286155237512" CI_START="1.0674670736111984" EFFECT_SIZE="3.1621621621621623" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="4" LOG_CI_END="0.9716137874172471" LOG_CI_START="0.028354487941086207" LOG_EFFECT_SIZE="0.49998413767916666" MODIFIED="2015-03-12 08:00:42 -0400" MODIFIED_BY="[Empty name]" ORDER="611" O_E="0.0" SE="0.5540751817211333" STUDY_ID="STD-Huang-2008" TOTAL_1="74" TOTAL_2="78" VAR="0.30699930699930694" WEIGHT="25.94281545095417"/>
<DICH_DATA CI_END="37.29180808758506" CI_START="0.7627531595582243" EFFECT_SIZE="5.333333333333333" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="1" LOG_CI_END="1.5716134405730129" LOG_CI_START="-0.11761598470048806" LOG_EFFECT_SIZE="0.7269987279362623" MODIFIED="2015-03-12 08:00:42 -0400" MODIFIED_BY="[Empty name]" ORDER="291" O_E="0.0" SE="0.9922617262261673" STUDY_ID="STD-van-der-Heijde-2006b" TOTAL_1="150" TOTAL_2="25" VAR="0.9845833333333334" WEIGHT="11.418845410844693"/>
<DICH_DATA CI_END="16.19143966438161" CI_START="1.086120100463198" EFFECT_SIZE="4.193548387096774" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="2" LOG_CI_END="1.2092854658317753" LOG_CI_START="0.03587785111335301" LOG_EFFECT_SIZE="0.6225816584725641" MODIFIED="2015-03-12 08:00:42 -0400" MODIFIED_BY="[Empty name]" ORDER="292" O_E="0.0" SE="0.6892654413469718" STUDY_ID="STD-van-der-Heijde-2006b" TOTAL_1="155" TOTAL_2="26" VAR="0.47508684863523576" WEIGHT="22.816661640453944"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.21794177916215673" CI_END="11.43843870292556" CI_START="1.553085245409243" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="4.21483930654915" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="1.0583667491966697" LOG_CI_START="0.1911952938449823" LOG_EFFECT_SIZE="0.624781021520826" METHOD="PETO" MODIFIED="2015-03-12 09:04:14 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.8967565241946923" P_Q="0.896756524194692" P_Z="0.004739351498861607" Q="0.21794177916215757" RANDOM="NO" SCALE="99.19" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="655" TOTAL_2="406" WEIGHT="100.0" Z="2.8242357214314424">
<NAME>Withdrawals due to adverse events</NAME>
<GROUP_LABEL_1>Etanercept</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-03-12 08:00:42 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="88" TOTAL_2="94" WEIGHT="0.0" Z="0.0">
<NAME>6 weeks</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-03-12 08:00:42 -0400" MODIFIED_BY="[Empty name]" ORDER="1778" O_E="0.0" SE="0.0" STUDY_ID="STD-Brandt-2003" TOTAL_1="14" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-03-12 08:00:42 -0400" MODIFIED_BY="[Empty name]" ORDER="1537" O_E="0.0" SE="0.0" STUDY_ID="STD-Huang-2008" TOTAL_1="74" TOTAL_2="78" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.40870460101958" CI_START="0.7321492780078993" DF="0" EFFECT_SIZE="3.3587902507708756" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="0" I2="0.0" ID="CMP-004.04.02" LOG_CI_END="1.1877661294207915" LOG_CI_START="-0.13540036155705917" LOG_EFFECT_SIZE="0.5261828839318662" MODIFIED="2015-03-12 08:00:42 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.11903530077850753" STUDIES="3" TAU2="0.0" TOTAL_1="370" TOTAL_2="110" WEIGHT="42.95175955390054" Z="1.5588355793770488">
<NAME>12 weeks</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-03-12 08:00:42 -0400" MODIFIED_BY="[Empty name]" ORDER="338" O_E="0.0" SE="0.0" STUDY_ID="STD-Barkham-2010" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-03-12 08:00:42 -0400" MODIFIED_BY="[Empty name]" ORDER="1779" O_E="0.0" SE="0.0" STUDY_ID="STD-Calin-2004" TOTAL_1="45" TOTAL_2="39" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="15.40870460101958" CI_START="0.7321492780078993" EFFECT_SIZE="3.3587902507708756" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="0" LOG_CI_END="1.1877661294207915" LOG_CI_START="-0.13540036155705917" LOG_EFFECT_SIZE="0.5261828839318662" MODIFIED="2015-03-12 08:00:42 -0400" MODIFIED_BY="[Empty name]" ORDER="150" O_E="2.0056179775280896" SE="0.7772345465801533" STUDY_ID="STD-van-der-Heijde-2006b" TOTAL_1="305" TOTAL_2="51" VAR="1.655372774457628" WEIGHT="42.95175955390054"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.04.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-03-12 08:00:42 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>16 weeks</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-03-12 08:00:42 -0400" MODIFIED_BY="[Empty name]" ORDER="1780" O_E="0.0" SE="0.0" STUDY_ID="STD-Gorman-2002" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="19.11151600758696" CI_START="1.1533057051885918" DF="0" EFFECT_SIZE="4.694829117907609" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" I2="0.0" ID="CMP-004.04.04" LOG_CI_END="1.2812951385262603" LOG_CI_START="0.06194444040734187" LOG_EFFECT_SIZE="0.6716197894668011" MODIFIED="2015-03-12 08:00:42 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.030842339374480054" STUDIES="1" TAU2="0.0" TOTAL_1="138" TOTAL_2="139" WEIGHT="50.57695570628809" Z="2.159100906228251">
<NAME>24 weeks</NAME>
<DICH_DATA CI_END="19.11151600758696" CI_START="1.1533057051885915" EFFECT_SIZE="4.694829117907609" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.2812951385262603" LOG_CI_START="0.06194444040734179" LOG_EFFECT_SIZE="0.6716197894668011" MODIFIED="2015-03-12 08:00:42 -0400" MODIFIED_BY="[Empty name]" ORDER="1781" O_E="3.0144404332129966" SE="0.716252635958354" STUDY_ID="STD-Davis-2003" TOTAL_1="138" TOTAL_2="139" VAR="1.9492499576431335" WEIGHT="50.57695570628809"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="414.5378214174319" CI_START="0.16169620029420947" DF="0" EFFECT_SIZE="8.187135677478315" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-004.04.05" LOG_CI_END="2.617564160660836" LOG_CI_START="-0.7913001854779309" LOG_EFFECT_SIZE="0.9131319875914525" MODIFIED="2015-03-12 09:04:14 -0400" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.29370409415716536" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="43" WEIGHT="6.471284739811383" Z="1.0500305245868344">
<NAME>Advanced AS</NAME>
<DICH_DATA CI_END="414.5378214174319" CI_START="0.16169620029420947" EFFECT_SIZE="8.187135677478315" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.617564160660836" LOG_CI_START="-0.7913001854779309" LOG_EFFECT_SIZE="0.9131319875914525" MODIFIED="2015-03-12 09:04:14 -0400" MODIFIED_BY="[Empty name]" ORDER="681" O_E="0.524390243902439" SE="2.002383791072568" STUDY_ID="STD-Dougados-2011" TOTAL_1="39" TOTAL_2="43" VAR="0.24940511600237955" WEIGHT="6.471284739811383"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7427513333600609" CI_END="3.8232018104020153" CI_START="0.8137591058922717" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.763849564696054" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-004.05" LOG_CI_END="0.5824272231643955" LOG_CI_START="-0.08950413867980041" LOG_EFFECT_SIZE="0.2464615422422976" METHOD="PETO" MODIFIED="2015-03-12 08:34:29 -0400" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.9459540466778809" P_Q="0.9626816549436058" P_Z="0.15048718501601327" Q="0.07606499777264988" RANDOM="NO" SCALE="90.69847717330204" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="655" TOTAL_2="406" WEIGHT="100.0" Z="1.4378127701713348">
<NAME>Serious adverse events</NAME>
<GROUP_LABEL_1>Etanercept</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.05.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-03-12 08:00:42 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="88" TOTAL_2="94" WEIGHT="0.0" Z="0.0">
<NAME>6 weeks</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-03-12 08:00:42 -0400" MODIFIED_BY="[Empty name]" ORDER="1774" O_E="0.0" SE="0.0" STUDY_ID="STD-Brandt-2003" TOTAL_1="14" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-03-12 08:00:42 -0400" MODIFIED_BY="[Empty name]" ORDER="1538" O_E="0.0" SE="0.0" STUDY_ID="STD-Huang-2008" TOTAL_1="74" TOTAL_2="78" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6666863355874109" CI_END="5.5901014476349955" CI_START="0.43441208415192467" DF="2" EFFECT_SIZE="1.558334887143264" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="2" I2="0.0" ID="CMP-004.05.02" LOG_CI_END="0.7474196894156363" LOG_CI_START="-0.362098102370625" LOG_EFFECT_SIZE="0.19266079352250565" MODIFIED="2015-03-12 08:00:42 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7165243317418124" P_Z="0.49607978130166586" STUDIES="3" TAU2="0.0" TOTAL_1="370" TOTAL_2="110" WEIGHT="36.6759424180064" Z="0.6806708632028169">
<NAME>12 weeks</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-03-12 08:00:42 -0400" MODIFIED_BY="[Empty name]" ORDER="339" O_E="0.0" SE="0.0" STUDY_ID="STD-Barkham-2010" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="329.18927194638593" CI_START="0.12703412260494568" EFFECT_SIZE="6.466704750695673" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.517445673410207" LOG_CI_START="-0.8960796076380664" LOG_EFFECT_SIZE="0.8106830328860702" MODIFIED="2015-03-12 08:00:42 -0400" MODIFIED_BY="[Empty name]" ORDER="1775" O_E="0.4642857142857143" SE="2.005121647310412" STUDY_ID="STD-Calin-2004" TOTAL_1="45" TOTAL_2="39" VAR="0.24872448979591835" WEIGHT="3.8747490147584034"/>
<DICH_DATA CI_END="8.914663513688936" CI_START="0.2780852970951779" EFFECT_SIZE="1.5744957452174106" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" LOG_CI_END="0.9501049552616783" LOG_CI_START="-0.5558219725138813" LOG_EFFECT_SIZE="0.1971414913738984" MODIFIED="2015-03-12 08:00:42 -0400" MODIFIED_BY="[Empty name]" ORDER="622" O_E="0.5801104972375697" SE="0.8845889318338802" STUDY_ID="STD-van-der-Heijde-2006b" TOTAL_1="155" TOTAL_2="26" VAR="1.2779592265871684" WEIGHT="19.90865981143648"/>
<DICH_DATA CI_END="8.623362157815846" CI_START="0.1159640499493162" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="0.9356766256736623" LOG_CI_START="-0.9356766256736623" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-03-12 08:00:42 -0400" MODIFIED_BY="[Empty name]" ORDER="614" O_E="0.0" SE="1.09924216318941" STUDY_ID="STD-van-der-Heijde-2006b" TOTAL_1="150" TOTAL_2="25" VAR="0.8275862068965516" WEIGHT="12.892533591811514"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.05.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-03-12 08:00:42 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>16 weeks</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-03-12 08:00:42 -0400" MODIFIED_BY="[Empty name]" ORDER="1776" O_E="0.0" SE="0.0" STUDY_ID="STD-Gorman-2002" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.3681910859448125" CI_START="0.6275243723237728" DF="0" EFFECT_SIZE="1.83539389279838" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" I2="0.0" ID="CMP-004.05.04" LOG_CI_END="0.7298279665674879" LOG_CI_START="-0.20236940202194742" LOG_EFFECT_SIZE="0.26372928227277026" MODIFIED="2015-03-12 08:00:42 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.2674334816526728" STUDIES="1" TAU2="0.0" TOTAL_1="138" TOTAL_2="139" WEIGHT="51.955805038250574" Z="1.1089923922556877">
<NAME>24 weeks</NAME>
<DICH_DATA CI_END="5.368191085944812" CI_START="0.6275243723237729" EFFECT_SIZE="1.83539389279838" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.7298279665674878" LOG_CI_START="-0.20236940202194734" LOG_EFFECT_SIZE="0.26372928227277026" MODIFIED="2015-03-12 08:00:42 -0400" MODIFIED_BY="[Empty name]" ORDER="1777" O_E="2.025270758122744" SE="0.5475773487608296" STUDY_ID="STD-Davis-2003" TOTAL_1="138" TOTAL_2="139" VAR="3.335101460986068" WEIGHT="51.955805038250574"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="21.754393100029013" CI_START="0.22114705790829703" DF="0" EFFECT_SIZE="2.19338095885142" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-004.05.05" LOG_CI_END="1.3375469719318849" LOG_CI_START="-0.6553188340139847" LOG_EFFECT_SIZE="0.3411140689589501" MODIFIED="2015-03-12 08:00:42 -0400" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.5022430308914014" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="43" WEIGHT="11.36825254374302" Z="0.6709646859158507">
<NAME>Advanced AS</NAME>
<DICH_DATA CI_END="21.754393100029013" CI_START="0.22114705790829703" EFFECT_SIZE="2.19338095885142" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3375469719318849" LOG_CI_START="-0.6553188340139847" LOG_EFFECT_SIZE="0.3411140689589501" MODIFIED="2015-03-12 08:00:42 -0400" MODIFIED_BY="[Empty name]" ORDER="1027" O_E="0.5731707317073171" SE="1.1706192392574415" STUDY_ID="STD-Dougados-2011" TOTAL_1="39" TOTAL_2="43" VAR="0.7297408949699253" WEIGHT="11.36825254374302"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2015-03-23 08:30:33 -0400" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Etanercept versus infliximab</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2015-03-23 08:30:17 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="15.51" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>ASAS40 - 12 weeks</NAME>
<GROUP_LABEL_1>Etanercept</GROUP_LABEL_1>
<GROUP_LABEL_2>Infliximab</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours infliximab</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3788372780445863" CI_START="0.44773009013145315" EFFECT_SIZE="0.7857142857142857" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" LOG_CI_END="0.13951301641723254" LOG_CI_START="-0.34898371745725854" LOG_EFFECT_SIZE="-0.104735350520013" MODIFIED="2010-07-04 18:18:12 -0400" MODIFIED_BY="[Empty name]" ORDER="261" O_E="0.0" SE="0.2869453995757073" STUDY_ID="STD-Giardina-2009" TOTAL_1="25" TOTAL_2="25" VAR="0.08233766233766232" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.0571264423020015" CI_START="0.9428735576979982" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.4999999999999998" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-005.02" MODIFIED="2015-03-23 08:30:33 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="1.313290774860013E-7" Q="0.0" RANDOM="YES" SCALE="4.3" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="SUB" TOTAL_1="25" TOTAL_2="25" UNITS="" WEIGHT="0.0" Z="5.276981585477188">
<NAME>BASFI - 12 weeks</NAME>
<GROUP_LABEL_1>Etanercept</GROUP_LABEL_1>
<GROUP_LABEL_2>Infliximab</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours infliximab</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.0571264423020015" CI_START="0.9428735576979984" EFFECT_SIZE="1.5" ESTIMABLE="YES" MEAN_1="5.0" MEAN_2="3.5" MODIFIED="2014-11-14 09:19:32 -0500" MODIFIED_BY="[Empty name]" ORDER="383" SD_1="1.1" SD_2="0.9" SE="0.28425340807103794" STUDY_ID="STD-Giardina-2009" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2015-03-23 08:32:15 -0400" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Etanercept versus sulphasalazine</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="227" EVENTS_2="61" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2015-03-23 08:31:01 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="3.12" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="379" TOTAL_2="187" WEIGHT="0.0" Z="0.0">
<NAME>ASAS40 - 16-week</NAME>
<GROUP_LABEL_1>Etanercept</GROUP_LABEL_1>
<GROUP_LABEL_2>Sulphasalazine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sulphsalazine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours etanercept</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.292177873836768" CI_START="1.4707827292150837" EFFECT_SIZE="1.8361088282365154" ESTIMABLE="YES" EVENTS_1="227" EVENTS_2="61" LOG_CI_END="0.3602483160128071" LOG_CI_START="0.16754852148875748" LOG_EFFECT_SIZE="0.2638984187507823" MODIFIED="2014-10-08 06:34:01 -0400" MODIFIED_BY="[Empty name]" ORDER="137" O_E="0.0" SE="0.11319281318279364" STUDY_ID="STD-Braun-2011" TOTAL_1="379" TOTAL_2="187" VAR="0.012812612956234821" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-006.02" MODIFIED="2015-03-23 08:31:40 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="20.4486086980294" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="379" TOTAL_2="187" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>BASFI</NAME>
<GROUP_LABEL_1>Etanercept</GROUP_LABEL_1>
<GROUP_LABEL_2>Sulphasalazine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours sulphasalazine</GRAPH_LABEL_2>
<CONT_DATA CI_END="-6.0434486887293" CI_START="-15.216551311270706" EFFECT_SIZE="-10.630000000000003" ESTIMABLE="YES" MEAN_1="28.72" MEAN_2="39.35" MODIFIED="2014-10-08 06:03:18 -0400" MODIFIED_BY="[Empty name]" ORDER="342" SD_1="25.58" SD_2="26.48" SE="2.3401201998857295" STUDY_ID="STD-Braun-2011" TOTAL_1="379" TOTAL_2="187" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="126" EVENTS_2="29" I2="0.0" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2015-03-23 08:31:54 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.06" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="379" TOTAL_2="187" WEIGHT="0.0" Z="0.0">
<NAME>ASAS Partial remission</NAME>
<GROUP_LABEL_1>Etanercept</GROUP_LABEL_1>
<GROUP_LABEL_2>Sulphasalazine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours sulphasalazine</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.084078068883726" CI_START="1.490131256858739" EFFECT_SIZE="2.143753980529524" ESTIMABLE="YES" EVENTS_1="126" EVENTS_2="29" LOG_CI_END="0.48912536304178605" LOG_CI_START="0.17322452453228082" LOG_EFFECT_SIZE="0.33117494378703344" MODIFIED="2014-10-08 06:31:20 -0400" MODIFIED_BY="[Empty name]" ORDER="346" O_E="0.0" SE="0.18556171627485357" STUDY_ID="STD-Braun-2011" TOTAL_1="379" TOTAL_2="187" VAR="0.034433150546869254" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="15" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-006.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2015-03-23 08:32:00 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="379" TOTAL_2="187" WEIGHT="0.0" Z="0.0">
<NAME>Withdrawals due to adverse events</NAME>
<GROUP_LABEL_1>Etanercept</GROUP_LABEL_1>
<GROUP_LABEL_2>Sulphasalazine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours sulphasalazine</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.323973930578778" CI_START="0.25628336211154873" EFFECT_SIZE="0.5825053564361202" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" LOG_CI_END="0.12187943380666669" LOG_CI_START="-0.5912795872519131" LOG_EFFECT_SIZE="-0.23470007672262322" MODIFIED="2014-10-08 06:43:53 -0400" MODIFIED_BY="[Empty name]" ORDER="348" O_E="-3.0795053003533575" SE="0.4189131391638982" STUDY_ID="STD-Braun-2011" TOTAL_1="379" TOTAL_2="187" VAR="5.6983882477204295" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-006.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2015-03-23 08:32:15 -0400" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="379" TOTAL_2="187" WEIGHT="0.0" Z="0.0">
<NAME>Serious adverse events</NAME>
<GROUP_LABEL_1>Etanercept</GROUP_LABEL_1>
<GROUP_LABEL_2>Sulphasalazine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours etanercept</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours sulphasalazine</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.0485800487621684" CI_START="0.2415545535275988" EFFECT_SIZE="0.8581365815369316" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.484097603090682" LOG_CI_START="-0.6169847712461027" LOG_EFFECT_SIZE="-0.06644358407771037" MODIFIED="2014-10-08 06:41:33 -0400" MODIFIED_BY="[Empty name]" ORDER="347" O_E="-0.36572438162544163" SE="0.6467812371310839" STUDY_ID="STD-Braun-2011" TOTAL_1="379" TOTAL_2="187" VAR="2.3904803306763704" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2015-03-23 08:36:50 -0400" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Infliximab + methotrexate versus placebo + methotrexate</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-007.01" MODIFIED="2015-03-23 08:36:50 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.053620246695907" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="28" TOTAL_2="14" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>BASDAI</NAME>
<GROUP_LABEL_1>Infliximab + MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo + MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Infliximab + MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo + MTX</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.4776574013531494" CI_START="-2.7576574013531507" EFFECT_SIZE="-1.1400000000000006" ESTIMABLE="YES" MEAN_1="4.6" MEAN_2="5.74" MODIFIED="2015-03-23 08:36:36 -0400" MODIFIED_BY="[Empty name]" ORDER="353" SD_1="2.85" SD_2="2.34" SE="0.825350574864143" STUDY_ID="STD-Marzo_x002d_Ortega-2005" TOTAL_1="28" TOTAL_2="14" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.797438666263349" CI_START="0.8009552879772192" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.3333333333333335" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-007.02" LOG_CI_END="0.8323452976095113" LOG_CI_START="-0.0963917270203224" LOG_EFFECT_SIZE="0.36797678529459443" METHOD="MH" MODIFIED="2015-03-23 08:36:50 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.12039384005544622" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="28" TOTAL_2="14" WEIGHT="100.0" Z="1.5531226325593945">
<NAME>ASAS20</NAME>
<GROUP_LABEL_1>Infliximab + MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo + MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo + MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours infliximab + MTX</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.79743866626335" CI_START="0.800955287977219" EFFECT_SIZE="2.3333333333333335" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="3" LOG_CI_END="0.8323452976095114" LOG_CI_START="-0.09639172702032248" LOG_EFFECT_SIZE="0.36797678529459443" MODIFIED="2010-07-07 09:36:42 -0400" MODIFIED_BY="[Empty name]" ORDER="1109" O_E="0.0" SE="0.545544725589981" STUDY_ID="STD-Marzo_x002d_Ortega-2005" TOTAL_1="28" TOTAL_2="14" VAR="0.29761904761904767" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.220688218191751" CI_START="0.8655684626091174" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-007.03" LOG_CI_END="0.8585785930154424" LOG_CI_START="-0.06269857567136713" LOG_EFFECT_SIZE="0.3979400086720376" METHOD="MH" MODIFIED="2015-03-23 08:36:49 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.09041953860098288" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="28" TOTAL_2="14" WEIGHT="100.0" Z="1.6931887851220504">
<NAME>&gt; 50% BASDAI</NAME>
<GROUP_LABEL_1>Infliximab + MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo + MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours infliximab + MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo + MTX</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.220688218191751" CI_START="0.8655684626091174" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="3" LOG_CI_END="0.8585785930154424" LOG_CI_START="-0.06269857567136713" LOG_EFFECT_SIZE="0.3979400086720376" MODIFIED="2010-07-08 16:20:05 -0400" MODIFIED_BY="[Empty name]" ORDER="1121" O_E="0.0" SE="0.541162769282166" STUDY_ID="STD-Marzo_x002d_Ortega-2005" TOTAL_1="28" TOTAL_2="14" VAR="0.2928571428571428" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2015-03-12 08:03:49 -0400" MODIFIED_BY="[Empty name]" NO="8">
<NAME>TNF-inhibitors versus placebo</NAME>
<DICH_OUTCOME CHI2="8.50735641362908" CI_END="4.7189954378697525" CI_START="1.2618732254826353" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.4402405607280904" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="0.6738495574851511" LOG_CI_START="0.10101572555872675" LOG_EFFECT_SIZE="0.3874326415219389" METHOD="PETO" MODIFIED="2015-02-19 21:33:10 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4839323368859182" P_Q="0.8178245685283274" P_Z="0.008020177398221879" Q="0.4022150477459716" RANDOM="NO" SCALE="814.1006869495268" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1637" TOTAL_2="986" WEIGHT="100.00000000000001" Z="2.6512191895668287">
<NAME>Withdrawals due to AE</NAME>
<GROUP_LABEL_1>Anti-TNF drugs</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours anti-TNF drugs</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-008.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-11-14 12:35:27 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="88" TOTAL_2="94" WEIGHT="0.0" Z="0.0">
<NAME>6 weeks</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-26 09:16:11 -0400" MODIFIED_BY="[Empty name]" ORDER="780" O_E="0.0" SE="0.0" STUDY_ID="STD-Brandt-2003" TOTAL_1="14" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-11-14 12:35:27 -0500" MODIFIED_BY="[Empty name]" ORDER="391" O_E="0.0" SE="0.0" STUDY_ID="STD-Huang-2008" TOTAL_1="74" TOTAL_2="78" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.404274747195294" CI_END="6.163000606330973" CI_START="1.0014070195961806" DF="5" EFFECT_SIZE="2.484285021682366" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="3" I2="21.9271471419974" ID="CMP-008.01.02" LOG_CI_END="0.7897922104576238" LOG_CI_START="6.106313620730548E-4" LOG_EFFECT_SIZE="0.3952014209098484" MODIFIED="2014-11-16 17:35:40 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.26884396980514713" P_Z="0.04964651805801809" STUDIES="9" TAU2="0.0" TOTAL_1="944" TOTAL_2="472" WEIGHT="52.686996361941794" Z="1.9629970393127356">
<NAME>12 weeks</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-10-11 13:38:29 -0400" MODIFIED_BY="[Empty name]" ORDER="338" O_E="0.0" SE="0.0" STUDY_ID="STD-Barkham-2010" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="80.50798829669249" CI_START="0.8133951638037232" EFFECT_SIZE="8.092268429068355" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.9058389747908584" LOG_CI_START="-0.08969841410453225" LOG_EFFECT_SIZE="0.9080702803431631" MODIFIED="2010-03-26 10:03:37 -0400" MODIFIED_BY="[Empty name]" ORDER="825" O_E="1.5217391304347827" SE="1.1721885403065389" STUDY_ID="STD-Braun-2002" TOTAL_1="34" TOTAL_2="35" VAR="0.7277882797731569" WEIGHT="8.240196742807251"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-12-11 18:07:37 -0500" MODIFIED_BY="[Empty name]" ORDER="783" O_E="0.0" SE="0.0" STUDY_ID="STD-Calin-2004" TOTAL_1="45" TOTAL_2="39" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="414.5378214174319" CI_START="0.16169620029420947" EFFECT_SIZE="8.187135677478315" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.617564160660836" LOG_CI_START="-0.7913001854779309" LOG_EFFECT_SIZE="0.9131319875914525" MODIFIED="2014-11-16 17:35:40 -0500" MODIFIED_BY="[Empty name]" ORDER="385" O_E="0.524390243902439" SE="2.002383791072568" STUDY_ID="STD-Dougados-2011" TOTAL_1="39" TOTAL_2="43" VAR="0.24940511600237955" WEIGHT="2.823825666940993"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-11-14 12:37:56 -0500" MODIFIED_BY="[Empty name]" ORDER="392" O_E="0.0" SE="0.0" STUDY_ID="STD-Giardina-2009" TOTAL_1="25" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="36.66906884699879" CI_START="0.5649276224900655" EFFECT_SIZE="4.5514140530893865" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.56429988187921" LOG_CI_START="-0.24800718964369772" LOG_EFFECT_SIZE="0.6581463461177562" MODIFIED="2014-10-11 13:39:12 -0400" MODIFIED_BY="[Empty name]" ORDER="1094" O_E="1.3372093023255816" SE="1.0645581448772437" STUDY_ID="STD-Huang-2014" TOTAL_1="229" TOTAL_2="115" VAR="0.8823913170305594" WEIGHT="9.99065010876917"/>
<DICH_DATA CI_END="6.470361215147391" CI_START="0.0025406380103987544" EFFECT_SIZE="0.1282140618037403" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8109285263203826" LOG_CI_START="-2.595057208733742" LOG_EFFECT_SIZE="-0.8920643412066795" MODIFIED="2014-11-14 12:33:19 -0500" MODIFIED_BY="[Empty name]" ORDER="678" O_E="-0.5131578947368421" SE="2.0006928806720943" STUDY_ID="STD-Inman-2010" TOTAL_1="39" TOTAL_2="37" VAR="0.24982686980609417" WEIGHT="2.8286008665645967"/>
<DICH_DATA CI_END="3.8865539330003505" CI_START="0.060760555838592765" EFFECT_SIZE="0.48595182607514725" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.5895646987086686" LOG_CI_START="-1.216378261857811" LOG_EFFECT_SIZE="-0.3134067815745712" MODIFIED="2014-11-14 12:21:52 -0500" MODIFIED_BY="[Empty name]" ORDER="827" O_E="-0.6412698412698412" SE="1.0608198345985802" STUDY_ID="STD-van-der-Heijde-2006a" TOTAL_1="208" TOTAL_2="107" VAR="0.8886213376598575" WEIGHT="10.061187924675144"/>
<DICH_DATA CI_END="15.40870460101958" CI_START="0.7321492780078993" EFFECT_SIZE="3.3587902507708756" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="0" LOG_CI_END="1.1877661294207915" LOG_CI_START="-0.13540036155705917" LOG_EFFECT_SIZE="0.5261828839318662" MODIFIED="2010-12-11 18:07:38 -0500" MODIFIED_BY="[Empty name]" ORDER="782" O_E="2.0056179775280896" SE="0.7772345465801533" STUDY_ID="STD-van-der-Heijde-2006b" TOTAL_1="305" TOTAL_2="51" VAR="1.655372774457628" WEIGHT="18.742535052184635"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.18920705448763284" CI_END="7.545951821915936" CI_START="0.35005636451119904" DF="1" EFFECT_SIZE="1.6252718115923108" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" ID="CMP-008.01.03" LOG_CI_END="0.8777140280657649" LOG_CI_START="-0.4558620218630102" LOG_EFFECT_SIZE="0.21092600310137744" MODIFIED="2014-11-14 12:32:02 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.6635774075810349" P_Z="0.5352589811841129" STUDIES="2" TAU2="0.0" TOTAL_1="246" TOTAL_2="183" WEIGHT="18.45107800804294" Z="0.6199981913348896">
<NAME>14 weeks</NAME>
<DICH_DATA CI_END="15.647882985486957" CI_START="0.060388783221392614" EFFECT_SIZE="0.9720887888893124" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1944555898114118" LOG_CI_START="-1.2190437209391023" LOG_EFFECT_SIZE="-0.012294065563845139" MODIFIED="2014-11-14 12:30:15 -0500" MODIFIED_BY="[Empty name]" ORDER="1117" O_E="-0.014084507042253502" SE="1.417701442149119" STUDY_ID="STD-Bao-2014" TOTAL_1="108" TOTAL_2="105" VAR="0.4975427906262983" WEIGHT="5.633301052888526"/>
<DICH_DATA CI_END="12.853859592995482" CI_START="0.32286799502892505" EFFECT_SIZE="2.037179391996141" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.1090335516565095" LOG_CI_START="-0.4909750032058835" LOG_EFFECT_SIZE="0.309029274225313" MODIFIED="2014-11-14 12:32:02 -0500" MODIFIED_BY="[Empty name]" ORDER="1115" O_E="0.8055555555555554" SE="0.9398529452962511" STUDY_ID="STD-Inman-2008" TOTAL_1="138" TOTAL_2="78" VAR="1.1320879988515649" WEIGHT="12.817776955154416"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-008.01.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-11-14 12:30:10 -0500" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>16 weeks</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-26 09:16:11 -0400" MODIFIED_BY="[Empty name]" ORDER="781" O_E="0.0" SE="0.0" STUDY_ID="STD-Gorman-2002" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.511659564200184" CI_END="10.452566793400344" CI_START="0.897337575364119" DF="1" EFFECT_SIZE="3.0625938259458056" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" I2="33.84753924213763" ID="CMP-008.01.05" LOG_CI_END="1.0192229514353215" LOG_CI_START="-0.04704414609988404" LOG_EFFECT_SIZE="0.48608940266771866" MODIFIED="2014-11-14 12:30:09 -0500" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.21888642192303343" P_Z="0.07393504184091373" STUDIES="2" TAU2="0.0" TOTAL_1="339" TOTAL_2="217" WEIGHT="28.861925630015282" Z="1.7870151385100963">
<NAME>24 weeks</NAME>
<DICH_DATA CI_END="19.11151600758696" CI_START="1.1533057051885915" EFFECT_SIZE="4.694829117907609" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.2812951385262603" LOG_CI_START="0.06194444040734179" LOG_EFFECT_SIZE="0.6716197894668011" MODIFIED="2010-03-26 09:16:11 -0400" MODIFIED_BY="[Empty name]" ORDER="784" O_E="3.0144404332129966" SE="0.716252635958354" STUDY_ID="STD-Davis-2003" TOTAL_1="138" TOTAL_2="139" VAR="1.9492499576431335" WEIGHT="22.069884330776148"/>
<DICH_DATA CI_END="9.599172397442704" CI_START="0.06084567010759385" EFFECT_SIZE="0.7642434670971808" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="0.9822337915065039" LOG_CI_START="-1.2157703215470759" LOG_EFFECT_SIZE="-0.1167682650202859" MODIFIED="2014-11-14 12:22:53 -0500" MODIFIED_BY="[Empty name]" ORDER="826" O_E="-0.16129032258064502" SE="1.2911184963035074" STUDY_ID="STD-van-der-Heijde-2005" TOTAL_1="201" TOTAL_2="78" VAR="0.5998847124173711" WEIGHT="6.792041299239133"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.686670953763904" CI_END="2.4768973550298883" CI_START="0.853351595565776" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.453844665006343" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-008.02" LOG_CI_END="0.39390800938447157" LOG_CI_START="-0.0688719951477616" LOG_EFFECT_SIZE="0.162518007118355" METHOD="PETO" MODIFIED="2015-02-22 20:43:38 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8408651323648167" P_Q="0.9519822033627359" P_Z="0.16863867327559712" Q="0.0036261846151082614" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1530" TOTAL_2="878" WEIGHT="100.0" Z="1.3765911995837494">
<NAME>Serious adverse events</NAME>
<GROUP_LABEL_1>Anti-TNF drugs</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours anti-TNF drug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-008.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-11-14 13:04:17 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="88" TOTAL_2="94" WEIGHT="0.0" Z="0.0">
<NAME>6 weeks</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-26 09:16:42 -0400" MODIFIED_BY="[Empty name]" ORDER="785" O_E="0.0" SE="0.0" STUDY_ID="STD-Brandt-2003" TOTAL_1="14" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-11-14 13:04:17 -0500" MODIFIED_BY="[Empty name]" ORDER="1538" O_E="0.0" SE="0.0" STUDY_ID="STD-Huang-2008" TOTAL_1="74" TOTAL_2="78" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.243991207639499" CI_END="3.189038289230864" CI_START="0.6857339079935307" DF="7" EFFECT_SIZE="1.4787939980995608" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="8" I2="0.0" ID="CMP-008.02.02" LOG_CI_END="0.5036597336367671" LOG_CI_START="-0.16384437512206612" LOG_EFFECT_SIZE="0.16990767925735042" MODIFIED="2014-11-14 13:13:41 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6302150419468548" P_Z="0.3183834374368021" STUDIES="9" TAU2="0.0" TOTAL_1="874" TOTAL_2="443" WEIGHT="48.06636559442223" Z="0.9977854148655328">
<NAME>12 weeks</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-10-11 13:46:30 -0400" MODIFIED_BY="[Empty name]" ORDER="339" O_E="0.0" SE="0.0" STUDY_ID="STD-Barkham-2010" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="80.50798829669249" CI_START="0.8133951638037232" EFFECT_SIZE="8.092268429068355" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.9058389747908584" LOG_CI_START="-0.08969841410453225" LOG_EFFECT_SIZE="0.9080702803431631" MODIFIED="2010-04-14 07:06:59 -0400" MODIFIED_BY="[Empty name]" ORDER="1104" O_E="1.5217391304347827" SE="1.1721885403065389" STUDY_ID="STD-Braun-2002" TOTAL_1="34" TOTAL_2="35" VAR="0.7277882797731569" WEIGHT="5.378106938504286"/>
<DICH_DATA CI_END="329.18927194638593" CI_START="0.12703412260494568" EFFECT_SIZE="6.466704750695673" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.517445673410207" LOG_CI_START="-0.8960796076380664" LOG_EFFECT_SIZE="0.8106830328860702" MODIFIED="2010-12-11 18:08:46 -0500" MODIFIED_BY="[Empty name]" ORDER="786" O_E="0.4642857142857143" SE="2.005121647310412" STUDY_ID="STD-Calin-2004" TOTAL_1="45" TOTAL_2="39" VAR="0.24872448979591835" WEIGHT="1.8379890711682"/>
<DICH_DATA CI_END="21.754393100029013" CI_START="0.22114705790829703" EFFECT_SIZE="2.19338095885142" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3375469719318849" LOG_CI_START="-0.6553188340139847" LOG_EFFECT_SIZE="0.3411140689589501" MODIFIED="2014-11-14 13:12:34 -0500" MODIFIED_BY="[Empty name]" ORDER="395" O_E="0.5731707317073171" SE="1.1706192392574415" STUDY_ID="STD-Dougados-2011" TOTAL_1="39" TOTAL_2="43" VAR="0.7297408949699253" WEIGHT="5.392536098233599"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-11-14 13:10:12 -0500" MODIFIED_BY="[Empty name]" ORDER="394" O_E="0.0" SE="0.0" STUDY_ID="STD-Giardina-2009" TOTAL_1="25" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.983344790664294" CI_START="0.025000801850767813" EFFECT_SIZE="0.47391014239887846" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.9534380687013259" LOG_CI_START="-1.6020460619767956" LOG_EFFECT_SIZE="-0.32430399663773485" MODIFIED="2014-10-11 13:46:56 -0400" MODIFIED_BY="[Empty name]" ORDER="1093" O_E="-0.3313953488372092" SE="1.5011040282107897" STUDY_ID="STD-Huang-2014" TOTAL_1="229" TOTAL_2="115" VAR="0.44379092709478135" WEIGHT="3.279463451922607"/>
<DICH_DATA CI_END="2.748464779224724" CI_START="0.17180938022537912" EFFECT_SIZE="0.6871768551762226" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.4390901759801709" LOG_CI_START="-0.7649531288114607" LOG_EFFECT_SIZE="-0.1629314764156449" MODIFIED="2014-10-11 13:47:19 -0400" MODIFIED_BY="[Empty name]" ORDER="1101" O_E="-0.75" SE="0.7072609973450865" STUDY_ID="STD-Inman-2008" TOTAL_1="138" TOTAL_2="78" VAR="1.999127906976744" WEIGHT="14.772872779457648"/>
<DICH_DATA CI_END="354.250375643412" CI_START="0.13909918467159138" EFFECT_SIZE="7.019682216568182" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5493103194410915" LOG_CI_START="-0.8566754156130331" LOG_EFFECT_SIZE="0.8463174519140292" MODIFIED="2010-12-11 18:08:45 -0500" MODIFIED_BY="[Empty name]" ORDER="591" O_E="0.48684210526315785" SE="2.0006928806720943" STUDY_ID="STD-Inman-2010" TOTAL_1="39" TOTAL_2="37" VAR="0.24982686980609417" WEIGHT="1.8461352831179763"/>
<DICH_DATA CI_END="8.623362157815846" CI_START="0.1159640499493162" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="0.9356766256736623" LOG_CI_START="-0.9356766256736623" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-11-14 13:13:41 -0500" MODIFIED_BY="[Empty name]" ORDER="614" O_E="0.0" SE="1.09924216318941" STUDY_ID="STD-van-der-Heijde-2006b" TOTAL_1="150" TOTAL_2="25" VAR="0.8275862068965516" WEIGHT="6.1155795513883024"/>
<DICH_DATA CI_END="8.914663513688936" CI_START="0.2780852970951779" EFFECT_SIZE="1.5744957452174106" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" LOG_CI_END="0.9501049552616783" LOG_CI_START="-0.5558219725138813" LOG_EFFECT_SIZE="0.1971414913738984" MODIFIED="2014-11-14 13:13:41 -0500" MODIFIED_BY="[Empty name]" ORDER="622" O_E="0.5801104972375697" SE="0.8845889318338802" STUDY_ID="STD-van-der-Heijde-2006b" TOTAL_1="155" TOTAL_2="26" VAR="1.2779592265871684" WEIGHT="9.443682420629603"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-008.02.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-07-19 13:42:08 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>16 weeks</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-07-19 13:42:08 -0400" MODIFIED_BY="[Empty name]" ORDER="788" O_E="0.0" SE="0.0" STUDY_ID="STD-Gorman-2002" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.43905356150929753" CI_END="2.9975316002003476" CI_START="0.6832717300323046" DF="2" EFFECT_SIZE="1.4311284366874253" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="10" I2="0.0" ID="CMP-008.02.04" LOG_CI_END="0.4767637701596433" LOG_CI_START="-0.16540654758546036" LOG_EFFECT_SIZE="0.15567861128709148" MODIFIED="2010-12-11 18:08:42 -0500" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.80289878400862" P_Z="0.34196420943167394" STUDIES="3" TAU2="0.0" TOTAL_1="548" TOTAL_2="321" WEIGHT="51.93363440557777" Z="0.9502914191279174">
<NAME>24 weeks</NAME>
<DICH_DATA CI_END="5.368191085944812" CI_START="0.6275243723237729" EFFECT_SIZE="1.83539389279838" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.7298279665674878" LOG_CI_START="-0.20236940202194734" LOG_EFFECT_SIZE="0.26372928227277026" MODIFIED="2010-03-27 15:48:44 -0400" MODIFIED_BY="[Empty name]" ORDER="789" O_E="2.025270758122744" SE="0.5475773487608296" STUDY_ID="STD-Davis-2003" TOTAL_1="138" TOTAL_2="139" VAR="3.335101460986068" WEIGHT="24.645261275072414"/>
<DICH_DATA CI_END="5.727147785131136" CI_START="0.2896997517290256" EFFECT_SIZE="1.288081244125513" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="0.7579383899299632" LOG_CI_START="-0.5380518769838819" LOG_EFFECT_SIZE="0.10994325647304067" MODIFIED="2010-12-11 18:08:42 -0500" MODIFIED_BY="[Empty name]" ORDER="1105" O_E="0.4368231046931408" SE="0.7612710980404778" STUDY_ID="STD-van-der-Heijde-2005" TOTAL_1="202" TOTAL_2="75" VAR="1.725525239309212" WEIGHT="12.751042466616289"/>
<DICH_DATA CI_END="4.163841284074374" CI_START="0.25452811341066645" EFFECT_SIZE="1.0294730042972944" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.6194941668604996" LOG_CI_START="-0.594264241520516" LOG_EFFECT_SIZE="0.012614962669991715" MODIFIED="2010-03-27 19:23:39 -0400" MODIFIED_BY="[Empty name]" ORDER="1106" O_E="0.05714285714285694" SE="0.7129676972840291" STUDY_ID="STD-van-der-Heijde-2006a" TOTAL_1="208" TOTAL_2="107" VAR="1.9672533471987521" WEIGHT="14.537330663889067"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2015-03-23 06:22:31 -0400" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="antiTNF flowchart final2.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2015-01-14 05:49:19 -0500" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow chart<BR/>Note: October 2013 search included retrospective search for golimumab from database inception</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAa0AAAIoCAIAAABVoSOWAAA8RUlEQVR42u2dv8vkSLamZZbXZTYN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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2015-03-23 06:22:31 -0400" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAdwAAAR8CAIAAAC45bLrAABTeElEQVR42u3dsW4US/q/8ZGQEIED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=
</FILE>
</FIGURE>
<FIGURE FILENAME="ASAS40 evidence diagram.jpg" FILE_TYPE="JPG" ID="FIG-03" MODIFIED="2015-03-20 06:44:32 -0400" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>ASAS40 Evidence Diagram</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
<FIGURE FILENAME="ASAS40_NMA_ForestPlot-final2.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2015-03-20 06:39:17 -0400" MODIFIED_BY="[Empty name]" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Forest Plot: ASAS40</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAzwAAAJyCAIAAACOsVIRAABCDklEQVR42u3dT6gsV2Lf8evYMcQw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</FILE>
</FIGURE>
<FIGURE FILENAME="WD_AE_NMA_ForestPlot-final2.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2015-03-20 09:28:28 -0400" MODIFIED_BY="[Empty name]" NO="5" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Forest Plot: Withdrawals due to adverse events</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAx4AAAJhCAIAAABAW/HJAABC30lEQVR42u3dO6wsRZ7n8RrtaIyR
2hljZ4WAdjEwcfZIGBhrYLZAQtqrK41V62FeD0Qb10Qq42Lh4iBMpIOQ2sFAwgMLjLMzu6tdzQzz
nu6hXzzuZr0yIzP+EZl1HnXq8fnqp0ORlY/IqKyKb0VE5Z09BQAAwC0xUwUAAADUCgAAgFoBAABQ
KwAAAFArAAAAagUAAECtAOAGXM5nDfPL0lMXi6va5leLi/GVbsz6KGEh77FU1ziFgyoSQK0A3Etr
2DLesu9qAHerS10zvv7/tGCdNaVqNSj/OavVrb+Up6pWh3LNg1oBOBKt2jYZm/+d5BkH0Mz0u6Ja
RWxLVigotaJW1ArUCsAe3GTQNPZak3Z5v49r3YYmy7b72vQgzVJTW612sbhs125WbtdLCpEeom2k
wzY7taJuq97xhj1Vefk3O1nkJWkLdzGf96tlu/pq3eRck4rbliIv4/p/hlsN2+/u+UGDXi5V9mJV
6vPp06fRSxm+cOHRg/7CtEj9MvT+LypPVqvR6ZdOpHLl7FiM1WEHl2hYUcVXB6BWALMatA3dKFux
ta70+lzOW1npOU3S/Pcej4zWrZ7I9hP3kawbxcU8LmaoWT0vSCxp/VRyXptVeiXvdtxrqpeL84Ol
+9nUbbZV7/Fleh7z5KyrpRp7sZL6LHfgVSo8LnZcpN723SqF8gxqNTj9+okUV9itGMWLoV9RxVcH
oFYAtcpaqK4pmqhW+Xhaf8lwh0HbXGry4iY0bk43aybH6G07plZ5H1NvcSaIxQ6dwVksH83n86SZ
H255GcrgcB5ZWLejXYyj9Vl7KetjeztV1PjrOzhYfvqjF8aEPU+4zAoXQ1RRJuuDWgHYoddq2PdS
Vqt8EsqwSU67akbVKh2PmjLkst3N6r+9UkeesINaFUeSshPuFzmpok0H3np8adub1ztQOHqVDQhm
Q2I7qNVIfdbGEcNJaHmxy0Nu0UtRKk+tVoejrvGFUVxhl2JMVKvCqwNQK+DsGUxin9ha19vjQudH
1jNRU6tdugPWG6ym+PRKN+/v6LZ7raLesGxW1VqqNhO8NoOV/da+3n6P6c5UtSrX53ivVWn4cLyi
2vUXSWddqTzVXxwkM+KuRi6E8gysScWYrFZTOvYAagWcb7/VcMJzr98k7TOIGqbBZJZhM5i0SVPU
qngDqmIr1k2hzvqDkrVLhyu3psGU85JapSv152VfXHT1t/yfVO7yrXoWGktAqVTFF6tyQ696VZQ8
Lyt2sUjRTwtK5clqNTv9kROprTC9GEW1GlbNmKKdPb98oamZF355r4dePvjZL3515mr1q1/8bNhB
e/1Kubsqre159Yre09V0ilW6rs+bFRtTu67qgyybH01lTebwF4J5m5r18Iyo1dNstKYyjb23+nBe
emWqTq/8xdY0Pv3y0NCqp2x4Fv0f3mVl7G0VTH+v/kKw/6KUlsf1mb382Y89i+aRn2zx0L1fK+Q7
CUbt8qsyHIUbK150F44JxahcDL2KKr86J8agEVm3buHCyqd690nerpssaj/g2922O1yuFex9pGXo
rO4e/e7geq1WtXvjlnT/HtBdbAf3Qh5nlTalTt/G5AoA7q/1WH8SLz+Vw4WlPqvVGuuHq6Xr7QJp
2ixqn1luGDYMSXvwyxeCliE5+On1W92WWq2q+YXuBUl9uavdnvz2jLq9DtY7Wa/zy+0a3XHy3a5f
11+8MNxRbOrLp174ZcWR0/PKLszsdJJT7jtbeoTuqql73ZFWaf+NQq0A4J7VqmuUhgtHt8r6k6pq
FYtV4Xj9Rm3odSfVeNymWnUvQeK/3eNf/epXdVdNNHfTknd9hd3SbLeDrTa7q1pwrfsx2cl2H+Fx
+6ecrjI8QrSbk6vSU3xzAMDxqNXwq3e4sNQSpo+7D/PegODgS37zv4WRwGonWX+wMeuAoFaZBwyt
YPiS9JaWPCBpxjOfDXdb2OraatXtsN1F+XTyUw4u02w/41J3pFVKrADgHnutUqkJFxZbwuGc36Cz
avARvxarxLSmqNWgUQtaTGpV94DohRlOWbuGBwxr/9bVarvHX7yQ9l6NXSXJpTno6oz6kcrTwI6y
SktvXADAHtUq/cwOF05pCaPP+uGn/HYksFl32+QNx23CAcGyWum1GvWAqKltqzF9MpfmmgeELXjF
A4qN/YghD6dExeYwcJgXehfwsNDrbw4vVC7yo61SXgUAh6JWg4Yh/yQvtjm1pYPP+V+mPQ+JYRXW
3/zaqahW5lpN84Cn0RBtKyw/+9nP+t2A9esgn16X7za4euLRt5E+z8Fa3bPBiPPglH/5wiwfElz9
/y/aeX7DdU6hSodDigYFAeD+1Cr4hl9yq2GrMPwUD6acbBf3LCv86E/3GI18+IUgAAA4MQ5jjpP7
Wq23Aar4wAKAPbXiGg69VgAAAKfsu6oAAACAWgEAAFArAAAAagUAAABqBQAAQK0AAACoFQAAALUC
ANyIv/qrv1IJAKgVcFf8z7/9tZxVZrOZSji3+KADtQKolVAroVagVsCx8RO1olZyBvnJhx2oFbAP
r/rp6Y8//aTVoVZy8mne6T/RK1ArYA9e9f0P1IpayemneaezK1Ar4K7V6qcffvzp93/8QatDreTk
07zTf+BWoFbAHXrV02WX1R9/+PG733+v1aFWcvJp3unN+/1HbgVqBdyhWv340x++//E3v6NW1EpO
P807vXm/L93Kxx+oFXAnavXTUq1+/8cff/3bP2p1qJWcfJp3evN+120FagXcoVr9sFar76gVtZIz
UKvvlmr1A7UCtQLuWK1++HdqRa3kDPLvS7X6gVqBWgHUSqiVUCtQK4BaCbUSagVqBVAroVZCrUCt
AFAroVZCrUCtAGol1EqoFagVQK2EWgm1ArUCQK2EWlGr4/qsulpczC+P+LP2cn6xuKJWI3U0q73G
zSVwf3U4UrYDeYvcuH6O4DSplVArOV+1aj6kZ8WP6dWTa7ardIui9iH9yE82zldt2pfsyWRZpUyl
YlcPV3l2fdS01IfcaM326Cil12AHtVruZa/VeVAvX++CTi9zakWt5EjV6surbx8+etL8VYHUqtZ8
zi9LH9NBs7hsK1LHGm6X7Kp5uG1AllsNGpOucyjZZbr3XYs9drhZcLy2nVukuzrsVmu2Nym4mM8v
iheGXqupapW/XagVtZI8r73x4PDVqjGqVx6+M3/8YfP3NOxq/9V+PgOChY/pYHFfSxJfyZcUxSc4
TMF6din2yOFKB9m0cr2tdyvFaarVul6yl3vTnTjfVlfSFZhUeKoOyeOlTS/mbY/kZtvoerns9j+y
SX705baLbWdRehGk10R7Yl23Umf3K6XcbJt2O7WnnJczXy24lNoC9OokqsC8ZzgrZ+E0g15mUCvD
c7dzxLVXvfX+Z+99/E3z9zTs6txGRe9frZYNwEXQsPS8ZLBht6eob+gqHivpS830piEt9ujhSsdb
r5aJ2ZmrVVAxnZmsajKroL68xmq1lYCVALTqUlGW+ibh0btNhr2XvTPY7mpodv2TC66EqJzFC2bQ
Izs4fOUU+s8H5YxOMz3foOcW1Eobf/0jpl61zmnYFbW6B7XqT5vKOypmeRMwWa16G+XPTZijs5Na
bZrMdF5Vss3kLrbzUKt+U7562KuTvkFnF0NZrfKLI7TbVK0qm4RHn9CXmZhVdi0Prpz11Z5eiEUF
jK7X+LvCoH6GpxCZVVbO6DSP6CqmVhK18YfMMy+9/ujJp61XrdMsaZbPjhxqdX9qFa6TLyv2WlU/
58Mnx1uGiloNN+79/3bdviQWxqbOUa2GFbMZMs3VKq31xBf2pFbx0StqtTmJdt2o/yv8DpCaU1jO
kofFY8t9N8xOIVSrWudZUa2MCVIr3Se3dcRPPv/65Qdvv/vRV61XNY+bJc1y1U6tdplrFY9mVPuV
CnPJ882HPySMtG2XXqvxw/XnoxSV0FyrYdPe+kg+INifWnfjXqt04tIEtYqPXh4Q7GZSVeb2lbpX
21XDcpYsaEytwlMIix1csQYEqRW12usRU7s6Da+iVnvpnxi2celIRDAANDr1vXDnhsH84Vl4t4ba
jK7CoGTtcKX5wpU+gHNVq9JPAK66SdOX7b3Lumqdz+c3UqtuX8kPNkc2iY5enMbeXb/J0uwWID21
isfzsnKWpwiOqVW5AovT2Lt3qWns1Oqk8uxzzx++Vazt6vEHX5yGV91Ltbtl6C32gB3UHg/reAc4
1wqgVqKfrGRXL7765ml4lftana1b7f3m7oc+RYVaAdRKjIWJf0MQ1AqgVkKthFqBWgHUSqiVUCtQ
KwDUSqiVUCtQK4BaCbUSagVqBVAroVZCrUCtAGpFraiVUCtQKwDUSqiVUCtQK4BaCbUSagVqBVAr
oVZCrUCtAFAroVZCrUCtAGol1EqoFagVQK2EWgm1ArUCqBW1olZCrUCtAFAroVZCrUCtAGol1Eqo
FagVQK2EWgm1ArUCQK2EWgm1ArUCqJVQK6FWoFYAtRJqJdQK1AqgVkKthFqBWgGgVkKthFqBWgHU
SqiVUCtQK4BaCbUSagVqBYBaCbWiVtQK1AqgVkKthFqBWgHUSqiVUCtQK4BaCbUSagVqBYBaCbUS
agVqdSZcLS4uFlc328flfDa/VJXUSqiVUCscrVo1bXnCslm/DUM4NGO5/SJ1ddYWjlpRK6FWQq1A
rZq2fOAD1GqSWm0NaOmm68fUiloJtRJqBWo1UKukP2a5OO3TaldbNv+L7XqtCHRbbhYtTWM+v+i2
7Ha2WZBt0tvzaqVBeUZOoFWescKk3U7rNVKnaR/nq+Vq1RUgUauw3q5XA8P9MS9qJdRKqBWOZUAw
M4RYYVabtELSukyiFZ3edCKQdY8Fmyx3lyyrlico2HbN0cIEfUORWhW7kBK1Wj4cHL5Sb7vUQLvn
5BC9x6BWQq2EWuHoBgSjWUWBhfRW63qG+h02mVdkm/RcJrGiukxsd52Y1UhhNkKZelPYa5WvFpQ9
7bfr9Z8N6u3aNdA3vPwFA7USaiXUCkeiVunAV7e4oFZDA5mgVrWuo+lqtdl3u954YQLBCtWq5GHR
EdJjhPV27RrI1MqYILUSaiXUCsepVsmTyUhVZCGBJvRtJh/JCjaJhsOmzA7fzKSKjLCmVumqvdno
s2DzdNGYWoX1du0aMCBIrYRaybmoVfMpf9Rfny/nB9xG3ePNF7YDVdsBqu1T83lFrYIJ50ObyWek
Z0uqE+Rrr9ZqlYHIlQsTj+dtT/VisQhGOXuX+phaxfW2cw2Yxk6thFrJIavV6C+tsg/v/kyQ/AM9
GjWJP/bbXQcNz4TmItxz6XClPWe/zTrwoZXzvGWowS5QK6FWcixqdTmvDJakoyFj38zDVnC9eaFd
bA9dGMuoNqfhnquHi/Yc34booFtyagVQKzkptfry6tuHj540f70opzcgGP3AKGzR6moV7Ga0XYzm
u4wIXGXPY4fr9tw/RlLySQenVgC1klNUq9feeLBPr3rl4Tvzxx82f+/RrvZ5yuc1IBjPEbnI7o1Y
nmlSEJvprlMXvdtRq3TPvU65QRcWtQKolZylWu2tQ2vtVW+9/9l7H3/T/L1HuzqT4dH991oFw3LD
e0uHE5v6y0Z/Nz5JrKb2Gu2uVsM996dgpc51oFPZqRVAreQU1Cr1qnXu0a6o1f6GBLMBs6iPaqAg
u/VaxdOsIou7HbWq7blyAyNqBVArOSe12gPPvPT6oyeftl61TrOkWT67D6jVbdpUrVsq/nc7qqay
w1yrkudM7zLaVa0qey6ODVIrgFqJXqtbzyeff/3yg7ff/eir1quax82SZrleqyPvtQr/ndlEM5Ln
89sVlO5ykN0RaHCDnuifQElvUj1yX8biQF7tcOFuSv/Krl8IAtRKqNU+7eoevYpaHQG37yX7Nh33
tQKolZyvWj373PN7K8barh5/8MU9etWeT5laHYKZ7P3m7gd9EyVqBVArOal+msaoXnz1zXv0Kve1
wplDrQBqJYbAhFqBWgHUSqiVUCtQK4BaCbUSagVqBYBaCbUSagVqBVAroVZCrUCtAGol1EqoFagV
QK2oFbUSagVqBYBaCbUSagVqBVAroVZCrUCtAGol1EqoFagVAGol1EqoFagVQK2EWgm1ArUCqJVQ
K6FWoFYAtaJW1EqoFagVAGol1EqoFagVQK2EWgm1ArUCqJVQK6FWoFYAqJVQK6FWoFYAtRJqJdQK
1AqgVkKthFqBWgHUSqiVUCtQKwDUSqiVUCtQK4BaCbUSagVqBVAroVZCrUCtAFAroVbUilqBWgHU
SqiVUCtQK4BaCbUSagVqBVAroVZCrUCtAFAroVZCrUCtAGol1EqoFahVjavFxcXi6p4OfjmfzS9P
v36O4DSplVAroVagViNCMNtSN4NUHRoF2K8DHJRzpHXWVRq1olZCrYRa4dzVamlInQ40blBr1/Va
pWq1LU0nmdSKWgm1EmqF81ar1BAC59rQrpGqQ/L4cn6xWMzbdTdbds92O2gfj26Sdwktt11sO4tS
g2meSEu1PkLXrbQ5+LK88/nFdtu022lbpKCc+WpBxbUF6NXJLOoK7BZvFmblLJxm9HKAWgm1EmqF
w1Krolktn9g268njolptJWAlAK26VJSlvknf8DaHSfrX0uL11tkWql+4zrXygsTdRdvHxS6kpKyF
+imcQv/5oJzRaRZeDlAroVZCrXCwatX2igRKEfXKRFYwNI7WnUK1qmwSTmXqlSkuYGJWs9lgBwPt
WZ9v6k1FBYz6iXpHKPXqDU8hMqusnNFpFl4OUCuhVkKtcGADgsO56HFvTTo8tg+1SruvusNU1Gpj
G+26Uf9X2KOUmlNYzpKHxf19fTfMTiFUq1rnWVGtjAlSK6FWckJqNTLR+eBZTvI52G/8s/t4OQcz
etrRs50GBOtqlU5cmqBWiYIkw2PlAcGn7UyqtMyDy7Q0xbxdNSxnyYLG1Co8hbDYw90YEKRWQq3k
4NVq9Y07tqFsTm1v8m04EjL4al/+zX4y1tF7cup03EGxRwrWH1nJOhxK4z7UKqvb3s0VJk9jr47u
tbtazVyfNCDYHXw+nye9VuE09sgR8+uvp1bxeF5Wzni1KWoVn0LwrsiWmMZOrYRayUGr1fqLeCwT
8c/Hn9YdJFmWfC8PvkhfzqMOhIn3QqoVOy5Y3NLF+zlgt3I3doBaCbWSIxgQDF2iLyP5zNiRn2tN
n1lb3OZaxS4UrHITgWw/tXWpFUCthFpt8+XVtw8fPWn+qlJqNclRej1ImW7ErhQO48QTWbL79axX
uriYPK5RLHZQsPLITbCfw+22olYAtTrNvPbGg6NTq8aoXnn4zvzxh83fM7GrPb9MJ6hWw/lLqbAU
OnYGN/OpqlVvo+B3W+Njg1GxJ/Q4ZTuO1OpA5wFTK4Ba6UY6iMOtveqt9z977+Nvmr9nYldHPZB6
IGpVXKWoPcVeq6qtJHcdKv98flKxJ83VGpZFrxVArcgNtbqmV61zJnZFrW5RrQbGUvakwtT1fBr7
8IeE3Y/a81tYTy/2pO6m0V4rc60AaiX7b7OPiGdeev3Rk09br1qnWdIsn5061GqKVM2CW0JnPywf
vxlipCnB78FbrynsPVmc3FAxurVPPlJZWLG9J1F+uHg/fiEIUCvRa1XJJ59//fKDt9/96KvWq5rH
zZJmuZeJWt3L4OK97/GwjketAGolRzfXKrWrM/EqanUybrX3m7sf9L8SQq0AanWaefa5549OEdZ2
9fiDL87Eq/b/MlErUCuAWsl59b40RvXiq2+eiVe5rxWoFQBqJe7GLtQK1AqgVkKthFqBWgHUSqiV
UCtQK4BaUStqJdQK1AoAtRJqJdQK1AqgVkKthFqBWgHUSqiVUCtQKwDUSqiVUCtQK4BaCbUSagVq
BVAroVZCrUCtAGol1EqoFagVAGol1EqoFagVQK2EWgm1ArUCqJVQK6FWoFYAqJVQK2pFrUCtAGol
1EqoFagVQK2EWgm1ArUCqJVQK6FWoFYAqJVQK6FWoFYAtRJqJdQK1AqgVkKthFqBWgGgVkKtqBW1
ArUCqJVQK6FWoFYAtRJqJdQK1AqgVkKthFqBWgGgVkKthFqBWgHUSqiVUCtQK4BaCbUSagVqBYBa
CbWiVgC1AqiVUCuhVqBWALUSaiXUCtQKoFZCrYRagVrtm6vFRfP5NLtYXN3pYS7ns/nlkbxCTZXc
rDqO6WSplVAroVagVrdpCY0FtCs0jytKUH/2OG1j45Vr2nqgVtRKqJVQK1Cr66vVXizgcNVqW6xO
HakVtRJqJdQK1GpUrZbt/WLbS7Nu+Zc2kfTYdCt3fVndst6uLhaLebunzW6SA+U9Qb2jh+KS9p+1
ytN1K21cZVmK+fwiKXJ7rPacWq1pH+er5WrVFaBfadm5DGotKGThZJOdMS9qJdRKqBVOQK1SpUos
4DLo4lp7RrpksKv149VOW8nJhKHTpW6T1ZqRXOU+NxDD1rVyd4p7jLaPi71ISaGTUsW9VpvipQYY
2etl4WTTsy7VAKiVUCuhVjiuXqtcSUpqte1j6ZQk3FXfTbJenK7Tpmc3BdXZWktiVrPZYE8D7RkW
snCa+WqdWuU9SQOh7JUgMquskNHJ9s852w2olVAroVY4bbXaKMPuapV2X/WGGEfVathVFnWEhT1K
qTnFp1nwsLCrbSCJ/XMJ1arWc1ZUK2OC1EqolZyTWjXNxbF88C+n/RzXt/+jUKuNMMSaVFerRD6S
gbEJA4JP25lUg1KMqlW6am82+izYPF00plb5ueSFD/ZhQJBayaGr1ZdX3z589KT5qxqpVUUw4qmx
6Szc9ht7uLAyXSWbkhyOqqQN9NgW19zz02gm8NF9/z8CtUpsIfzd3MiAYPcizefzpNeqPo29e8WT
p7OLKepZG1zG28Ovptovl8arTVGr6Fzy6ztbYho7tZIur73x4NDUqjGqVx6+M3/8YfP3KOzq7uqQ
WtUUZX45bhjhGtHCZFnyrb30TXvVDi3STSp9Dk+jySal9YZ7LtxZ6djcyt3YAWqlb+ne9rz2qrfe
/+y9j79p/h6FXRn6vK8BwTHBCP1l5FddE6bebr7gl7St3D0xqlb5ngunWDU4agVQK6FWgVetcxR2
Ra0OVK1CzYndJxztiae5tEsGw0qTRj2q6wV7Xi66iG5PdGTdVtQKoFbnpVaHwzMvvf7oyaetV63T
LGmWzw4bF9LhqdX0LqvsVj8VterPyIl/2T4yq2Z+mU+nKu15eHvHaNSSWgHUSvRalfLJ51+//ODt
dz/6qvWq5nGzpFmu14pa7aZW4Ryl4j8JV+y1GirMcDp8Ljhl6ek9k0leuOf+WuMDhdQKoFZCrSp2
dRReRa0OU612GAwcPDP5B+PxL84q/6Bv7/C1f/g32V9862xzrQBqRa0ON88+9/yhCcfarh5/8MVR
eNWd1iG1qkhV1nOUyMoug4GBpQU/GA9MaCBA0f2to3v/RP86W3nPvX0f7VQragVQK7nvvpzGqF58
9c2j8Co5kVuG3r6s3KH+uK8VQK2oFbUSanVebnWXN3c/vn8xhFoB1Eqolfg3BEGtAGol1EqoFagV
QK2EWgm1ArUCQK2EWgm1ArUCqJVQK6FWoFYAtRJqJdQK1AqgVtSKWgm1ArUCQK2EWgm1ArUCqJVQ
K6FWoFYAtRJqJdQK1AoAtRJqJdQK1AqgVkKthFqBWgHUSqiVUCtQK4BaUStqJdQK1AoAtRJqJdQK
1AqgVkKthFqBWgHUSqiVUCtQKwDUSqiVUCtQK4BaCbUSagVqBVAroVZCrUCtAGol1EqoFagVAGol
1EqoFagVQK2EWgm1ArUCqJVQK6FWoFYAqJVQK2pFrUCtAGol1EqoFagVQK2EWgm1ArUCqJVQK6FW
oFYAqJVQK6FWoFYAtRJqJdQK1AqgVkKthFqBWgGgVkKtqBW1ArUCqJVQK6FWoFYAtRJqJdQK1Aqg
VkKthFqBWgGgVkKthFrheNXqcj6bX5afvlpcXCyuDrNsALUSakWtgHtRq8ZRZgVL2UGtlnvZq+oc
plqtKrNlWcB79c9D82FqJdRKqBVOXq2WLe18fhFril6ra5RqUCXUilrJpHx59e3DR0+av9RKzlit
mo/oYxmQuZwfVWMy23tD2/xNPKXteZnPt/qSdsZ0dZm20snjZXUv5m2/zWbb7tnuUJfd/kc2yY++
3HbRlHtQpoLmtGd4td1kW4qtW2520j0/6849L3C+WqhWyWrLxeMn0u5rrJxprWwWZJvkVTQoD7U6
+rz2xoOT8apXHr4zf/xh8/cW7epw1OpkXilqVRqoKH2mrj92u0/l2XBoo9hpUN95/uzozgstU/HJ
bB+9czm2eTmzfZtVr4Y6OVhVYvTCb1+LolptX67VC9226RVTqW8SHr3bZLVmdFX3TmW7z6Hi9c8y
uFKiAhcvqFyeCr1E/RNJqmFbqHo58+6xYJOkirr19VoZ8DpQr3rr/c/e+/ib5u8t2tXh1I/+s1NU
q35zGDZDq0/cRdhiRO1Isqy+87FD16yn622Kmtmw6S2cy1G51Wz/ZtW9Tr0mu6u2nseOq1WyVdLp
MpC4vlpVNgmPfjnh9d2eTGJWqdIPbatzo0FHVOyC0XeCkQHBsRPZPB4vZ2RW2SZhFVEranW4XrXO
LdoVtaJWe5uWkn/6t5+3UQs10nkwsvORQ5f1aKzFKm8bncvU45yXWg17DzfVlqtVWn1J07wntYqP
PkWtNmfTblQw9Fw1UnMKC1zxsLJajZ9Iolb1ck56J1Grs1CrY+eZl15/9OTT1qvWaZY0y2enBek5
MbUafOrmn61hs1eRmkJTGOx85NDxzqOv4kHD2fuens5Ric7lmLqtZvszq0F/zWbaVTYg2DfpG/da
pfOVJqhVfPQJA4LdDKVK72dJNdpVwwKXrvCqWhVPJFO30XLmpxxsElYRtdJrdVj55POvX37w9rsf
fdV6VfO4WdIs12slR6xWydOZgBR6e/rt33XVaoeupErjOZyjEp/LmMSdoVplVbJZcNVNfL5sf6rQ
dXDN5/MbqVW3r2TQdmST6Ojj09g7AR9cdOW5ULGuZwWOV8s7AtOJ81tLDE/ksjYCGytRPg8xW1Kd
IG8aO7U6SLu6Ra+iVtRqn2oVjNnl40IDZZncaxX8Qqr07G53Qqq7UTJTKD4XvVY4O9xV9fTV6tnn
nj+NE1nb1eMPvrhFrzoooTmZV4paxX0+1f6ffCpJYdXC5PR4mCJ+drwfafgjxHIzET1rrhWoFbVy
X6tjsqsXX33zFr1KXxG12sen7HAAI/CR6ToynCFb2XnwbGkySXgLhWB0pp0DU7l9w6VfCAKgVu7G
LtTqjL8R36H+uK8VQK2oFbUSanVebnWXN3c/soERagVQK6FW4t8QBLUCqJVQK6FWoFYAtRJqJdQK
1AoAtRJqJdQK1AqgVkKthFqBWgHUSqiVUCtQK4BaUStqJdQK1AoAtRJqJdQK1AqgVkKthFqBWgHU
SqiVUCtQKwDUSqiVUCtQK4BaCbUSagVqBVAroVZCrUCtAGpFraiVUCtQKwDUSqiVUCtQK4BaCbUS
agVqBVAroVZCrUCtAFAroVZCrUCtAGol1EqoFagVQK2EWgm1ArUCqJVQK6FWoFYAqJVQK6FWoFYA
tRJqJdQK1AqgVkKthFqBWgGgVkKtqBW1ArUCqJVQK6FWoFYAtRJqJdQK1AqgVkKthFqBWgGgVkKt
hFqBWgHUSqiVUCtQK4BaCbUSagVqBYBaCbWiVtQK1AqgVkKthFqBWgHUSqiVUKvb5WpxMb88jqJe
zi8WV9QKoFZCrYRa3aJdzLZkmtFI0qxj60vJ0khMmh22ZlXbefHZZHFN0cqrxcVONuiOlhaWWl3f
pe/PUI/lFQS1EmolZ6JWTcO0bRWXQjJoIZeLsnar6+kpPN0uq+88fnbpPxOayupqUbnSZenGR9Iy
34NapYJaN6dUrSa+fieqVonub6T+XrXz0DSYWgm1knNQq367lMhORa2eltfvL6vvPH52YkNZXy0o
dn/RwOqOwK1m9+AI3cs1MsSr16r8jqBW1EpuJ19effvw0ZPmL7WSA1ergVdkH7u9kbV2xW5p0KZ1
LV195/Gzy/9cXIyOB46sFhW715sy6MKiVhO6/SrDsOlLmzxedm8u5u26my0j8W4fj26S96Mtt11s
X/DBuHJaqvURsmt3Wd75/GK7bXrpbIsUlDNfLVSrwdD5ePnL77FBOYPh7WyTvGZGhvKp1ZHmtTce
nINXvfLwnfnjD5u/N7SrE1Orc3j1T06tRkbg6kOI11Sr/tyouIGfuFr/yf5gTdq0HUEzMzsIs0pf
8ORxUa221byq+rZxryhLfZOweyjpXxtcj90620L1C9e5Vl6QuFds+7io47k8Fd5T/fInZ78tVL2c
YQfzcJO057FdX6/VCarVyXfDrL3qrfc/e+/jb5q/N7SrE6sunXCHr1ZVywifzBcWe62CL/T5s9m4
3QS1qvc7lYpda02p1UXmo4FShM110MQPhbt1p1CtKpv0uyM7NSldCtsCJmaV2fVANdbnO+iIihUw
EvqRAcGx8m8ej5czHLofbhLWDLWiVkfsVevc0K6oFbXaSyNamWkedf8MfwA4aF8KU9fzncfPDnq9
SuWZuFrcpVUcG6RWhVqLe2vS4bF9qFX6UnWHqajV5mJs1y38vCFU7/qAYMXDymo1Xv5ErerlnDQr
klqdkVqdMM+89PqjJ5+2XrVOs6RZPsMK5nTgN1/IfkGXjm8E00BGJluN7Lxw+4Rk9+ndHirzqSYV
uzI7xi8EQ3UNblGx84BgXa3SiUsT1Kr/C4nxAcFuhlLlNwsl1WhXDcs5vd+3Xx9x+TN1Gy1n/E0l
/5aT1wy10mt1ZPnk869ffvD2ux991XpV87hZ0ixXXXqtzuiWobcvK3eoP+5rNcW5+1PTpk9jr47u
tbtazVyfNCDYHXw+nydqEk5jjxwxn8hdHrDL7ofWljNeLZ/Pl06c38phWP7LcDS9Omcrn5GeLalO
kDeNnVodp13d0KuoFbXiVm1bcGf2czT3m3Q3dpzsxU2tbphnn3v+5JvGtV09/uCLG3rV6bnIObz6
1ArUCtSKWsmd2NWLr755Q6/SzUOtAGoFUCsxgibUCtQKoFZCrYRagVoB1EqolVArUCsA1EqolVAr
UCuAWgm1EmoFagVQK6FWQq1ArQBQK2pFragVQK0AaiXUSqgVqBVArYRaCbUCtQKolVAroVagVgCo
lVAroVagVgC1Emol1ArUCqBWQq2EWoFaAdSKWlEroVagVqoAoFZCrYRagVoB1EqolVArUCuAWgm1
EmoFagWAWgm1EmoFagVQK6FWQq1ArQBqJdRKqBWoFUCtqBW1EmoFagWAWgm1EmoFagVQK6FWQq1A
rQBqJdRKqBWoFQBqJdRKqBWoFUCthFoJtQK1AqiVUCuhVqBWALWiVtRKqBWoFQBqJdRKqBWoFUCt
hFoJtQK1AqiVUCuhVqBWAKiVUCuhVqBWALUSaiXUCtQKoFZCrYRagVoB1EqolVArUCsA1EqolVAr
nJZaXS0umk+p2cXi6k4PczmfzS9dAqBWQq2EWuGo1aoRp7o0NcrTrtA8rvhP/dnjVKvlOXUsCzha
YYf2AlIrakWthFqBWh2YWu1FeQ5WrQbVQ62olVAroVagVpNa5qXcLNajf9vup67TZrVSt3KnHN2y
3q4uFot5u6fNbpIDzXr7zY4eykKqOctRylURr7abbMVsWYr5/CIpcq/Tqe9w7eN8tVCtktWWi8dP
pN3XWDmzug42yatoUB5QK6FW1Ipa4bDUKlWqpD2/DHpI1tKRLhnsav14tdNWA7J+qU5duk1Wa0am
kPvcQAxb18rdKe4e2z4udpnl8lToJeqfyLAaR8uZd48FmyRV1K2v14panUi+vPr24aMnzV9qJWes
Vs1H+rFMO172oRxF43P/vVa5kpTUaqsd3UUQ7ioRql7/Vtbd07ObgupsfSIxq3Qq1NC2okIWTjNf
bdKA4NiJbB6PlzMyq2yTsIqoFbUa5rU3HhyjV73y8J354w+bv7diV/tXq2Osdmp1C3NGxkYO1h/m
vc/uyhaDBqSyavhsfef5tqURouFe+i3StoTH8uuzo1KrTVXvrlZp91VviHFUrYZdZVFHWKgaqTnF
p1n2sLJajZ9Iolb1coZqVetvo1bU6nQ6bNZe9db7n7338TfN31uxq/1Xgn6y81Or5IO7NNiy+oRe
RC1i+Muv5FO+vvPo2bGdZ71NYaEHe+7mzAS7OxK3OiK12lR0bBd1tUpeuGSIa8KAYDdDKZKbmlql
q3ZX3GBMLtpjVa2KJ5JV42g581MONgmriFpRq+Nu41OvWudW7IpaUat9mFW1tWg/n3uzeivzQAaN
SmXn0bNjO68LwLXUqrCYWl1TrZL67JnKxAHBrrtxPp8nRlKfxt71lQ2cpDwXqteJmfWytt8l4tWG
c61mvYnzW0sMTySvxno5oxXyJdUJ8vyKWiVt/BHxzEuvP3ryaetV6zRLmuWzY4PcnJVaDbwi15R2
Sa9B7X9498UkbDqDncfPjuz86VQzyn5CVW4kj6Pbyt3YMfkrEqjVSXSffPL51y8/ePvdj75qvap5
3Cxpluu1kiNWq34PRDSBKvtO3O+K2Fmt6juf3OW0Gc8ZzhFLOxzSszmCr/XUCtSKWp1dG5/a1a14
FbWiVvtXq2DMrk809JbP+ojVKrgP0MhY5Eh7UZx309vXyA/79VoB1Opc8uxzzx9dmdd29fiDL27F
q+5FdI6x2qnVjd1qbBp7WUAKs9ijHcaTcWuHvv4/ndJTq0IZ0xnW1AqgVnLIdvXiq2/eilfpQ6JW
+xtLCO5IUO+MCuf1RhJW33n+bLzzTH8Gt/bJ7mYZ3Qs7XXZ0U62oFUCthFrJ2d4y9PZl5Q71x32t
AGol1Eqo1Xm51V3e3P1opv9SK4BaCbUS/4YgqBVArYRaCbUCtQKolVAroVagVgColVAroVagVgC1
Emol1ArUCqBWQq2EWoFaAdSKWlEroVagVgColVAroVagVgC1Emol1ArUCqBWQq2EWoFaAaBWQq2E
WoFaAdRKqJVQK1ArgFoJtRJqBWoFUCtqRa2EWoFaAaBWQq2EWoFaAdRKqJVQK1ArgFoJtRJqBWoF
gFoJtRJqBWoFUCuhVkKtQK0AaiXUSqgVqBVArYRaCbUCtQJArYRaCbUCtQKolVAroVagVgC1Emol
1ArUCgC1EmpFragVqBVArYRaCbUCtQKolVAroVagVgC1Emol1ArUCgC1Emol1ArUCqBWQq2EWoFa
AdRKqJVQK1ArANRKqBW1olagVgC1Emol1ArUCqBWQq2EWoFaAdRKqJVQK1ArANRKqJVQK1ArgFoJ
tRJqBWoFUCs5wnx59e3DR0+av9SKWgGHqVaX89n8svz01eLiYnF1mGU7OJrKaj7sZ3ddYcdWLdTq
jvPaGw/OyqteefjO/PGHzd8/+U9/5hWnVsB9qVXTGM8KzfEOarXcy17b9MNyiFHLbIo7sa5uVpPU
ilqd6bjY2qveev+z9z7+pvn7/H/9780Srzi1Amb34wTz+UXcHuu1uk212ktxqRW1OseGNvWqdZrH
zZIztCtqdYRq1TQgx/K5fTm/v1b/iNRqrQTLwaruhV11Yy2Zz7ftdLuoN6SV+kTyeFn1i80Gzeab
bbtnu0Nddvsf2SQ/+nLbxXqQrT/MlvYPtSd2tV1ze/CtUm627Z6fdaeclzNf7Wlw+knBhtW3Pdhm
5a6s3bJdanKHaqFWZ6tW58AzL73+6MmnrVet0yxpls/OD2p1t2qVfPQGn7GDj/tsVkjgUIPWprLz
cJxpdJOxgtV3Mij2MX59n92PWfVqq9faB5dBYi5Ftdq+NqsXq1WXirLUNwmP3m2yWjO5GHJfGYjP
ZXZywcUSlbN8TQ1OPzmtrlrbTQcDqWu33b0md6wWaqXX6nTzyedfv/zg7Xc/+qr1quZxs6RZ7hWn
VrctVkkTOPiMTT+fB3M7Vp/si6gNSVqH6s63u+w3RCObjBcs2Em12EfoVrP7MquuZtM+n6QK0+6a
CWqVbJX0Eg0krq9WlU3Co1+WX+vtOSRmlX6lG9pWZ+zp9VJUwPBbR3j6A2MN1Srf5+Sa3LVaqBW1
Ohe7av6+8N/+xxl6FbW6c7Uqek2uJYMRlOXj6DM5Wa2687gI0zYpF6yuVlGxw6/31CruAWxb51Ct
0qpMWv49qVV89JpDDLqCoishnByVWk5sSAUPu4Fabfxod7XavVqo1Rnm2eeeP5+TXdvV4w++aP7+
6Z//hVecWt1Ff0TWp3M17FbK1g3bv6dhF0Zl59EH+8RNSgUbDvsVGqPM36jVtH7Nno/kA4J9q75x
r1U6cWmCWsVHr458bWZSFXo4a1dgu2pYztL769pqtdlPwV1vu1qolZyBXb346pvNX/e1olb3oFbD
Hovh1+DASvof7nelVmHBhmY1v0znVRWLXeoao1Zx9WwWXHWToC/bny10r8p8Pr+RWnX7SgZwRzaJ
jl6fr706iWRpMnbW9mRlPUcDZc/KGa92A7XqX7rD7zd3UC3USoyLCbW6NbWqWkYySTcfIJrQazVl
QHCX8pS7nXqbbXdZLLZeK4BaUStqJdTqNt1qwrTxwh0KR+ZaTdt5NvNpUnlqBRtOBAqeN9cKALWi
VtSKWt3ZiM9w9GKrI8X789SmKQ1nyJZ2XhrUCzbJ9CcuWLzncBqyXwgCoFbUilpRqyPh9mXlDvXH
fa0AakWtqJVQq/Nyq7u8uftR/u6cWgHUSqiV+DcEQa0AaiXUSqgVqBVArYRaCbUCtQJArYRaCbUC
tQKolVAroVagVgC1Emol1ArUCqBW1IpaCbUCtQJArYRaCbUCtQKolVAroVagVgC1Emol1ArUCgC1
Emol1ArUCqBWQq2EWoFaAdRKqJVQK1ArgFpRK2ol1ArUCgC1Emol1ArUCqBWQq2EWoFaAdRKqJVQ
K1ArANRKqJVQK1ArgFoJtRJqBWoFUCuhVkKtQK0AaiXUSqgVqBUAaiXUSqgVqBVArYRaCbUCtQKo
lVAroVagVgColVArakWtQK0AaiXUSqgVqBVArYRaCbUCtQKolVAroVagVgColVAroVagVgC1Emol
1ArUCqBWQq2EWoFaAaBWQq2oFbUCtQKolVAroVagVgC1Emol1OpWuFpczC+P+OP2cn6xuKJWALWS
c1CrL6++ffjoSfNXnVCr23WJ5hor2lD4bGWT5qn2idVqa2Jd2XXntdUapZt1DLcvP5sdLj0DajVV
p+/PRw/59Rqrte1bYy8VeLQVRa32ldfeeHBuatUY1SsP35k//rD5y65O/sLYm1otvWJ+WfrMDZ8d
3WS7vHm4bS6Wjciw6bjGzqurLY9R3ip+Nj7cATdBs3to+itqHKnVuk6p1agtJe+PHSrwBtVLraiV
MbLeya696q33P3vv42+av+zq5C+MPQ8I1j9zw2cLmyTNRX+NtB257s7rq11HreLD1fd0Jmq1bMK7
V2xklFev1fXUqi23XitqpQXdc/7kP/1Z61XrsCtqdcBqtVk88JNS23G7alUcD6w+mx3ucNug2f68
oFQFyShvaAbJ4+W0tcW8XXezZeTe7ePRTfJ+tOW2i+3LW7rI0uKtD9VdEd0VezGfX2x3kl4x27IF
Bc5XexrUQ1LCdl/pecQV2JW7W7Z9dCcVRa20oOfDMy+9/ujJp61XrdMsaZbPkEGt7lOtkhZ572o1
edAkezZSqwNteWb3bFbpyG7yuKhW2yZ81dS3xlIxlfom4WuU9K9FA8+xowzEp3WtvETxdbJ9XL5U
B/WQnN9mg1Kv1WBwsHkcPXs3FUWtdE6czcn+6Z//xcsP3n73o69ar2oeN0s++fxrV4Jeq2Pptbr7
AcHpbjR8Vq9VRa3a/o/AJNqKLKtVfjW0z5fUqrJJv/OxM4auTCMD1YlZpV/Isp6j9sRLv2/oueCs
8DWj2j83Sa3y/SdqdRcVRa20oGd0so1FtXbFq6jVccy1KnRwHEGvlblWWR3FnTTpqNg+1Cp9YXrD
ZuPGMOj+iV7isGM1NZvYkAoedktqtVGkHdXqBhVFrc45zz73/LnpwtquHn/wBa86hwtjr78QHH67
7ZrV6Nl4YawpwbSca+w8aAZLxc4mvbSHC58tnItfCG6a9O7FTQfNdhoQrKtVOl9pglr1fySx2zjX
ZiZVWvjBi1was25XDQtcFPLbUKvNPiNTurOKolZyZj0xjVG9+OqbvMp9rQ6a2/eSfZuO+1pF4tm7
N8DkaezVQat2V6sJ2ZMGBLuDz+fzpDNmwuzsgSymQ2b5qGbhZw9ZgSu/jri5Wg2GZfsdhHdXUdRK
DHIJtTpxt9r7zd0PeqTE3dgBaiXUSvwbgqBWALUSaiXUCtQKoFZCrYRagVoBoFZCrYRagVoB1Eqo
lVArUCuAWgm1EmoFagVQK2pFrYRagVoBoFZCrYRagVoB1EqolVArUCuAWgm1EmoFagWAWgm1EmoF
agVQK6FWQq1ArQBqJdRKqBWoFUCtqBW1EmoFagWAWgm1EmoFagVQK6FWQq1ArQBqJdRKqBWoFQBq
JdRKqBWoFUCthFoJtQK1AqiVUCuhVqBWALUSaiXUCtQKALUSaiXUCtQKoFZCrYRagVoB1EqolVAr
UCsA1EqoFbWiVqBWALUSaiXUCtQKoFZCrYRagVoB1EqolVArUCsA1EqolVArUCuAWgm1EmoFagVQ
K6FWQq1ArQBQK6FW1IpagVoB1EqolVArUCuAWgm1EmoFagVQK6FWQq0OkavFxfzyiD90L+cXiytq
BVAroVZCra7tEs2VVrSh/NnVkhWRgzTPtmt3a85iXantfDZiOMNtG6WbdWTnkzyd7Lg9XH/ZAboh
tQKolVArOQK1WqrF/LIkE8GzS0PZ/t/66aJZNQ+3wrLcamhK0aFHNqlum5as1heVrNcu7B/sIN2K
WgHUSqiVHM2AYN0l0mf7/pKYUL6kKE3lQ0/bpFDsulo9re+22bhbOHVP1AqgVnL8avXl1bcPHz1p
/qocanUvatXvqcodpFt38FzPXSZ5W3GTilqVxwOTp4NTHRz5ELutDletRl+n+7t0D42R0qpJarXP
vPbGA2q19qpXHr4zf/xh85ddneoVcuhq1ZsNlU2IShRl72qVjReW269yqSf2l52BWqWmWq+M9HWq
1vyZCEFl7uIOaqUmqZVxsT2c+Nqr3nr/s/c+/qb5y65O9Qo5fLWqPlPstZoyIDhxk2kFq2zae7Yw
Dey8e62W7XqvivS17NKHN59fFCcvqklqpeE8lBNPvWoddkWt7l2tCrPYo3no5Tnp2Rz5SdPYd+61
Gv5usZ3HXho7PGe1qpx/0mWZGnH7QiWPl78RWMzbdTdbRjPx2sejm+T9aMttF9sOtvR6Sf25PaFs
VHgrQptt0666bZGCcuarDewom5K4WXfenWnU8XuYNUmtTrjhPHOeeen1R08+bb1qnWZJs1zlrKFW
Nxi8GHzMdr4RPFtpVXLdCRri6s7jTYKWvlTsrGTt4aJy92/X0CvjOf9CsGhWBfMtCkHvlWmvnoqy
1DcJDT7pXxvIeLfOtlD9wnWXRV6QopOvHleuj/YQ3Tq9csxq53KoNUmt9Emc6Il/8vnXLz94+92P
vmq9qnncLGmW67LSa3VwM01u2Uv2bTrnfl+r3t0pUuss/ICzLAT52HCgHn0hqGzSV+FOCMZ+YZqY
VfRNYdDVNfjKUBSX0s8hktNfPeyNPvdPMPtecag1Sa00nCd74qld8SpqdT5utfebux9oqzLbaw2E
epGZSzs8tg8hSDtdusPUhGBtNe26Ua9NOLspNaewnBUPmw3tLVSr+FwOtyap1Unm2eeeZwytXT3+
4AtedcJXiH9DEPetVutOjVgIdhoQrAtBOnFpghD0b5k2aRhrM5MquFlsVa3SVcNyFsZOBz+eaM0u
HxCMz+WAa5JayUl3xjRG9eKrb/Iq97UCtbr7rqtwrvP0aezVMal2V6v51pOGsbqDz+fzpK+lPPl6
4Ij5v3aU3So2nq7XK2fpBmrZz1I3C6664l22XbDRuRxyTVIrMc4l1ArUCgC1Emol1ArUCqBWQq2E
WoFaAdRKqJVQK1ArgFoJtRJqBWoFgFoJtRJqBWoFUCuhVkKtQK0AaiXUSqgVqBUAaiXUilpRK1Ar
gFoJtRJqBWoFUCuhVkKtQK0AaiXUSqgVqBUAaiXUSqgVqBVArYRaCbUCtQKolVAroVagVgColVAr
akWtQK0AaiXUSqgVqBVArYRaCbUCtQKolVAroVagVgColVAroVagVgC1Emol1ArUCqBWQq2EWoFa
AaBWQq2oFUCtAGol1EqoFagVQK2EWgm1ArUCqJVQK6FWoFYAqJVQK6FWoFYAtRJqJdQK1AqgVkKt
hFqBWgGgVtRKJVArgFoB1EqolVArUCuAWgm1EmoFagVQK6FWQq1ArQBQK6FWQq1ArQBqJdRKqBWo
FUCthFoJtQK1AqgVtaJWQq1ArQBQK6FWQq1ArQBqJdRKqBWoFUCthFoJtQK1AkCthFoJtQK1AqiV
UCuhVqBWALUSaiXUCtQKoFbUiloJtQK1AnC7avWf//IvZwBOmr/8y/9CrUCtgD2o1Y+//u6Pzcfu
//3H7/7X3//mr//u13+t88aJO/eTSPNebt7Rzfu6eXf/w7/9rjnx5v1OrUCtgDtUqx/XavXbpVr9
v3/67n9/+x9/8/e/+Zu/O6M0J35W5+vEz+7c//43zfu6eXf/41atfqRWoFbAXanV06Va/eH7H3/z
u++bz9y/+5ffNl9t/88//Mcy355LmhM/n5N14md37qu3c/O+bt7d//Tr3zcn3rzfl2rl4w/UCrgr
tfrppz/+8ON3v//++Z///B///fd//6+/bT6C//afzyjPPf/zszpfJ35u5968o5v3dfPu/rf/+MPP
f/7z5v2u0wrUCrhLu/rpp/VM9v/43ff//t0f//U3f/iXVf75178XkWPP+u3cvK+bd3fzHt/OYWdW
oFbAHarVsuPq+x+Ww4K/+8MPv/3999+JyGmleV837+7mPd6805kVqBWwJ7tqvss2H7vf//DjH0Xk
tPL9Msv3OK8CtQL2ZVcrwWo+dH8UkVPMiqe0CtQKAACAWgEAAFArAAAAagWgyuW8/RfE5pfXX239
/MXi6pQr4QTOdMcqOfnTrJ3sLlfFKZ/sidYDqBVw50pR++gcXW27wlG2xBMr4QTOdPc6OQu1Ck92
p6vihE/2VOsB1Aq4G64WF92HbO9/dlkt/ew9wpZ4YiWcwJleRzXPpHMuO9kdroqTPtnTrAdQK2A/
UtH+b/altLba5n+aZy+O9FN3YiWcwJnuUh2nfppjJzv1qjj1kz3BegC1AvbxYdt+UBZm19RWWz63
enS0X2gnVsIJnOnk6jiD0xw72alXxamf7AnWA6gVcKdshgcGn5uleVT11Y62JZ5YCSdwptdSzvNo
RbOT3fmqONGTPeV6ALUCqBW1olbUilqBWgHH8Bl7kwHB42+Jdx7yoFZncLKnPBBmQBDUCtjbZ+x1
prGfjFpNn6hLrc5HrU5y+vYuJ2saO6gVcJMP2WvffOHIW+Jdf15Orc7hZE/4pgM7naybL4BaAbtS
uh/g4EN0/LaBx/ypO7ESqNVZnezJ3ipzx5N1y1BQK+AmYtF9aFZvDBp9th55SzyxEqjVWZ3saf4D
L7ufrH/ohlqpAgAAAGoFAABArQAAAKgVAAAAqBUAAAC1AgAAoFYAAADUCgAAANQKAACAWgEAAFAr
AAAAUCsAAABqBQAAQK0AYJTL+Sxmfrld5Wpx0V9Q39XYehOOOKHQm5Wnli1mtfXF4iovWbcwPUxQ
2O6ZwSarnQ2WFUowKx02Xnm10qDoAKgVgANXq04f9qVW0xSpX5obqVVqP7k8pd6Sl3l9xE5wVmsM
dbRerEJFlH0pVatJRwCoFQDck1oNmujN0t16RXZTq+se8Wb9VNmONgfsH77nMMNVh7tITGe7xi5i
lfUOliuhX6z1DnRcAdQKwBGoVa/dHspMv7el27K/q6Ge7HLE/DBx39L8Mhet3ioV8ehtmRV2ffCx
rrGCWk0YC4xrZ7l0WIaLxWKrfZf9jbgVQK0AHIlabfWk5x29/4lGsNJdVXqwJhwxHCxbPjWmVtEY
W6HzqCcmBbXqd2mVpqENBgSndFkVvTOoqK6WB1vdWv8dQK0A4LbVqjbpJ23CazOdOmeq9qdMOGK/
06gvY5USDMfYhr4WyM3gEMPOsfSc45IOp7FPmwI1yYqyIcOhkOm2AqgVgCNRq15zHepL0CO0NaB5
vcWfcMThoWeT1CrwlXLn2VBLIn/q9cAN+uYKWpSMBXbnWRhJnKhW2WSsgVrptgKoFYDDU6t+x1O/
uQ5lJhCs8rjZrkesjeyV1SowjfLAW9Tjk8jQojBxvbrPtMuqHSAM75Kww4Bgsk48u55aAdQKwMGq
VfgztbAFDyaZbxc1/1frT5lwxEHPUDQt6nZ6rYpakoxIFspb6opKOveyh6NutVx38HOBilrptQKo
FYCDV6tAdYKeoXC6T7qrSrfM+BGvol/CxU/e1lyryl4Hxy/eJaL3u8AxtRpM5wqrYaJamWsFUCsA
B61WWRs/9gvBgXSM3bFgwhHj6Vj5uGN7P4Kb/kKwfsvQ8hjo8AwGd6IoDggWC1s1J78QBKgVgKNU
q6e9wb2sCe+bRjaMN7z/VWHXtSP2jpH94jD9Ud7l7dzXKtuyMIBX2mn0u8DaNPa4tINdj6mVTiuA
WgHA4XBVnqmu/AC1AgCclZv4NwQBagUAB8aEf5GGWQHUCgAAgFqpAgAAAGoFAABArQAAAKgVAAAA
qBUAAAC1AgAAoFYAAADUCgAAANQKAACAWgEAAFArAAAAUCsAAABqBQAAQK0AAACoFQAAAG7G/wel
FapVJf8DoQAAAABJRU5ErkJggg==
</FILE>
</FIGURE>
<FIGURE FILENAME="ASAS40 consistency.jpg" FILE_TYPE="JPG" ID="FIG-06" MODIFIED="2015-03-20 09:28:50 -0400" MODIFIED_BY="[Empty name]" NO="6" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>ASAS40: Plot of Posterior Mean Deviance of the Individual Data Points in the Inconsistency Model against Their Posterior Mean Deviance in the Consistency Model</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2015-02-20 16:42:07 -0500" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2015-01-28 13:45:20 -0500" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2015-01-28 13:45:04 -0500" MODIFIED_BY="[Empty name]">MEDLINE search</TITLE>
<APPENDIX_BODY MODIFIED="2015-01-28 13:45:08 -0500" MODIFIED_BY="[Empty name]">
<P>Database: Ovid MEDLINE(R) In-Process &amp; Other Non-Indexed Citations and Ovid MEDLINE(R)</P>
<P>1 exp spondylitis, ankylosing/<BR/>2 exp spondylarthropathies/<BR/>3 (ankylosing or spondyl$).tw.<BR/>4 (bekhterev or bechterew).tw.<BR/>5 4 or 1 or 3 or 2<BR/>6 exp Receptors, Tumor Necrosis Factor/<BR/>7 exp tumor necrosis factor/<BR/>8 exp Antibodies, Monoclonal/<BR/>9 anti-tumo?r necrosis factor$.sh,rn,tw.<BR/>10 antitumo?r necrosis factor$.sh,rn,tw.<BR/>11 anti-tnf.sh,rn,tw.<BR/>12 antitnf.sh,rn,tw.<BR/>13 etanercept.sh,rn,tw.<BR/>14 enbrel.sh,rn,tw.<BR/>15 infliximab.sh,rn,tw.<BR/>16 remicade.sh,rn,tw.<BR/>17 adalimumab.sh,rn,tw.<BR/>18 humira.sh,rn,tw.<BR/>19 or/6-18<BR/>20 5 and 19<BR/>21 randomized controlled trial.pt.<BR/>22 controlled clinical trial.pt.<BR/>23 randomized.ab.<BR/>24 placebo.ab.<BR/>25 drug therapy.fs.<BR/>26 randomly.ab.<BR/>27 trial.ab.<BR/>28 groups.ab.<BR/>29 27 or 25 or 28 or 21 or 26 or 22 or 24 or 23<BR/>30 (animals not (humans and animals)).sh.<BR/>31 29 not 30<BR/>32 20 and 31<BR/>33 from 32 keep 1-10</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2015-01-28 13:45:20 -0500" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2010-08-17 20:18:47 -0400" MODIFIED_BY="[Empty name]">Additional search strategies (January 2009 search)</TITLE>
<APPENDIX_BODY MODIFIED="2010-08-17 20:33:01 -0400" MODIFIED_BY="[Empty name]">
<P>Database: EMBASE &lt;1980 to 2009 Week 04&gt;<BR/>Search Strategy:<BR/>--------------------------------------------------------------------------------<BR/>1 exp Spondylitis/ (10156)<BR/>2 (ankylosing or spondyl$).mp. (21570)<BR/>3 (bekhterev or bechterew).mp. (201)<BR/>4 or/1-3 (21620)<BR/>5 exp Tumor Necrosis Factor Receptor/ (5586)<BR/>6 exp Tumor Necrosis Factor/ (19676)<BR/>7 exp Monoclonal Antibody/ (170176)<BR/>8 anti-tumo?r necrosis factor$.mp. (1439)<BR/>9 anti-tnf.mp. (3283)<BR/>10 etanercept.mp. (7693)<BR/>11 enbrel.mp. (1723)<BR/>12 infliximab.mp. (11164)<BR/>13 remicade.mp. (2218)<BR/>14 exp adalimumab/ (3580)<BR/>15 humira.sh,rn,tw. (966)<BR/>16 trudexa.sh,rn,tw. (10)<BR/>17 Monoclonal antibody D2e7.rn,tw. (4)<BR/>18 or/5-17 (195408)<BR/>19 4 and 18 (1592)<BR/>20 random$.ti,ab. (388596)<BR/>21 factorial$.ti,ab. (8106)<BR/>22 (crossover$ or cross over$ or cross-over$).ti,ab. (39123)<BR/>23 placebo$.ti,ab. (108834)<BR/>24 (doubl$ adj blind$).ti,ab. (84015)<BR/>25 (singl$ adj blind$).ti,ab. (7379)<BR/>26 assign$.ti,ab. (107363)<BR/>27 allocat$.ti,ab. (33957)<BR/>28 volunteer$.ti,ab. (98245)<BR/>29 crossover procedure.sh. (20893)<BR/>30 double blind procedure.sh. (71118)<BR/>31 randomized controlled trial.sh. (164870)<BR/>32 single blind procedure.sh. (7912)<BR/>33 or/20-32 (652278)<BR/>34 exp animal/ or nonhuman/ or exp animal experiment/ (3407483)<BR/>35 exp Spondylitis/ (10156)<BR/>36 (ankylosing or spondyl$).mp. (21570)<BR/>37 (bekhterev or bechterew).mp. (201)<BR/>38 or/35-37 (21620)<BR/>39 exp Tumor Necrosis Factor Receptor/ (5586)<BR/>40 exp Tumor Necrosis Factor/ (19676)<BR/>41 exp Monoclonal Antibody/ (170176)<BR/>42 anti-tumo?r necrosis factor$.mp. (1439)<BR/>43 anti-tnf.mp. (3283)<BR/>44 etanercept.mp. (7693)<BR/>45 enbrel.mp. (1723)<BR/>46 infliximab.mp. (11164)<BR/>47 remicade.mp. (2218)<BR/>48 exp adalimumab/ (3580)<BR/>49 humira.sh,rn,tw. (966)<BR/>50 trudexa.sh,rn,tw. (10)<BR/>51 Monoclonal antibody D2e7.rn,tw. (4)<BR/>52 or/39-51 (195408)<BR/>53 38 and 52 (1592)<BR/>54 random$.ti,ab. (388596)<BR/>55 factorial$.ti,ab. (8106)<BR/>56 (crossover$ or cross over$ or cross-over$).ti,ab. (39123)<BR/>57 placebo$.ti,ab. (108834)<BR/>58 (doubl$ adj blind$).ti,ab. (84015)<BR/>59 (singl$ adj blind$).ti,ab. (7379)<BR/>60 assign$.ti,ab. (107363)<BR/>61 allocat$.ti,ab. (33957)<BR/>62 volunteer$.ti,ab. (98245)<BR/>63 crossover procedure.sh. (20893)<BR/>64 double blind procedure.sh. (71118)<BR/>65 randomized controlled trial.sh. (164870)<BR/>66 single blind procedure.sh. (7912)<BR/>67 or/54-66 (652278)<BR/>68 53 and 67 (230)<BR/>69 from 68 keep 1 (1)</P>
<P>Database: EBM Reviews - Cochrane Central Register of Controlled Trials &lt;4th Quarter 2008&gt; Search Strategy:<BR/>--------------------------------------------------------------------------------<BR/>1 exp Spondylarthropathies/ (363)<BR/>2 (ankylosing or spondyl$).ti,ab. (668)<BR/>3 (bekhterev or bechterew).ti,ab. (4)<BR/>4 or/1-3 (790)<BR/>5 exp Receptors, Tumor Necrosis Factor/ (417)<BR/>6 exp Tumor Necrosis Factors/ (1445)<BR/>7 exp Antibodies, Monoclonal/ (1920)<BR/>8 anti-tumor necrosis factor$.ti,ab. (88)<BR/>9 antitumor necrosis factor$.ti,ab. (2)<BR/>10 anti-tnf.ti,ab. (121)<BR/>11 antitnf.ti,ab. (1)<BR/>12 etanercept.ti,ab. (224)<BR/>13 enbrel.ti,ab. (25)<BR/>14 infliximab.ti,ab. (256)<BR/>15 remicade.ti,ab. (10)<BR/>16 adalimumab.ti,ab. (73)<BR/>17 humira.ti,ab. (4)<BR/>18 6 or 11 or 7 or 9 or 17 or 12 or 15 or 14 or 8 or 16 or 10 or 13 or 5 (3597)<BR/>19 4 and 18 (89)<BR/>20 from 19 keep 1 (1)</P>
<P>Database: CLEED, CDSR, ACP Journal Club, DARE, CLHTA Search Strategy:<BR/>--------------------------------------------------------------------------------<BR/>1 exp Spondylarthropathies/ (40)<BR/>2 (ankylosing or spondyl$).ti,ab. (61)<BR/>3 (bekhterev or bechterew).ti,ab. (0)<BR/>4 or/1-3 (74)<BR/>5 exp Receptors, Tumor Necrosis Factor/ (43)<BR/>6 exp Tumor Necrosis Factors/ (57)<BR/>7 exp Antibodies, Monoclonal/ (237)<BR/>8 anti-tumor necrosis factor$.ti,ab. (4)<BR/>9 antitumor necrosis factor$.ti,ab. (1)<BR/>10 anti-tnf.ti,ab. (9)<BR/>11 antitnf.ti,ab. (0)<BR/>12 etanercept.ti,ab. (70)<BR/>13 enbrel.ti,ab. (2)<BR/>14 infliximab.ti,ab. (91)<BR/>15 remicade.ti,ab. (5)<BR/>16 adalimumab.ti,ab. (30)<BR/>17 humira.ti,ab. (4)<BR/>18 6 or 11 or 7 or 9 or 17 or 12 or 15 or 14 or 8 or 16 or 10 or 13 or 5 (363)<BR/>19 4 and 18 (26)<BR/>20 from 19 keep 1-26 (26)<BR/>21 from 20 keep 1 (1)</P>
<P>Web of Knowledge 1900-2008</P>
<P> #5      #4 AND #3</P>
<P>#4      TS=(trial* or random* or placebo* or control* or double or treble or triple or blind* or mask* or allocat* or prospective* or volunteer*or comparative or evaluation or follow-up or followup)</P>
<P>#3      #2 AND #1</P>
<P>#2      TS=(tumor necrosis factor* or tumour necrosis factor* or monoclonal antibod* or anti-tnf or antitnf or etanercept or enbrel or infliximab or remicade)</P>
<P>#1      TS=(ankylos* or spondyl*)</P>
<P>CINAHL</P>
<TABLE COLS="2" ROWS="12">
<TR>
<TD>
<P>S12</P>
</TD>
<TD>
<P>S4 and S11</P>
</TD>
</TR>
<TR>
<TD>
<P>S11</P>
</TD>
<TD>
<P>S5 or S6 or S7 or S8 or S9 or S10</P>
</TD>
</TR>
<TR>
<TD>
<P>S10</P>
</TD>
<TD>
<P>TX etanercept or TX enbrel or TX infliximab or TX remicade or TX adalimumab or TX humira</P>
</TD>
</TR>
<TR>
<TD>
<P>S9</P>
</TD>
<TD>
<P>(MH "etanercept+")</P>
</TD>
</TR>
<TR>
<TD>
<P>S8</P>
</TD>
<TD>
<P>TX "anti-tnf" or TX antitnf</P>
</TD>
</TR>
<TR>
<TD>
<P>S7</P>
</TD>
<TD>
<P>TX "anti-tumor necrosis factor*" or TX "anti-tumour necrosis factor*" or TX "antitumor necrosis factor*" or TX "antitumour necrosis factor*"</P>
</TD>
</TR>
<TR>
<TD>
<P>S6</P>
</TD>
<TD>
<P>(MH "Antibodies, Monoclonal")</P>
</TD>
</TR>
<TR>
<TD>
<P>S5</P>
</TD>
<TD>
<P>(MH "Tumor Necrosis Factor")</P>
</TD>
</TR>
<TR>
<TD>
<P>S4</P>
</TD>
<TD>
<P>(S1 or S2 or S3)</P>
</TD>
</TR>
<TR>
<TD>
<P>S3</P>
</TD>
<TD>
<P>TX (bekhterev or bechterew)</P>
</TD>
</TR>
<TR>
<TD>
<P>S2</P>
</TD>
<TD>
<P>TX (ankylosing or spondyl*)</P>
</TD>
</TR>
<TR>
<TD>
<P>S1</P>
</TD>
<TD>
<P>(MH "Spondylarthropathies+")</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2015-02-20 16:42:07 -0500" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2015-02-20 16:42:07 -0500" MODIFIED_BY="[Empty name]">Updated search strategy (October 2013, including golimumab)</TITLE>
<APPENDIX_BODY MODIFIED="2014-11-17 15:53:33 -0500" MODIFIED_BY="[Empty name]">
<P>
<B>Database: Ovid MEDLINE(R) In-Process &amp; Other Non-Indexed Citations and Ovid MEDLINE(R) &lt;1946 to Present&gt;</B>
</P>
<P>
<B>Search Strategy:</B>
</P>
<P>--------------------------------------------------------------------------------</P>
<P>1 Spondylitis, Ankylosing/ (11743)</P>
<P>2 (bekhterev* or bechterew*).tw. (669)</P>
<P>3 (ankylosing adj (spondyl$ or rheumatoid)).tw. (9939)</P>
<P>4 or/1-3 (14314)</P>
<P>5 etanercept.sh,rn,tw. (4782)</P>
<P>6 enbrel.sh,rn,tw. (219)</P>
<P>7 infliximab.sh,rn,tw. (10011)</P>
<P>8 remicade.sh,rn,tw. (227)</P>
<P>9 adalimumab.sh,rn,tw. (5447)</P>
<P>10 humira.sh,rn,tw. (186)</P>
<P>11 Simponi.sh,rn,tw. (9)</P>
<P>12 Golimumab.sh,rn,tw. (335)</P>
<P>13 or/5-12 (15002)</P>
<P>14 4 and 13 (1224)</P>
<P>15 meta-analysis.mp,pt. (80626)</P>
<P>16 search.tw. (181139)</P>
<P>17 systematic review.tw. (46201)</P>
<P>18 medline.tw. (63445)</P>
<P>19 cochrane database of systematic reviews.jn. (18098)</P>
<P>20 or/15-19 (273222)</P>
<P>21 randomized controlled trial.pt. (388158)</P>
<P>22 controlled clinical trial.pt. (89760)</P>
<P>23 randomized.ab. (303172)</P>
<P>24 placebo.ab. (163015)</P>
<P>25 clinical trials as topic.sh. (175009)</P>
<P>26 randomly.ab. (214577)</P>
<P>27 trial.ti. (130732)</P>
<P>28 or/21-27 (928846)</P>
<P>29 exp animals/ not humans.sh. (4050087)</P>
<P>30 28 not 29 (858635)</P>
<P>31 14 and 30 (319)</P>
<P>32 14 and 20 (58)</P>
<P>33 11 or 12 (335)</P>
<P>
<B>Database: Embase Classic+Embase &lt;1947 to 2013 October 09&gt;</B>
</P>
<P>
<B>Search Strategy:</B>
</P>
<P>--------------------------------------------------------------------------------</P>
<P>1 (bekhterev* or bechterew*).tw. (1228)</P>
<P>2 (ankylosing adj (spondyl$ or rheumatoid)).tw. (14716)</P>
<P>3 ankylosing spondylitis/ (20512)</P>
<P>4 or/1-3 (22655)</P>
<P>5 etanercept/ (16881)</P>
<P>6 (enbrel or etanercept).tw. (8641)</P>
<P>7 infliximab/ (26746)</P>
<P>8 (remicade or infliximab).tw. (13987)</P>
<P>9 adalimumab/ (13106)</P>
<P>10 (adalimumab or humira).tw. (7067)</P>
<P>11 golimumab/ (1576)</P>
<P>12 (Golimumab or Simponi).tw. (830)</P>
<P>13 or/5-12 (36950)</P>
<P>14 4 and 13 (3140)</P>
<P>15 randomized.tw. (399359)</P>
<P>16 meta-analysis.tw. (60911)</P>
<P>17 systematic review.tw. (52090)</P>
<P>18 or/15-17 (473294)</P>
<P>19 random$.tw. (872666)</P>
<P>20 factorial$.tw. (22787)</P>
<P>21 crossover$.tw. (49676)</P>
<P>22 cross over.tw. (22540)</P>
<P>23 cross-over.tw. (22540)</P>
<P>24 placebo$.tw. (205650)</P>
<P>25 (doubl$ adj blind$).tw. (150905)</P>
<P>26 (singl$ adj blind$).tw. (14326)</P>
<P>27 assign$.tw. (239903)</P>
<P>28 allocat$.tw. (82346)</P>
<P>29 volunteer$.tw. (184925)</P>
<P>30 crossover procedure/ (38960)</P>
<P>31 double blind procedure/ (122751)</P>
<P>32 randomized controlled trial/ (360167)</P>
<P>33 single blind procedure/ (18364)</P>
<P>34 or/19-33 (1431673)</P>
<P>35 14 and 18 (288)</P>
<P>36 14 and 34 (501)</P>
<P>37 11 or 12 (1626)</P>
<P>38 4 and 37 (423)</P>
<P>39 34 and 38 (67)</P>
<P>40 18 and 38 (53)</P>
<P>41 39 or 40 (74)</P>
<P>
<B>Cochrane Library 2013 Issue 9</B>
<BR/>
<BR/>ID Search</P>
<P>#1 MeSH descriptor: [Spondylarthropathies] this term only</P>
<P>#2 ankylosing or spondyl:ti,ab</P>
<P>#3 bekhterev or bechterew:ti,ab</P>
<P>#4 MeSH descriptor: [Receptors, Tumor Necrosis Factor] this term only</P>
<P>#5 MeSH descriptor: [Tumor Necrosis Factors] this term only</P>
<P>#6 MeSH descriptor: [Antibodies, Monoclonal] this term only</P>
<P>#7 anti-tumor necrosis factor:ti,ab</P>
<P>#8 anti-tnf:ti,ab</P>
<P>#9 antitnf:ti,ab</P>
<P>#10 etanercept:ti,ab</P>
<P>#11 enbrel:ti,ab</P>
<P>#12 infliximab:ti,ab</P>
<P>#13 remicade:ti,ab</P>
<P>#14 adalimumab:ti,ab</P>
<P>#15 humira:ti,ab</P>
<P>#16 (golimumab or simponi):ti,ab</P>
<P>#17 #1 or #2 or #3</P>
<P>#18 #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15</P>
<P>#19 #17 and #18</P>
<P>
<B>CINAHL via Ebscohost</B>
</P>
<P>
<B>2012-2013</B>
</P>
<P/>
<TABLE COLS="2" ROWS="14">
<TR>
<TD VALIGN="TOP">
<P>S14</P>
</TD>
<TD VALIGN="TOP">
<P>S1 OR S2</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S13</P>
</TD>
<TD VALIGN="TOP">
<P>S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 or S12</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S12</P>
</TD>
<TD VALIGN="TOP">
<P>"simponi"</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S11</P>
</TD>
<TD VALIGN="TOP">
<P>"golimumab"</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S10</P>
</TD>
<TD VALIGN="TOP">
<P>"humira"</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S9</P>
</TD>
<TD VALIGN="TOP">
<P>"humira"</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S8</P>
</TD>
<TD VALIGN="TOP">
<P>"adalimumab"</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S7</P>
</TD>
<TD VALIGN="TOP">
<P>(MH "Adalimumab")</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S6</P>
</TD>
<TD VALIGN="TOP">
<P>"remicade"</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S5</P>
</TD>
<TD VALIGN="TOP">
<P>(MH "Infliximab")</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S4</P>
</TD>
<TD VALIGN="TOP">
<P>"enbrel"</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S3</P>
</TD>
<TD VALIGN="TOP">
<P>(MH "Etanercept")</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S2</P>
</TD>
<TD VALIGN="TOP">
<P>"(bekhterev or bechterew)"</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S1</P>
</TD>
<TD VALIGN="TOP">
<P>(MH "Spondylitis, Ankylosing")</P>
</TD>
</TR>
</TABLE>
<P/>
<P>Database: Web of Science &#8211; Oct 09, 2013<BR/>Search Strategy</P>
<P>Topic=(ankylosing spondylitis) AND Topic=(( anti-tnf or etanercept or enbrel or infliximab or remicade or adalimumab or humira or golimumab or simponi))</P>
<P>Timespan= Limited to 2012-2013</P>
<P>Databases=SCI-EXPANDED, SSCI, A&amp;HCI, CPCI-S, CPCI-SSH.</P>
<P>Refined by document type (Meeting or Abstract)</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>